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Abstract
This thesis investigates Endomyocardial Fibrosis (EMF), the commonest form of 
restrictive cardiomyopathy affecting children and young adults from poor developing 
countries. EMF is the second cause of admission for acquired cardiovascular disease in 
these age groups in endemic areas and has an unclear etiology and pathogenesis. It has no 
specific treatment and carries a poor prognosis. 
The methodology followed for this investigation was the implementaion of large-scale 
epidemiological studies on incidence, prevalence and determinants of EMF in an endemic 
area of Mozambique, using echocardiography. New classification and scoring system for 
diagnosing and assessing EMF severity was evolved and applied in community and 
hospital-based studies. Concomitantly, characterization of the clinical and biological 
profile of EMF in its different stages was done, as well as investigation of the genetic 
susceptibility to the disease. Finally, new surgical procedures based on the specific 
pathophysiology were developed and applied, with attempts at optimizing the timing of 
surgery and its results. 
This work has established that echocardiographic screening is able to detect early and 
asymptomatic stages of EMF, and that it is a useful tool in assessing its progression, 
identifying patients that can benefit from surgery and monitoring response to treatment. It 
also shows that novel surgical approaches based in tailored techniques to the specific 
components of the disease can improve the outcome. The use of the standardized criteria 
in prospective studies may improve knowledge of the natural history and pathogenesis of 
EMF allowing better management of EMF and identication of new therapeutic targets. 
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1.1. Background
Summary
Endomyocardial Fibrosis (EMF) is a progressive disease that, in its established stage, is 
characterized by fibrosis in the ventricular cavities affecting particularly the apex and the 
subvalvar regions (Davies, 1960). This definition of the disease, based on the knowledge 
about its clinical and pathology findings, applies entirely to the advanced phases of this 
condition, and allows easy clinical and echocardiographic diagnosis in the presence of 
heart failure, mainly in patients with predominant right ventricular disease. In contrast, 
there is lack of diagnostic criteria for early stages of EMF.   
EMF is a restrictive cardiomyopathy of unclear etiology and pathogenesis affecting 
mainly children and adolescents from tropical regions of Africa, South America and Asia 
(Bukhman et al, 2008). Its pathophysiology associates restriction to diastolic filling 
caused by endocardial fibrosis, with atrioventricular valve regurgitation that results from 
involvement of the leaflets and the subvalvar apparatus in the fibrotic process. 
There is no specific treatment for Endomyocardial Fibrosis. Advanced forms of EMF 
carry high morbidity and mortality, with death occurring due to progression to chronic 
heart failure or as a result of arrhythmia and thromboembolism. Surgery can correct some 
structural and functional abnormalities in patients with EMF, but has been associated 
with high morbidity and mortality (Valiathan et al, 1987), as well as uncertain long-term 
outcome.
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1.1.1. History of EMF
Arthur Williams (1938) reported for the first time two hearts with large endocardial 
patches of fibrosis in Uganda. The same findings were described some years later by 
other authors (Bedford, 1946), but Jack Davies (1948) was the first to describe EMF as a 
distinct pathological entity and the correlation between the pathology features and the 
clinical signs (Davies, 1960), allowing the diagnosis of endomyocardial fibrosis in life. 
Several designations have been used to describe EMF namely tropical endomyocardial 
disease, endocarditis parietalis fibroplastica, endocardial fibrosis, constrictive 
endocarditis, endocardial fibroelastose and Davies diease. The expression “Heart of 
Africa” was also used to designate this entity due to the similarity of the heart shape in 
right ventricular EMF with retraction of the apical region to the map of Africa, and 
because the entity occurred frequently in Uganda, a country located in a central position 
in Africa. However, the term “Endomyocardial Fibrosis” is the one that best describes 
the abnormalities found in this condition, and has been adopted worldwide. In 1965 the 
World Health Organization classified EMF as a restrictive cardiomyopathy of unclear 
etiology (Hutt et al, 1965). 
Research on EMF has been largely concentrated in description of clinical features, 
characterisation pathology changes and results of surgical management. Most 
publications came from Uganda, Nigeria, Ivory Coast, India and Brazil, but there have 
been reports of cases outside the tropics in all regions of the world. Few studies have 
looked at mechanisms of the disease and the various etiological hypotheses have been 
incompletely investigated. 
Chapter 1 Introduction and Aims
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
34
1.1.2. Epidemiology
The majority of literature available describes the advanced stages of EMF seen in 
hospital. Data on incidence, rate of progression and prevalence are scarce. 
EMF is thought to be the most widely prevalent form of restrictive cardiomyopathy 
(Somers, 1990). In endemic areas of Africa, EMF is as common a cause of cardiac failure 
as rheumatic heart disease and accounts for 25% of all cardiac necropsies (Somers, 1989). 
It has also been stated that undiagnosed EMF may also be common in populations living 
in areas from where patients have been reported (Mayosi, 2007). 
EMF is very prevalent near the Equator (Figure 1.1) and high prevalence has been 
reported from several tropical countries, namely: Uganda (Davies, 1948; Connor et al, 
1967; Shaper, 1967; Shaper, 1968), Kenya (Somers, 1989), Zambia (Lowenthal, 1978), 
Nigeria (Abrahams, 1962; Ikeme, 1972; Falase et al, 1976; Andy et al, 1981; Jaiyesimi, 
1982), Ghana and Ivory Coast (Dienot, 1981; Bertrand, 1993) in Africa; Brazil, 
Colombia, Venezuela and Mexico in South America; and India (Cherian et al, 1982; 
Vijayaraghavan et al, 1983; Valiathan et al, 1987).  More recently, cases have been 
reported from Zimbabwe (Hakim et al, 1996), Mozambique (Bijlsma, 1979; Ferreira et 
al, 1992; Ferreira et al, 2002), Egypt (Rashwan et al, 1995), Guine Equatorial (Perez et 
al, 2005), South Africa (Beck and Schirire, 1972), Saudi Arabia (Graham et al, 1981), 
USA (Eterovic et al, 1979; Gonzalez-Lavin et al, 1982), Korea (Yie et al, 2003), England 
(Wiseman et al, 1986), Spain (Estornell et al, 2003), Switzerland (Schneider et al, 1998), 
Japan (Niino et al, 2001) and China (Yin, 2000).
Chapter 1 Introduction and Aims
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
35
Variations in distribution of EMF have been noted in different countries where the 
disease has been reported to be endemic (Kartha, 1995). In India the prevalence of EMF 
is highest in the coastal areas of Kerala (Kutty et al, 1996) with very few cases reported 
from the northern areas of the country. In Nigeria, it is endemic in the South-West but 
rare in the hot and dry north (Parry, 1964; Ijaola and Falase, 1988). Several studies from 
Uganda reported preponderance of the condition in patients from Rwanda and Burundi 
that immigrate to the South-West (Connor et al, 1967; Shaper 1972). More recently, in 
Mozambique, an analysis of referrals to a cardiovascular unit over a 10-year period 
showed a striking high attack rate in Inharrime, a rural coastal area in the south of 
Mozambique (Figure 1.2) (Ferreira et al, 2002). 
Figure 1.1. World map showing endemic areas for EMF worldwide (Buckman, 2008)
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Figure 1.2. Map of Mozambique in the south coast of Africa 
It is not clear whether the reported variations in prevalence and incidence of EMF are 
related to environmental or genetic factors (Mayosi and Somers, 2007). Several 
environmental factors have been implicated in the origin of the disease, namely 
geography (Mayanga-Kizza et al, 2000; Kutty et al, 1996), social deprivation 
(Rutakingirwa et al, 1999), infectious diseases (Shaper et al, 1968) and diet (Ojo, 1970; 
McKinney, 1975; Jaiyesimi, 1980; Sezi, 1996a; Sezi 1996b). Ethnicity is also thought to 
play a role in pathogenesis, since in Uganda it affects almost exclusively individuals from 
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certain ethnics groups of immigrants from Rwanda and Burundi (Somers, 1973). Familial 
occurrence of the disease has also been noted in some clinical series (Patel et al, 1971; 
Lowenthal et al, 1978).
While EMF may be found in any age group, hospital-based series show that it affects 
predominantly children and adolescents (Jaiyesimi, 1982; Somers, 1990), with a peak 
incidence at the ages 11-15 years in both sexes (Somers, 1968). In most series women 
show a second peak between 26 and 30 years (Rutakinguirwa et al, 1999). Although most 
patients are under 15 at the time of first presentation, there are reports of the disease in 
infants (Bijlsma, 1976; Jatene et al, 2003).  
There is no clear gender preponderance in prevalence of EMF. Whereas in Uganda there 
seems to be female preponderance with a female: male ratio of 2:1 (Connor et al, 1967; 
Shaper, 1972), in Nigeria no sex difference was found (Parry, 1964), and in some 
countries a male preponderance has been noted (Brockington and Edington, 1972; 
Bijlsma, 1976).  
The only epidemiological survey performed in Africa aiming at determining the 
prevalence of EMF was performed in the Inharrime district of Mozambique (Ferreira, 
2001). In this study 948 inhabitants between 4 and 45 years had cardiac auscultation and 
those with abnormal findings were submitted to echocardiography. A prevalence of 8.9% 
was found, suggesting that EMF was a major public health problem in this rural area.
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1.1.3. Natural History
EMF appears to evolve in three successive stages after an unknown stimulus or trigger. 
Initial endocardial necrosis would be followed by thrombosis, and later fibrosis would 
develop in the area adjacent to the thrombus leading to the characteristic lesions found in 
advanced disease (Brockington and Olsen, 1973; Olsen, 1990) (Diagram 1.1). This 
sequence of events has been difficult to prove for several reasons: (1) initial and acute 
EMF are rarely reported in hospital-based studies; (2) research has been based in clinical 
series, which included only patients with advanced disease; (3) studies on the natural 
history of EMF have been done retrospectively based on follow-up of patients from 
clinical series;  (4) most research on this issue took place before the advent of 
echocardiography making it difficult to document and monitor progression of intra-
cardiac lesions in vivo. 
The mode and rate of progression of EMF to advanced forms is variable (Parry, 1965; 
Andy 1998)  (Diagram 1.2). After the initial insult most patients have a rapidly 
progressing heart failure that leads to death within 2 years (Sliwa et al, 2005). Some 
patients, however, have a history of slowly progressive chronic heart failure with several 
admissions to hospital or have a steady period without any deterioration after an initial 
febrile episode with or without heart failure (Somers, 1972b). 
The reported mean survival time after the onset of symptoms is two years, but isolated or 
predominant LEMF determines earlier fatality due to complications of pulmonary 
hypertension and systemic thromboembolism (Somers 1978). Death results usually from 
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complications of progressive chronic heart failure (protein-losing enteropathy, cardiac 
cirrhosis, hepatic failure), but can sometimes be sudden due to pulmonary embolism or 
arrhythmias (Diagram 1.3).
Necrotic Phase
Acute myocarditis with inflammatory infiltrate composed of eosinophils
↓
Thrombotic Phase
Endocardial thickening, thrombosis and less inflammatory infiltrate
↓
Fibrotic Phase
Replacement of endocardium by collagen and superficial thrombosis
Diagram 1.1. The natural history of EMF (as described by Olsen)
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Triggers
↓
Subclinical illness ← Initial illness → “Burnt out case”
(Systemic illness) No residual heart disease
Pancarditis, eosinophilia
↓
Thrombotic Phase
↓
Restrictive Cardiomyopathy
due to Endomyocardial Fibrosis
↓
Death
Diagram 1.2. Natural history and progression of EMF (by Parry, Andy and Jaiyesimi)
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Poverty
↓
Low protein cassava diet →     Stunted body growth
↓
Low plasma aminoacid profiles due to overuse for growth and pregnancies
↓
Plasma aminoacid profiles below critical levels
Most prominent at the apices due to poor apical endomyocardial supply and to maximal 
mechanical stress and sluggish flow at the apices
↓
Failure of cardiac cell repair
(because the endocardium receives a poorer blood supply from end arteries)
↓
Endomyocardial degeneration
(associated with cerium and cassava)
↓
Endomyocardial Fibrosis
↓
Mural thrombosis and Thromboembolism
Diagram 1.3. Proposed pathophysiology of endomyocardial fibrosis ( adapted from Sezi)
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1.1.4. Etiology and Pathogenesis
The cause of EMF is unknown and the mechanisms involved in its pathogenesis are 
incompletely understood. None of the hypotheses studied - including geochemical actors, 
infectious agents, dietary factors, hypersensitivity, autoimmunity, hypereosinophilia, 
genetic susceptibility and ethnicity - can explain the occurrence of EMF worldwide. 
Overall, there seems to be a preponderance of environmental factors playing a role in the 
pathogenesis of EMF (Mayosi and Somers, 2007). 
Hypereosinophilia
Eosinophils have been considered an etiological factor in the pathogenesis of EMF 
(Andy, 1998; Patel et al, 1977) and some authors consider the condition to be a variant of 
the Hypereosinophilic Syndrome (HES) seen in temperate climate, owing to the fact that 
the late fibrotic lesions in both condition are identical (Brockinghon and Olsen, 1973). 
Eosinophilia from 10 to 30% of the total WBC counts, presenting sometimes over several 
months or even years, is a frequent finding in EMF (Somers, 1972b) and its level seems 
to be inversely related to the duration of the illness (Andy, 1998). 
Hypereosinophilia could probably be induced by parasitic infections by helminths (Andy, 
1998), schistosomiasis (Rashwan et al, 1995), microfilaria loa-loa (Beck and Schrire, 
1972), or filariasis (Ive, 1967), but this theory is difficult to establish because eosinophil 
count peaks during larval migration returning to normal thereafter. On the other hand 
several studies failed to show an increased prevalence of these infections in EMF patients 
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when compared to the general population (Brockington, 1974; Connor et al, 1967; 
Carlisle et al, 1972; Brockington and Olsen, 1973). In the Ugandan experience 
eosinophilia did not affect patients with EMF any more than the population at large (Patel 
et al, 1977), nor has eosinophilia been recognized in the thrombotic and fibrotic 
endocardial lesions studied in biopsy (Somers, 1971) and necropsy specimens (Connor et 
al, 1968). Another study showed no difference between the mean eosinophil counts in 
patients with EMF and controls from the general population; degranulated eosinophils 
were absent in the blood and bone marrow aspirates of the patients; the mean 
concentrations of eosinophil granule basic proteins were not different in the two groups 
(Urhoghide and Falase, 1987). However, some authors argue that these studies were done 
in patients with advanced disease and, assuming that cardiac damage in EMF is triggered 
by parasite induced eosinophilia, a raised eosinophil count need not to be present in 
chronic disease (Jaiyesimi, 1982; Andy et al, 1981). If parasite-induced eosinophilia is 
related to cardiac damage, the eosinophilia in EMF should be sought in early disease. 
Although few studies looked at this issue, one suggested that there is a highly significant 
inverse relationship between hypereosinophilia and the duration of symptoms in EMF 
patients (Andy, 1998). 
The fibrotic lesions characteristic of EMF, considering this hypothesis of 
hypereosinophilia as the pathogenic mechanism, would represent the end result of an 
acute eosinophilic endocardial injury. The cardiotoxicity of the eosinophil has long been 
demonstrated (Spry et al, 1983). Human eosinophil granule basic proteins have been 
shown to injure heart cells in rats, and eosinophils in patients with an eosinophilia are 
metabolically and functionally more effective than normal. Why is the endocardium so 
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susceptible to eosinophil dependent injury and what determines the rate at which 
endocardial disease progresses to the late fibrotic stages is not known.
The possibility of hypereosinophilia being an independent risk for EMF not attributable 
to parasitism was also postulated (Rutakingirwa et al, 1999). 
Infectious agents
Several infectious agents have been studied in an attempt to establish the etiology and 
pathogenesis of EMF. The role of infectious agents appears plausible in view of climatic 
restrictions of the disease and of the reports of sporadic cases in foreigners after short 
visits to endemic areas (Brockington et al, 1967; Beck and Schrire, 1972). Plasmodium 
species (Shaper et al, 1968), Schistosoma (Barbosa et al, 1998; Victor et al, 1996), 
Microfilaria (Berenguer et al, 2003), Helminths (Andy, 1998), Toxoplasma (Ludman and 
Somers, 1966) and Coxsackie B virus (Ijaola and Falase, 1990), have been implicated as 
possible causes or triggers for disease, but none has been proven to cause EMF. 
In Africa EMF is endemic were malaria is also prevalent (Sliwa et al, 2005). The finding 
of endomyocardial fibrotic lesions mimicking human disease in mice infected with 
Plasmodium berghei (Eling et al, 1988) supports the hypothesis of malaria being 
involved in the pathogenesis of this condition, and provides one of the best models of the 
disease. This theory could also be reinforced by reports of increased eosinophil activity in 
acute Plasmodium falciparum infection (Kurtzhals et al, 1998; Shanks et al, 1992). 
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Autoimmunity
The role of autoimmunity has been postulated to be of importance in EMF (Van der Geld 
et al, 1966; Shaper et al, 1968) but this remains to be firmly established. An 
immunological syndrome consisting of high titres of anti-malarial antibody associated 
with the presence of IgM and circulating autoantibodies to the heart has been identified in 
populations with high prevalence of EMF (Shaper et al, 1968; Jayesimi et al, 1984). 
Moreover, EMF patients have been shown to have high prevalence of antimalarial and 
antiheart antibodies (Van der Geld et al, 1966) that seem to correlate (Shaper 1974). 
Whether these antibodies are the cause or the result of EMF is not clear, but these 
findings led to the hypothesis that the presence of tissue autoantibodies associated with an 
unusual response to malarial infection may play a role in the pathogenesis of EMF 
(Shaper et al, 1967). Pathological studies however failed to confirm the existence of large 
numbers of immunologically competent cells at the endomyocardial junction (Connor et 
al, 1968) and antiheart antibodies (IgG, IgM and IgA) were not detected in Indian 
patients with angiographic diagnosis of EMF and matched voluntary blood donors 
controls, when analysed by indirect immunoflorescent technique (Kartha et al, 1984; 
Vijayaraghavan and Sadanandan, 1984).
Geochemical factors
The equatorial distribution of EMF mentioned previously stimulated several theories for 
the causation of the disease. One of the main factors that characterize the equatorial 
regions is the intensity of the ultraviolet radiation. Since plants can synthesize vitamin D 
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on exposure to sunlight, because they contain pro-vitamin D2 (ergosterol), it was thought 
that the practice, common to poorer people in the tropics, of drying staple foods in the 
sun would increase the levels of vitamin D in plants (particularly roots of cassava), 
leading to increase levels of calcium in people eating these plants (Davies, 1990). 
Vitamin D-induced calcinosis would be the basis for cellular hyperplasia and excessive 
production of collagen and elastin in the endomyocardium, and would explain the fibrosis 
and calcification characteristic of this entity. Initial research on this issue showed that 
EMF patients in Kerala were found to have high blood levels of calcium (Valiathan et al, 
1986), but no further studies confirmed this hypothesis.
Children have high needs of Mg for growth and development. It is thought that poor 
children from tropical regions are prone to develop magnesium deficiency because of 
insufficient intake, or chronic diarrhoea due to malnutrition. In Kerala (Valiathan et al, 
1993) it was shown that the deficiency of magnesium promotes the absorption of cerium 
and enhances its toxicity, which could form the basis for the initial injury of the heart in 
EMF. Interestingly, the cardiac tissue of EMF patients showed high levels of cerium (a 
major constituent of monazite, which is found in the soil of tropical regions in high 
concentrations) and low concentrations of magnesium. Both, hypomagnesemia and EMF 
are widely prevalent in children from low-income groups in the equatorial regions of 
India (Eapen et al, 1993), Africa (Cadell 1967) and Brazil (Cerci Neto, 2006).
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Dietary factors
Because EMF affects mainly poor people from deprived rural areas, initial studies on 
pathogenesis concentrated on the role of nutritional deficiencies with deceiving results 
(Falase, 1983). Despite the high prevalence of malnutrition in some areas of the world, 
there is no correlation between the prevalence of the two diseases, since nutritional 
deficiencies neither explain the confinement of EMF to certain areas of these low-income 
countries, nor the differences among various ethnic groups. Furthermore, EMF has been 
found in well-nourished Caucasians resident in tropical Africa (Brockington, 1967; Beck 
and Schrire, 1972). 
Vitamin E deficiency also produces cardiac enlargement and fibrosis similar to EMF in 
malnourished animals (Lee et al, 1960; Ferrans, 1985). This is due to auto-oxidation of 
unsaturated lipids with deposition of ceroid bodies in the tissues, that later become 
fibrosed leading to endocardial fibrosis when the heart is affected. However, 
measurement of blood levels of vitamin E was normal in EMF patients (Jaiyesimi, 1978). 
The fact that tropical EMF occurs near the equator and afflicts relatively poor people 
whose staple diet is tuberous (roots of cassava) has led to the hypothesis that such a diet, 
rich in vitamin D, could be the critical background to EMF (Davies, 1990). However, in 
countries like Mozambique, both endemic and non-endemic areas for EMF have cassava 
dried through sunlight as the basis of their diet (Figures 3 and 4). 
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Plantains and bananas which contain high levels of serotonin (5-hydroxytryptamine) are 
consumed in large quantities in some communities from India where EMF is common. 
Because excess of serotonin in the blood stream produces a cardiac lesion which some 
authors felt was similar to EMF (Ball, 1957), it was suggested that the disease could 
result from excessive ingestion of plantains. However, there is no correlation between the 
geographical distribution of EMF and the plantain-eating habits of the African 
population.  
Figure 1.3. Cassava plants (left) and their roots (right), which are usually dried at 
sunlight, constitute the basic food in this area
In summary, all these association studies searching for factors potentially involved in the 
etiology of EMF did not prove any of the hypotheses. 
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Figure 1.4. Fresh cassava roots are used for production of “tapioca”, as represented in 
this picture. 
Experimental models
Both animal models and in vitro studies were performed aiming to clarify the role of 
several factors in the etiopathogenesis of EMF.
a. Animal models
In a study that attempted at developing an animal model for EMF (Kartha and Gupta, 
1993) different degrees of magnesium deficiency were induced in rats through dietary 
means. The effects of cerium supplementation in the same animals were explored through 
autopsy and measurement of the levels of the two elements in the tissues. The results 
included myocardial lesions consisting of interstitial haemorrhages or myocarditis, and 
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increase in calcium levels in the heart tissue while there was a decrease of calcium levels 
in bones. Cerium appeared to intensify the cardiac histologic lesions in the presence of 
magnesium deficiency. Although unsuccessful in creating the animal model, this 
experiment has provided supportive evidence for a hypothesis on the possible connection 
of EMF with myocardial levels of cerium and magnesium.  
Another experiment was performed to test the effects of protein deficient cassava diet in 
African green monkeys Cercopithecus aethiops (Sezi, 1996a). Three monkeys were fed 
on uncooked banana diet while other three were fed on uncooked cassava. The hearts 
were harvested for histology whenever the animal health deteriorated. Later five other 
monkeys were fed on cassava for longer periods. The histological findings in monkeys 
fed on cassava included some features of EMF namely endocardial thickening, interstitial 
fibrosis, fibrous septa formation, papillary muscle fibrosis and apical fibrosis in the left 
ventricle. Animal on banana diet, which also lacked protein, did not develop similar 
lesions. It was concluded that EMF could be experimentally induced in the monkey and 
that protein deficient cassava diet could be one of the causes of the disease.
The role of malaria in the pathogenesis of EMF was also explored through animal 
experiments. C57B1/Rij mice infected with Plasmodium berghei developed progressive 
endocardial edema and extensive endocardial thrombosis with a predilection for the right 
half of the heart (Eling et al, 1984). Mural thrombus grew out until death of the host or 
until chemotherapy cleared the infection, in which case there was evolution to fibrosis of 
the affected areas. 
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b. In vitro studies
The increased production of collagen that is characteristic of EMF can be due to 
hyperfunction of individual cells or to increase in number of cells. An interesting study 
using non-myocardial rat heart cells and human cardiac explants evaluated the influence 
of high levels of cerium and low levels of magnesium on heart cell proliferation in vitro 
(Nair et al, 1993) and suggested that low levels of cerium may have a stimulatory effect 
on heart cell proliferation.
The relationship between magnesium deficiency and the expression of cerium toxicity 
was examined in more detail in a study aiming to understand the molecular basis of 
endomyocardial damage induced by cerium (Shivakumar and Prakash Kumar, 1993). 
Very high concentrations of cerium had an inhibitory effect on protein biosynthesis in 
cultured cardiac myocytes, the effect being more pronounced in cells exposed to a 
magnesium-deficient medium. At levels comparable with those found in the cardiac 
tissue in EMF, cerium was found to stimulate collagen and non-collage protein synthesis 
in cardiac explants and fibroblasts. This study suggested that magnesium deficiency may 
amplify the cardiotoxicity of cerium, and that stimulation of collagen synthesis by low 
levels of cerium may contribute to the accumulation of collagen observed in EMF.
1.1.5. Pathophysiology and Progression
Endomyocardial Fibrosis appears to start as a febrile episode triggered by unknown 
factors, followed by ventricular thrombosis which appear to be associated with 
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pancarditis, hypereosinophilia, facial swelling, body itching, urticaria and neurological 
features caused by thromboembolism (Parry and Abrahams, 1965; Andy, 1998). Later, 
mural and valvar thrombosis evolves to organization of the thrombus and endocardial 
fibrosis. 
The sites most frequently affected by EMF lesions are RV “apex”, the left ventricular 
apex and the recess behind the posterior leaflet of the mitral valve (Connor et al, 1967). 
Endocardial fibrosis of these areas reduces ventricular cavity size and impedes adequate 
filling leading to restrictive physiology. On the other hand fibrosis of the endocardium 
affecting the papillary muscles, chordae and/or leaflets causes valve distortion, and 
usually leads to severe atrioventricular regurgitation. The combination of these two 
abnormalities is responsible for the typically small ventricles with severely dilated atria 
found in this entity.
The sustained low cardiac output results in finger and toe clubbing, growth retardation, 
testicular atrophy, failure to develop male secondary sexual characters and cachexia 
(Jaiyesemi and Falase, 1976; Somers, 1993; Bolarin and Andy, 1982; Abrahams, 1962). 
In right ventricular EMF, the most common form of presentation either in isolation or as 
part of biventricular disease, the chronic systemic venous hypertension is responsible for 
the exophthalmos, elevated jugular pressure, gross hepatomegaly and congestive 
splenomegaly (Abrahams, 1962). Some distinctive clinical features of EMF cannot be 
explained solely by low cardiac output and retrograde congestion. For instance, there is 
still some controversy regarding the pathophysiology of the central cyanosis and the 
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voluminous ascites that can lead to ventral or inguinal hernia in the absence of pedal 
edema (Jayiesimi, 1982). 
1.1.6. Diagnosis
The clinical picture of EMF depends on the ventricle affected, the duration of disease and 
the presence of active disease. Although not clearly defined there are three clinical forms 
of the endomyocardial fibrosis that have been usually described namely acute, chronic 
and steady (Guimaraes, 1993). Acute EMF is suggested by fever, abdominal distension, 
facial or periorbital swelling, body itching, urticaria, and neurological features, associated 
with hypereosinophilia and myopericarditis (Andy, 1998). Clinical features of chronic 
EMF include finger and toe clubbing, growth retardation, testicular atrophy, failure of the 
development of male secondary sexual characters and cachexia (Andy, 1998; Abrahams, 
1962). Patients are said to be in a steady phase when there is neither amelioration nor 
deterioration of the clinical signs during several years (Bertrand, 1993).
By the time of clinical presentation patients with EMF are usually at an advanced stage 
(Somers, 1990). Few patients recall a febrile illness at the beginning of the disease, and 
most present a poor clinical history particularly in lone or predominant right EMF. 
Interestingly, patients are mildly symptomatic while having severe structural 
abnormalities detected on echocardiography (Ikeme, 1972; Salemi et al, 2005).
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Right Ventricular EMF
Patients with REMF often present with exophtalmus, jaundice, peripheral cyanosis, finger 
clubbing, atrial fibrillation and ascitis in the absence of pedal edema (Freers et al, 1996a) 
(Figure 1.5). The dilated and pulsatile right ventricular outflow tract causes a heave at 
the left upper parasternal area. Cardiac murmurs are often absent, but a third sound is 
usual. In advanced disease with free atrioventricular regurgitation cardiac auscultation 
can be normal (Somers, 1990).
Left Ventricular EMF
In LEMF the patients are usually in a better general status and have shorter duration of 
the disease. There is usually a systolic murmur that is typically soft, short and confined to 
early systole, associated with a delayed opening snap, a combination that is unique to left 
endomyocardial fibrosis (Somers, 1989). A loud second sound, indicating increased 
pulmonary pressures is also a common feature.
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Figure 1.5. Ascitis without pedal edema is a distinctive finding of REMF
Laboratory
The biological profile of EMF patients is unspecific and does not reveal evidence of 
infection or parasitism (Kartha, 1995). The presence of high eosinophil counts is variable 
(Somers, 1972b). High anti-streptolysin O and anti-malaria antibodies titres have been 
shown in some series, and in advanced cases mild hypoproteinemia is common (Somers, 
1972b; Shaper et al, 1967). 
The effusions, particularly the ascitic fluid, are typically exudates having more leukocytes 
(predominantly lymphocytes) and higher protein content than expected in right heart 
failure (Freers et al, 1996a).
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Electrocardiography
The electrocardiogram shows no constant pattern. Atrial fibrillation is present in many 
cases at first admission (Somers, 1972). In advanced disease there are low voltage QRS 
complexes, non-specific ST-T wave changes and conduction disturbances (Zabsonre et 
al, 2000). In advanced REMF the electrocardiogram shows a tall and broad right atrial 
wave, a characteristic “qr” pattern in the leads V3R or V1, and delayed right ventricular 
conduction can also occur (Jaiyesimi, 1982; Abrahams, 1962) (Figure 1.6). The ECG in 
left EMF shows signs of left trial hypertrophy and pulmonary hypertension.
Chest X-Ray
The chest x-ray in REMF (Figure 1.7) shows severe right atrial enlargement, a bulge 
over the left heart border due to dilatation of the infundibulum, and hypoperfused lungs. 
Figure 1.6. Electrocardiogram of a patient with right EMF with atrial flutter and the 
characteristic qr pattern in lead V1.
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Figure 1.7. Chest radiography shows cardiomegaly due to enlargement of the right 
atrium. Notice the bulge over the left heart border due to dilatation of the infundibulum, 
and hypoperfused lungs are usual findings in REMF (left). LEMF causes less impressive 
cardiomegaly, main pulmonary artery dilatation, pulmonary changes of hypertension in 
the lung fields and LA enlargement (right).
In LEMF there is prominent main pulmonary artery, exaggeration of the blood vessels in 
the lung fields and left atrial enlargement (Figure 1.7). 
Echocardiography
Echocardiography is the main tool for the diagnosis of EMF, by demonstrating dense 
endocardial echos along different parts of the ventricular wall, the atrioventricular valve 
and the subvalvar apparatus, associated with a restrictive filling pattern. This diagnostic 
technique has added precision to the non-invasive diagnostic of EMF, being essential for 
recognition of involvement of the contralateral ventricle in dominant univentricular 
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disease, and allowing comprehensive pre- and postoperative care (Venkitachalam et al, 
1993; Berensztein et al, 2000; Okerere et al, 1991; Freers, 1996b). 
REMF is diagnosed in the presence of thickening of the endocardium at the apex and 
obliteration of the trabecular portion of the right ventricle. In advanced cases there is a 
shrunken RV cavity with an apical notch, free tricuspid regurgitation, signs of 
spontaneous contrast, right atrial thrombi and pericardial effusion (Figure 1.8).
Echocardiography of LEMF shows patchy enhancement of the endocardial echo and 
thickening of the endocardium of the LV apex that can be obliterated. The posterior 
mitral leaflet is plastered-down causing eccentric mitral regurgitation. There is rapid early 
filling followed by restriction, and left atrial enlargement (Figure 1.8). Moderate to 
severe tricuspid regurgitation is usually present allowing the confirmation of the presence 
of pulmonary hypertension.
The main echocardiographic criteria used for the diagnosis of EMF are summarized in 
Table 1.1. 
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Figure 1.8. Transthoracic echocardiography showing obliteration of the left apex (arrow) 
in a patient with bilateral disease. Retraction of the right ventricle and aneurismal right 
atria in REMF cause compression of the left cavities (right). 
Computed Tomography
This technique is seldom used in clinical practice since it adds little to the 
echocardiography. Computed Tomography accurately depicts morphologic and dynamic 
features of EMF, by allowing direct visualisation and mapping of fibrosis in the 
endocardium and within the myocardial wall. The presence of a linear calcification distal 
to the pericardium (along the inner border of the myocardium) suggests EMF at 
conventional and spiral computed tomography (Mousseaux et al, 1996).
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Table 1.1. Usual findings on echocardiography of endomyocardial fibrosis (EMF) as 
reported in the literature (after Venkytachalam et al, 1993, Hassan et al, 2005; Freers, 
1996; Wiseman, 1986; Vijayaraghavan et al, 1983)
RIGHT VENTRICULAR EMF LEFT VENTRICULAR EMF
. Enhanced endocardial echos in the right 
ventricle usually in septal and apical portions
. Enhanced endocardial echos in the left ventricle 
usually in the apex and posterior wall
. Adherent tricuspid valve apparatus . Plastered posterior mitral leaflet
. Obliterated trabecular portion of the right 
ventricle
. Obliterated left ventricular apex or posterior 
papillary muscle recess
. Tricuspid regurgitation . Mitral regurgitation 
. Endocardial calcification on the right ventricle . Endocardial calcification on the left ventricle
. Pulmonary valve diastolic opening and dilated 
hypercontractile right ventricular outflow tract
. M-movement of interventricular septum and/or 
posterior wall
. Tall E wave on tricuspid Doppler flow . Tall E wave and small A wave (E/A => 2)
. Dilated right atrium . Dilated left atrium
. Large pericardial effusion . Pulmonary Hypertension
. Spontaneous contrast or intra-cavitary thrombi . Spontaneous contrast or intra-cavitary thrombi
. Apical notch or shrunken right ventricle . Left ventricle reduced longitudinal dimension 
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Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) has many advantages over other diagnostic 
techniques, mainly in patients with severe structural abnormalities leading to distorted 
anatomy. This technique confirms the existence of thrombus or calcifications, allows an 
exact deliniation of hypoperfused areas that correspond to fibrosis (Estornell et al, 2003), 
and provides information hemodynamic information thorugh the cine mode. Myocardial 
suppression scans, acquired 10’ after injection of gadolinium, also allow exact 
appreciation of disease extension by delayed hyperenhancement of the pathologic areas 
(Estornell et al, 2003; Smedema et al, 2004). 
MRI is therefore the ideal diagnostic tool for management, allowing monitoring of the 
response to medical and surgical treatment (Smedema et al, 2004). Unfortunately it is a 
technique that is expensive and therefore not available in most endemic areas for EMF 
(Cury et al, 2005).
Cardiac catheterisation
Before the advent of echocardiography cardiac catheterisation was the only diagnostic 
method available to confirm the clinical diagnosis of EMF (Tharakan et al, 1993; 
Abrahams, 1962; Hutt et al, 1965). However, this technique is not adequate for diagnosis
of localized or mild forms of disease, and can be technically challenging and dangerous 
in advanced disease. Cardiac catheterisation is associated with (1) bleeding from venous 
puncture sites due to high venous pressure; (2) difficulty in entering the right ventricle 
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and pulmonary artery due to markedly dilated right atrium, tricuspid regurgitation, small 
right ventricular cavity, and distorted and displaced right ventricular outflow tract; (3) 
high risk of pulmonary thromboembolism from right atrial thrombi; (4) considerable risk 
of acute hemodynamic deterioration, mainly in severe REMF with ascitis and low basal 
cardiac output, but also due to stimulation of atrial tachyarrhythmia. 
In REMF pressures in the right atrium, right ventricle, and pulmonary artery are equal 
both in form and amplitude. Angiograms show flattened apex, loss of trabeculated 
pattern, dilated and hypercontractile infundibulum (with contractility of the remaining 
parts of the ventricle varying from normal to severely impaired), free tricuspid reflux, 
large right atrium and dilated cava veins (Hassan et al, 2005). 
LEMF is characterised by very high left ventricular end-diastolic pressure with dip-
plateau pattern, and pulmonary hypertension variably damped by the presence of the RV 
disease. The angiogram shows left apical obliteration with varying degree of mitral 
regurgitation. The increased distance from coronary arteries to the contrast inside the 
ventricular cavity demonstrates the obliteration of the apices.
Endomyocardial Biopsy is not essential for the diagnosis and management of EMF, and 
can be misleading when tissue is obtained from unaffected sites. EMB is technically 
difficult in areas of dense endocardial fibrous thickening and, due to the imbalance 
between the information obtained and the risk of the procedure, is rarely used. 
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1.1.7. Differential Diagnosis
In endemic areas for EMF it is important to differentiate this condition from Rheumatic 
Heart Disease, Dilated Cardiomyopathy, apical type of Hypertrophic Cardiomyopathy, 
Constrictive Pericarditis and Tuberculous Pericarditis. Amyloidosis, heamochromatosis, 
myocardial sarcoidosis and neoplastic infiltration from lymphomas are other entities that 
must be considered in the differential diagnosis. 
1.1.8. Pathological Spectrum
The basic lesion in EMF is ventricular endocardial fibrosis without primary involvement 
of extracardiac organs. The macroscopic appearance and the sites of involvement in the 
ventricle are distinctive and differentiate this condition from any other form of cardiac 
disease. The end result is restriction of ventricular filling and distortion of the papillary 
muscles, chordae and leaflets, resulting in restrictive cardiomyopathy with dysfunction of 
the atrioventricular valves. 
The classical descriptions of the pathology of EMF have been based on autopsies done on 
two sets of patients: those with advanced disease dying from complications of long-
standing heart failure or those with acute EMF who died as a result of febrile episodes 
with rapidly progressive heart failure (Connor et al, 1967; Connor et al, 1968; Shaper et 
al, 1968). Few studies, mainly case reports, have documented the histological findings in 
vivo using endomyocardial biopsies in patients submitted to cardiac catheterization 
(Chopra et al, 1990) or surgery (Santos et al, 2001; Saraiva et al, 1999). However, 
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because facilities for cardiac catheterization and open-heart surgery are not available in 
most endemic areas knowledge about the macroscopic and microscopic features of 
intermediate stages of EMF is scarce. 
Macroscopical appearance
At opening of the pericardial sac adhesions between the parietal and visceral layers are 
frequent. A “right border notch” is frequently visible in hearts with right ventricular 
disease causing retraction.  There is usually cardiomegaly due to dilatation of the atria but 
the heart is not very heavy. 
Thrombosis and fibrosis are characteristically prominent in the ventricular apices, and the 
posterior wall of the left ventricle behind the posterior leaflet of the mitral valve. In the 
right ventricle the scar tissue may be massive, engulfing and fusing the trabeculae 
carneae, obliterating the apex of the right ventricle, fixing and obliterating the papillary 
muscles, chordae tendineae, and leaflets of the tricuspid valve. The tricuspid annulus is 
usually severely dilated. In the left ventricle the lesions affect mainly the posterior wall of 
the left ventricle; the thrombus and scar tissue may engulf and obliterate the posterior 
leaflet of the mitral valve, its attached chordae and the posterior papillary muscle (Figure 
1.9). The left ventricular apex is frequently scarred and thrombosed, but the left ventricle 
is never contracted at the apex. The semilunar valves and the great vessels are not 
involved. 
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Microscopy
All three layers of the heart appear to be involved (Farrer-Brown, 1972; Andrade and 
Teixeira, 1973) but the hallmark of EMF is endocardial thickening due to acellular fibro-
collagen tissue deposition underneath the endothelial layer of the endocardium (Connor et 
al, 1968; Chopra et al, 1990; Seth 2004). A marked degree of myocardial loss is not 
found, although myocytolytic lesions are present in the subendocardium. Intense 
inflammatory infiltrates, including eosinophils, are conspicuously absent. Small vessel 
disease is unusual. 
A study of 42 autopsies and 89 biopsies from patients submitted to surgery (Kartha et al, 
1993) failed to detect a dominant lesion such as necrosis, inflammation, thrombosis or 
small vessel lesions to explain the pathogenesis of the disease. It revealed increase in 
interstitial cellularity, even in ventricles that macroscopically had no lesions, a finding 
that has also been reported from other studies (Connor et al, 1968; Somers, 1971). These 
findings did not confirm the theories about eosinophil mediated myocardial injury 
inducing necrosis and setting the stage for endocardial thrombosis that would heel and 
lead to fibrosis. Also, no support was found for the theory of endocardial fibrosis being 
secondary to subendocardial myofibre atrophy due to coronary arterial changes of an 
unknown etiology, a theory previously proposed (Connor et al, 1968). Several other 
studies have contributed little to support either of the two above views or the contention 
that EMF is a sequel to a pancarditis of undetermined etiology.
To date there is consensus that EMF is a disease where the cardinal feature is abnormal 
stimulation of cardiac fibroblasts leading to enhanced collagen synthesis. It may be a 
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reactive stromal change, and progressive interstitial fibrosis a result of cardiac fibroblast 
growth, with or without proliferation and enhanced collagen synthesis. It would seem that 
EMF is the outcome in circumstances where an unidentified form of cardiac injury results 
in a response mediated mainly or entirely by the interstitial tissue and cardiac fibroblasts, 
ather than the myocardial cell or the microvasculature. Entry of trophic factors into the 
interstitium could be mediated by injury to microcirculation and alteration of 
permeability. Myocytolisis seen in EMF is a minor component and could be caused by 
entrapment by fibrosis and toxicity by the same factors, which produce the interstitial 
injury. 
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Figure 1.9. Photograph of the heart of a patient with bilateral EMF. There is gross 
dilatation of the right atrium that contained a thrombus. The interatrial septum has 
irregularities that result from thickening of the septum in some areas as well to recoil of 
the aneurismal septum that bulged to the left ante-mortem. The right ventricular
endocardium is white, opaque and thick in the admission chamber and the trabecular part, 
where it forms the floor of a retracted ventricle with obliteration of the trabeculae. The 
tricuspid valve annulus is severely dilated, and its leaflets are thin although some chordae 
were thickened and stretched. The papillary muscles were completely encased in the 
fibrous endocardium. The left ventricle has a small area of apical fibrosis.  
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1.1.9. Management
There is no specific therapy for EMF. Symptomatic medical therapy with corticosteroids, 
diuretics, ACE-inhibitors, digitalis, β-blockers and warfarin is used in the management of 
these patients aiming to control acute disease, heart failure and arrhythmias, as well as to 
prevent thromboembolism. 
The overall results of medical therapy are poor. Patients presenting with advanced disease 
need frequent admissions to hospital to treat episodes of heart failure, despite the large 
doses of drugs administered. Admissions to hospital are also needed to perform invasive 
procedures for alleviation of effusions (paracentesis, thoracocentesis, pericardiocentesis) 
and treatment of arrhythmias (electrical cardioversion).
The use of short courses of oral corticosteroids in patients with hypereosinophilia and 
other signs of activity is not based on systematic studies of the effects of these drugs on 
the progression of the disease. 
Surgery of EMF
The unsatisfactory response of patients with symptomatic EMF to medical treatment has 
prompted the search for surgical correction of the structural and functional abnormalities 
characteristic of this condition. 
The initial procedures were intended to be palliatives. Pericardiectomies and valve 
pericardio-peritoneal shunts have been tried for massive and recurrent pericardial 
effusions (Adebonojo, 1977), and later, connections between the right atrium and the 
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pulmonary arteries were also used for palliation. 
The first attempts to corrective surgery consisted of total stripping of the endocardial 
fibrous membrane from the myocardium, excision of the damaged papillary muscles, and 
replacement of the damaged atrioventricular valves. The main complications of these 
extensive procedures were low cardiac output syndrome and complete atrioventricular 
block.  In the medium and long term complications of valve prostheses were very 
important with both, documented valve thrombosis and uncontrolled bleeding being 
frequent, due to poor compliance and inadequate control of anticoagulation. The 
immediate surgical mortality was around 18 % (Dubost et al, 1989; Moraes et al, 1999), 
remaining high thereafter: 21,7% within 30 days and 13% during the first postoperative 
year (Valiathan et al, 1987). This scenario was improved with the introduction of changes 
to the operative technique including avoidance of atrioventricular block by subtotal 
endocardial resection on the RV (Metras et al, 1982), the use of mitral valve repair to 
treat mitral incompetence (Metras et al, 1983) and improvements in myocardial 
protection (Moraes et al, 1993). 
The rational for surgical treatment of EMF is based on several important facts: (1) The 
disease is fatal if untreated; (2) Severe hemodynamic derangement caused by restriction 
of the diastolic filling and atrioventricular regurgitation can be corrected; (3) In most 
cases the myocardium remains healthy and unaffected and endocardectomy is feasible 
through a well preserved cleavage plan; (4) Evidence of recurrence is controversial and 
low rates have been reported, even for those patients that go back to their areas of origin 
(4,5-5.8%). All these factors contribute to the acceptance of the superiority of surgical 
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treatment of EMF in patients in NYHA class III and IV (Valiathan et al, 1993; Barretto et 
al, 1993). 
Although it is accepted that surgery must be indicated in all symptomatic patients with 
significant severe hemodynamic lesions (Dubost et al, 1989) the high morbidity and 
mortality associated with it, led to a general preference for medical treatment for patients 
in NYHA class I/II. Also, due to the infrequent diagnosis of EMF in western countries 
and the lack of human and material resources for open-heart surgery in most areas where 
EMF is endemic, the surgical experience is growing slowly. However, surgery has been 
shown to increase survival and quality of life (Cherian et al, 1982b), when compared to 
medical therapy, and the low incidence of recurrence after surgery suggests that it should 
be performed before irreversible cardiac and hepatic damage occur (Gonzalez-Lavin et 
al, 1982).
There is need for further systematic studies of different phases of the disease and its 
progression, coupled with accurate definition of structure-to-function relationship using 
modern imaging techniques. This could lead to the development of targeted approaches 
to surgical treatment followed by adequate follow up using integrated approaches that 
could lead to evidence-based guidelines for the management of the disease.
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1.2. Research Aims
Almost seven decades after it was first described, there are many gaps in our knowledge 
of EMF and it can be considered a neglected disease. Data on epidemiology are scarse, 
the etiology remains unknow and the pathogenesis is incompletely understood, resulting 
in the inexistence of standardised methods for prevention, systematic programmes for 
early detection or consensus about management, including the timing of surgery. To date 
no genetic studies have been done in order to investigate the role of heriditry in 
determining susceptibility and phenotypic variability of this entity.
In this context of prevalent disease with no adequate treatment operational research 
combining both basic and clinical aspects of the disease is mandatory. 
Large-scale community studies can now be done using portable echocardiography to 
detect early stages of the disease, which are probably associated with specific immune 
system activation. The description of these changes in early stages would allow better 
understanding of the mechanisms involved in the pathogenesis of EMF, and description 
of its natural history.  
The great variability in the mode of presentation and rate of progression of EMF is not 
accurately demonstrated by using the current simplistic classifications of the disease. We 
believe that a comprehensive classification can be achieved by using detailed clinical, 
laboratory and echocardiographic criteria, resulting in improvement of the management 
of the disease and the surgical outcome. Also knowledge of the pathogenesis can help 
identify new therapeutic targets for the disease preventing its progression to advanced 
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and deforming stages, and therefore improving the prognosis.
We therefore designed this research aiming at
(1) Determine the prevalence of EMF in a known endemic area (Inharrime) 
(2) Detect early cardiac changes using echocardiography 
(3) Evolve a comprehensive classification of EMF using clinical, biological and 
echocardiographic criteria
(4) Establish a national registry to determine the prognosis of the disease, search for 
prognostic indicators, and help in design and implementation of therapeutic trials 
in the future
(5) Describe the immune response in blood and cardiac tissue through measurement 
of pro-inflammatory cytokines, pro-thrombotic factors, antiheart antibodies and 
malaria mimicry
(6) Investigate the role of genetic susceptibility for EMF through HLA-typing
(7) Establish the role and timing of surgery in management, and evolve tailored 
approaches to specific types of structural and functional defects with optimal 
follow up through the database
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1.3. Layout
The work presented in this thesis has been divided in twelve chapters, starting with the 
current introductory chapter.
Chapter 2 details the design of research and the procedures used to implement the three 
branches of the research programme, in three different sites: Maputo (at the Heart 
Institute of Mozambique), Inharrime (at the Research Centre) and London (at the 
Imperial College and other laboratories). 
Chapter 3 presents a new classification of EMF evolved by the researcher and tested in 
two different situations: in large-scale echocardiographic screening in a rural area of 
Mozambique, and as a diagnostic and management tool in the clinical setting. The issues 
related to relevance and accuracy of the criteria are discussed.
In Chapter 4 we present the work related to determination of prevalence of EMF in 
Inharrime district using echocardiographic screening of the population. In the first part, a 
description of the sampling method, issues related to preparation and implementation of a 
prevalence study in general population, and the results found are presented. In the second 
part of this chapter, the procedures for the creation of a cohort of children from Inharrime 
to be used in follow-up studies are present. 
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Chapter 5 describes the clinical profile of EMF patients who present to hospitals. The 
major signs of established disease are described and discussed.
The pathological features of established EMF are presented in Chapter 6, which involves 
macroscopic evaluation of the cardiac lesions, as well as detailed description of histology 
and immunochemistry on tissue obtained during surgery and at autopsy. 
Echocardiographic findings are compared with intraoperative features and, finally, a 
clinicopathological correlation is attempted.  
Chapter 7 describes the pattern of immune activation in chronic established EMF,
including cellular and humoral changes in blood and cardiac tissue. Particular emphasis is 
given to changes in eosinophils and its related cytokines, namely IL-5 and Eotaxins. First, 
the results of eosinophil studies in the rural community and at the hospital are presented. 
Then, tissue studies are described and the adaptation of the technique of detection of 
eotaxins in the lung is described and apllied to cardiac tissue of patients with EMF. The 
cytokine profile of these patients is explored and, finally, the presence and level of 
antiheart antibodies is determined. The results of these studies are discussed together.
Chapter 8 presents and discusses the results of investigation on the presence of 
prothrombotic factors, endothelial activation and inflammation markers in recent onset 
EMF. The implications of the results to management of the disease are highlighted.
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Chapter 9 describes the results of a multifaceted investigation on the role of malaria in 
pathogenesis of EMF, involving studies of prevalence of the infection in individuals from 
the rural area studied and patients from the clinical registry, the determination of the rate 
of concurrence of EMF and Malaria, and also the presence of cardiac damage in severe 
and complicated malaria. An interpretation of the results is described and new strategies 
for research in this topic are proposed.
Genetic susceptibility to EMF is explored through determination of HLA-typing in EMF 
patients and ethnically matched controls, whose results are presented and discussed in 
Chapter 10. 
Chapter 11 presents the different therapeutic options available for the management of 
EMF. A new surgical approach has been evolved and applied and its results are 
described, detailing the procedures used pre- and intra-operatively. The major issues on 
the post-operative period and those raised in the mid-term follow up are also presented 
and discussed. 
The last chapter summarizes the conclusions of our work and proposes new research lines 
into the mechanisms of this cardiomyopathy.
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Chapter 2
METHODS
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2.1. Design of the Investigation
Our research project included three main branches, namely community-based studies, 
hospital-based research and laboratory work (Diagram 2.1).
The investigator was based in Maputo-Mozambique, where the clinical research took 
place. This included the establishment and management of the National EMF registry at 
the Heart Institute in Maputo, the site of referral for patients from all regions of the 
country. 
Frequent trips to the rural area endemic for EMF (Inharrime-Inhambane Province) were 
necessary to prepare and implement the epidemiological research. During these visits the 
researcher worked in close collaboration with the local authorities to organize the 
fieldwork, establish facilities for clinical follow up at the village, and train the local 
personal involved in the epidemiological surveys.  
Significant amount of time was spent in the United Kingdom where the researcher did 
several transferable skill courses, including some training on the laboratorial techniques 
and methods used in the various studies, and worked with collaborators in performing the 
tests.  
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(1) Community Work (Inharrime District – Inhambane Province, Mozambique)
Training of local people
Design and Installation of Research Facilities
Epidemiology studies
Prevalence study (January 2005 -May 2005)
Establishing cohort of school children (October 2006)
Follow-up of participants in epidemiology and clinical studies
(2) Clinical Research (Instituto do Corao – Maputo, Mozambique)
Establishment of a National EMF Registry
Clinical follow-up of patients
Organization and participation in surgical missions
Pre- and post-operative management
Blood and tissue collection and storage
(3) Laboratory Studies (United Kingdom)
Participation in laboratory work
Diagram 2.1. Work undertaken by the investigator in the three main sites of research 
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2.1.1. Epidemiology research 
Inharrime District - Mozambique
Mozambique is a country located on the east coast of Southern Africa (Figures 2.1, 2.2, 
2.3). It has a total surface of 799 380 km2 and a coast of over 2500kms. The population 
reaches 20 million and is predominantly rural (71,4%). Given that previous studies in 
Mozambique revealed that Inharrime district, in the south of Inhambane province was an 
endemic area for EMF, we chose this rural district as the area for our community studies.
Study Area
Inharrime is a coastal district in Mozambique with a total surface area of 2744Km2, 
situated 400Kms from the main referral units for cardiovascular diseases, which are 
located in Maputo (Figure 2.4). It has a total population of 76518 inhabitants. Some areas 
of the district are located more than 100kms from the village (Inharrime Sede).
The district is divided into five main zones called Localidade that are in turn subdivided 
into smaller administrative areas under the administration of traditional leaders, the 
Povoados. There are 59 “Povoados” in Inharrime. The community of this rural area is 
primarily composed of very low-income people working in agriculture, and living in 
small houses made of local materials (Figures 2.5, 2.6). Electricity and pipe-borne water 
supply are available for less than 1% of the households. There are no conventional roads 
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Figure 2.1. A map of Africa where Mozambique is shown in blue.
Figure 2.2. Mozambique has 20 366 795 inhabitants distributed by 10 provinces; 
43.1% of the population is under 15 years and the life expectancy is 47.6 years. 
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Figure 2.3. Inhambane province, although being the least accessible of the 3 
southern provinces of Mozambique, was the origin of most EMF patients assisted 
at the national referral units.
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Figure 2.4. Inharrime is one of the 14 districts of Inhambane province, and is the 
district from where most patients are referred. 
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Figure 2.5. Typical houses and schools in Inharrime are built using local materials.
Figure 2.6.  Mandioc, the basis of diet in Inharrime, is produced and sold by the families. 
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(Figure 2.7) apart from the main national road linking the north and the south of the 
country, a conventional road that crosses the district. 
Our community research consisted in determining the prevalence of EMF in the 
population and establishing a cohort of school children to be followed for future studies 
on incidence and rate of progression of Endomyocardial Fibrosis. Given that there were 
no facilities to allow accommodation of the research team for fieldwork, clinical 
assessment and follow-up of participants in the studies, and storage of blood samples 
collected in the community, the initial phase of the research was the design and 
construction of the Inharrime Research Centre in the village of Inharrime. 
Research Facilities
The research facilities are located next to the Public Health Centre in Inharrime District 
(Figure 2.8). They accommodate five divisions: (1) a room for clinical observation of the 
participants with portable electrocardiography and echocardiography machines; (2) small 
laboratory for blood preparation and conservation at -80ºC; (3) bedroom for researchers; 
(4) a room for keeping the files; (5) and a kitchen. 
From these facilities we were able to organize our daily visits to the several areas and 
schools involved in the studies, recharge the electrical equipment used during the day, 
and preserve the blood collected. The facilities were also used for follow-up of the 
participants in community studies, clinical evaluation of EMF patients (Figure 2.9), and 
training of collaborators from the Health and Education Departments that were involved 
in the research. 
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Figure 2.7. Inharrime district has no conventional roads.                 
Figure 2.8. The research facilities, seen in this picture, were also used for accomodation 
of the research team during community work.
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Preparation of Fieldwork
The preparation of the fieldwork involved the local authorities in Inharrime, namely the 
community leaders for the prevalence study and the teachers for the work at schools. The 
local authorities agreed to participate in the teams to guide the researcher and introduce 
her to the population and parents. They were trained by the researcher regarding the 
procedures of the studies, namely the information to the participants and the informed 
consent, and were involved in the process of randomisation (Figure 2.10). 
The community leaders and teachers of the randomly selected areas and schools were 
introduced to the project, trained on the procedures of the fieldwork and helped with the 
translation of the informed consent to the local languages. Teachers in charge of the 
selected classrooms were trained to identify symptoms and signs of cardiac disease, 
register them using a standardized protocol, and refer the children for evaluation by the 
researcher during the periods in between the visits to the schools (Figure 2.11). 
The schedule of fieldwork was agreed with these authorities that had the responsibility of 
informing their communities of the dates for the studies. Periodic follow-up meetings 
were scheduled to allow the feedback to the leaders and the community.
Prevalence Study
For the prevalence study we used clustering at two levels selecting 33 “povoados” out of 
the 59 in Inharrime district, and then including all members of families randomly selected 
in the area, in order to achieve clusters of at least 30 people. The families were visited in 
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their houses, where epidemiological data were collected and transthoracic 
echocardiography performed. 
Figure 2.9. Accommodation of the team and storage of material in the research facilities
Figure 2.10. Community leaders assisting in randomization of povoados and houses
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Cohort of School Children
A cohort of school children randomly selected from Inharrime district was established for 
future studies on pathogenesis and rate of progression of EMF. The selection of these 
children was done using clustering at two levels. First, 10 schools were randomly selected 
from a total of 54 in the district. Then, all children from second grade in these schools 
were invited to participate in the study, and were submitted to clinical evaluation and 
transthoracic echocardiography. 
These children will be followed thorugh clinical examination, echocardiography and 
blood sampling every 12 months, in order to evaluate the incidence of EMF and natural 
history of the disease.
This approach was chosen due to the logistical and financial aspects related to such long 
follow-up of children in this remote area. Financial constraints make it more feasible to 
follow-up children at their schools with the help of their teachers. It is expected that 
children at the second year of school will be available for follow up for the next two 
years, since “schooling” is compulsory until the 5th degree and the highest rates of 
withdrawal are reported in the first year.
Diagnosis and classification of EMF
Transthoracic echocardiography using a portable Vivid-i (GE) machine was performed to 
all members of the selected families and school classes (Figure 2.12). The examinations 
were recorded for re-evaluation by two blinded experienced cardiologists. The diagnosis 
of EMF was accepted when there was agreement of at least two cardiologists. 
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Figure 2.11. The teachers from the selected schools (left) were trained and participated in 
planning and implementaton of the research in each school (right).
Figure 2.12. Echocardiography performed by the researcher inside a selected house 
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Based on knowledge of advanced disease and pathology findings of early stages 
described in post-mortem studies we defined major and minor criteria for the diagnosis of 
EMF that were used to make the diagnosis and to classify the disease. A score was 
attributed to each criterion. Diagnosis was made in the presence of two major criteria, or 
one major criterion associated with two minor criteria. According to the location of 
structural lesions EMF was classified as: (1) Biventricular when lesions were equally 
distributed in both ventricles without predominance of one side; (2) Right ventricular 
when lesions affected in isolation or were predominant in the right ventricle; (3) Left 
ventricular when lesions were confined to or affected predominantly the left ventricle. A 
scoring system that considered the extension and severity of the structural and functional 
changes of the heart was also developed allowing classification of EMF in mild, 
moderate, severe and advanced.
Further management of cases detected in the community
Participants with EMF detected during community studies were included in the registry 
and evaluated further at the Inharrime Research Centre (described above) to be treated 
according to the stage of disease. The follow up of these patients was done through 
monthly visits to the site by the researcher (Figure 2.13). Participants with severe or 
advanced disease needing surgery were offered surgical treatment at the Heart Institute in 
Maputo at the expenses of the project.  
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2.1.2. Clinical research
Heart Institute, Maputo - Mozambique
The Maputo Heart Institute is the main referral unit for cardiovascular diseases in 
Mozambique, and the only hospital with capacity of performing invasive cardiology and 
open-heart surgery in the country. The hospital-based research included the establishment 
of a national registry of Endomyocardial Fibrosis and clinical follow-up of patients 
referred from all regions of the country, including participants in community studies. 
National EMF Registry
The registry was started at the beginning of the research project in order tpo insure the 
systematization of information regarding epidemiology data, clinical characterization and 
management of the patients. Standardized procedures for medical attention prior and after 
surgery were elaborated (Diagram 2.2).
The diagnosis of Endomyocardial Fibrosis was established or confirmed by using 
transthoracic echocardiography. Classification of the disease was done using the criteria 
that will be detailed in next chapter. The researcher assessed all patients clinically, and 
was responsible for the medical management and follow up, including performing 
invasive procedures like pericardial drainage, paracenthesis, and cardiac catheterization. 
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Admission to ICOR 
(referred by health unit, referred by the community or self-referral)
↓
Registration (after informed consent)
↓
Clinical history and examination 
Chest Xray, ECG, Echocardiography
24h-ambulatory monitoring of the rhythm
↓
Blood collection
Full Blood count, Eosinophils (manual count and characterization), Blood Group
ESR, CRP, Urea, Creatinine, Proteins, Albumin, Glicemia
Malaria test, Tuberculosis test, HIV, Schistosomiasis (urine and stools)
Storage of plasma and blood cells at -80˚C for studies on pathogenesis (UK)
↓
Managemen options: 
Medical treatment, Invasive procedures, Surgery
If surgery is indicated: Use of new surgical approach
↓
Follow-up: medical appointment at least every three months 
Diagram 2.2. Flowchart for clinical investigation in EMF patients 
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Surgical Programme
The researcher was also responsible for the selection of patients to surgery, as well as for 
the pre-operative preparation and post-operative care. Health professionals from different 
surgical groups that operate in Mozambique, who agreed to participate in this project, 
composed the surgical team (Figure 2.14). They worked under the leadership of the main 
supervisor of this research project, Professor Magdi Yacoub. The researcher was present 
in the operating room to describe the intraoperative findings, and receive and prepare the 
cardiac tissue for pathology studies.
2.1.3. Laboratory Research
Mozambique and United Kingdom
Laboratory work related with clinical diagnosis was done in Mozambique, namely 
routine blood studies, inflammation markers (erythrosedimentation rate, C-reactive 
protein), urinalysis, stool examination and histology of cardiac tissue. 
Due to lack of human and material resources at the local laboratory, blood and tissue 
samples were periodically transferred to the UK using specialized mailing services. In the 
UK the researcher was involved in several steps of the laboratory work designed to 
understand the pathogenic mechanisms involved in EMF, which was done essentially by 
collaborators from Imperial College, the Kings College London, and the National Blood 
Service. These studies included the assessment of (1) the immune activation (eosinophil 
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studies, cytokine profile, autoimmunity), (2) the presence of endothelial activation and 
hemostatic dysfunction and (3) genetic susceptibility (HLA-typing).
Figure 2.13. Follow-up of participants in community studies at the research facilities 
Figure 2.14. Surgical procedure performed at the Heart Institute in Mozambique
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2.2. Statistical Analysis
The statistical methods used are discussed in the individual chapters.
2.3. Ethical issues
Every participant was informed of all procedures of the research project. Eligible 
participants were invited to participate in the studies and to sign a written informed 
consent (or finger-print whenever the participant or parent was not capable of giving a 
signature). The informed consent was typed in Portuguese (the official language of 
Mozambique) but its information was translated to the local language before obtaining 
the consent. 
No charges were made to participants for clinical visits or laboratory exams done during 
the study. The best available management was warranted to every participant, using the 
local health care facilities in the National Health System and the Heart Institute, and 
following the rules for referral of patients at the various levels of health care defined by 
the Ministry of Health of Mozambique.
In order to achieve sustainability and obtain acceptance of this long research programme 
both official and traditional authorities were involved in all phases of preparation and 
implementation of the research programme. The authorities beonging to the selected 
zones were invited to participate or send their representatives to the fieldwork. 
Ethical approval was obtained from the National Bioethical Committee in Mozambique. 
The research project has an international registration number (IRB 00002657).
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Chapter 3
EVOLVING AND APPLYING NEW CRITERIA FOR DIAGNOSIS 
AND CLASSIFICATION OF ENDOMYOCARDIAL FIBROSIS
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3.1. Introduction
Great variability in mode of presentation and echocardiographic features is found in EMF 
patients that seek medical attention. However, no attempt has been made to 
systematically define the disease and classify the patients. 
Echocardiography has the potential for detection of earlier stages of EMF (Wiseman et al
1986; Vijayaraghavan et al, 1983) and for detailed characterization of the structural and 
functional changes that occur in this condition. Portable echocardiography is a potentially 
useful tool for large-scale community studies, to identify initial stages of the disease and 
to describe its natural history through imaging and hemodynamic changes.
We hypothesized that detailed characterization of echocardiographic abnormalities would 
allow early diagnosis and comprehensive classification of EMF. After extensive review 
of literature we systematized the available criteria for diagnoses of established disease 
and identified echocardiographic signs that could represent early stages of this condition. 
The aim was to evolve echocardiographic criteria for early diagnosis that could be used 
for screening purposes, and propose a new classification of EMF to be used on follow-up 
of individuals participating in large-scale community studies and for clinical management 
of patients.
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3.2. Population and Methods
3.2.1. Population
The criteria selected were applied to study individuals from the endemic community 
(Inharrime District) randomly selected from villages and schools, as well as patients from 
the national EMF registry seen at the referral unit in Maputo. 
3.2.2. Evolving Echocardiographic Diagnosis and Classification
The diagnosis of endomyocardial fibrosis was based on transthoracic echocardiography 
using a portable ultrasound machine (Vivid I, General Electrics) for community studies 
and a HP 5500 (Philips) for the clinical research. Both machines have the possibility to 
do 2D, M-mode and Doppler (continuous, pulsed and colour) evaluation. The 
echocardiographic exams were recorded and kept as part of the database and can be 
recalled. The collection of echocardiographic data was standardized (Appendix 1).
3.2.2.1. Diagnosis
The hallmark of established EMF is the presence of thickened endocardium, but we 
wanted to detect initial phases of the disease using echocardiographic screening. 
Applying knowledge obtained from pathological examination of hearts from EMF 
patients who died or were submitted to catheterization (Connor et al, 1967; Kartha et al, 
1993; Kinare and Deshpande, 1993), from surgical series (Moraes et al, 1993; Metras, 
1993; Valiathan and Shyamkrishnan, 1993; Moraes et al, 1999) and echocardiographic 
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studies (Hassan et al, 2005; Freers et al, 1996b; Wiseman et al, 1986; Vijayaraghavan et 
al, 1983; Venkitachalam et al, 1993) we defined criteria for diagnosis and classification 
of EMF. 
The features used for diagnosis were classed as major and minor criteria, according to 
their specificity for the diagnosis, and their importance for management and prognosis. 
The diagnosis of EMF was made in the presence of two major criteria or one major 
criterion associated with one or more minor criteria (Table 3.1). For echocardiographic 
diagnosis of EMF endocardial plaque or thickening had to be present.
3.2.2.2. Echocardiographic measurements
In community studies one echocardiographic examination was considered for the 
diagnosis of EMF for each individual. All measurements were recorded for offline re-
evaluation by the investigator, blinded to the epidemiological and clinical data. In cases 
where doubts persisted after full examination two other cardiologists blinded for 
demographic data and to the results of the main investigator, were asked to review the 
recorded exams using the same criteria and the scoring system to classify the disease. 
Regarding the patients from the clinical registry we had scheduled one echocardiographic
examination every three months, but some patients had more exams done due to sudden 
aggravation of their clinical condition and the need to adapt the medical therapy. 
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Table 3.1. New criteria for Diagnosis and Assessment of Severity of EMF
MAJOR CRITERIA SCORE
Endomyocardial plaques (2 or more mm in thickness) 2
Thin endomyocardial “patches” affecting more than one ventricular wall 3
Obliteration of the right ventricular or left ventricular apices 4
Thrombi/Spontaneous contrast without severe ventricular dysfunction 4
Retraction of the right ventricular apex (right ventricular apical notch) 4
Atrioventricular valve dysfunction due to adherent valvar apparatus to the ventricular wall. 1-4*
MINOR CRITERIA SCORE
Thin endomyocardial “patches” localised to one ventricular  wall 1
Restrictive flow pattern across mitral or tricuspid valves 2
Pulmonary valve diastolic opening 2
Diffuse thickening of the anterior mitral leaflet 1
Enlarged atrium with normal sized ventricle 2
M-movement of the interventricular septum and/or posterior wall observed by m-mode echo 1
Enhanced density of the moderator or other intraventricular bands. 1
Definite case: presence of 2 major or 1 major associated with 2 minor criteria. 
The severity score applies as follows
Mild EMF score < 8; 
Moderate EMF score 8-15; 
Severe EMF score 16-23; 
Advanced EMF score >24.
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Evaluation of the Left Atrium
The left atrium maximal linear dimensions were measured in three plans: anteroposterior, 
lateral and superoinferior at the end of left ventricular systole. The left atrial 
anteroposterior diameter was measured by bidimensional-guided M-mode 
echocardiography from the parasternal short-axis view at the base of the heart (or the 
parasternal long-axis), from the trailing edge of the posterior aortic wall to the leading 
edge of the posterior left atrial wall (Lang et al, 2005). The lateral and superoinferior 
dimensions were measured by bidimensional echocardiography from the apical 4 
chambers view using an inner-edge-to-inner-edge measurement. The left atrial area was 
measured by planimetry of the inner contour from the apical 4 chambers view, excluding 
the confluences of the pulmonary veins and the left atrial appendage from the tracing. 
Table 3.2 indicates the criteria used for definition of left atrial enlargement. Additionally 
an sphericity index for the left atrium was calculated as the ratio between lateral and 
superoinferior diameters.
Due to the frequent distortion of the left cavities shape in patients with REMF or BEMF 
the volumes were not consistently measured. However, whenever possible for clinical 
follow up of patients submitted to surgery, the left atrial volume was determined using 
the Simpson’s rule from the apical 4-chamber view at the end-systole, from the frame 
preceding mitral opening. The plane of mitral annulus was taken as the inferior left atrial 
border. 
For participants from the clinical registry left atrial volume and area were indexed to 
body surface area, while in community studies the area was indexed to age.
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Evaluation of the Left Ventricle
Left ventricle end-systolic diameters, left ventricle end-diastolic diameters, septal and 
posterior wall thickness at end-diastole were measured in the parasternal long axis view, 
using bidimensional-guided M-mode echocardiography according to current 
recommendations for chamber quantification (Lang et al, 2005). An sphericity index was 
calculated as the ratio between lateral and superoinferior diameters in 4-chambers view. 
The criteria used for classification of left ventricular reduction are presented in Table 3.3. 
For follow up of patients submitted to surgery and without severe distortion of the left 
ventricular shape, the left ventricular end-systolic and end-diastolic volumes and ejection 
fraction were determined from the apical 4-chamber view according to the modified 
Simpson’s rule. 
In patients with heart cavity distortion the left ventricular systolic function was evaluated 
through a visual semi-quantitative scale (good contractility,+++; moderate 
dysfunction,++ ; and poor contractility,+) using bidimensional guided M-mode in 
several incidences (4-chambers, parasternal long axis, parasternal short axis and sub-
costal views). 
The left ventricular inflow velocities were recorded using the apical four-chamber view. 
The pulsed-wave Doppler sample volume was placed at the level of the leaflets tips of the 
mitral valve, where the highest peak velocity was recorded. Peak flow velocities of the 
left ventricular inflow in early diastole (E) and late diastole with atrial contraction (A) 
were measured. E/A velocity ratios were calculated for each cardiac cycle. The duration 
of the Isovolumetric Relaxation Time (IVRT) and Deceleration Time (DT) was also 
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LA DILATATION Features
Mild LA area increased but less than the LV area
Moderate LA area up to 1.5 times the LV area with sphericity index 0.75-1
Severe LA area > 1.5 the LV area with sphericity index > 1
There is compression of right cavities
Table 3.2. Classification of left atrial (LA) enlargement
LV REDUCTION Criteria
Mild Obliteration or occupation by thrombus of less than 10% the LV 
cavity area measured in two planes
Moderate Obliteration/occupation by thrombus of 10-25% the LV cavity 
area measured in two planes and/or reduction of the longitudinal 
diameter with sphericity index 0.50-0.75
Severe Obliteration/occupation by thrombus of >25% the LV cavity area 
measured in two planes and/or reduction of the longitudinal 
diameter with sphericity index > 0.75 
Table 3.3. Classification of left ventricular (LV) reduction
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measured. Restriction to the left ventricular filling was defined by the presence of any of 
the following: (1) E/A ration > 2; (2) IVRT < 160ms; or (3) DT < 120ms (Mandinov, 
2000). 
The aortic root dimension on diastole, left atrial dimension, left atrial end-systolic and 
end-diastolic dimension, left ventricular posterior wall thickness and septal thickness 
were measured by M-mode according to the American Society of Echocardiography 
recommendations (Lang et al, 2005). 
Left ventricular dimensions were indexed to body surface area for participants from the 
clinical registry, and for age in participants in community studies and compared to 
normal values. 
Evaluation of the Mitral Valve
The evaluation of the mitral valve was done using bidimensional in several planes, using 
the M-mode along the leaflets to confirm their thickening and measuring the length of the 
leaflets. The dimensions of the mitral annulus were measured from both 4-chambers and 
long axis views. Colour Doppler evaluation was used for semi-quantitative estimation of 
mitral regurgitation severity according to previous validated criteria (Table 3.4), taking 
into account the width and depth of regurgitant jets from different views (4-chambers, 
short-axis, parasternal). The relation between jet size and left atrial size was assessed by 
visual integration of the information obtained from all the different transducer positions, 
to ensure exploration of the entire receiving chamber.
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Mitral Regurgitation Visual evaluation of the regurgitant jet in the LA
Mild (grade 1) jet width visually judged to be <=1/3 LA width 
(or less than 1/3 the anteroposterior LA dimension);
Moderate (grade2) jet width visually judged to be between 1/3 and < 1/2 LA 
width (and not reaching the roof of the atrium)
Severe (grade 3) jet width greater than one half of LA width 
(or jet reaching the roof of the atrium)
Table 3.4. Classification of mitral regurgitation
Evaluation of the Right Atrium
The lateral and superoinferior dimensions of the right atrium were measured by 
bidimensional echocardiography from the apical 4-chamber view using an inner-edge-to-
inner-edge measurement. The right atrial area was measured by planimetry of the inner 
contour from the apical 4-chamber view, excluding the confluences of the inferior vena 
cava from the tracing. The plane of tricuspid annulus was taken as the inferior right atrial 
border. The right atrial area was indexed to body surface area, for participants from the 
clinical registry. Additionally, an sphericity index was calculated as the ratio between 
lateral and superoinferior diameters.
The classification of right atrial enlargement was done using the criteria presented on 
Table 3.5.
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RA DILATATION Features
Mild RA area increased less than 1.5 times the RV area 
Moderate RA area between 1.5 and 2 times the RV area + sphericity index 
between 0.75-1.0
Severe RA area is greater than twice the RV area; dilated RA 
compresses the left cavities; dilated IVC; sphericity index > 1
Table 3.5. Classification of right atrial (RA) enlargement
Right Ventricle
The lateral and superoinferior dimensions of the right ventricle were measured by 
bidimensional echocardiography from the apical 4-chamber view using an inner-edge-to-
inner-edge measurement. An sphericity index was calculated as the ratio between lateral 
and superoinferior diameters in 4-chambers view. 
The right ventricular end-systolic and end-diastolic areas were determined by planimetry 
of the inner contour from the apical 4-chamber view. In few cases for patients submitted 
to surgery the area-shortening fraction was used to estimate the ejection fraction of the 
RV since it is not influenced by the ventricular geometry. It was calculated using the 
following formula: 
Area Shortening Fraction = (End diastolic area – End systolic area)/End diastolic area.
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The right ventricular systolic function was evaluated through a visual semi-quantitative 
scale (+++ good contractility; ++ moderate dysfunction; + poor contractility) as 
previously done by Cherian et al (1982) using bidimensional guided M-mode in several 
incidences (4-chambers, parasternal long axis, parasternal short axis and sub-costal 
views). 
The diastolic function parameters were measured through evaluation of the tricuspid 
inflow by pulsed Doppler, namely E wave peak, A wave peak, and E/A ratio.
RV dimensions were indexed to body surface area for participants from the clinical 
registry, and age in participants in community studies. The criteria used to classify 
reduction in right ventricular size are presented in Table 3.6.
RV REDUCTION Criteria on 4-chambers view
Mild RV trabecular portion obliteration with cavity reduction < 25% 
Moderate RV trabecular portion obliteration with cavity reduction 25-50%; 
Absence of RV apical notch; sphericity index 0.75-1.0
Severe RV wall retraction (apical “notch”) or obliteration with cavity 
reduction > 50%; sphericity index >1.0
Table 3.6. Classification of reduction of right ventricular (RV) cavity size
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Evaluation of the Tricuspid Valve
The evaluation of the tricuspid valve was done using bidimensional mode in several 
planes, M-mode along the leaflets to confirm their thickening and also by measuring the 
length of the anterior and septal leaflets. The dimensions of the tricuspid annulus were 
measured from both the 4-chambers and short axis views. The antero-posterior diameter 
of the right ventricular outflow tract was measured by bidimensional-guided M-mode 
echocardiography from the parasternal short-axis view at the base of the heart, from the 
trailing edge of the anterior RV wall to the leading edge of the aortic valve.
Colour Doppler evaluation of tricuspid regurgitation was used for semi-quantitative 
estimation of tricuspid regurgitation severity taking into account the width and depth of 
regurgitant jets from different views (4-chambers, short-axis and sub-costal). The relation 
between jet size and right atrial size was assessed by visual integration of the information 
obtained from all the different transducer positions, to ensure exploration of the entire 
receiving chamber. Another criteria used to define severe tricuspid regurgitation was the 
lack of aliasing of the jet (indicating absence of turbulence across the annulus)  and its 
large width at origin, associated with severe distortion of the tricuspid valve leaflets that 
causes non-cooptation. 
Chapter 5 Clinical Characterisation
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
109
DEGREE OF TR Criteria
Mild (grade 1) Jet width <= ¼ RA width 
Moderate (grade 2) Jet width between ¼ and 1/2 of the RA width
Severe (grade 3) Non-turbulent jet or free tricuspid regurgitation
Table 3.7. Classification of tricuspid regurgitation (TR)
3.2.2.3. Definition of Echocardiographic Features 
The echocardiographic features were divided in major or minor criteria according to their 
specificity for diagnosis, relevance for decision on the management option and 
importance for prognosis.
Major criteria
Echocardiographic features that are distinctive or pathognomonic of endomyocardial 
fibrosis and that have a major impact on management were considered major criteria. An 
individual score was attributed to each feature according to its relevance for structural 
and hemodynamic changes. The following were considered major criteria for diagnosis of 
EMF: 
(1) Endocardial plaque of at least 5mm width or endocardial thickening greater than 1mm
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(2) Patchy endocardial thickening in two or more ventricular walls
(3) Obliteration of ventricular apices or valve recesses 
(4) Ventricular thrombi or spontaneous contrast in the absence of ventricular dysfunction 
(5) Reduction of the RV cavity volume due to exclusion of the trabecular portion 
(6) Restriction of AV valve leaflet movements due to adherence to the ventricular walls
We defined endocardial plaques as areas of endocardial thickening of more than 5mm 
width and thicker than 1mm as a major criterion for diagnosis of EMF. The term large 
plaque was used when endocardial thickening exceeded 10 mm in width and 2mm in 
depth.
Minor criteria
The echocardiographic findings that are not specific but may suggest EMF were 
classified as minor criteria. Although commonly found in patients with EMF, these 
features are not exclusive to this condition and do not define the disease if found in 
isolation. They were considered to have little influence on management and prognosis, 
when compared to major criteria previously described. The following were considered 
minor criteria for the diagnosis of EMF:
(1) Patchy endomyocardial thickening localized to one ventricular wall
(2) Ventricular restrictive filling pattern 
(3) Diffuse thickening of the atrioventricular valve leaflets 
(4) Enhanced density of the moderator band or intraventricular trabeculae 
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(5) Abnormal M-movement of the interventricular septum and/or posterior LV wall 
(6) Enlarged atrium with normal-sized homolateral ventricle
(7) Presence of thickened “false tendon” of the LV
Patchy endocardial thickening corresponded echocardiographically to small areas of 
enhanced density of the endocardium with less than 1mm in depth and evenly distributed 
in the ventricular walls.
3.2.2.4. Classification
The echocardiographic appearance of EMF varies both in terms of distribution and 
severity of structural lesions and hemodynamic abnormalities. 
3.2.2.4.a) Distribution of lesions
We used the criteria described above to describe lesions in each side of the heart. The 
scoring system was applied to each ventricle separately, and according to the distribution 
of the cardiac lesions we classified the disease in three types REMF, LEMF and BEMF.
REMF was defined when characteristic lesions affected exclusively or predominantly the 
right side of the heart, with a score that was greater than the score of left heart lesions by 
more than 3 points. LEMF designated patients with isolated or predominant affection of 
the left side of the heart, with a score greater than that of right-sided lesions by more than 
3 points. Finally, BEMF designated patients with no clear predominance of lesions in one 
side of the heart, in which the difference of scores between the two sides of the heart was 
3 points or less.
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3.2.2.4.b) Severity of EMF
The assessment of the severity of the disease was done through a scoring system to 
quantify the structural and hemodynamic lesions (Table 3.1). Four progressive grades of 
severity were defined in view of management and prognosis namely: 
Grade I (or Mild EMF)
Endocardial plaque or patchy thickening associated with thickening of the 
atrioventricular valve leaflets without any other structural or hemodynamic abnormality. 
Grade II (or Moderate EMF)
Large endocardial plaques, apical/valve recess ventricular obliteration, and mild to 
moderate atrioventricular valve regurgitation. There is mild to moderate atrial dilatation, 
mild ventricular cavity reduction, and preserved myocardial function.
Grade III (or Severe EMF) 
Large endocardial plaques, moderate reduction of ventricular cavity dimensions, marked 
atrial dilatation and severe atrioventricular valve dysfunction. Myocardium is visible 
underneath the endocardial thickening and ventricular function is nearly normal.
Grade IV (or Advanced EMF)
Presence of large endocardial plaques associated with severe reduction of the ventricular 
size and compression of the contralateral cavities by the severely dilated atrium. 
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Endocardial calcification, poor ventricular contractility, and large persistent effusions 
(pericardial, peritoneal and/or pleural) are other features of advanced EMF. 
3.2.3.  Staging and Mode of Progression 
The staging and characterisation of the mode of progression of EMF needed a minimum 
six months follow up with monthly visits and, for logistical reasons was only used for 
patients from the clinical registry. This classification aimed at distinguishing activity and 
chronicity, which are though to influence management and prognosis.
Activity was defined as the finding of two or more of the following signs in a patient with 
echocardiographic diagnosis of EMF:
(1) unexplained fever, recurrent facial edema, urticaria or asthma-like episodes 
(2) severe hypereosinophilia (absolute eosinophil count > 1.5 x 109/L)
(3) ventricular thrombi not attributable to severe myocardial dysfunction
(4) evidence of pancarditis with acute heart failure
(5) increased C-Reactive Protein and/or erythrosedimentation rate
The persistence of signs of activity and the progression of structural and/or functional 
abnormalities during the first 6 months after diagnosis, defined three distincte stages of 
the disease: Active with remission, Active persistent and Rapidly progressive. 
Active EMF with remission refers to patients that had signs of activity at diagnosis that 
regressed during the first six months of follow up, while Active persistent disease 
signified persistence of signs of activity for 6 months or more. Finally, we used the 
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expression Active rapidly progressive to define patients with persistence of signs of 
activity after the initial episode of heart failure, who progressed to death or a higher 
degree of severity in less than six months.
Patients with history of recent onset of symptoms (less than 6 months) were considered to 
have acute disease. The definition of chronicity was the presence of signs and symptoms 
attributable to EMF for more than six months and echocardiographic features of 
established EMF on admission. Depending on the occurrence of recrudescence of disease 
during the first six months of follow up the patients were classified as having quiescent or 
recurrent disease. Patients who develop recrudescence of active disease in the course of 
follow up, going back to a quiescent stage thereafter, were considered to have chronic 
recurrent disease.
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3.3. Results
We performed transthoracic echocardiography on 1534 individuals between November 
2004 and October 2007: 1063 individuals of all ages randomly selected from the 
community, 296 school children randomly selected in Inharrime district, and 175 patients 
from the national clinical registry established at the Heart Institute – Maputo (Table 3.8). 
The patients from the clinical registry were submitted to several echocardiographic 
examinations according to their clinical needs. A total of 411 individuals with the 
diagnosis of Endomyocardial Fibrosis were studied, of which 236 detected in the 
community.
During the prevalence study 184 eligible individuals were not present at home (99 men 
who worked in the neighboring countries and represented 53% of the eligible 
participants) and 2 had psychiatric problems with uncontrolled behavior that prevented 
their evaluation. Regarding the school children cohort, 36 eligible students were not 
examined: 24 were absent, 7 did not have the informed consent, and 5 abandoned the 
school during the period between preparation of fieldwork with signature of the informed 
consent and the visit to school to perform the echocardiographic evaluation.
The mean age of the different populations varied between 8 and 22 years (Table 3.9). 
There were slightly more males than females on the clinical registry, while in the 
community more females were studied.
Of the 236 individuals with echocardiographic signs of EMF found during the 
community research only 52 (22.0%) had complaines or recalled any particular disease, 
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confirming the high occurrence of clinical-echocardiographic dissociation in EMF (Table 
3.10). 
Table 3.8. Summary of the population studied 
Clinical Registry Prevalence Study Prospective Study 
Participants 175 1063 296
Cases of EMF 175 211 25
Mean age (range) years 15.7 (3-64) 22.6 (0-96) 8.6 (6-16)
Female/Male ratio 83/92 611/452 157/139
Severe Malnutrition 25/175 3/211 0/296
Table 3.9. Epidemiological features and prevalence of evidence of malnutrition
Prevalence Study Prospective Study
Individuals with EMF 211 25
Presence of symptoms/signs of disease 48 (22.7%) 4 (14.3%)
Table 3.10. Number of individuals with EMF who were symptomatic 
Clinical Registry Prevalence study Prospective study 
Period Nov04 – Oct07 Jan06-May06 Oct06 -
Eligible individuals 183 1249 332
Examined 175 1063 296
Cases of EMF 175 211 25
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According to the distribution of lesions in the heart cavities, bilateral disease was the 
most frequent form of affection (Table 3.11). 
Echocardiographic 
Features
Clinical Registry Community Studies
Prevalence Study          Prospective Study
BEMF 95 (54.3%) 117 (55.45%) 16 (64.0%)
REMF 55 (31.4%) 59 (27.96%) 7 (28.0%)
LEMF 25 (14.3%) 35 (16.59%) 2 (8.0%)
Table 3.11. Distribution of EMF lesions in individuals from all studies
Abnormalities of the Left Side of the Heart
Early left EMF, usually detected in the community, was characterized by fibrosis of the 
false tendons, thickening of the mitral leaflets (Figure 3.1), apical thrombus (Figure 3.2), 
and/or obliteration of the apex or the recess between the posterior leaflet and the posterior 
wall (Figure 3.3). In two cases, thrombi were found in the subvalvar apparatus (Figure 
3.2) involving the free edges of both papillary muscles. Flow across the mitral valve 
showed usually a tall E wave and small A wave, corresponding to early diastolic filling 
followed by restriction (Figure 3.4). There was no dilatation of the left atrium. 
In established LEMF thickening of the endocardium was prominent in the apex (Figure 
3.5) and posterior wall behind the recess of the posterior leaflet of the mitral valve 
(Figure 3.6). The ventricle assumed a spherical shape being hypercontractile in its basal 
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Figure 3.1. Mild EMF. There is patchy apical thickening of the endocardium, the 
moderator band on the right ventricle, the false tendon on the left ventricle, and 
the leaflets of both atrioventricular valves.
Figure 3.2. Early EMF. Left ventricular thrombi are usually located at the apex 
and subvalvar apparatus, and are associated with septal endocardial thickening on 
the left side and diffuse thickening of the mitral leaflets.
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Figure 3.3. Apical obliteration in LEMF associated with a plaque of fibrosis and mild 
mitral regurgitation
Figure 3.4. LEMF with marked diastolic dysfunction. There is a tall E wave, short 
isovolumetric relaxation and deceleration times and the ratio E/A is grater than 3.
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Figure 3.5. Echocardiography of moderate LEMF, presenting apical and septal 
endocardial thickening, spherical left ventricle, thickening of the anterior leaflet of the 
mitral valve, and increased echos at the posterior papillary muscle. 
Figure 3.6. This image of moderate BEMF shows obliteration of the posterior recess of 
the mitral valve, septal wall endocardial thickening and left atrial dilatation. On the right 
side thickening of the moderator band and right atrial dilation are visible. 
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portion. At this stage most cases had a competent mitral valve, but in some cases from the 
clinical registry there was progression of the lesion in the posterior leaflet with restriction 
of its movement with appearance of an eccentric mitral regurgitation and passive 
pulmonary hypertension, that progressed from mild to severe during the six months 
follow up period. Another common finding in predominant left forms was the so-called 
M-movement of the interventricular septum (Figure 3.7).
The most characteristic picture of advanced LEMF was the association of septal and 
apical fibrosis with severe eccentric mitral regurgitation due to fusion of posterior leaflet 
to the wall, disproportionally small left ventricle, aneurismal left atrium and severe 
pulmonary hypertension (Figures 3.8). Even in patients with extensive endocardial 
thickening there was never retraction of the LV apex. 
The most frequent lesions affecting the left side of the heart are listed in Table 3.12.
Abnormalities of the Right Side of the Heart
Initial lesions consisted of thickening of the moderator band associated with turbulent 
blood flow inside the trabecular portion of the ventricle between this structure and the 
ventricular wall, as assessed by color flow Doppler. In the longitudinal view of the right 
ventricle (short axis of the left ventricle at the level of the aorta) there seemed to be a 
stretched moderator band separating the inflow and outflow tracts from the trabecular 
portion (Figure 3.9). 
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PML posterior mitral leaflet; AML anterior mitral leaflet
Table 3.12. Comparison of frequencies of echocardiographic features on the left side of 
the heart in EMF patients in clinical and community studies
Echocardiographic features Community 
Studies
Clinical 
Registry
Thickening of the AML 121 (51.3%) 148 (84.5%)
Thickening of the PML 117 (49.6%) 102 (58.3%)
Endocardial thickening of the septal wall 106 (44.9%) 140 (80.0%)
Restrictive filling pattern 81 (34.3%) 57 (24.2%)
Enhanced density of the papillary muscles 78 (33.1%) 130 (74.3%)
Apical endocardial thickening 55 (23.3%) 57 (32.6%)
Thickening of the false tendon 47 (19.9%) 11 (6.29%)
Obliteration of the recess behind the PML 27 (11.4%) 30 (17.1%)
Mitral regurgitation 26 (11.0%) 107 (61.1%)
Severe dilatation of the left atrium 13 (5.5%) 87 (49.7%)
Apical thrombus/obliteration 4 (1.7%) 13 (7.4%)
Non-apical intraventricular thrombus 1 (0.4%) 5 (2.9%)
Left atrial thrombus 0 (0%) 7 (4.0%)
Total 236 175
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Figure 3.7. Typical M-movement of the interventricular septum, found in some patients 
with predominant LEMF. There is thickening and abnormal movement of the posterior 
leaflet of the mitral valve. 
Figure 3.8. Severe LEMF endocardial thickening and organized thrombus are visible 
(arrow). Mitral regurgitation is usually directed to the posterior atrial wall, and there is 
dilatation of the right cavities due to passive pulmonary hypertension.
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Figure 3.9. This picture of the longitudinal view of the right ventricle shows reduction of 
ventricular cavity size, which in the initial stages is due to obliteration of the trabecular 
portion of the right ventricle (arrow). 
Figure 3.10. Restriction of the movements of tricuspid valve leaflets (arrow) is the 
mechanism that explains regurgitation in initial phases of EMF, but later on progressive 
enlargement of the right atrium leads to dilatation of the tricuspid ring and free 
regurgitation. The atrium and the ventricle work as a single chamber and spontaneous 
contrast is usually seen in both cavities in advanced disease (right).
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RV trabecular cavity obliteration was usually associated with mild to moderate tricuspid 
regurgitation caused by restriction to the movement of the anterior and septal leaflets of 
the tricuspid valve. The leaflets had some attachments to the wall leading to an 
echocardiographic picture similar to the “Ebstein Malformation”, with dilatation of the 
tricuspid annulus (Figure 10), and usually tricuspid regurgitation with the jet originating 
inside the ventricular cavity, from the trabecular portion of the ventricle. 
Severe REMF was characterized by retraction of the ventricular cavity due to elimination 
of the trabecular portion of the cavity (Figure 3.11) Severe tricuspid regurgitation with 
almost no turbulence was associated with restriction of leaflet movements caused by 
involvement of the papillary muscles in the fibrotic process, as well as to dilatation of the 
annulus that followed severe right atrial dilatation (Figure 3.11). Most patients had 
spontaneous contrast inside the right atrium extending in anterograde fashion to both the 
inflow tract of RV and retrograde to the inferior vena cava and dilated supra-hepatic 
veins. These did not usually show the normal respiratory changes, indicating increased 
systemic venous pressure. 
The reduction of the right ventricular cavity size was partially compensated for by 
dilation of the outflow tract. In patients with advanced REMF free tricuspid regurgitation 
was the rule due to a completely adherent valve apparatus and aneurismal RA, and was 
usually associated with dynamic intracavitary echos or large thrombi (Figure 3.12). 
There was equalization of high-pressure in the atrium, ventricle and pulmonary artery, 
diastolic opening of the pulmonary valve could be noticed. The aneurismal right atrium 
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caused heart distortion and compression of the left cavities making it difficult to evaluate 
the presence of mitral dysfunction. Abundant pericardial effusion and compression of left 
cavities prevented adequate evaluation of the left ventricular function in very advanced 
cases of REMF, as shown in Figure 3.13. The structural features of REMF were 
distinctive and are summarized in Table 3.13. 
Figure 3.11. Severe REMF has fibrous plaques separating the trabecular portion of the 
right ventricle from its admission chamber (left) or retraction of the right ventricle with 
the characteristic “apical notch” (arrow), right atrial thrombi and pericardial effusion. 
Figure 3.12. Advanced EMF. Severe cavity distortion, intra-atrial thrombi and large 
pericardial effusion are common features.
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Echocardiographic features Community Registry
Thickening of the moderator band 141 (59.7%) 28* (16.0%)
Apical endocardial thickening 115 (48.7%) 143 (81.7%)
Tricuspid regurgitation 49 (20.7%) 87 (49.7%)
Apical /obliteration of trabeculae 32 (13,6%) 49 (28.0%)
Apical notch 24 (10.2%) 14 (8.0%)
Apical retraction 4 (1.6%) 37 (21.1%)
STL fusion to the septal wall 27 (11.4%) 53 (30.3%)
Severe dilatation of the right atrium 20 (8.5%) 66 (37.7%)
Intraventricular thrombus 14 (5.9%) 6 (3.4%)
Distended IVC 6 (2.5%) 52 (29.7%)
Right atrial thrombi 0 (0%) 33 (18.9%)
Total 236 175
STL septal tricuspid leaflet; IVC inferior vena cava
Table 3.13. Comparison of echocardiographic features most frequently found on the right 
side of the heart in patients with EMF in clinical and community studies
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Echocardiographic findings in Bilateral EMF
Individuals with initial BEMF had usually fibrosis of the moderator band, fibrosis of the 
false tendon, thickening of both atrioventricular valves and occasionally, left apical 
thrombus (Figure 3.14). In established disease the heart had a peculiar aspect of enlarged 
atria with small ventricles, the so-called “Mickey mouse heart” in the two-dimensional 
four chambers view (Figure 3.15). 
In patients with severe BEMF coexistence of mitral and tricuspid regurgitation and 
biventricular size reduction was notorious (Figure 3.16). The affection of the right 
ventricle, by reducing the right ventricular output and pulmonary perfusion, partially 
reduced the effects of the pulmonary venous hypertension caused by left ventricular 
disease, favoring a better outcome than in pure LEMF.
Severity of EMF
While the majority of individuals with EMF in the community have mild to moderate 
disease (224/236; 94.9%) those that seek medical attention have predominantly severe to 
advanced (94; 57.3%), as shown in Table 3.14. Remarkably, six out of 12 individuals 
with severe disease found in the community denied having any symptoms and did not 
present any clinical signs of the disease. 
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Figure 3.13. Advanced EMF is associated with multiple effusions (pericardial, pleural 
and peritoneal). Pericardial effusion further impairs diastolic function and precipitate low
cardiac output syndrome. 
Figure 3.14. Mild BEMF. Right ventricular obliteration coexists with endocardial 
thickening of the left side of interventricular septum (arrow).
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Figure 3.15. Progression of BEMF is characterized by bilateral apical fibrosis (arrows), 
ventricular size reduction and atrial enlargement, resulting in the classical “Mickey 
mouse heart”.
Figure 3.16. Right ventricular cavity obliteration progresses to fibrosis but there is 
normal myocardium underneath it (arrow). 
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Echocardiography Clinical Registry Prevalence Study Prospective Study
Grade I 20 (11.4%) 163 (77.2%) 12 (48.0%)
Grade II 61 (34.9%) 39 (18.5%) 10 (40.0%)
Grade III 73 (41.7%) 9 (4.3%) 3 (12.0%)
Grade IV 21 (12.0%) 0 0
Table 3.14: Distribution of EMF by severity in the three populations studied 
Follow-up and Staging
Signs of activity were present in 90 (51.4%) patients from the clinical registry. The most 
frequent clinical features associated with laboratory signs of active disease were facial 
edema in 54 patients and hypereosinophilia present in 43. 
Sixty-six (37.7%) patients had recent onset EMF with signs of activity at time of 
diagnosis. Of these, 10 had rapidly progressive disease and died within 2 months of 
diagnosis. In all cases there were intraventricular thrombi and myocardial dysfunction. 
There was persistence of activity in 18 patients. 
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3.4. Discussion 
The most important outcome of this study was the improvement in echocardiographic 
assessment of EMF patients, including the possibility of diagnosis of early stages in 
large-scale community research, and risk stratification of patients in the clinical setting. 
By applying these new diagnostic criteria we were able to standardize the diagnosis of 
EMF in asymptomatic individuals in the community, and describe systematically the 
structural and hemodynamic abnormalities in the clinical setting, contributing in this way 
to a comprehensive classification and tailored management of EMF patients. 
The clinical diagnosis of EMF can only be done when structural changes are advanced 
and lead to hemodynamic abnormalities. On the other hand, there is no knowledge of a 
single biological marker for the disease. Echocardiography is a non-invasive diagnostic 
tool for cardiovascular diseases that has become widely available in developed countries. 
Despite its use being currently restricted to some referral centres of urban areas in most 
developing countries, this technique has the potential to be increasingly used in health 
structures from these poor areas. Moreover, the use of new portable user-friendly and 
battery-operated machines can potentially increase the accessibility of echocardiographic 
diagnosis for people from rural areas of developing countries that are endemic for EMF.  
We therefore concentrated our efforts in developing echocardiographic criteria that could 
be applied for early diagnosis, follow-up and management of this condition in endemic 
areas. 
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Echocardiographic features: implications for diagnosis and management
Endocardial thickening was the hallmark of established EMF on echocardiography, 
forming large plaques or having a patchy distribution in one or both ventricles. Mural 
endocardial plaques interfered mainly with diastolic ventricular function by preventing 
normal relaxation of the underlying myocardium. When endocardial fibrosis was 
extensive, besides impeding normal filling of the ventricles due to marked reduction of 
the ventricular cavity size, there was also variable compromise of the systolic function 
leading to further reduction in cardiac output. We therefore considered the extension of 
endocardial fibrosis an important marker of the severity of the disease.
Ventricular thrombosis or “spontaneous contrasts”, echocardiographic findings usually 
associated with stasis and severe myocardial dysfunction, were frequently seen in 
otherwise normal ventricles. Most left ventricular thrombi were apical, but there were 
also thrombi involving the subvalvar apparatus and the left ventricular outflow tract. On 
the right side the trabecular portion of the ventricle was the area most prone to thrombi. A 
high score was attributed to the presence of ventricular thrombi because they pose an 
enormous vital risk to the patient and are a major determinant of management and 
prognosis. Interestingly, most patients with intraventricular thrombi claimed being 
asymptomatic and did not recall any illness that could be related to thromboembolism.
Obliteration of the ventricular cavity causes reduction of the effective volume of the 
affected cavity. When obliteration involves the valve apparatus it additionally leads to 
restriction of the leaflet and chordae movements that may progress to its fusion to the 
ventricular wall, resulting in severe atrioventricular valve dysfunction. Right ventricular 
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obliteration, consisting of partial or complete exclusion of the trabecular portion of the 
right ventricle from the circulation, was frequent in asymptomatic individuals from the 
community. Although organization and fibrosis of the mural thrombus and its adjacent 
endocardium has been said to be the main mechanism for ventricular retraction 
(Brockington et al, 1967; Connor et al, 1967), in view of our findings in initial phases of 
the disease in the community, progressive fusion of the obliterated trabeculae following 
its exclusion from the circulation seems to be the most plausible process leading to cavity 
retraction. On the right ventricle this process is associated to compaction of the trabecular 
portion that in severe cases results in thinning of the apical wall and the creation of an 
“apical notch”, which is a distinctive feature of advanced right endomyocardial fibrosis 
(Connor et al, 1967). 
Left ventricular obliteration affected usually the apex and/or the posterior leaflet recess 
excluding these parts from the ventricular cavity. This abnormality is associated with 
increased thickness of the apex and seemed to correspond to early phases of left 
affection. Although there was never retraction of the apical wall, individuals with large 
apical plaques had thin wall with a spherical left ventricle, due to considerable reduction 
of its longitudinal diameter with dilatation of the basal portion when it was spared from 
the fibrous process. The restricted movement of the fibrotic apex of the left ventricle and 
its obliteration are associated with a compensatory contractile mechanism that results in 
exaggerated and distinctive motion of the basal portion of the left ventricle in early 
diastole (Dienot et al, 1981; Acquatella, 1983). On M-mode the septal wall can assume 
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an M-shaped movement on the basal portion of the ventricle, a finding that was common 
only in advanced lone or predominant left EMF. On the posterior wall on mode-M there 
is a rapid increase in left ventricular dimensions in early diastole, which is not followed 
by any further variation in dimensions through the remaining of the diastole (Dienot et al, 
1981).
Patchy endocardial thickening was extremely frequent in individuals from the 
community, and was considered a feature that suggested the diagnosis of EMF in the 
presence of other minor or major criteria. The low score attributed to this characteristic 
was due to the fact that patchy endocardial thickening may be present in patients with 
other cardiac pathology affecting the endocardium, although it is also true that most of 
that pathology afflicts adults and not children and adolescents as is the case in EMF.  On 
the other hand, no large-scale echocardiographic screening studies have been performed 
in African populations. It can therefore be argued that these small-thickened areas in the 
endocardium constitute a normal phenotype in these populations, highlighting the need 
for further research in the communities to determine the spectrum of normal variants in 
African hearts. 
The most common ventricular filling pattern was the characteristic brisk early diastolic 
filling with poor filling in the remainder of diastole, the absence of respiratory changes 
and the presence of a normal pericardium, which enabled distinction from constrictive 
pericarditis. The tricuspid filling pattern was difficult to evaluate since most patients with 
severe diastolic dysfunction had free tricuspid regurgitation, and the right cavities acted 
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physiologically as a single chamber due to severe restriction of the tricuspid leaflets 
movement.  
Diffuse irregular thickening of the atrioventricular valve leaflets associated with thin 
chordae was a common finding of EMF. This contrasted with the more prominent 
thickening of the free borders of the leaflets extending to the chordae that is typical of 
rheumatic valve disease, constituting one of the pitfalls in differentiating the two diseases 
(Hassan et al, 2005), which are almost equally prevalent in some areas of Africa (Freers 
et al, 1996b). The presence of diffusely thickened atrioventricular valve leaflets, 
obliteration of left ventricular apex, small or normal-sized ventricle with severe atrial 
dilatation, and significant pulmonary hypertension should favour the diagnosis of EMF. 
Enhanced densities of moderator band and/or left ventricular false tendons were 
considered the initial echocardiographic features of EMF, and constituted the most 
common mural changes in mild or grade I disease. The moderator band is a cordlike 
structure crossing at mid-right ventricle between septum and free walls, which contains 
the right bundle branch conduction tissue. The left ventricular false tendons are fibrous or 
fibromuscular bands that stretch across the left ventricle from the septum to the free wall. 
They can also tether to a papillary muscle, but unlike the chordae tendineae, do not 
connect to the mitral leaflets, being considered anatomic variants. Thickening of these 
structures was frequently associated with patchy endocardial thickening and the 
association was thought to correspond to early phases of EMF, an hypothesis that needs 
to be confirmed in follow up studies. 
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Most echocardiographic criteria for assessing ventricular size and function have been 
developed for the left ventricle, but the ability of two-dimensional apex echocardiography 
to evaluate right ventricular and right atrial size has also been shown in children with 
congenital heart defects (Fontana et al, 1982). Our criteria for assessment of left 
ventricular function did not include the conventional volume measurements, which are 
difficult to apply in severe and advanced EMF owing to the fact that there is marked heart 
cavity distortion. The Simpson’s method assumes an ellipsoid shape of the left ventricle, 
which is not the case in most cases of EMF. In LEMF there is reduction of the 
longitudinal dimension of the ventricle that assumes a round shape, while in REMF the 
bulging of the interventricular septum compresses and deforms the left ventricle, which 
assumes a “banana” shape. 
The evaluation of myocardial function in EMF is biased by the presence of endocardial 
fibrosis, which restricts the function of the underlying myocardium, even if the 
myocardial texture seems to be maintained. We therefore frequently evaluated the 
ventricular function using the visual semi-quantitative scale, a tool that has been 
proposed for estimation of myocardial function in EMF (Cherian et al, 1982). However, 
in mild and moderate disease with no paradoxical movement of the interventricular 
septum, it seems reasonable to use the shortening fraction of the left ventricle.
Another important part of our study was to develop and apply criteria for determination 
of the degree of cavity distortion and estimation of ventricular function, based on 
measurements of cavity dimensions, area-shortening fraction and sphericity index. The 
area-shortening fraction of the left ventricle, despite its well-known limitations and 
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disadvantages, was considered a reasonable tool for assessment of its systolic function in 
EMF patients and was used in the clinical setting, mainly for follow-up of patients 
submitted to surgery.
The evaluation of the right ventricle, the ventricle more frequently affected in EMF 
(Somers et al, 1978), is still the subject of debate among the medical community. The 
irregular geometry of the right ventricle, does not allow the use of parameters used for the 
left ventricle. Also, remodeling of the right ventricle seems to be a complex process that 
may include unique elements not observed in left ventricular remodeling (Kret and Arora, 
2007). However, it has been proven that two-dimensional echocardiography, with apical 
and four-chambered view, enables accurate visualization of the right atrium and ventricle 
(Bommer et al, 1979). The right ventricular outflow tract shortening fraction, a simple 
and noninvasive measure of systolic function (Lindqvist et al, 2003), does not seem 
adequate to assess the global right ventricular function in EMF, owing to the presence of 
compensatory mechanisms leading to dilatation and hypercontractility of the right 
ventricular outflow tract as a result of trabecular cavity obliteration or retraction. 
The sphericity index is a measure of ventricular size and shape that has been used to 
assess changes that occur in non-ischemic cardiomyopathy from valvular or diffuse 
myocyte origin, and is a way to quantify the abnormal geometrical changes that 
accompany heart failure in dilated failing left ventricles (Di Donato et al, 2006). The 
global measurements of sphericity index may be useful for global disease but fails to 
detect regional apical shape abnormalities in dilated cardiomyopathy. We think that due 
to geometrical changes associated with EMF the sphericity index may be good tool for 
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measurements of abnormalities of ventricular shape and volume associated with the 
severity of this condition. 
A major limitation of the sphericity index is that it relies on analysis of the entire 
chamber obtained by the global axis ratio, which corresponds to a single plane ratio, 
reflecting a linear alteration in the two axes of the entire chamber. This is of particular 
importance in EMF where regional changes seem to be present in all phases of the 
disease in a high proportion of patients. Its use needs to be further tested, validated and 
eventually widespread.
The use of the new criteria of diagnosis and classification of EMF in the clinical setting 
allowed identification of patients who can benefit from surgery. We think that patients 
with mild or grade I EMF do not benefit from surgery at thos stage, while structural 
abnormalities characteristic of advanced or grade IV disease are very often unsuitable for 
corrective surgery. This unsuitability is usually related to the severity of heart 
abnormalities, such as extensive endocardial thickening with disappearance of the 
atrioventricular valve apparatus, thick endocardium without reasonable amount of 
myocardium visible underneath it, extensive calcification, severe myocardial dysfunction. 
For patients whose abnormalities can be total or partially corrected by surgery (grades 
II/III) the new classification allows the planning of tailored surgical techniques and the 
anticipation of post-operative complications. The addition of a scoring system to the 
traditional topographic classification improved the management of EMF patients by 
identifying those that can benefit from surgery and by attempting the stratification of 
their operative risk.
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We found remarkable differences in the frequency of several echocardiographic features 
used for diagnosis and classification of EMF, when comparing the participants in the 
community studies with patients from the clinical registry. We here discuss some of these 
differences. 
In severe and advanced disease, which constitutes the major group of patients from the 
clinical registry, the posterior mitral leaflet was engulfed in the fibrous tissue of the 
posterior wall, thus explaining the low prevalence of thickening of the posterior leaflet in 
the first group, which had preponderance of mild disease. For similar reasons, there was 
high frequency of thickening of false tendons in the LV and the moderator band on the 
RV in the community, which contrasts with the low frequency in patients of the national 
registry, who presented mostly severe and advanced forms od the disease. We think that 
false tendons and the moderator band are involved in process that leads to obliteration 
and retraction of the ventricle, becoming part of the left ventricular apical fibrosis or the 
floor of the RV obliterated cavity respectively. The evaluation of the restrictive filling 
pattern was conditioned by the existence of severe atrioventricular valve regurgitation in 
severe and advanced EMF, more frequent in the clinical setting.
Ventricular thrombi were more frequent in the community group, probably representing 
early stages of the disease, while atrial thrombi occurred mainly in patients with 
advanced stages found in the clinical series. 
Atrioventricular valve regurgitation, a feature that follows distortion of the subvalvar 
apparatus and the fusion of leaflets to the ventricular walls, was a major determinant of 
clinical symptoms, being therefore more common in the clinical series. 
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The size of the left atrium has been shown to correlate with the exercise capacity in EMF 
patients (Mady et al, 2005). In a large cohort of patients with hypertrophic 
cardiomyopathy from a nationwide registry, a marked increase in left atrial dimension 
was predictive of long-term outcome, independent of co-existent atrial fibrillation or 
outflow obstruction (Nistri et al, 2007). This study concluded that left atrial dimension is 
a novel and independent marker of prognosis in hypertrophic cardiomyopathy, 
particularly relevant to the identification of patients at risk for death related to heart 
failure. 
We consider that systematic echocardiographic evaluation, in addition to serum markers 
of diastolic dysfucntion such as NT-proBNP (Mady et al, 2008), could help identifying 
prognostic indicators in EMF patients. However, at this stage of our research we were not 
able to carry out research aiming at identification of such indicators.
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Conclusions
These studies confirm the need for using echocardiographic screening in epidemiological 
research on EMF, since most individuals affected by the disease in the community were 
asymptomatic. Research aiming at characterization of the spectrum of normal features on 
echocardiography of the African population is mandatory, since it can be argued that 
some echocardiographic features considered being mild or initial EMF lesions represent 
in fact variants of the normal features in this population. 
The use of criteria for standardization of the diagnosis and classification of EMF is useful 
for better understanding of the pathogenesis and pathophysiology, and will allow 
comparison between series in different endemic areas. The usefulness of these new 
criteria and scoring system needs validation on follow-up studies.
The usual assumptions made when calculating parameters for assessment of systolic and 
diastolic function of both ventricles are not present in a considerable number of 
individuals with moderate, severe and advanced disease. Therefore, non-conventional 
measurements and indexes must be used to evaluate left and right ventricular function in 
EMF.
Tissue Doppler Imaging has a great potential for research on early stages of EMF and 
must be envisaged in thE future, since it could probably uncover early regional 
myocardial changes on echocardiography, improving the diagnosis of the initial phases of 
the disease. 
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The addition of new markers of diastolic dysfunction like NT-proBNP to the above-
described criteria may eventually improve the pre-clinical diagnosis of EMF, and be used 
in community research.
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Chapter 4
EPIDEMIOLOGY OF EMF IN INHARRIME
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4.1. Background
In Mozambique, EMF has been reported from clinical series (Bijlsma, 1979; Ferreira et 
al 1992). An analysis of referrals to a cardiovascular unit over a 10-year period showed a 
striking high attack rate in the district of Inharrime (Figure 4.1a) (Ferreira et al, 2002).
Subsequent research, using clinical screening followed by echocardiographic 
confirmation of diagnosis, showed a prevalence of 8.9%, indicating that EMF is a major 
form of heart disease in that region (Ferreira, 2001). It was thought that these figures 
represent an underestimation of the problem since cardiac auscultation can be normal in a 
considerable number of EMF patients with severe echocardiographic abnormalities 
(Chimenti et al, 2001; Salemi et al, 2005).
Because most studies on EMF have been retrospective and looked at patients in advanced 
stages of the disease, there is no clear understanding of the natural history of the disease, 
and its initial stages have not yet been characterized. 
We designed two studies using systematic sampling of the community coupled with 
detailed echocardiographic examination of all selected individuals. The first aimed at 
determining the prevalence of EMF in Inharrime and investigating its determinants, while 
the second established a cohort of children selected by echocardiography aiming at 
determining the incidence and describe the natural history of the disease. Research 
facilities were implanted in Inharrime village to allow the implementation of such large-
scale studies in this remote area (Figure 4.1b).
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Figure 4.1a. Inharrime’ s main village, in the main National Road.
Figure4.1b. Inharrime Research Centre is located in the main village (Vila Sede)
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4.2. A population study of Endomyocardial Fibrosis in Inharrime
Study area – Inharrime District
Inharrime is a district of Inhambane province in the South East of Mozambique. It is a 
coastal district with 76518 inhabitants, mostly peasants that rely on subsistence 
agriculture and small-scale fishing for food supply. This district has two Posto 
Administrativo (Inharrime and Mocumbi), divided in several Localidades that are in turn 
subdivided into Povoados. The distibution of the population of Inharrime by Localidades 
is as follows:
Localidade Inhabitants Povoados (Selected)
Vila Sede 3970 8(5)
Nhanombe 19603 11(7)
Chacane 12175 7(4)
Dongane 19169 8(5)
Mahalamba 13420 14(7)
Nhapadiane 8181 15(5)
TOTAL 76518 63(33)
There are in total 63 Povoados in Inharrime that belong to the 5 Localidades of the 
district namely: Vila Sede, Nhanombe, Dongane, Chacane, Mahalamba and Nhapadiane. 
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In the Posto Administrativo of Inharrime the povoados randomly selected for the 
prevalence study were: Cambula, Mafassane, Doropa, Chichacha, Nhamuessa, 
Macupulane, Chemane, Chinhembue, Conge, Sihane, Mazonda, Calangane, Muchipa, 
Ngulela, Chirreu, Mavunjane, C Aviação, Nhamibe II, 7 De Abril Chilengue -Sede, 7 De 
Abril Nhacondo-Sede, and 25 De Junho. 
The povoados randomly selected for the prevalence study in the Posto Administrativo of 
Mocumbi were: Cove, Nhapadiane, Muenda, Malene, Marrucula, Mahalamba, Boquisso, 
Cuaiaia, Mavela, Naila, Chambe, and Chitava.
The population density varies from high in the main village (Vila Sede) to extremely low 
in Nhapadiane (where many families have their nearest neighbour as far as 0.5 to 1 Km 
from their house). There is no electricity or tap water, except in the main village (Vila 
Sede) where the main administrative headquarters and the Research Centre are located.
4.2.1. Population and Methods
Sample size calculation
The sample size for the prevalence study in the general population was calculated using 
an adaptation of the two-stage cluster sampling approach. For practical and logistic 
reasons we opted for a cluster size of 30 subjects. Calculation of the number of clusters 
was done using the following formula (Bennet et al, 1991): 
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C = p (1-p) D / s2 b
p: expected prevalence of the condition = 7% (lower prevalence in a previous study) 
D: study design effect (with a rate of homogeneity of 0.02) = 1.58
s: the required standard error of the estimated prevalence, taken to be 1%
b: cluster size
Using the formula we arrived at a sample size of 33 clusters, corresponding to a 
minimum of 990 subjects. 
Sample selection
Selection of the sample was done in two stages: povoados and households. Since there 
was no data on population size of individual povoados, we could not use probability 
proportional to size sampling. We therefore selected 33 villages by simple random 
sampling (Figure 4.2a, 4.2.b). 
The community leaders from the selected villages were asked to create a list of all 
households of each povoado. By this mean we were able to get the number of families in 
each area of the district (Table 4.1) from the community leaders. The first household to 
be studied in each povoado was then selected by random sampling. Second stage 
clustering was done after arrival to the index household.
A household was defined as a group of people living together for more than three months 
and sharing the same food on a daily basis. Upon arrival at the index household informed 
consent was obtained (Figure 4.3a, 4.3b, 4.3c, 4.3d). An identification card was issued to 
the whole family and each member was assigned a unique identification number. 
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Figure 4.2a. Posto Administrativo de Inharrime-Sede with 4 localidades: NHANOMBE 
and VILA SEDE crossed by the main road, CHACANE at 25 kms from the main road 
and DONGANE at 27 kms.
Figure 4.2b. Posto Administrativo de Mocumbi with 2 localidades (MAHALAMBA at 
25 km and NHAPADIANE at 60 km from the national road) 
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The exact location of the house was registered using a GPS system (Garmin e-trex 
Legend) to enable future follow up.
Table 4.1. Eligible participants, families observed, sex distribution, mean age and 
percentages of absent people by localidade in Inharrime District. 
Localidade Eligible 
Participants 
(families 
observed )
Percentage 
from the total 
sample (%)
Female/Male 
ratio
Mean 
Age 
(years)
Absents 
(%)
Chacane 167 (28) 13.37 95/72 22.5 13.2
Dongane 152 (26) 12.17 78/74 21.7 22.4
Nhanombe 298 (50) 23.86 135/105 22.6 9.6
Vila Sede 221 (41) 17.69 153/145 21.9 16.4
Nhapadiane 171 (27) 13.69 91/80 23.8 15.2
Mahalamba 240 (45) 19.22 130/91 23.2 14.5
All 1249 (217) 100.0 682/567 22.6 14.9
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Figure 4.3a. The team had the help of local people to transport material from the nearest 
point accessible by car to the selected houses 
Figure 4.3b. Collection of epidemiological data was done at arrival to the selected 
houses
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Figure 4.3c. GPS registration was performed in all selected houses
Figure 4.3d. Preparation of the houses for echocardiographic examination
Chapter 5 Clinical Characterisation
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
154
Households surrounding the index family within the limits of the village were noted. A 
number was attributed to each of them for simple random selection of the next household 
to be visited. This procedure was repeated for the following families until we reached a 
minimum of 30 subjects.
Data Collection
Demographic data from every subject of the selected family were collected in the form of 
a questionnaire (Appendix 2A). A cardiologist then performed detailed transthoracic 
echocardiography using a hand-carried echocardiography battery-operated system (Vivid 
I, General Electrics) with M-mode, two-dimensional and Doppler (pulsed, continuous 
and colour). The following views were obtained: apical two-, four-, and five-chamber 
views; parasternal long-axis and short-axis at the level of papillary muscles and aortic 
valve; subcostal views; and suprasternal views (parallel to the aortic arch). Hard copies 
with detailed location and type of lesions (Appendix 3) and electronic records of relevant 
data were kept.
EMF Diagnosis and Classification
We defined major and minor criteria for the diagnosis of EMF and used them to define 
the disease and evaluate its severity (Chapter 3). Two blinded experienced cardiologists 
reviewed the records. The diagnosis of EMF was accepted when there was agreement of 
at least two cardiologists, including the researcher.
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Detailed clinical examination was performed in all subjects with echocardiographic 
features of EMF.
Statistical analysis 
Frequencies are given as absolute numbers and percentages or proportions; continuous 
data are reported as mean (standard deviation). We used the chi-square test to compare 
percentages between groups and logistic regression to test for trends in percentages with 
a continuous variable. Association between continuous variables was measured using the 
Pearson correlation coefficient, with a t-test for zero correlation. Analysis of variation 
within the family was carried out using mixed model analysis of variance (ANOVA). The 
“” sign indicates the range of a 95% confidence interval.
Analyses were performed using Minitab, Release 13 (Minitab Inc, State College, PA) and 
SAS, Release 8.02 (SAS Institute, Cary, NC).
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4.2.2. Results
Characterisation of the population
We visited 217 households/families of all selected areas in the district. The average 
family size was 5.8 (range 1 to 19); the mean number of members per family varied 
between 5.6 in Mahalamba and 4.4 in Chacane (Table 4.2). 
There was an acceptable proportional distribution of the individuals observed in the two 
main Administrative Councils: 838 (67.09%) in Inharrime Sede and 411 (32.91%) in 
Mocumbi, which have 53 658 (70.12%) and 22 860 (29.88%) inhabitants, respectively. 
GPS marking confirmed the random distribution of the households selected which is 
presented in Figure 4.4a, 4.4b, 4.4c).
The mean age for each Localidade varied from 21.7 to 23.2 years. In all areas the ratio 
female/male was greater than 1. The mean age, sex ratio and percentage of individuals 
submitted to echocardiography out of the eligible ones after randomisation is shown in 
Table 4.2.  
Characterisation of the Absents
One hundred and eighty-six eligible individuals were absent and therefore not observed 
(14,9%). The distribution of the absent people by Localidade varied from 9.6 in 
Mahalamba to 22.4% in Dongane. The mean age of these people was 22.6 years (Se = 
0.5). From the 186 eligible people who did not participate, 99 were adult male who lived 
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in the neighbouring country (South Africa) working as miners; 79 other selected people 
were not at home but the family denied any disease as the reason for their absence; and 6 
people had travelled to hospitals outside the community searching for treatment, but no 
clear diagnosis of cardiac disease was suggested by the history given by the family. 
Echocardiography was not performed to two participants because they had psychiatric 
problems showing uncontrolled behaviour. There were no refusals to participate.
Characteristics of Participants with EMF
We screened 1063 subjects using transthoracic echocardiography. The mean age (±SE) of 
all screened subjects was 22.5 ± 0.7 years, and 611(57.5±3.0%) were female. All but four 
were black.
Of the 1063 subjects observed, 211 (19.8 ± 2.4%) had EMF. The prevalence of EMF was 
higher in Nhapadiane (35/145; 24.1%), while the lowest prevalence was found in 
Chacane (20/145; 13.8%), as shown in Table 4.2. The distribution of the disease inside 
the district varied between different povoados, with the highest prevalences being found 
in the following povoados: Muenda-Mahalamba (50.0%), Cove-Mahalamba (44.4%), 
Mavela-Nhanombe (39.4%), Chemane-Nhanombe (32.4%) and Cambula-Dongane 
(32.1%). 
There was not significant evidence that the prevalence differed between the different 
Localidade in the district (p=0.32) (Table 4.2). However, the proportion of individuals 
with EMF did differ by Povoado within the Localidade (p=0.009, mixed model ANOVA) 
and between families within a povoado (p=0.039, mixed model ANOVA).
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Localidade Subjects 
Observed
EMF cases EMF Prevalence 
(%)
Chacane 145 20 13.8
Dongane 118 26 22.0
Nhanombe 249 49 19.7
Vila Sede 189 34 18.0
Nhapadiane 145 33 22.8
Mahalamba 217 49 22.6
All 1063 211 19.9
Tabela 4.2. Distribution of subjects observed by localidade
Figure 4.4a. GPS location of houses with cases of EMF           
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Figure 4.4b. GPS location of houses where no echocardiography was done
Figure 4.4c. GPS location of houses whit no case of EMF
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EMF was biventricular in 117 subjects (55.5 ± 6.7%); right-sided in 59 (28.0 ± 6.1%) and
left-sided in 35(16.6 ± 5.0%). Most subjects studied (163/211=77.2%) had mild lesions, 
39/211=18.5% had moderate affection, and 9/211=4.3% had advanced EMF. 
The most frequent lesions in mild disease were apical obliteration of the right ventricle, 
diffuse thickening of the mitral valve, and mild mitral or tricuspid regurgitation.
Echocardiographic Findings  
According to the scoring system used 181 (85.8%) participants had mild EMF, 29 
(13.7%) had moderate lesions, and 1 (0.5%) presented severe structural abnormalities on 
echocardiography. The most frequent lesions were plaques of fibrosis in the right 
ventricular apex (present in 108 individuals, 51.18%), thickening of the anterior leaflet of 
the mitral valve (107, 50.71%), plaques of fibrosis in the interventricular septum (103, 
48.82%), thickening of the posterior leaflet (102, 48.34%) and fibrosis of the moderate 
band (78, 36.97%). (Table 4.3). 
Clinical-echocardiographic correlation
Among the 211 subjects with echocardiographic findings of EMF only 48 (22.7%) had 
symptoms or showed abnormalities on physical examination. Eight (16.6%) individuals 
complained of having atypical chest pain or palpitations. The most common findings on 
physical examination were abnormalities in auscultation (third sound, cardiac murmur 
and premature beats) present in 21 subjects, periorbital edema in 6 and jugular vein 
distension in 4 (Table 4.4).
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Table 4.3. Distribution of specific lesions in individuals with EMF found during the 
study
Echocardiographic features N a Percentage (%)
RV apical endocardial thickening and enhanced density 108 51.18
Thickening of the AML 107 50.72
Enhanced density of the left side of the IVS 103 48.82
Thickening of the PML 102 48.34
Fibrosis of the moderator band 78 36.97
Restrictive filling of the LV 64 30.33
Endocardial thickening of the right side of the IVS 63 29.86
Tricuspid regurgitation 49 23.22
LV apical endocardial thickening or enhanced density 42 19.91
Enhanced density of the MV posterior papillary muscle 42 19.91
Enhanced density of the false tendon 39 18.48
Enhanced density of the TV septal papillary muscle 31 14.69
Enhanced density of the MV anterior papillary muscle 29 13.74
Reduction of TV leaflet mobility 27 12.80
LVPW endocardial thickening and enhanced density 27 12.80
Mitral regurgitation 26 12.32
Retraction of the RV trabecular portion (“apex”) 20 9.48
Obliteration of the RV trabecular portion (“apex”) 17 8.06
LV thrombus 4 1.90
a Number of individuals presenting the specific feature out of the 211 participants diagnosed with EMF
RV right ventricle; LV left ventricle; AML anterior mitral leaflet; PML posterior mitral leaflet; 
IVS interventricular septum; MV mitral valve; TV tricuspid valve; LVPW left ventricular posterior wall
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Possible determinants
Age: The percentage of subjects with EMF differed between the various age groups 
(p=0,001) but there was no evidence for systematic increase or decrease with age 
(p=0.95) as shown in Figure 4.5. The prevalence was highest in the 10-19 years old 
group (28.1 ± 5.5%). Left-sided EMF was more common among those over 30 (32.7% 
versus 11.3%, p=0.001).
Gender: The prevalence of EMF was significantly higher in men (23.0% vs. 17.5%, 
p=0.026), the main difference occurring in the 20-29 age group. The percentage of each 
type of EMF lesions (left, right and bilateral) did not differ between the two sexes 
(p=0.29) (Table 4.5).
Familial predisposition: Out of 214 families, 99 had no EMF cases, 63 had one case and 
52 had more than one case. There was no correlation between the percentage of subjects 
with EMF in a family and the observed family size (correlation = 0.095; p = 0.17). 
However, the chance of having the disease was higher when other members of the family 
had it (p=0.001, using a logistic regression model). If EMF status was independent of 
other members of the family, the prevalence among families with at least one case would 
be approximately 28%. The observed prevalence was approximately 32% when another 
member of the family had the disease, and reached 39% for subjects with three or more 
family members having the condition.  
Chapter 5 Clinical Characterisation
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
163
Table 4.4. Clinical findings in 48 individuals with echocardiographic features of EMF
Clinical Features N Percentage (%)
Abnormal auscultation 21 43.75
Periorbital edema 6 12.50
Jugular vein distension 4 8.33
Cyanosis 3 6.25
Hepatomegaly 3 6.25
Splenomegaly 3 6.25
N = Number of individuals presenting the clinical feature
Table 4.5. Distribution of frequencies and percentages of EMF by gender.
Gender Bilateral EMF Right EMF Left EMF All
Female 57(53,3%) 28(26,2%) 22(20,6%) 107
Male 60(57,7%) 31(29,8%) 13(12,5%) 104
All 117(55,5) 59(28,0%) 35(16.6%) 211
Chapter 5 Clinical Characterisation
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
164
0
5
10
15
20
25
30
35
40
45
0-9 10-19 20-29 30-39 >40 All
Age groups (years)
Pr
ev
al
en
ce
(%
)
p=0.026
dark bar = all slashed bar = male blank bar = female
Figure 4.5. Age distribution of EMF cases detected in the community 
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4.2.3. Discussion
A high prevalence of EMF was found in this rural community using echocardiographic 
screening. We found a non-uniform distribution of the prevalence of EMF inside the 
district with 12 out of the 33 povoados reaching prevalence of more than 25%, while 
others had less than 5% of people affected (Mazonda-Chacane and Malene-Mahalamba 
with 3.6% and 3.5% respectively). Inharrime district is crossed by several rivers and is 
part of the Mozambican Coast (Indian Ocean), and it is interesting to notice that the areas 
with higher prevalence of EMF were located mainly near the lakes or rivers. Weather this 
is of relevance in search for an environmental factor like a vector for infectious disease as 
the trigger of EMF is an issue that needs to be further studied.  
Mild asymptomatic EMF was the most common form in contrast with findings from 
clinical series, which reveal predominance of severe debilitating disease (Freers et al, 
1996b; Tharakan et al, 1993; Venkitachalam et al, 1993). An extreme phenotypic 
variability of EMF was found in this community, with EMF lesions varying from patchy 
endocardial fibrosis without any hemodynamic changes, to extensive mural and 
atrioventricular valve endocardial fibrosis with resulting structural and hemodynamic 
changes. Our findings suggest that patients seeking medical attention represent a minority 
of the affected individuals, stressing the importance of community research to uncover 
the natural history and pathogenic mechanisms of this condition.
The most frequent type of EMF in the community was BEMF. There was predominance 
of structural lesions on the right side of the heart, either in isolation or as part of bilateral 
disease. Interestingly LEMF, was the less common form of disease, and affected 
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predominantly adults over 30 years. Since LEMF is known to be the most lethal form of 
disease in children, these adults could represent a particular subset of patients affected in 
their childhood, who had mild abnormalities and entered a long steady period (without 
progression of the disease), reaching adulthood without major cardiac abnormalities. 
Inharrime, like other areas of Mozambique, is an area with high prevalence of rheumatic 
heart disease. The use of standard criteria and a scoring system to diagnose and classify 
EMF in the community was of extreme relevance in differential diagnosis. In the absence 
of large plaques of fibrosis the distinction between left-sided EMF and mitral 
regurgitation due to Rheumatic Heart Disease relied on specific echocardiographic 
features. The diagnosis of EMF was favoured when echocardiography revealed diffuse 
thickening of the anterior mitral leaflet, areas of endocardial thickening involving the 
posterior wall and the papillary muscles, and obliteration of either the trabecular portion 
of the right ventricle or the recess behind the posterior mitral leaflet.  
This study showed that EMF in the community affects mainly children and young 
adolescents, corroborating findings from in vivo hospital-based studies (Parry, 1964; 
Somers, 1990) or autopsies (Bijlsma, 1976; Shaper et al, 1968). Females present a second 
peak of prevalence in the fourth decade of life (Figure 4.5). The reason for this bimodal 
age distribution in women that has been reported previously in some clinical series 
(Shaper, 1972; Rutakingirwa et al, 1999) is not fully understood. The second peak during 
reproductive years may be related to the increased number of pregnancies and prolonged 
time of breast-feeding in women from these poor settings, which would become more 
prone to reactivation of a quiescent disease acquired early in life. 
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The higher frequency of male individuals found in our study suggests that gender is a 
determinant of the disease in this particular area. The results of gender distribution of 
EMF patients in several clinical series have not been consensual with some showing male 
(Brockington an Edington, 1972; Jaiyesimi, 1982) or female (Connor et al, 1967; Shaper, 
1972) preponderance, while others show no difference between sexes (Parry, 1964). Our 
findings are important since male predominance in hospital setting in poor endemic areas 
could be interpreted as being due to cultural believes and misconceptions that would 
determine selective referral of male children to medical care in detriment of girls.
The familial occurrence of EMF in the community that was found in our study needs to 
be further explored. There is the possibility of this pattern being linked to genetic 
susceptibility or to several environmental factors affecting people who live together, like 
exposure to the same transmissible diseases or poisoning agent. Although we did not 
systematically collect data on the characteristics of the environment, dietary factors and 
economic status of the families, there was no evidence of variation in the standard of 
living inside the same area, which would explain the difference in prevalence between 
families from the same povoado.
The prevalence of endomyocardial fibrosis was higher than that found in a previous 
survey in Inharrime using clinical screening followed by echocardiographic confirmation 
of those individuals with abnormal auscultation (Ferreira, 2001). This is understandable 
since EMF can course with few or no auscultatory signs, particularly in right forms of the 
disease when there is free tricuspid regurgitation, and in mild EMF where there are no 
hemodynamic changes. Our results show that echocardiographic screening adds 
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sensitivity and precision to the diagnosis of EMF, by detecting early disease and 
asymptomatic individuals.
There are some limitations to this study. Some participants had echocardiographic 
findings suggesting EMF but did not reach the necessary scores to be considered definite 
cases. Weather these individuals represent early stages of the disease or have forms of 
mild disease that will persist in quiescent stage forever are questions that cannot be 
answered with certainty now. The clarification of these important issues requires cohort 
studies looking at incidence and mode of progression of the disease in this endemic area, 
and should be facilitated by use of the new standard criteria for diagnosis. Such follow up 
studies would also be used to validate our classification.
We acknowledge that 186 (14.9%) eligible individuals were absent and therefore were 
not submitted to echocardiographic screening. This value should be considered 
acceptable in a large-scale community study like ours. Importantly, the results of the 
analysis of the demographic characteristics of these individuals did not show any 
difference to that obtained for the whole sample of the population. 
In conclusion, this study showed a high prevalence of EMF in a rural community of 
Mozambique and demonstrated that echocardiography detectes and characterizes early 
and asymptomatic stages of the disease. In this population the disease appeared to affect 
predominantly children, with higher prevalence in males. The newly described scoring 
system has the potential to evaluate the mode, mechanisms and rate of progression of 
EMF. Further research is needed to determine the role of genetic susceptibility in 
determining the different phenotypes and in explaining the familial occurrence.
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The large population of subjects affected offers unique opportunities for studying the 
basic molecular mechanisms responsible, which could help in evolving strategies for 
prevention and treatment of the disease, and could be valuable for understanding other 
forms of cardiomyopathy and diseases involving fibrosis.
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4.3. Establishing a cohort of school children in Inharrime 
4.3.1. Population and Methods
Sample selection and inclusion criteria
We randomly selected 10 out of 50 schools from Inharrime (Figure 4.6, Table 4.6). In 
each school all children from the second level were invited to participate in the study, 
through meetings between the parents and the teachers, who had been trained by the 
researcher. Parents had to give informed consent for their children to be included in the 
study. 
Data collection
Between July and September 2006 teachers collected demographic data from every 
selected child by filling in a standardized questionnaire (Appendix 2B). A unique 
identification number was attributed to all participant children. During the month of 
October 2006 detailed transthoracic echocardiography was performed to all children 
using a hand-carried echocardiography battery-operated system (Vivid I, General 
Electrics). We obtained M-mode, two-dimensional and Doppler (pulsed, continuous and 
color) images. The following views were obtained: apical two-, four-, and five-chamber 
views; parasternal long-axis and short-axis at the level of papillary muscles and aortic 
valve; subcostal views; and suprasternal views (parallel to the aortic arch). Hard copies 
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with detailed location and type of lesions (Appendix 3) and electronic records of relevant 
data were kept.
Figure 4.6. Pictures of 2 classes selected for the prospective studies in different schools 
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SCHOOLS STUDENTS TEACHERS
Senduza II 31 Armando Francisco
Cuaiaia 43 Armando António/Gaspar Languisso
Mahalamba 118 P. Mahique/ Olga Malate/ R. Cumbi/C. Lisure
Inhantumbo 47 Teresa Júlio/Luis Nhiuane
Mahessa 35 Jerónimo Muholiciane/Ernesto Hele
Coche 47 Julião Paulo/Francelino Deve
Magula 38 Domingas Fernando/Mariamo Abdula
Incuane 58 Horácio Xavier/Arlindo Afonso Cumbi
Cambula 33 Lídia Machava/João Chambe
Chilorane 40 Basílio Zango/Rafael Augusto
Table 4.6. List of the 10 schools randomly selected from a total of 50. All students from 
second level were invited to participate in the cohort follow-up study. The teachers 
responsible for each group of selected students are also included in the table.
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Blood collection and Assays
Blood samples were collected from every fifth child included in the study (following the 
code number), by puncture of the antecubital vein. A rapid test for malaria antigen was 
performed on site. Blood smears were prepared for leukocyte count, eosinophil count and 
search for malaria parasites. 
Statistical analysis
Frequencies are given as absolute numbers and percentages or proportions; continuous 
data are reported as mean (standard deviation). We used the chi-square test to compare 
percentages between groups and logistic regression to test for trends in percentages with 
a continuous variable. Association between continuous variables was measured using the 
Pearson correlation coefficient, with a t-test for zero correlation. Analysis of variation 
within family was carried out using mixed model analysis of variance (ANOVA). The 
“” sign indicates the range of a 95% confidence interval.
Analyses were performed using Minitab, Release 13 (Minitab Inc, State College, PA) and 
SAS, Release 8.02 (SAS Institute, Cary, NC).
Ethical Issues
Signed informed consent was obtained from parents of all children participating in the 
study. Children with cardiac disease were offered free treatment and follow-up in 
Inharrime Research Centre or, if surgery was indicated, at the Heart Institute in Maputo. 
Oral treatment with Arinate was provided to all children with malaria infection. 
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4.3.2. Results
There were 363 eligible children. The mean age of participants was 8 (± 1) years, and 195 
(53.7%) were girls. 
Two hundred ninety-six children were included in the study: 268 (90.5%) had normal 
hearts; 25 (8.5%) had endomyocardial fibrosis; and 3 (1.0%) had rheumatic heart disease.
Children with EMF were found in all schools.
Blood was collected from a sample of 72 children randomly selected showing that most 
children (49; 68.1%) had malaria infection, although denying any symptoms. The mean 
eosinophil count was 1.2 x 109/L (± 2.4).
There was no statistically significant difference in any of the measured parameters 
between the participants with and without malaria infection. Also no difference was 
found when comparing participants with and without hypereosinohilia. 
Classification of Endomyocardial Fibrosis (25 children)
Most children (16; 64.0%) had BEMF, 7 had REMF (28.0%) and the remaining 2 (8.0%) 
had LEMF. Regarding the severity 12 (48.0%) children had mild lesions, 10 (40.0%) had 
moderate lesions and 3 (12.0%) had severe EMF. 
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Comparison between participants with and without EMF
There was no significant difference in age (p=0.69), sex (p=0.69), leukocyte count 
(p=0.99), malaria infection (p=0.34) and eosinophil count (p=0.54) between children with 
and without EMF.
Other Diseases
We found 3 children with rheumatic heart disease (1%) and 2 children had Atrial Septal 
Defect.
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4.3.3. Discussion 
The prevalence of EMF in school children was high, but corresponded only to nearly half 
of that found in the general population, in concordance with the fact that in the whole 
population of Inharrime the disease affects mostly older children than the group selected 
for this study. However, since EMF in its severe forms is a very debilitating disease, we 
must also consider the possibility of children with severe EMF being symptomatic and 
therefore absent from school during this study. 
The prevalence of malaria, an infection that has been implicated in the pathogenesis of 
EMF, was also very high in these children, a finding that can be explained by the fact that 
Inharrime District has the highest transmission rate for malaria in Mozambique. The 
finding of almost no symptomatic malaria might be explained by acquisition of immunity 
due to frequent inoculation of the parasite in early years of life, a common event in 
endemic areas (Riley et al, 1994). There is need to test the immune response in these 
children to corroborate this hypothesis and explain this interesting result. Considering 
that malaria and EMF are highly prevalent in Inharrime we think that the occurrence of 
both diseases in 3 children is explained by chance. 
Blood hypereosinophilia was common in school children in this district, but no 
statistically significant difference was detected when comparing children with EMF from 
those without the disease. Hypereosinophilia is a common finding in people from 
endemic areas for EMF as reported from studies in Nigeria (Ijaola and Falase, 1988; 
Urhoghide and Falase, 1987).  Blood films and stool specimens of primary and secondary 
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school children from two rural communities (one an endemic area for EMF and one a 
non-endemic area for EMF) areas were examined, and the results showed that the mean 
eosinophil counts and the parasitic infection rates were similar in both communities 
(Ijaola and Falase, 1988).
Several parasitic infestations are endemic in Mozambique (Dgedge et al, 2001) and could 
be the reason for such high prevalence of high eosinophil counts in children from 
Inharrime, namely helminths, schistosomiasis and filariasis. The burden of 
schistosomiasis, for instance, is significant and affects over 80% of children in school 
surveys carried out in parts of the country (Gujral et al, 2000; Traquinho et al, 1998). In 
our study the presence of parasitic infestations was not investigated for logistical reasons. 
Inharrime, like other rural districts of Mozambique has a high of dropout rate among 
school children, which has been shown to be more important in the first year. By 
selecting children in their second years of studies we expect to lose few children 
participating in our prospective studies.
The involvement of teachers and parents at the beginning of this long-term project was of 
paramount importance. They participated as partners of the research team and helped 
with the organization of the fieldwork. They have been trained for detection of signs of 
cardiovascular disease, and will be integrated in the prospective studies.
All children will be followed through clinical and echocardiographic evaluation every 18 
month. While the follow up of children with EMF is expected to help to understand the 
natural history of this condition and identify predisposing factors, the establishment of a 
cohort of 271 children without EMF will allow to determine the incidence and rate 
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of progression of the disease, including the assessment of the value of the minor lesions 
as predictors of EMF.  
This group of children will constitute a cohort that will be followed by serial 
echocardiographic screening for determination of the incidence and rate of progression of 
EMF in the community.
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4.4. Conclusions
This epidemiological research showed a high prevalence of EMF in a rural community of 
Mozambique and demonstarted that echocardiography detects and characterizes early and 
asymptomatic stages of the disease. In the population studied EMF affects predominantly 
children, with higher prevalence in males. Further work is required to evaluate the mode, 
mechanisms and rate of progression of EMF, as well as the role of genetic susceptibility 
in determining the different types and familial occurrence.
The large population of subjects affected who were identified and echocardiographic 
phenotype was extensively characterized offers unique opportunities for studying the 
basic molecular mechanisms responsible for EMF, which could help in developing 
strategies for prevention and treatment of the disease. This knowledge could also be 
valuable for understanding other forms of cardiomyopathy and diseases involving 
fibrosis. 
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Chapter 5
CLINICAL CHARACTERISATION OF ESTABLISHED EMF
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5.1. Background
EMF has been classified according to the mode of presentation, the type of evolution of 
the disease and the distribution of lesions inside the heart, but the different types seem to 
overlap. Designations such as acute, chronic, steady (Abrahams, 1962; Guimaraes, 1993) 
and active (Andy, 1998) have been used without any clear definition of their meaning. 
Some clinical features of EMF are striking and have stimulated a lot of publications. 
Advanced stages of REMF have distinctive clinical features like the typically enormous 
ascitis with no pedal edema, central cyanosis, exoftalmus, and clinical feminization of 
male patients (Abrahams, 1962; Bolarin and Andy, 1982). The pathophysiology of ascitis 
in EMF patients remains the subject of controversy since not fully explained by heart 
failure and retrograde congestion (Jaiyesimi, 1982). Similarly, the origin of cyanosis has 
been debated, since not always related to the presence of a persistent foramen ovale or 
low cardiac output syndrome.
Describing the clinical profile of EMF patients in this era of use of echocardiography and 
the possibility of early recognition of the disease is of paramount importance. We 
therefore designed a study to characterize the clinical, echocardiographic and biological 
profile of EMF patients who seek medical care in Mozambique.
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5.2. Population and Methods
A national registry for EMF patients was established at the Heart Institute. Tertiary and 
quaternary referral hospitals from Mozambique were contacted and asked to transfer all 
patients with the diagnosis of EMF to be evaluated and included in the registry. In 
addition, we assessed all patients already diagnosed and assisted at the Heart Institute. 
A standard flowchart was designed (Diagram 5.1) and clinical, echocardiographic and 
laboratory data were collected.
Clinical examination
Complete physical examination was performed in all patients. Scoring systems were 
developed and applied for the evaluation of ascitis, hepatomegaly and splenomegaly 
(Tables 5.1, 5.2, 5.3).
Cardiovascular diagnostic techniques
Electrocardiography, chest radiography and echocardiography were performed to all 
patients. Computed Axial Tomography of the chest and cardiac catheterization were 
indicated when there was severe distortion of the cardiac anatomy with lesions that 
seemed suitable for surgery. The 24h monitoring of the cardiac rhythm was indicated in 
patients with suspicion of paroxysms of atrial or ventricular arrhythmia.
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Classification of EMF
Patients were classified as detailed in Chapter 3, using the following flow chart:
Diagram 5.1: Flowchart used to assess and manage EMF patients included in the registry
Patients with EMF
Informed Consent Obtained
Inclusion in Registry
Collection of Demographic and Clinical Data
Blood Collection and Storage
Electrocardiography, Chest Radiography
Detailed Echocardiography
Cardiac lesions 
suitable for surgery
Cardiac lesions 
unsuitable for surgery
Pre-operative Programme
Surgery
Medical Therapy
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0 Absence of ascitis
1 Small (changes with position)
2 Moderate (easily detected and allowing palpation of abdominal organs) 
3 Severe (difficult palpation of abdominal organs)
4 Giant (under tension, palpation of abdominal viscera impossible)
Table 5.1. Classification used for assessment of the severity of the ascitis
0 Absence of hepatomegaly
1 Lower liver border palpable at costal border or only on inspiration
2 Lower liver border palpable between costal border and umbilicus
3 Lower liver border palpable at the level of the umbilicus
4 Lower liver border palpable below the level of the umbilicus
Table 5.2. Classification used for assessment of the decree of hepatomegaly
0 No palpable spleen
1 Spleen border at the level of the costal border
2 Spleen border palpable between the costal border and the umbilicus
3 Spleen border palpable at the level of the umbilicus
4 Spleen border palpable below the level of the umbilicus 
Table 5.3. Classification used for assessment of the degree of splenomegaly
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Other Investigations
The laboratory workout included a complete hematological evaluation, measurement of 
inflammatory markers (C-reactive protein and eritrosedimentation rate), renal function, 
liver function, urinalysis and stool examination. Blood smears were prepared for all 
patients for manual count and characterization of eosinophils (using May-Grunvald 
staining). 
Hypereosinophilia was defined as an absolute eosinophil count of 1,5 x109/L or greater.
Patients were also submitted to a screening for infectious diseases with known high 
prevalence in our setting, namely malaria, tuberculosis, schistosimiasis, helminths and 
HIV. 
The inflammation markers and eosinophil count were repeated every three months and 
whenever there was recrudescence of heart failure or clinical signs of activity.
Statistical Analysis
Frequencies are presented as absolute numbers and percentages or proportions; 
continuous variables are reported as means ( SD) or medians (IQrange) according to the 
distribution of the values. The ‘’ sign indicates the range of a 95% confidence interval.
We used the chi-square test to compare percentages between groups; p values <0.05 were 
considered for significance. 
Analyses were performed using SPSS software. 
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5.3. Results
Patients
There were 64 EMF patients already followed at the Heart Institute at the beginning of 
the research programme; 98 new patients were referred from other hospitals after the 
starting of the project; 8 were detected in the community and referred to the Heart 
Institute for further follow-up; and 5 had the diagnosis done at the Heart Institute for the 
first time without being referred. The registry had 175 patients who were submitted to the 
investigations described above in Figure 5.1. 
Epidemiological profile
The patients were referred from all regions of the country. They came mostly from 
tertiary hospitals (91; 52.0%) and from the quaternary hospital in Maputo (69; 39.4%). 
Origin: Most patients 101 (57.7%) were originally from Inhambane (one of the 10 
provinces of Mozambique) where Inharrime district is located.  
Age and Gender: The median age at diagnosis was 13 years (IQ range 8-20), ranging 
from 3 to 64. The age distribution of patients at the time of diagnosis is shown in Figure 
5.2. Ninety-two patients were males (52.6%).
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Clinical findings on presentation
Most patients (155; 88.6%) presented in classes III and IV of the NYHA (Figure 5.3). 
The median BMI was 17.0 (IQrange 14.9-20.0) and 19 patients (10.9%) had extreme 
Nothern Region
Central Region
Southern Region
Figure 5.1: The 175 patients were referrals from the all regiosn of the country
137
Inhambane 101 (57.7%)
Gaza 19 (10.9%)
Maputo 17 (9.7%)
6
Niassa 1 (0.6%)
Cabo Delgado 1 (0.6%)
Nampula 4 (2.3%)
32
Zambezia 18 10.3%)
Sofala 13 (7.4%)
Manica 1 (0.6%)
Tete 0
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Figure 5.2. Distribution of EMF patients by age at diagnosis 
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Figure 5.3. NYHA functional class of EMF patients at presentation
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cachexia. The children and adolescents were in general small for age and presented poor 
development of the secondary sexual characters.
Sixty-eight patients (38.9%) had severe ascitis (Figure 5.4). Periorbital edema was 
present in 54 (30.9%) patients (Figure 5.5); cyanosis in 89 (50.9%); and proptosis in 38 
(21.7%). Severe splenomegaly was found in 25 patients (14.3%).
Investigations at time of diagnosis
The median cardio-thoracic index at admission was 74.0% (IQrange 67 to 86). Examples 
of chest radiographies of EMF patients are shown in Figures 5.6 - 5.9). Patients with 
REMF had the higher cardio-thoracic indexes than those with LEMF or BEMF, 
sometimes ratios approaching 1. In certain patients the evaluation of the cardiothoracic 
was difficult due to the presence of pleural effusion.
Rhythm disturbances were common (47; 26.9%) mainly atrial fibrillation which was 
found in 35 patients (20.0%). Figure 5.10 shows some of the most common 
electrocardiographic features in patients with EMF. In advanced REMF there is 
commonly low voltage, broad tall right atrial p waves, qr pattern in V1 and T wave 
changes. Atrial flutter and fibrillation are the most common arrhythmia but ventricular 
ectopic beats are also frequent in late stages of the disease.  
Inflammation markers that are considered laboratory signs of activity (high CRP or ESR 
>30) were present in 87 (49.7%) patients. The mean eosinophil count was 1.2 (range 0-
8.8); 43 patients (25.4%) had absolute eosinophilia greater than 1.5 x 109/L. 
Characterization of eosinophils was performed in 95 patients; degranulation was found in 
50 (52.6%) with a median percentage of 8% (IQrange 0-32%). 
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Figure 5.4. Large ascitis and evidence of severe emaciation
Figure 5.5. Facial edema, a common finding both in initial and late phases of EMF
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Figure 5.6. The chest radiography in BEMF shows cardiomegaly mainly due to 
enlargement of atria and mild pulmonary congestion
Figure 5.7. BEMF with predominance of right lesions with aneurysmal right atrium and 
mild left pleural efusion.
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Figure 5.8. The chest radiography in predominant LEMF presents cardiomegaly due to 
bi-atrial dilatation and pulmonary congestion
Figure 5.9. Pericardial effusion is a common finding in both early and late stages of the 
disease and further impedes ventricular filling
Chapter 5 Clinical Characterisation
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
193
The median hemoglobin level was 11.5g% (IQrange 10.4-13.1); 97 patients (58.4%) had 
hemoglobin below 12g%. The median platelet count was 207 (IQrange 151-283).
Hypoproteinemia was present in 45 (25.7%) patients, liver dysfunction in 31 (17.7%) and 
renal dysfunction in 5 (2.9%). Two patients had kwashiorkor.
Associated Conditions
Malaria infection was present in 13 (7.4%) patients at diagnosis, while active tuberculosis 
was found in 6 (3.4%). Three patients (1.7%) had hepatic schistosomiasis and three 
(1.7%) had HIV infection. None of our patients had associated infective endocarditis.
There was association of EMF with Myasthenia Gravis in two patients. In six patients 
(3.4%) there was association with Rheumatic Heart Disease. 
Episodes of bronchospasm occurred in 45 (25.7%) patients.
Classification
Echocardiography revealed that most patients had biventricular EMF (95; 54.3%), 55 
(31.4%) had REMF and the remaining 25 (14.3%) had LEMF (Figure 5.11).  Only 20 
(11.4%) had minimal lesions for which there was no clear benefit of surgery. Ninety-four 
patients (53.7%) had severe or advanced disease, meaning grades II or IV of severity 
(Figure 5.12). Seventy patients (40.2%) presented with intracavitary thrombi and 12 
(6.9%) had ventricular calcification when first diagnosed.
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Figure 5.10: The ECG in advanced REMF commonly shows low voltage, broad tall right 
atrial p waves, qr pattern in V1 and T wave changes (top). Atrial fibrillation is the most 
common arrhythmia but ventricular ectopic beats are also frequent in late stages of the 
disease (bottom).  
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Figure 5.12.  Distribution of grades of severity of EMF from mild (I) to advanced (IV)
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Most patients (153; 87.4%) had cardiac lesions that needed surgical correction. However, 
63 (36%) had advanced lesions or other medical conditions that were considered contra-
indications to surgery, mainly severe and persistent ascitis (49; 26.9%), severe pulmonary 
hypertension (4; 2,3%) and extreme cachexia (19;10.9%).
Determinants for type and severity of EMF 
The features that differed between the BEMF, REMF and LEMF were the age (p=0.014) 
and the cardiothoracic ratio (p<0.001). Bilateral EMF was diagnosed later in life when 
compared to REMF (at 18 years versus 13 years for REMF and LEMF). Patients with 
REMF presented the highest cardiothoracic index.
The parameters that differed according to the severity of EMF were the body mass index 
(p=001) lower in patients with grade IV and the cardiothoracic index (p<0.001) that was 
also higher in patients with Grade IV. 
The mean hemoglobin levels were higher in both extremes of the severity classification, 
11.9 and 12.3 g/dL for mild and advanced EMF respectively (p=0.046).
The demographic and clinical characteristics of patients according to the type and 
severity of EMF are presented in Tables 5.4 and 5.5.
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Follow-up
Staging and Mode of Progression
Of the 175 patients from the National Clinical Registry 11(6.3%) did not complete the six 
months follow up immediately after diagnosis. The mean follow-up of patients was 21 
months (range 0.2 to 78 months). 
Clinical Features BEMF
N 95
(mean ± SD)
REMF
N 55 
(mean ± SD)
LEMF
N 25
(mean ± SD)
p value
Age (years) 18 ± 12 13 ± 8 13 ± 6 0.014
Body Mass Index 17.9 ± 4.4 18.5 ± 3.0 16.5 ± 4.1 0.145
CTRatio (%) 72.1 ± 13.1 82.5 ± 12.9 68.4 ± 12.8 <0.001
Hemoglobin (g/dl) 11.4 ± 1.8 12.1 ± 1.7 11.5 ± 2.3 0.129
Hematocrit (%) 36.8 ± 5.4 38.6 ± 5.0 36.5 ± 6.3 0.133
Eosinophils (x109/L) 1.02 ± 1.5 1.20 ± 1.4 1.55 ± 1.6 0.306
ESR (mm/1h) 37 ± 39 31 ± 30 36 ± 27 0.532
ESR erythrosedimentation rate
Table 5.4. Demographic and clinical characterization of patients according to EMF type 
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The majority of patients had chronic disease which was either quiescent (64;36.6%) or 
with recurrence of activity within the period of follow up (34;19.4%). Considering the 
patients with signs of activity at diagnosis 38 (21.7%) had remission, 18 (10.3%) had 
persistence of activity and in 10 (5.7%) there was progression of the disease to a higher 
degree of severity during the first 6 months after diagnosis. The results of the first 6 
months of follow up are presented in Figure 5.13.
Clinical 
Features
Mild 
Grade I
Moderate 
Grade II
Severe 
Grade III
Advanced 
Grade IV
p value
Age (years) 21 ± 14 15 ± 12 15 ± 8 14 ± 11 0.133
BMI 20.7 ± 5.5 16.7 ± 3.8 18.0 ± 3.6 18.4 ± 3.5 0.001
CTR (%) 53.9 ± 12.0 71.2 ± 11.4 79.3 ± 10.8 83.5 ± 12.6 < 0.001
Hb (g/dl) 11.9 ± 2.1 11.1 ± 2.1 11.8 ± 1.7 12.3 ± 1.6 0.046
Htc (%) 37.4 ± 5.6 36.4 ± 6.4 37.4 ± 4.8 39.1 ± 4.6 0.326
Eos (X109/L) 0.5 ± 0.6 1.4 ± 1.8 1.3 ± 1.5 0.8 ± 1.1 0.112
ESR (mm/h) 28 ± 26 39 ± 30 34 ± 29 37 ± 31 0.603
BMI body mass index; CTR cardiothoratic ratio; Hb hemoglobin; Htc hematocrite; Eos absolute eosinophil 
count; ESR erythrosedimentation rate
Table 5.5 Demographic and clinical characteristics of EMF patients according to severity 
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Twenty-nine patients were lost for follow up, since they did not appear fo evaluation in 
the last 12 months.
Mortality
Twenty-three patients (13.1%) died during the period of the study. Most had chronic 
disease with frequent recurrences of activity (19; 39.1%) or active disease without 
remission of activity and rapid progression of structural changes (6; 26.1%), as shown in 
Figure 5.14. The survival rate of patients with EMF from the clinical registry was 70% at 
5 years after diagnosis (Figure 5.15).
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19.4%); active persistent (AP) 18 (10.3%); active rapidly progressive (ARP) 10 (5.7%); patients not 
classified 11 (6.3%).
Figure 5.13: EMF patients by clinical stage. 
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Figure 5.15. The survival curve of EMF patients from the clinical registry shows that 
nearly 70% of patients are alive five years after  the diagnosis.
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5.4. Discussion
The establishment of a National Registry for EMF was important for improvement in 
management and follow up of patients from around the country. The distribution of 
patients according to the region of the country is related to the geographical accessibility 
to the Heart Institute in Maputo. More than ¾ of the patients are residents in one of the 
three provinces of the South of Mozambique, and interestingly more than half (100; 
57.5%) are originally from Inhambane province. This is remarkable since, of the three 
southern provinces, Inhambane is the one that is located farer from the Heart Institute. 
These findings corroborate data from Ferreira et al (2002), who studied the geographical 
distribution of EMF in Mozambique in another referral centre and showed a striking high 
prevalence area in Inhambane province, particularly in Inharrime. The closer provinces, 
Maputo and Gaza, referred respectively 19 (10.9%) and 17 (9.8%) patients.
The rate of lost for follow up of 16.5% is acceptable, if we consider that only 17 (9.7%) 
patients were referred from areas within 200km from the referral centre. Importantly, 
22.3% of patients were sent from the seven provinces located between 1000 and 2000km 
from the Heart Institute. Some of the patients lost for follow up may have died, but 
because their houses are located in remote areas so far from the Institute and the families 
do not have a mean of contact, we were not able to contact any next to keen.  
The Mozambican health system is based on nursing personal for assistance at the primary 
level of health care (Health Posts and Health Centres). There are approximately 500 
doctors for 20 millions people, with more than 75% of them concentrated in the Southern 
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region, near the capital Maputo. Each province has a tertiary level hospital where doctors 
specialized in Pediatrics and Internal Medicine send patients that need further assistance 
from Cardiologists to the quaternary hospitals located in each of the three main 
geographical regions (South, Centre and North), which have one cardiologist each.
Once the National Registry was started most EMF patients were referred directly from 
tertiary hospitals or by cardiologists from the quaternary hospitals. This can be partially 
explained by the absence of knowledge of the real importance of the disease in the 
country that leads to underdiagnosis but can also surely related to the difficulty of 
diagnosing EMF on the basis of the clinical examination. Even in endemic areas with 
high index of awareness the diagnosis of early phases of this condition needs 
echocardiography and warrants a certain level of clinical knowledge and laboratory 
capacity to differentiate it from diseases that are also prevalent in the same communities. 
In Mozambique these include rheumatic heart disease, constrictive and tuberculous 
pericarditis, tuberculous peritonitis, intestinal schistosomiais.
The male predominance found in this clinical series has been attributed to cultural 
misperceptions that influence the access of girls from remote rural areas to treatment at 
referral units. However, gender seems to be an independent determinant for EMF, as 
suggested by our epidemiological studies (Chapter 4). 
More than 50% of patients included in our registry were diagnosed between 8 and 20 
years of age. Despite their young age most had chronic and severe disease, associated 
with signs of malnutrition, stunted growth, long-standing heart failure, atrial fibrillation 
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and presence of endocardial calcification. This suggests that considerable amount of time 
had passed between the initial injury and presentation to medical institutions, confirming 
that initial injury occurs early in life, and most importantly attests for the malignant 
nature of EMF.
Approximately ¾ of our patients had right lesions either in isolation or as part of bilateral 
EMF. These patients presented acceptable tolerance to exercise and had persisted 
relatively asymptomatic for several months, despite severe disease associated with 
cardiomegaly and intermittent pericardial effusion. This unexpected exercise capacity has 
also been reported in studies from Nigeria, where patients with REMF without severe 
heart failure had considerable lack of disability and relative longevity, associated with the 
capacity to increase cardiac output and slightly decrease the right atrial pressure on 
exercise (Abrahams, 1962). 
Ascitis was a peculiar finding in EMF patients irrespective of the ventricle affected, but 
more prominent in REMF. Accumulation of fluid in the peritoneal space could not be 
fully explained by congestion due to right heart failure since not associated to pedal 
edema in most cases. The pathophysiology of this peculiar feature has been the subject of 
controversy (Jaiyesimi, 1982). Its origin has been attributed to protein losing enteropathy 
due to inflammatory changes in the bowel and peritoneum (Freers et al, 2000), which 
would cause both peritoneal inflammation and decreased reabsorption of peritoneal fluid. 
Cachexia was another very distinctive clinical feature in Mozambican patients with EMF. 
In severe and advanced disease it could be explained by the sustained low cardiac output. 
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However, the body mass index of patients was low for all degrees of severity with no 
particular trend. One possible explanation for these findings comes from a study in 
Uganda that demonstrated the presence of skeletal muscle fibrosis in biopsies samples 
from EMF patients suggesting a generalized fibrous process that would explain the 
remarkable skeletal muscle atrophy common in these patients (Freers et al, 2000). 
The mean levels of hemoglobin were above the normal for our population, which has a 
high prevalence of anemia due to repeated episodes of malaria infection and intestinal 
parasitic diseases (Dgedge et al, 2001). Indeed the mean levels of hemoglobin in EMF 
patients were higher than those found usually in children from these rural areas without 
any the disease. Interestingly, and linked to this finding, central cyanosis was frequent in 
our EMF patients, mostly those with right-sided disease. Similarly, central cyanosis 
occurred in about 50% of patients with REMF in Nigeria (Jaiyesismi and Falase, 1976; 
Parry and Abrahams 1963; Somers et al, 1968). The pathophysiology of cyanosis remains 
incompletely understood since it occurs in the absence of atrial septal defect or patent 
foramen ovale. There were attempts to relate the arterial desaturation to intracardiac 
shunts, chronic hepatic dysfunction and azygos-pulmonary venous shunt (Parry and 
Abrahams, 1963) but were soon disproved (Cockshot, 1965). Later, in studies of lung 
function in EMF patients it was shown that vital capacity and arterial saturation were 
inversely related to cardiothoracic ratio (Jaiyesimi, 1977), and that after hyperoxia 
arterial oxygen tension increased significantly in these patients, but not in children with 
cyanotic congenital heart disease. It was concluded that ventilation/perfusion imbalances 
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caused by the large heart were in the origin of the arterial desaturation, but further 
research is needed to unveil the pathophysiology of cyanosis in these patients.
Cardiomegaly, measured by the cardiothoracic ratio, increased with the severity of EMF 
lesions related to severe atrial dilatation and/or pericardial effusion. Although atrial 
enlargement is one of the most important pathophysiological adaptative mechanisms in 
restrictive cardiomyopathy playing an important role in maintaining cardiac output, it has 
been associated with impairment in exercise capacity in patients with BEMF (Mady et al, 
2005). Owing to the fact that cardiopulmonary exercise testing is of limited clinical 
application in patients with EMF due to presence of advanced heart failure, ascitis and 
cachexia, the left atrial dimension has been proposed to estimate the functional capacity 
(Mady et al, 2005). On the other hand, the presence of pericardial effusion further 
impairs the diastolic function, already compromised by the endocardial thickening, 
further decreasing exercise capacity.
A remarkable finding of the study was that despite the poor social conditions of the 
patients, the high frequency of cutaneous and other infections, and the need for several 
invasive procedures, none of the patients in our registry had infective endocarditis. This 
is in contrast with findings from an autopsy study in Uganda (Shaper et al, 1968a) in 
which infective endocarditis was found in 10 out of 173 cases of EMF. However, in that 
study of the 10 patients with EMF 7 had concurrence of rheumatic heart disease. When 
compared to its occurrence in rheumatic heart disease infective endocarditis was rare in 
EMF patients, this despite the higher prevalence of invasive procedures performed in 
these patients. The explanation for this phenomenon might be in the characteristic 
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pathological findings, which consist of the presence of thickened fibrous avascular 
endocardium separating the subendocardial vessels from the circulating blood (Connor et 
al, 1968). 
We found a frequent association between EMF and RHD (12/175). There is lack of data 
on the epidemiology of these two conditions in our population and it is therefore difficult 
to say whether this finding results from a particular association between the two diseases 
or occurs just by chance. In Uganda EMF and RHD a higher than expected prevalence of 
concomitant disease in the same patients was found, but no clear explanation to the
findings could be given (Shaper et al, 1968a). From Brazil there was also the description 
of a mitral valve disease with rheumatic appearance in the presence of left ventricular 
endomyocardial fibrosis (Saraiva et al, 1999). 
At 70%, survival at 5-years follow up was better than the 2 years mean survival reported 
from Uganda (Somers, 1990). This may be explained by improvements in therapies for 
heart failure and its complications, mainly in the control of arrhythmias and prevention of 
thromboembolism, from which our patients have been benefiting.  
Most hospital deaths were related to active disease, as defined in Chapter 3. Despite using 
the same criterion used for definition of hypereosinophilic syndromes (absolute 
eosinophil count over 1.5 x 109/L) we were intrigued to verify that only the heart was 
primarily affected in EMF. Multi-organ affection was absent in any of the patients, with 
death resulting from either episodes of severe myocardial dysfunction with recrudescence 
of heart failure or complications of thromboembolism, both in patients with active 
persistent or rapidly progressive disease. We also noticed that eosinophil counts varied 
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between normal levels and hypereosinophilia without any apparent cause (parasitic 
infection). 
The control of hypereosinophilia in Hypereosinophilic Syndromes with intracavitary 
thrombus causes remodeling of the heart (Lofiego et al, 2005). Evaluation of the effects 
of new available anti–hypereosinophilia drugs must be carried out in patients with EMF 
and severe hypereosinophilia. This approach may be of value in changing the natural 
history of the subset of EMF patients who have recurrent hypereosinophlia, by inducing 
favorable long-term ventricular remodeling. 
We acknowledge the lost of 29 patients for follow up, since having no contact with them 
for more than 12 months. A considerable number of families of EMF patients are poor 
and reside in areas of Mozambique with no access to telephone land lines or mobile 
phones making it impossible to actively search patients who do not come for follow up, 
while living in remote areas. 
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5.5. Conclusions
Most EMF patients presenting to medical attention are males in the second decade of life. 
The majority of patients from the seen in the referral centre reside in Inhambane 
province. Bilateral affection is the commonest phenotype in EMF patients, who usually 
have advanced heart failure, severe cardiac lesions and poor general condition. 
The survival of our patients is good. It seems to be negatively influenced by persistence 
of hypereosinophilia and clinical signs of activity. In the absence of consensual criteria to 
define activity and monitor progression we suggest periodical assessment of these cilinal 
and laboratory signs of activity in order to detect recrudescence of disease and use 
adequate therapies for controlling hypereosinophilia. 
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Chapter 6
EVALUATION OF PATHOLOGICAL CHANGES
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6.1. Introduction 
The pathological findings of advanced EMF are well characterized. Most classical 
descriptions have been based on autopsy studies of patients who died with complications 
of long-standing heart failure or following episodes of rapidly progressive heart failure 
(Connor et al, 1967; Shaper et al, 1968a). The scarcity of facilities for cardiac 
catheterisation and open-heart surgery in most endemic areas for EMF has prevented the 
studies in vivo. On the other hand, EMF patients usually seek medical attention with signs 
of advanced disease and poor general condition, being therefore contraindicated for 
cardiac catheterisation or surgery. Few studies have documented the histology findings in 
vivo using endomyocardial biopsies obtained during cardiac catheterisation (Chopra et al, 
1990; Andrade and Teixeira, 1973) or surgery (Santos et al, 2001; Saraiva et al, 1999).
The most salient pathological feature of established EMF is sub-endocardial deposition of 
fibrous tissue, mainly type I collagen fibers (Radhakumary et al, 2001), which leads to 
restriction of ventricular filling and distortion of the atrioventricular valve apparatus, 
resulting in restrictive cardiomyopathy with atrioventricular valve dysfunction.
We evaluated the heart of EMF patients on autopsy and during surgery, and obtained 
cardiac tissue from necropsies and excisional biopsies, aiming at describing the pathology 
features, and relate them to clinical, echocardiographic and intraoperative abnormalities. 
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6.2. Patients and Methods
6.2.1. Autopsy Examination
The autopsy examinations were done in another institution, the Central Hospital of 
Maputo, since the Heart Institute does not have facilities for post-mortem examination. 
Permission for autopsy was obtained for two patients who died at the Heart Institute. The 
autopsy examination was performed in the presence of the investigator. Due to work 
overload pathologists only agreed to perform detailed examination of the heart and lungs. 
Tissue samples were obtained from the posterior wall of the left ventricle, left ventricular 
apex, trabecular right ventricular and atrioventricular valves. Liver, lungs and kidneys 
were also sampled.
6.2.2. Surgical studies
Patients from the Maputo Heart Institute’s EMF Registry were examined on 
echocardiography and classified as described in Chapter 3.  All patients with moderate 
(Grade II) and severe (Grade III) EMF were considered for surgery. 
Preparation for Surgery
Pre-operative care included medical management of (1) heart failure with diuretics and 
ACE-inhibitors; (2) atrial arrhythmias with digoxin and β-blockers; (3) thrombotic risk 
with oral anticoagulation; and (4) hypereosinophilia through short courses of oral 
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prednisolone. All patients were followed up for at least 3 months prior to surgery in order 
to monitor changes in eosinophil counts, treat concomitant infections, improve general 
condition through high protein diet and correct anemia. In patients with refractoriness to 
medical therapy drainage of pericardial, pleural and peritoneal effusion was considered. 
Cardiac catheterisation was considered in patients with severe distortion of the heart not 
allowing accurate echocardiographic evaluation of cavity dimensions and pulmonary 
pressures.
Intra-operative evaluation
The presence and extent of the mural and valvular changes was evaluated by the surgeon 
and the investigator, and systematically annotated. Details of the distribution of the intra-
cardiac lesions were noted on a standard manner. Intra-operative photography was done 
using a Sony digital camera (model DSC-T9).
Tissue sampling 
Targeted incisional endomyocardial biopsies were obtained in all patients from one or 
both ventricles during surgery for valve repair and/or endocardial resection performed via 
atriotomy. Biopsies of the left ventricle were taken from fibrotic areas of the posterior 
wall and the area surrounding the papillary muscles, whilst for the right ventricle tissue 
was collected at the admission chamber and the trabecular area. In patients who required 
endocardial resection the excised fibrous tissue was also made available for histology and 
immunostaining. Mitral valve tissue was obtained from one patient who underwent valve 
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replacement. Atrial tissue from patients who underwent atrial reduction was also 
examined. 
6.2.3. Sample processing and staining
All specimens, obtained by surgery or during autopsy, were fixed in 10% buffered 
formalin, routinely processed for light microscopy, embedded in paraffin wax blocks and 
cut into 4 to 5 μm thick sections. These were stained for cell and for tissue morphology 
(Hematoxylin and Eosin, H&E) and collagen content, elastic fibers and mucins 
(Masson’s Trichrome, Verhoeff Elastic-Van Gieson, Alcian Blue-Sirius Red). The was 
used to identify eosinophils. 
Immunostaining
Immunohistochemistry using the Avidin-Biotin peroxidase complex technique was done 
for identification of leucocytes (CD45), macrophages (CD68), endothelial cells (CD31), 
vessels (CD34) and myofibroblasts (Smooth Muscle Actin, SMA). 
All the primary antibodies were supplied by Dako. Paraffin wax 5m-thick sections 
were dewaxed and rehydrated through xylene and graded alcohols to water, washed in 
phosphate buffered saline (PBS) for 5 minutes before blocking for endogenous 
peroxidase using 0.3% hydrogen peroxide in PBS for 15 minutes. Sections were then 
washed twice in PBS and blocked with 3% bovine serum albumin (BSA) in PBS for 30 
minutes. Details of antigen retrieval, dilutions, and incubation times are given in Table 
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6.1. Negative control sections were incubated in 3% BSA only in PBS. Excess primary 
antibody was removed by washing the sections 3 times in PBS followed by a second 
layer of biotinylated goat anti-mouse immunoglobulins (GAM IgG-Vector laboratories) 
diluted 1/250 in PBS for 1hour. Sections were then washed 3 times in PBS before 1-hour 
incubation with Avidin-Biotin Complex ABC-Vector laboratories). Reactivity was 
detected using diaminobenzidine tetrahydrochloride (DAB tablets-Sigma) (25mg/ml) and 
hydrogen peroxide (0.01% W/V). Sections were then counterstained with haematoxylin, 
dehydrated, mounted and viewed on a Ziess Axioskop microscope. Photomicrographs 
were taken using Nikon DMX1200 camera.
6.2.4. Evaluation of cardiac tissue
The tissue was assessed for endothelial integrity, presence of inflammation, evidence of 
myofibroblastic proliferation, neovascularization, fibrosis, myocyte characterization, 
microvascular abnormalities, and fibrosis. This microscopic evaluation of the cardiac 
tissue was performed using several definitions that are discussed below. 
Inflammatory changes 
We assessed the presence of inflammatory cells. When it was present the phenotype and 
density of inflammatory cells was evaluated. According the its distribution in the tissue 
inflammation was classified as (1) Focal, when small foci of inflammation were found in 
parts of the tissue evaluated; or (2) Diffuse, when inflammation was diffusely present in 
all areas of the tissue evaluated.  The intensity of the inflammation was classified as (1) 
rare when there were less than 5 inflammatory cells per/field observed at high power 
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magnification; (2) mild when the number of cells varied between 5 and 10; and (3) 
intense when more than 10 inflammatory cells were present per field of high power 
magnification.
Table 6.1. List of primary antibodies (all supplied by DAKO©) used for 
immunostainning. This table shows the antibodies used for biopsy evaluation, their
specificity, dilutions used, method of antigen retrieval, and the incubation times).
Antibody Specificity Dilution Antigen 
retrieval
Incubation time/T°
CD45 Leukocytes 1/50
CD68 Macrophages 1/50
CD31 Endothelium 1/40
CD34 Immature Fibroblasts 1/100
SMA Smooth Muscle Cells 1/200
0.1 molar
citrate 
buffer
10min microwave at 
medium power, then 
left for 20 min in the 
same buffer
Endocardial fibrosis
Endocardial fibrosis was classified as (1) Focal when fibrous tissue was present in certain 
areas of the endocardium obtained; or (2) Diffuse, when all the extension of the 
endocardium in the specimen had fibrous tissue. 
The type of fibroblastic response was also assessed and classified as (1) Early when there 
was a predominance of cells on the background of loose fibrous tissue, or (2) Hyaline 
when there was plaque-like collagen with little cellular response. 
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The measurement of the endocardium was done at the site of maximal thickening using 
the JULIA software. Endocardial thickening was considered mild (<1000 m), moderate 
(1000-3000 m) or severe (> 3000 m).
Myocardial fibrosis
The presence of excessive collagen in the myocardium was classified according to its 
distribution as (1) interstitial – in the intercellular spaces that separated individual 
myofibers; (2) septate – extension of subendocardial fibrosis forming septa that separated 
groups of myofibers; (3) perifascicular – fibrosis entrapping several myofibers that 
become isolated from the rest of myocardium; and (4) replacement scars – presence scars 
inside the myocardium expressing the loss of myocardial fibers that are replaced by 
fibrous tissue. Table 6.2 presents a summary of the parameters evaluated, the staining 
methods used to detect them and the scoring system applied to each characteristic. 
6.2.5. Clinical-pathological correlation
In the absence of a gold standard for early or active Endomyocardial Fibrosis, clinical 
and laboratory signs described earlier were used (Chapter 3) to classify the patients and 
evaluate whether in “acute and active fibrosis” there were signs of tissue inflammation, 
thrombus formation and intense fibroblastic response. The criteria compared were the 
following: 
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Clinical diagnosis versus operative findings 
We compared the EMF stage and grade (using clinical, laboratory and echocardiographic 
criteria) with the operative pathology findings. The description of the echocardiographic 
features was compared to the lesions found at surgery, particularly the following: (1) LV 
plastered posterior mitral papillary muscle and leaflet; (2) fibrosis of the posterior wall; 
(3) apical fibrosis; (4) thickening of leaflets; (5) RV trabecular obliteration; (6) RV apical 
retraction; (7) size of the RV; (8) presence of intra-cardiac thrombus.
Clinical classification versus severity of pathology findings
EMF stage and grade were compared to findings in histology and immunochemistry, 
specially the presence, type and intensity of tissue inflammation (edema, inflammatory 
infiltrates, eosinophilia) and vascular lesions (arteritis and mural thickening). The 
severity of EMF assessed by echocardiography was also related to the intensity of 
endocardial fibrosis, presence of myocardial fibrosis, pattern of fibrosis and presence of 
myofibroblastic proliferation.
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Table 6.2. Summary of the parameters evaluated, the staining methods and the scoring 
system applied for evaluation of the ventricular tissue samples. For the atrial samples 
evaluation of the epicardium was added, looking mainly for presence of inflammation.
Parameters Staining Score
Endocardium 
Integrity of the endothelial layer 
Presence of elastin fibers
CD31
EVG
Yes/No
Present/absent
Subendocardium 
Myofibroblastic proliferation 
Presence, type of fibroblastic response
Distribution of the fibrosis
Fibrous septae extending into myocardium
Neovascularisation
Presence and distribution of inflammatory cells
Type of inflammatory cell
SMA
SR, MT 
SR, MT, VG
SR, MT, VG
H&E, CD34 
H&E, 
H&E, Ch2R, CD45, 
CD68
Yes/no
Hyaline/cellular,
Focal/diffuse 
Yes/No
Yes/No
Yes/No, 
focal/diffuse
Cell type
Myocardium
Myocyte changes (necrosis, hypertrophy, 
degeneration)
Patterns of fibrosis (scars, interstitial, perivascular)
Changes in myocardial microvasculature
Presence and distribution of inflammatory cells
Type of inflammatory cell
H&E
SR, MT, VG
H&E, CD34
H&E
H&E, Ch2R, CD45, 
CD68
Present/absent
Yes/No
Yes/No
Yes/No, 
focal/diffuse
Cell type(s)
H&E hematoxillin-eosin; EVG elastin van Gieson; SMA smooth muscle actine; MT Masson Trichrome; 
Ch2R carbol chromatotrope technique; Vg Van Gieson;
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6.3. Results
Two autopsy examinations were performed. Twenty-nine patients were included in 
operative studies. 
6.3.1. Autopsy studies
Eleven patients died in hospital. From these, we obtained family consent for autopsy for 
two patients, which clinical characteristics are summarized in Table 6.3.
Patient 1
This boy was a 15-years old with chronic heart failure due to bilateral disease with 
predominance of lesions in the right side of the heart. The severity of the disease was 
graded III. Despite being admitted for intensive medical therapy including anticoagulants 
he had chronic pulmonary thromboembolism and refractory NYHA class IV heart failure. 
His body weight was 31kg and the height 136 cm.
On autopsy examination the body presented generalized edema, with bilateral 
hydrothorax and ascitis. At the opening of the chest there was a dilated pericardial sac 
with effusion of aproximately 350ml. The pericardial fluid was dark yellow and was an 
exudate with predominant lymphocytes (70%) and high protein content. 
The heart weight was 268g. On external observation of the heart there was right atrial 
dilatation, retraction of the right ventricle border originating a “notch” and dilatation of 
its outflow tract (Figure 6.1). 
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The most striking feature on examination of the heart cavities was the presence of white 
thickened endocardium in both ventricles that was very prominent in the right side and 
did not have its trabecular portion (Figure 6.2). The fibrous process also involved the 
atrioventricular valves; on the left side it formed gross nodules on the leaflets and 
chordae (Figure 6.3), while the tricuspid valve had the leaflets and chordae less involved 
but presented great dilatation of the annulus and fusion of the papillary muscles to the 
fibrosis of the trabecular portion with tethering of the valve (Figure 6.4). Despite the 
absence of gross myocardial lesions, it presented penetrating spurs of fibrous tissue 
extending from the subendocardium in several areas. There were no macroscopic lesions 
of the semilunar valves.
The lungs presented signs of chronic pulmonary embolism and areas of atelectasia on the 
lower lobe of the right lung. There were signs of chronic congestion of the liver. The 
other organs did not present any abnormalities other than congestion.
Table 6.3. Clinical characteristics and diagnosis of the two patients that were autopsied
Age/Sex Weight Height EMF Classification
15/M 31 Kg 136 cm REMF III RPD
22/F 41Kg 163 BEMF III CQD
RPD rapidly progressive disease; CQD chronic quiescent disease
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Figure 6.1. External aspect of a specimen at autopsy. The sulcus between the ventricles 
corresponds to the “notch” seen on echocardiography. Notice an aneurysmal right atrium.  
Figure 6.2. The right ventricle shows extensive endocardial fibrosis forming an artificial 
floor that excludes the trabecular portion from the “functional ventricular cavity”.
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Figure 6.3. Nodular aspect of the borders of the mitral leaflets with thickened chordae 
and whitening of the endocardium covering and surrounding the papillary muscles (top). 
Notice the diffuse whitening of the endocardial surface of the endocardium with thick 
fibrous tissue visible in the apex. The whitening of the endocardium extends through the 
outflow up to the valves but spares the aortic cusps, which are normal (bottom).
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Patient 2
This patient was a 22-years old female who had been operated on nine days before for 
correction of BEMF with predominant left-sided lesions. She died as a result of 
accidental perforation of the heart during pericardial drainage to relieve pericardial 
tamponade. The examination of the chest did not show any apparent macroscopic 
complications of the surgery. There was cardiomegaly and the pericardial sac was filled 
with clots. A laceration 18mm long was identified in the anterior wall of the right 
ventricle, near the apex. There were no coronary lesions. The weight of the heart is not 
available. 
The internal lesions of the heart were altered by the recent surgery that included left 
endocardial resection, and mitral and tricuspid repair with the use of bands of Goretex 
material (Figure 6.5). Fibrous plaques were visible in the left ventricular apex and the 
posterior wall of the left ventricle. The right ventricle was dilated with thin wall (5mm) 
and had scattered foci of fibrosis in the endocardium of the inflow tract. There were no 
lesions of the semilunar valves.
There was pulmonary and liver congestion, and the tissue samples from all main organs 
of the body showed no signs of disease apart from changes related to chronic passive 
congestion.  
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Figure 6.4. The tricuspid annulus was usually dilated, there is tethering of the leaflets 
due to fibrosis of the papillary muscles and partial fusion of the leaflets to the walls 
(bottom) starting at the level of the annulus and leading to an Ebstein-like abnormality of 
the tricuspid valve. 
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6.3.2. Operative studies
Characteristics of patients
15 patients had grade II EMF whereas 14 had grade III lesions. EMF was confined to the 
left ventricle in 13 patients (LEMF), to the right ventricle in 4 (REMF) and was 
biventricular in the remaining 12 (BEMF). Their mean (± SD) age was 12 (± 4.6) years. 
Seventeen 17/29 were male. The details of the relevant clinical and laboratory findings in 
these patients are presented in Table 6.4. Twenty-eight patients were in NYHA 
functional class III-IV. Mean body mass index was 15.7 (± 2.4) kg/m2. Sixteen patients 
had signs of active disease as defined by raised C-reactive protein (CRP) levels, increased 
erythrocyte sedimentation rate (ESR) and/or peripheral blood hypereosinophilia (EOS). 
The mean (±SD) ESR was 31.8 (± 28.0) mm/h and the mean absolute eosinophil count 
was 1.6 (± 1.5) x 109/L. 
At sternotomy there was cardiac enlargement in all patients with a mild to moderate 
pericardial effusion in 8. The pericardial fluid was yellow and constituted an exudate in 
all cases with high protein content (mean 52g/dL) and increased cellularity with 
predominance of lymphocytes (mean 61%). None tested positive for tuberculosis. 
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Table 6.4. Clinical data from the 29 patients operated from whom tissue was collected 
(this and next pages)
Code Tissue Age/
Sex
BMI ESR CRP NYHA Ex109/L EMF 
Classification
0029 LV 17/M 17.3 High N IV 0.3 LEMF II
0085 LV 6/F 14.2 High N IV 1.8 LEMF III
0064 LV LA 16/F 13.9 N High III 0.4 LEMF II
0123 LV 15/M 13.0 High N IV 2.0 LEMF II
0009 LV 7/M 20.5 High High IV 1.1 BEMF III
0048 LV LA 11/F 13.2 High N IV 0.5 LEMF III
0072 LV 14/F 18.2 High High IV 0.3 LEMF II
0125 LV 22/M 18.3 N N IV 2.0 LEMF III
0128 LV 16/M 16.9 High High II 6.9 LEMF III
0144 LV 16/F 16.7 N N III 1.3 LEMF II
0068 LV RV LA 12/M 14.1 High High IV 2.7 LEMF II
0062 LV RV 7/F 13.6 High N IV 1.3 BEMF III
0142 LV 22/M 20.3 N N IV 0.8 BEMF III
0146 LV RV 12/M 16.3 N N IV 1.1 BEMF III
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(continuation of previous page Table 6.4)
M male; F female; NYHA New York Heart Association; E eosinophil count
BMI body mass index; ESR erythrosedimentation rate; CRP C reactive protein
0065 LV RV 16/M 15.8 High High III 1.5 LEMF II
0059 LV LA 12/F 13.4 N High IV 1.8 LEMF II
0138 LV 13/M 15.3 N N IV 4.8 BEMF III
0139 LV 14/M 16.4 N High III 4.9 BEMF II
0179 LV RV 9/F 12.6 High High IV 0.6 BEMF II
0180 LV RV 10/M 12.7 High High IV 0.3 BEMF II
0169 LV 21/M 18.4 N N IV 0.9 BEMF III
0163 LV RV RA 10/F 13.9 High High IV 0.9 BEMF II
0052 RV 6/M 21.2 High High IV 0.6 REMF III
0167 LV RV  RA 10/F 14.8 N N IV 1.2 BEMF III
0152 RV 6/F 15.9 N High III 2.4 REMF III
0110 RV 8/M 16.3 N High IV 1.7 REMF III
0151 RV 9/M 15.7 N High III 1.2 REMF II
0107 LV 11/M 12.9 High High III 0.9 LEMF II
0140 LV 8/F 14.3 High N IV 0.1 BEMF II
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Figure 6.5. Specimen from a patient died after surgery for EMF, showing the 
aspect of the endocardium of the left ventricle. This patient benefited from mitral 
repair using Goretex bands with no endocardial resection.
Figure 6.6. This specimen reveals whitening of the endocardium with occasional 
strands of fibrosis, atrial hypertrophy and thrombus fixed to the atrial appendage. 
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All patients had dilatation of one or both atria. Atriotomy of the dilated atria revealed 
thickening of the wall due to edema and muscle hypertrophy. No major plaques of 
fibrosis were seen, but in 7/29 cases there was patchy whitening and thickening of the 
endocardium (Figure 6.6). 
In the typical case of REMF the tricuspid valve annulus was markedly dilated, affording 
wide access to the right ventricular cavity (Figure 6.7). Left atriotomy showed a 
moderately dilated mitral valve annulus, and in all but one patient assessment of the 
distribution and extent of subvalvar and wall involvement by EMF was achieved through 
gentle retraction of the valve apparatus (Figure 6.8). The exception was a patient with a 
large calcified thrombus involving the papillary muscles and chordae of the mitral valve 
as well as important left apical fibrosis, for whom left ventriculotomy was required. 
The most striking finding in the ventricles was the presence of fibrotic plaque-like lesions 
in the inflow tracts, the left ventricular apex, the recess behind the posterior mitral leaflet 
and covering the trabecular portion of the right ventricle. When the right ventricle was 
affected it was in the obliterative stage necessitating reopening of the cavity. Mural and 
valvular abnormalities coexisted in varying proportions, but all patients had severe valve 
dysfunction needing surgery. Mural involvement was present to a variable extent causing 
reduction of the ventricular cavity and effacement of the components of the valve 
apparatus, which were fused to the mural plaques. The distribution of plaques in these 
patients is shown in diagrams 2 (left ventricle) and 3 (right ventricle). A more detailed 
description of the changes in each side of the heart ventricle is now given. 
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Figure 6.7. Intraoperative visualization of lesions on REMF was made through right 
atriotomy and using retraction of the dilated tricuspid valve ring
Figure 6.8. Intraoperative evaluation of LEMF lesions through left atriotomy. Notice the 
complete fusion of the posterior leaflet to the posterior wall. 
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a) Left Cavities
In LEMF the mitral valve leaflets invariably showed diffuse irregular thickening, with 
fibrotic nodules in some cases. The chordae were frequently thickened but not fused. In 
most cases the posterior leaflet, its chordae and the posterior papillary muscle were 
partially or totally fused to the posterior wall (Figure 6.8). The anterior papillary muscle 
was usually fused to the wall, with variable restriction of its mobility, contributing 
significantly to mitral regurgitation. In cases of extensive involvement of the anterior 
papillary muscle there was restriction of the movement of the anterior leaflet leading to 
an additional component of mitral stenosis. 
The left atrium was variably dilated, in some cases being aneurismal. 
b) Right Cavities 
In REMF all right ventricles were in the obliterative phase. In these cases a layer of 
endocardial fibrosis 2-3 mm thick appeared to start just below the level of the tricuspid 
annulus and extended downwards into the ventricular cavity. The fibrotic area was firmly 
attached to the ventricular wall and usually spared the tricuspid leaflet and chordae. 
However, in more advanced cases, these structures were embedded in fibrous tissue 
extending along segments of the circumference of the annulus. The fibrosis extended all 
round the inflow tract to the level of its junction with the trabecular right ventricle where 
it formed an “artificial floor” isolating the trabecular right ventricle from the rest of its 
cavity (Figure 6.7). The trabecular cavity was obliterated due to separation of the 
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entrapped trabeculae from the main cavity and their fusion together and to the muscular 
septum, while being spared by the fibrotic process. 
The right atrium was markedly dilated and mural thrombi were present in three cases.
In the 12 patients with BEMF the above findings were observed in varying proportion. 
As a result of prolonged elevation in pulmonary arterial pressure there was hypertrophy 
and dilatation of the right ventricle in both LEMF and BEMF with predominance of 
LEMF. Two cases with severe pulmonary hypertension had thin-walled right ventricles, 
raising the suspicion of cardiomyopathy that was later excluded on histology. There was 
usually balanced bi-atrial dilatation.
6.3.3. Microscopic findings
a) Ventricles
Biopsies from 25 left ventricles and 12 right ventricles were evaluated. Adequate amount 
of myocardial tissue was available for evaluation in 26 of the 29 patients studied. The 
summary of the main abnormalities on histology of the 29 ventricles is given in Table 6.5
while Table 6.6 presents the frequency and intensity of fibrosis (6.6a) and inflammation 
(6.6b) according to the echocardiographic scoring system. 
The main finding in the ventricular tissue from these patients was endocardial thickening 
due to deposition of hyaline and cellular collagen in varying proportions (Figure 6.9a), 
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beneath a layer of apparently normal endocardial endothelial cells.  The thickened sub-
endocardium consisted of a superficial layer of collagen usually with hyalinization 
(calcification was found in only one case), and a deeper, loose spongy layer of fibrous 
tissue with numerous capillary channels and scanty mixed inflammatory infiltrates. 
Small amounts of fragmented elastic tissue were mixed with the fibrous tissue. There was 
mild proliferation of smooth muscle cells in the superficial subendocardium, usually 
forming a single thin layer with fibroblast above and below it. 
Deep in the sub-endocardium there were foci of intense neovascularisation associated 
with chronic inflammation the latter composed mainly of mononuclear cells, namely 
lymphocytes, macrophages and plasma cells (Figure 6.9b). These findings contrasted 
with the usually absent or very mild myocardial inflammation. In 2 cases there was a 
mixed inflammatory infiltrate with increased number of eosinophils. Significant 
endocardial and myocardial eosinophilia was found in only one patient (Figure 6.10). 
Strands of fibrous tissue penetrated the inner myocardium, seemingly tethering the 
subendocardium and the myocardium together and being in continuity with the 
perivascular spaces. In 23/29 cases an increase in fibroblasts in the interstitial spaces was 
noticed. Nine patients had foci of replacement fibrosis in the myocardium. 
Degenerative changes of the myocardium were usual including myocyte hypertrophy, 
enlarged bizarre nuclei and myocardial (but not myofibril) disarray often in relation to 
scars. The myocardial vessels showed thickening of the media in most cases. 
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Table 6.5. Histological abnormalities in ventricular tissue samples obtained surgically 
(this and next pages)
Code ESS Endocardium
Thickness     Collagen Type
Sub-endocardium
Inflammation     New vessels
Myocardium              
Pattern of Fibrosis
0029 II 1848 Mixed Chronic + + IF 
0085 III 5961 Hyaline Chronic + ++ IF WS PF RF
0064 II 314 Mixed No + None 
0123 II 2164 Hyaline Chronic ++ ++ IF RF
0009 III 2867 Hyaline Mixed ++ ++ IF WS PF RF
0048 III 5675 Cellular Mixed ++ ++ IF WS PF RF
0072 II 3936 Cellular Chronic + ++ IF
0125 II 1670 Cellular Chronic ++ ++ IF
0128 III 6054 Hyaline Chronic + ++ IF WS PF RF
0144 II 4036 Cellular Chronic ++ + None
0068 II 4189 Mixed Chronic + ++ IF WS PF
0062 III 1209 Mixed Chronic ++ ++ IF WS
0142 III 2156 Mixed Chronic ++ + IF WS PF RF
0146 III 2004 Mixed Chronic ++ ++ IF WS
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(continuation of previous page Table 6.5)
Code ESS Endocardium
Thickness     Collagen Type
Sub-endocardium
Inflammation New vessels
Myocardium              
Pattern of Fibrosis
0065 II 1689 Hyaline Mixed + ++ WS PF
0059 II 598 Cellular Chronic + No IF WS PF
0138 III 3878 Hyaline Chronic + + IF WS PF RF
0139 II 3056 Cellular Chronic + ++ IF WS
0179 II 1168 Mixed No + IF WS
0180 II 937 Mixed No ++ IF WS
0169 III 1232 Hyaline No + IF WS RF
0163 II 1228 Cellular No No IF WS PF
0052 III 4659 Hyaline Chronic + + IF WS RF
0167 III 1053 Hyaline No No ?
0152 III 2515 Hyaline No + IF WS
0110 III 4524 Mixed Chronic ++ ++ IF WS RF?
0151 II 876 Hyaline No + IF WS PF
0107 II 767 Cellular Acute ++ ++ None
0140 II 1432 Cellular No No None
ESS= EMF severity score; ?= unknown; Thickness in µm; IF= interstitial fibrosis; WS=wide septa; 
RF=replacement scars; PF=perivascular fibrosis
Chapter 6 Pathological Findings
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
236
Table 6.6. Distribution and intensity of fibrosis and inflammation in ventricular tissue 
samples according to the echocardiographic severity score  (ESS). The stromal changes 
were quantified without subtracting the SMA positive cells.
6.a) Fibrosis
ESS Subendocardium 
+                ++            +++
Myocardium*
Perifascicular     Interstitial       Scars
II   (N=16) 5                7              4 5                        3                        0
III  (N=13) 0                 7               6 8                       10                      8
Total 29 5                14              10 13                13                       8
* Two grade III and one grade II not evaluated; some patients with more than one pattern
b) Inflammation
EMF 
classification
Interface Endoc-myocardium 
0                +              ++ 
Myocardium
0         +             ++
II        (16) 6                6                4 15             0               1
III       (13) 3                4                6 13            0               0
Total  (29) 9               10              10 28     0               1
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Figure 6.9a. Microscopic findings in the ventricle affected by EMF include marked 
endocardial thickening (E) and fibrosis that affects the inner part of the myocardium 
stained in red (5X Van Gieson, top left). Vessels are seen in the endomyocardial 
interface, mainly in starnds of fibrosis that penetrate the myocardium (top right, H&E 
5x). The bottom picture amplifies and area of the myocardium that reveals large bands of 
fibrosis (F) separating groups of myofibers (M).
F
M
E
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Figure 6.9b. Endocardial thickening (E) and inflammatory infiltrates (I) in the interface 
between the endocardium and the myocardium (x5 H&E staining, top left), which is also 
E
V
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rich in vessels (V) with a thickened wall (5X H&E staining, top right). The inflammatory 
infiltrates were constituted mainly of lymphocytes (bottom). 
Figure 6.10. The endocardium in EMF patients had little mucopolisacharides that stain in 
blue in Alcian Blue staining (top left, x10). Mixed inflammatory infiltrates were also 
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frequently found (x5 H&E, top right) in some patients. Tissue eosinophilia was found in 
one patient with moderate LEMF (x40HE)
b) Atria
Atrial tissue from 6 patients was examined. The histopathological findings on atrial tissue 
are presented in Table 6.7.  
Table 6.7. Microscopic findings in 6 EMF patients from whom atrial tissue was obtained
EMF
grade
Age
(years)
NYHA 
Class
Endocardial 
thickness 
(µm)
Fibrosis 
pattern
Inflammation
0068 BEMF III 9 III 760 Patchy Mild chronic multifocal
0059 LEMF II 12 IV 450 Rare No
0064 LEMF II 12 III 1315 Patchy Mild mixed perivascular
0048 LEMF II 11 IV 1804 Patchy* Mild mixed multifocal
0163 BEMF IV 10 IV 929 Rare No
0167 BEMF IV 10 IV 499 Rare Mild chronic multifocal
* Patchy with replacement fibrosis
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The tissue showed diffuse irregular thickening of the endocardium to a much lesser 
extent, if compared to that observed for the ventricles. In two patients the left atrial tissue 
presented considerable endocardial thickening (more than 1mm) and there was deposition 
of fibrous tissue and moderate hypertrophy of the smooth cells in between the 
endocardium (Figure 6.11).
The evaluation of the atrial myocardium revealed no areas of fibrosis with overlying 
endocardial thickening, the myocardium being often involved without apparent 
endocardial lesions. Moderate hypertrophy of nuclei and contraction band necrosis, 
representing signs of reperfusion probably surgery-related were frequent. In some cases 
there was also focal myocardial hemorrhage related to the surgical trauma. There was 
usually mild interstitial fibrosis. Replacement fibrosis was present in one case.
Inflammation affected randomly all layers of the atrial wall, and was more intense in the 
subendocardium, the epicardium and surrounding the intramyocardial vessels. Mixed 
inflammatory infiltrates were the rule with predominance of lymphocytes and few 
eosinophils. 
Vascular changes occurred in most cases, the most frequent being in the muscularis of the 
subendocardial arterioles (medial focal proliferation in medium size arteries), which was 
replaced by a mixture of hyalinized collagen and elastic fibers (Figure 6.12). The 
majority of these vessels were surrounded by excessive fibrous tissue. In no case intimal 
proliferation was observed. 
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Figure 6.11. Atrial tissue showed fibrosis (red) in all three layers of the wall (Masson 
Trichrome, x5). Thickening of the atrial endocardium is also noticed (E) but to lesser 
extent when compared to the ventricles. Perivascular inflammation (I) was more 
prominent in the epicardium in areas surrounding the vessels (V) as shown in top right 
and bottom pictures.  
E
V I
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Figure 6.12. Immunostaining for CD34 showed medial proliferation in medium 
size arteries of ventricular tissue (x10 left, x20 right)
Figure 6.13. Microphotograph showing mitral valve tissue from an EMF patient 
with predominant left lesions (H&E, x25).
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c) Valves
There was thickening of the leaflets due to deposition of fibrous tissue in the fibrosa
layer. No inflammatory infiltrates or neovascularization where found in the leaflets or 
chordae. The spongiosa,auricularis and ventricularis were normal  (Figure 6.13).
d) Immunohistochemistry
Immunostaining of the tissue samples allowed characterization of the inflammatory 
infiltrates, evaluation of the endothelial integrity, determination of the presence of 
smooth muscle cells and immature fibroblasts.
In all samples the cells present in the inflammatory infiltrates were predominantly CD45 
and CD68 positive (Figure 6.14).
CD31 staining of ventricular and atrial tissue showed a preserved endothelial lining in all 
samples, as well as in the blood vessels located in the subendocardium and myocardium 
(Figure 6.15)
The positive staining for SMA was confined to one single layer of cells inside the 
thickened sub-endocardium. There is no smooth muscle cells proliferation (Figure 6.16). 
The thickened sub-endocardium stained positive for CD34 in all samples (Figure 6.17).
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Figure 6.14. CD45 immunostaining confirmed the presence of few granulocytes 
(left) while CD68 staining confirmed the presence of macrophages (right). 
Figure 6.15. CD31 staining of ventricular tissue of an EMF patient (left) and 
negative control (right). Notice concomitant staining of monocytes and 
macrophages inside the vessels in the patient’s sample. 
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Figure 6.16. SMA (smooth muscle actine) positive cells in normal amounts in the 
vessel wall in areas of with increased vascularization (left, x5). Strands of SMA 
positive cells were encased by fibroblasts in the subendocardium (right, x20).
Figure 6.17. CD 34 positive cells are seen in the subendocardium of trabeculae of 
the right ventricle of one patient with REMF, forming longitudinal strands. In a 
patient with LEMF (right, x5) smaller strands of CD34 positive cells were found.  
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6.3.4. Clinicopathological correlation
a) Concordance between echocardiographic diagnosis and surgical findings
In 24 of the 29 patients the echocardiographic description correlated well with the 
intraoperative findings, with absolute concordance for fusion of papillary muscle to the 
posterior wall, fusion of the posterior leaflet to the wall, left ventricular apical fibrosis, 
thickening of the atrioventricular leaflets, right ventricular obliteration, right ventricular 
retraction and ventricular thrombi (Table 6.8). 
Echocardiography overdiagnosed fibrosis of the left ventricular septum and posterior 
wall, and underdiagnosed abnormalities of chordae and the anterior wall including the 
anterior papillary muscle. 
In one case of left ventricular EMF the echocardiography did not reveal the extension of 
involvement of the anterior papillary muscle, which on surgery was completely fused to 
the anterolateral wall. In two cases severe fibrosis of the anterior wall was assessed as 
moderate on echocardiography. In one case of bilateral EMF there was an associated 
congenital malformation of the tricuspid valve (double orifice) not diagnosed on 
echocardiography.
An 8-years old boy with obliteration of the trabecular portion of the right ventricle and 
history of disease for less than 6 months was found to have more fibrosis than anticipated 
by echocardiography. No signs of thrombus were found in the obliterated part of the 
ventricle either on macroscopy or in histological examination. The fibrosis formed a false 
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floor that isolated the fused trabeculae. This could be separated, leading to reopening of 
the right ventricular cavity.  
Table 6.8. Comparison of the structural abnormalities detected by echocardiography with 
the findings during intra-operative evaluation of the operated hearts
Characteristic findings Echocardiography Surgery % 
Fusion papillary muscle-posterior wall 10 10 100%
Fusion posterior leaflet-posterior wall 10 10 100%
Fusion anterior papillary muscle to wall 8 11 73%
Fibrosis of the LV posterior wall 18 17 >100%
Fibrosis of the LV septum 5 3 >100%
LV apical fibrosis 6 6 100%
Thickening of mitral or tricuspid leaflets 16 16 100%
RV Obliteration 10 10 100%
RV apical retraction 2 2 100%
Thickening or fusion of chordae 3 5 80%
Ventricular Thrombus 1 1 100%
Ventricular calcification 1 2 50%
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Table 6.9. Presence of tissue inflammation according to EMF staging
Tissue EMF Type and Grade Sub-endocardium
Inflammation     New vessels
EMF Stage
0029 LV LEMF II Chronic + + CQD
0085 LV LEMF III Chronic + ++ ADR
0064 LV LEMF II No + CQD
0123 LV LEMF II Chronic ++ ++ ADR
0009 LV BEMF III Mixed ++ ++ ADR
0048 LV LEMF III Mixed ++ ++ CRD
0072 LV LEMF II Chronic + ++ CQD
0125 LV LEMF III Chronic ++ ++ APD
0128 LV LEMF III Chronic + ++ APD
0144 LV LEMF II Chronic ++ + CQD
0068 LV RV LEMF II Chronic + ++ ADR
0062 LV RV BEMF III Chronic ++ ++ ADR
0142 LV BEMF III Chronic ++ + CQD
0146 LV RV BEMF III Chronic ++ ++ APD
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(continuation of previous page Table 6.9)
Tissue EMF Type and Grade Sub-endocardium
Inflammation     New vessels
EMF Stage
0065 LV RV LEMF II Mixed + ++ ADR
0059 LV LEMF II Chronic + No CQD
0138 LV BEMF III Chronic + + APD
0139 LV BEMF II Chronic + ++ APD
0179 LV RV BEMF II No + CQD
0180 LV RV BEMF II No ++ CQD
0169 LV BEMF III No + CQD
0163 LV RV BEMF II No No ADR
0052 RV REMF III Chronic + + CRD
0167 LV RV BEMF III No No ADR
0152 RV REMF III No + CRD
0110 RV REMF III Chronic ++ ++ APD
0151 RV REMF II No + APD
0107 LV LEMF II Acute ++ ++ ADR
0140 LV BEMF II No No CQD
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b) Concordance between clinical classification and microscopic findings
Table 6.9 summarizes the way disease activity correlated with tissue inflammation and 
neovascularization. There was no clear correlation between clinically quiescent disease 
and absence of inflammation in the sub-endocardium and the myocardium: 5/9 had signs 
of mild chronic inflammation and the remaining 4 had no tissue inflammation at all. Of 
the 12 patients with severe blood hypereosinophilia, only one had mild tissue 
eosinophilia in atrial tissue. Conversely, eosinophilic infiltrates were found in ventricular 
tissue of a patient without severe eosinophilia (absolute eosinophil count 0.9x109/L) and 
who had only patchy deposition of cellular collagen in the sub-endocardium (Figure 
6.10).  
As shown in Table 6.6 and Figure 6.18 severe or Grade III EMF was more frequently 
associated with intense endocardial fibrosis than Grade II. 
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Figure 6.18. Graph showing the relation between the severity of EMF as assessed 
by echocardiography and the degrees of endocardial thickening on histology (mild 
<1000 µm, moderate 1000-1999µm; severe >2000µm.   
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6.4. Discussion
The pathological features of EMF were distinctive and allowed easy differential 
diagnosis from other heart conditions. 
On external examination of the heart the most striking findings were the aneurysmal atria 
contrasting with small ventricles and, in severe REMF, the “right apical notch”. 
The pathological hallmark of established EMF was focal or diffuse endocardial whitening 
and thickening, with a smooth and shiny surface, involving mainly the ventricles. 
Microscopically these lesions corresponded to deposition of dense fibrous tissue in the 
subendocardium, with variable involvement of the inner myocardium. The fibrous tissue 
markedly diminished the volume and compliance of the affected ventricles, and distorted 
the mitral and tricuspid valves, producing a restrictive functional abnormality associated 
with severe atrioventricular regurgitation, both resulting in extremely dilated atria.  
The mechanism of cavity retraction and apical notch in patients with severe REMF was 
obliteration of the right ventricular trabecular portion causing its exclusion from the 
circulation and subsequent fusion of the trabeculae. In the obliterative phase there was 
compaction of the trabeculae between the thickened endocardium and the epicardium, 
with no thrombus or blood in between them. Although progressive fusion of trabeculae 
leads to retraction of the ventricular wall towards endocardial fibrotic floor resulting in 
the typical right apical notch (Figure 6.1), the myocardium between the thickened 
endocardium and the epicardium was viable (Figure 6.2). In all hearts the moderator 
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band was lost, engulfed in the endocardial fibrosis, and there was the constitution of a 
false floor linking the admission chamber to the right ventricular outflow tract. 
There were no macroscopic signs of inflammation in mural and atrioventricular valve 
endocardium, even in patients with clinical and biological features of inflammation. 
Moreover, on microscopy the outer regions of the affected endocardium were avascular 
with inflammation being located essentially in the endomyocardial interface. This lack of 
vessels in the outer endocardium could explain why bacterial endocarditis did not occur 
in any patient with EMF from our series. Although most patients had chronic 
inflammation none could be considered as having severe endocarditis, myocarditis or 
pericarditis. Our results corroborate early findings in Uganda (Shaper et al, 1968a) where 
the degree of neovascularisation of the valves has been used as a pathological criterion to 
differentiate RHD from EMF, as well as to diagnose the concurrence of both diseases in 
the same heart. 
Fibrosis affected primarily the ventricular and, to a lesser extent, the atrial 
endomyocardium where it presented a patchy pattern more prominent in dilated and 
hypertrophied atria. Despite most authors referring to EMF as being a disease that affects 
the ventricles, fibrosis of the atrial endomyocardium has been noted in 19-60% of the 
cases (Ball et al, 1954; Edington and Gilles, 1976). This atrial patchy fibrosis is thought 
to constitute the structural basis for atrial fibrillation, rather than the atrial dilatation 
(Jaiyesimi, 1982). Unfortunately, we did not systematically obtain atrial tissue at the 
beginning of the studies and cannot comment on the relation between atrial fibrosis and 
rhythm disturbances. Evaluation of atrial tissue collected from patients submitted to atrial 
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reduction showed macroscopic and microscopic abnormalities and therefore we started 
collecting atrial tissue samples from all EMF patients submitted to surgery.
The distribution of endocardial lesions was variable with predominance of valvar lesions 
in some patients, mural abnormalities in others, or a mixture of both. An attempt at 
classifying the pathological patterns of distribution of endomyocardial lesions was done
by researchers in Uganda (Shaper et al, 1968a). They defined five patterns of endocardial 
lesions: type 1 affecting only the apex; type 2 extending from the apex to the valve; type 
3 affecting only the valvular region; type 4 affecting separately the valves and the apex 
with areas of unaffected ndocardium between them; and finally, type 5 when there was 
patchy involvement of areas away from the apex and the valve. Considering this 
classification our patients did fall mostly in intermediate or combined patterns, and we 
did not find the classification useful since it did not include any clinical-pathological 
correlation.
Mural thrombosis and endocardial fibrosis affected mainly the left ventricular apex, the 
recess behind the posterior leaflet of the mitral valve, and the trabecular portion of the 
right ventricle, and areas of poor blood supply from the end coronary arteries. This 
consistent distribution of thrombotic and fibrotic lesions in EMF has been attributed to 
the sluggish blood flow at these regions, which would result in relative hypoxia and 
increased susceptibility to injury, creating conditions for thrombotic damage and local 
fibrosis (Sezi, 1996a). Research using a model of the ventricle to study the diastolic flow 
patterns concluded that this distribution corresponded apparently to regions of low wall 
shear stress (Shaper and Bellhouse, 1973). Interesting for the exploration of the 
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mechanisms of EMF is the fact that these regions have recently been found to modulate 
the expression of genes encoding basic fibroblast growth factor (b-FGF) and platelet-
derived growth factor (PDGF) in the endothelium (Malek et al, 1993). 
The most salient histological abnormality in the hearts of patients with EMF was the 
increase in the number of fibroblasts in the subendocardium, responsible for endocardial 
fibrous thickening of variable intensity in different hearts and also varying from one area 
to the other in the same heart. There was also variation in the pattern of extension of the 
subendocardial fibrous tissue to the myocardial compartment. The most common pattern 
was the formation of fibrous septa that penetrated the inner portion of the myocardium 
separating groups of myofibers and occupying mainly the perivascular spaces. 
The most frequent vascular changes occurred in the muscularis of the subendocardial 
arterioles, which was replaced by a mixture of hyalinized collagen and elastic fibres. 
These abnormalities seemed to be the extension of the sub-endocardial changes rather 
than a fibroblast proliferation process, since there were not thickened sub-endothelial 
areas of the vessel wall and CD34 staining was negative in the vessels. As mentioned 
above the majority of these vessels were surrounded by excessive fibrous tissue.
Regarding the myocardium, the presence of inflammatory infiltrates, interstitial fibrosis 
and myocardial scars could be a secondary response to ischemic injury due to vascular 
wall changes that lead to low perfusion of the affected areas of the myocardium, since 
these abnormalities were more prominent in areas adjacent to the subendocardial fibrosis 
and abnormal vessels. 
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EMF appeared to be an interstitial disease, with preserved endothelial endocardium, 
elastic fibers and, to a certain extent, normal myocytes. The absence of smooth muscle 
cells proliferation, excessive mucoplisacharides or increase in elastin content 
differentiated EMF from fibroelastose. Our patients, who had severe disease and were 
submitted to surgery, had severe scarring and absence of acid mucopolysaccharides 
(AMP), corroborating studies that related the excessive content of AMP in cardiac tissue 
to short duration of the illness (Connor et al, 1968). 
The concurrence of both hyaline and acellular collagen, foci of collagen necrosis, and 
multifocal chronic inflammation in the same patient or in different areas of the same 
heart, point towards an ongoing injury but could also represent the result of a process 
involving temporally spaced insults. 
Despite our efforts to identify and characterize tissue eosinophilia, we found severe 
eosinophil infiltrates in only one patient. Similarly, the presence of clinical signs of 
disease activity did not coincide with tissue inflammation. Moreover, blood eosinophilia 
did not coexist with tissue eosinophilia, indicating that the insult to the heart is not 
entirely mediated by the eosinophil or that this cell does not cause direct damage. 
Eosinophil granule proteins and not the eosinophil itself could mediate cardiotoxicity of 
the eosinophils. Although we did not investigate this issue in our patients, previous 
research undertaken in Nigeria concluded that both degranulated eosinophils and 
significantly elevated serum levels of eosinophil granule basic proteins were not present 
in sera from EMF patients (Urhoghide and Falase, 1987). The results of these studies, 
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performed in patients with established disease, do not exclude the role of 
hypereosinophilia in cardiac damage, which could have occurred in earlier stages.
The heart was the sole organ primarily involved in EMF, with structural changes in all 
other parts of the body resulting from chronic congestion and low perfusion associated 
with heart failure and/or complications of thromboembolism. The reasons for this 
selective injury of the heart are not clear. The heterogeneity of the endothelium (Aird, 
2007) could be one explanation. On the other hand, the recent discovery of tissue factor 
(TF) expression in the myocardium but not in other muscles types (Mackman, 2008), 
might explain the particular predisposition of the heart tissue to local thrombosis. The 
mechanism would be initiated by injury to the endomyocardium by a yet unknown 
mechanism that could be an ongoing infection, autoimmune mechanism or cardiotoxic 
eosinophil products. Endothelial cell activation would induce leakage of plasma proteins 
leading to local TF exposure and fibrin deposition, which would initiate the process of 
endomyocardial thrombosis. Indirect support for this hypothesis comes from the findings 
of fibrin deposits detected by immunofluorescence in hearts of EMF patients studied on 
autopsy (Shaper et al, 1967), and concomitant peritoneal and skeletal muscle fibrosis in 
EMF patients with severe muscular atrophy and ascitis (Freers et al, 2000). 
Both the primary target of injury and the origin of the subendocardial fibroblasts found in 
heart of patients with EMF are unclear. Our patients with established disease had normal 
endothelial endocardium on histological examination, a finding confirmed by CD31 
immunostaining. This suggests that either there is re-endothelisation after endocardial 
disruption associated with endocardial thrombosis described in other series looking at 
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patients died in earlier phases of the disease (Connor et al, 1967), or that the sequence of 
events leading to fibrosis in this condition differs from that described for the 
Hypereosinophilic Syndrome. 
We found good concordance between echocardiography findings and pathological 
abnormalities considered as having diagnostic and prognostic value. This is of paramount 
importance since this suggests that echocardiography, a technique that has been made 
progressively more available, would ensure correct diagnosis and management of EMF in 
poor endemic areas, where MRI will continue to be unaffordable.
We acknowledge that obtaining informed consent from the families patients for post-
mortem examination was difficult due to local cultural believes. For ethical reasons most 
of the cardiac tissue for evaluation was obtained from fibrotic tissue excised during 
surgery of EMF. For the same reason in patients in whom endocardial resection was not 
performed we limited the amount of tissue collected. This resulted in availability of 
endocardium and underlying myocardium, therefore excluding other areas of the 
myocardium and the epicardium, which might present specific abnormalities. Another 
limitation of this study is the fact that, due to our preference for valve repair, we had only 
one mitral valve available for evaluation. 
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6.5. Conclusions
EMF is an interstitial and inflammatory disease with typical distribution in the heart, 
affecting all layers of the ventricular and atrial walls. 
Tissue eosinophilia is rare in established EMF. Fibrotic changes, chronic inflammatory 
infiltrates and neovascularization are more prominent at subendocardium and inner 
myocardium. 
The features detected by echocardiography are highly concordant with those found 
during surgical procedures and autopsies, confirming that correct diagnosis and 
management of EMF is possible in the majority of patients from endemic areas using that 
non-invasive diagnostic tool. 
The detailed intra-operative evaluation of the heart represents a powerful tool for 
understanding of the pathophysiology of EMF, and has allows the development and 
evolution of tailored techniques for the treatment of the specific lesions found in EMF 
patients. 
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Chapter 7
IMMUNE ACTIVATION IN CHRONIC ESTABLISHED EMF 
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7.1. Background
The study of the immune response in patients with EMF has been one of the many ways 
of trying to uncover the etiology and pathogenesis of this condition. Early studies 
demonstrated the presence of high levels of autoantibodies in African patients with EMF 
(Shaper et al, 1967; Van der Geld et al, 1966). This findings were difficult to interpret 
since not specific to EMF (Shaper et al, 1967; Shaper et al, 1968b), and no more studies 
deal with this issue. More recently, the pattern of serum immunoglobulins in Indian 
patients with EMF was described (Mathai et al, 1986; Vijayaraghavan et al, 1984).
The attention of researchers has always been concentrated on the usual finding of 
hypereosinophilia in EMF patients seeking medical attention (Patel et al, 1977; Andy, 
1981; Andy, 1983). Normally, the eosinophils constitute a minor population (1-4%) of 
circulating leukocytes and, under basal conditions, are only observed in the bone marrow 
(where they originate) and in the gut. During parasitic infection eosinophil production by 
the bone marrow is up regulated, blood eosinophils are increased in number and migrate 
to accumulate at sites where the worms are located. Once in contact with the foreign 
organisms, eosinophils release their toxic granular content in order to fulfill their 
defensive role.
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Eosinophilia from 10 to 30% of the total WBC counts, presenting sometimes over several 
months or even years, has been reported to be a frequent finding in EMF patients (Somers 
1972), and attempts at measuring the humoral and cellular changes related to it were 
made by characterizing the eosinophils, and measuring the blood levels of granule basic 
proteins and other humoral factors in Nigerian patients (Urhoghide and Falase, 1987).
Apart from studies investigating the role of eosinophilia and autoimmunity, research on 
the biological profile was scarce and up to date the pattern of the immune response in 
EMF has not been completely described.
We hypothesized that EMF patients present a singular immune system activation pattern 
including both cellular and humoral responses; the later involving increased circulating 
pro-inflammatory cytokines, eosinophil chemoattractant factors and autoantibodies. To 
investigate this hypothesis we designed a series of studies in patients with established 
EMF from our clinical registry to determine: 
(1) The prevalence of eosinophilia and eosinophil-attracting chemokines in the blood 
and cardiac tissue; 
(2) The cytokine profile, mainly the presence of pro-inflammatory cytokines and 
those involved in allergy; and
(3) The presence of circulating antiheart antibodies.
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7.2. Eosinophil Studies
7.2.1. Introduction
Cardiovascular diseases in which chronic and severe eosinophilia is a prominent feature, 
namely Loeffler’s eosinophilic parietal endocarditis and eosinophilic collagen vascular 
disease, are known to be associated with endomyocardial damage (Tai et al, 1987; Spry 
et al, 1985). The have also been reports of the same process occurring in diseases 
associated with transient hypereosinophilia such as eosinophilic leukaemoide reaction, 
Loeffler’s eosinophilic pneumonia, trichinosis and filariasis (Roberts, 1969; Brockington 
and Olsen,1973; Andy, 1977; Andy et al, 1981; Andy et al, 1998). Therefore, owing to 
the common finding of hypereosinophilia in patients with EMF, it was postulated that this 
cardiomyopathy could be the tropical variant of the hypereosinophilic syndrome (HES), 
an entity encountered in temperate climates (Andy, 1983; Andy, 1999) and recognized to 
be closely associated with overproduction of IL-5 (Fletcher and Bain, 2007). 
The late fibrotic lesions of the HES are identical to those of EMF (Brockinghon and 
Olsen, 1973) and, since an increase in eosinophil count resulting from frequent parasitic 
infestations is common in tropical Africa, there had been suggestions that EMF would be 
the “burnt out” phase of an eosinophilic heart disease (Andy et al, 1998). However, this 
has been difficult to investigate due to the usually late presentation of EMF patients seen 
in several regions of the world, and the rarity of diagnosis of this cardiomyopathy in its 
early phases. 
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We therefore planned and designed a sequence of community-based and clinical studies 
in order to explore this issue.
The specific objectives of our studies were to:
(1) Determine the prevalence of blood eosinophilia in children from an endemic area 
for EMF
(2) Determine the prevalence of blood and cardiac tissue eosinophilia in patients with 
established EMF; 
(3) Determine the presence of Eotaxins in blood and cardiac tissue of patients with 
established EMF; 
(4) Evaluate the relation between blood and cardiac tissue eosinophilia
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7.2.2. Population and Methods
7.2.2.1. Blood sample collection and assays
i. Hypereosinophilia in children from Inharrime
During the epidemiological work for the establishment of a cohort of school children in 
Inharrime we collected blood samples from every fifth child observed in the visited 
schools. The samples were collected by puncture of the antecubital vein and slides were 
prepared for manual total leukocyte and eosinophil count. 
ii. Hypereosinophilia in EMF patients with established EMF
Full leukocyte and eosinophil count were performed to patients with established EMF at 
admission to the clinical registry with history of more than 6 months of symptoms, who 
had not received steroid or other anti-inflammatory drug therapy. The eosinophil counts 
were repeated after 6 months of follow up. The full leukocyte count was done using the 
hemocoulter Symex, KX 2IN and slides were prepared for manual eosinophil count. The 
eosinophil count was related to the classification of EMF, specific clinical features and 
ESR and CRP. 
In both studies direct eosinophil counts were done on slides stained using the 
MayGrunvald-Giemsa method. Degranulated and vacuolated eosinophils were searched 
for in the blood films of each subject. Whenever applicable, between 25-50 eosinophils 
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were studied in each slide. An eosinophil was scored as vacuolated if it contained less 
than 50% of the usual expected compliments of cytoplasmic granules. 
iii. Measurement of blood levels of Eotaxin -1, -2 and -3
Venous blood was obtained by puncture of the antecubital vein and collected in 
heparinized tubes. Plasma was prepared by centrifugation at 3000rpm for 20 minutes at 
4C. Samples were aliquoted into Eppendorf tubes, snap frozen at -80 C and stored 
locally. They were transported to London on Cardice and restored at –80C. They were 
thawed immediately before analysis. 
The heparin-plasma samples were precipitated using high salt and low pH solution, prior 
to ELISA using matched antibodies purchased from Jackson ImmunoResearch Labs Inc. 
This extraction procedure is thought to be essential in Duffy positive patients since 
heparin interferes with ELISA measurements in this set of patients (Topping, 2003).  
Plates were coated with HuEot 1 MAB320 1/125, HuEot 2 MAB343 1/500 and HuEot 3 
MAB653 1/250 and incubated overnight. Block using 1%BSA and 0.02 Na Azide PBS 
was added. After 2h-incubation and washing, samples and standards were put in plates 
and incubated at 4C overnight. The detectors (HuEot1 BAF320 1/250, HuEot 2 BAF343 
1/1K and HuEot 3 BAF346 1/125) on A/B 0.1%BSA + 0.05% Thimerasol were added. 
Incubation followed for 4h. NA/HRP was added, incubation followed for 1hr at room 
temperature and finally the substrate was added. H2SO4 was added to each well and 
plates were read at 450nm using a Sunrise absorbance reader.
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New methodology was used after the results of this experiment using heparin samples, in 
which most patients had undetectable levels of eotaxins. It was decided to perform Duffy 
typing for all the patients to exclude the possibility of binding of the eotaxins to 
erythrocytes in Duffy positive patients (Topping, 2003). All patients were Duffy negative 
and we therefore switched from heparin to EDTA plasma samples, which do not need the 
extraction procedure. We therefore used plasma obtained from blood collected in EDTA 
tubes at the same time of the heparin samples that had been used in the first experiment. 
The extraction procedure was omitted in all experiments using EDTA samples (April 
2005, September 2005, and October 2005). Two dilutions (undiluted and at  dilution) 
were used each time. For the second experiment we included some of the 18 samples 
previously tested and two new samples (undiluted or at  dilution). A third experiment 
was performed using the remaining 34 plasma samples at  dilution.
7.2.2.2. Tissue collection and preparation 
i. Histology
Targeted endomyocardial biopsies were obtained intra-operatively in EMF patients who 
were submitted to surgery. The cardiac tissue was immediately fixed in 10% buffered 
formalin, routinely processed for light microscopy and embedded in paraffin blocks. 
Four μ thick sections were prepared, and Hematoxylin-Eosin (H&E) and Carbol 
chromatotrope (Ch2R) staining were used to identify eosinophils. 
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ii. Immunostaining for eotaxins
Sections from the paraffin blocks were dewaxed using Histoclear and alcohol. 
Endogenous peroxidases were blocked by incubating sections in 1% Hydrogen Peroxide 
in methanol. Antigen retrieval used MAB 320 for Eotaxin-1, MAB 343 for Eotaxin-2 and 
P156 for Eotaxin-3. 
All primary antibodies were used at 10 and 25 μg/ml (there were 2 sections, 1 for each 
concentration). The diluent was 5%BSA. Immunoglobulin controls were used on the 
negative controls at the same concentrations. All sections were incubated in primary 
antibody or Immunoglobulin in humidified chamber at 4C overnight.
Biotinylated secondary antibody was used. For MAB 320 and MAB 343 this was anti-
mouse (Jackson ImmunoResearch Labs inc. Biotin –SP-conjugated affinipure F(ab’) 
fragment donkey anti-mouse. Cat no 715-066-150) used at 1:500. For P156 this was anti-
goat (from Jackson labs. Biotin-SP-conjugated Affinipure Fab’ fragment donkey anti-
goat-cat no 705-066-147) was used at 1:250. Human adenoid was used as positive 
control.
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7.3. Results
We collected blood from 71 school children: 65 were healthy students and 6 had EMF. 
The mean (±SD) age of children was 8 years (±1.6), and there were 37 female (52.1%). 
The mean leukocyte count was 8.0 x 109/L (± 2.4). The age of children with 
hypereosinophilia did not differ from that of children with normal eosinophil counts 
(p=0.58 two-sample t-test), and there was no significant evidence that the incidence of 
severe hypereosinophilia differed between girls and boys (p=0.96; chi square test).
Prevalence of Eosinophilia in Children from Inharrime
Hypereosinophilia was common in school children from Inharrime district 19/71 
(26.8%). The mean absolute eosinophil count was 1.2 x 109/L (± 0.9) and the mean 
percentage of eosinophils was 14.5% (± 9.0; range 0-44). The mean percentage of 
degranulated eosinophils was 15.8% (± 14.3; range 0-52), while the mean percentage of 
vacuolized eosinophils was 7.8% (range 0-45). Eosinophilia in children with EMF (1.5 ± 
2.0) did not differ from that of healthy children (1.1 ± 0.8; p=0.54 Mann-Whitney test). 
Of the 71 children for whom eosinophil count was obtained 6 (8.5%) had EMF; of these 
only one had hypereosinophilia. There was no significant difference in eosinophilia in 
healthy children (17/65) when compared to children with EMF (1/6) (p=1, Fisher exact 
test). The numbers and percentage of severe eosinophilia according to EMF status are 
presented in Table 7.1.
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Table 7.1. Eosinophil counts in children from Inharrime schools according to EMF status
Healthy EMF All
Normal Eosinophil Count 48 (90.6%) 5 (9.4%) 53 (100%)
Hypereosinophilia (>1.5x109/L) 17 (94.4%) 1 (5.6%) 18 (100%)
All 65 (91.5%) 6 (8.5 %) 71 (100%)
No significant difference in hypereosinophilia levels was found when comparing 
participants with (1.3 ± 1.3) and without malaria infection (1.0 ± 0.7); (p=0.19, Mann 
Whitney test). Of the 48 participants with positive blood smear for malaria, 13 had severe 
hypereosinophilia, while 6 healthy children out of the 23 who were negative for malaria 
also had severe hypereosinophilia. There was no statistically significant difference in the 
presence of hypereosinophilia in participants with malaria when compared to those 
without the infection (p=0.93; chi-square test). Table 7.2 presents the relation between 
eosinophil count and malaria infection.
Hypereosinophilia was frequent in children from both sexes (10/37; 27% for females, and 
9/34; 26.5% for males) with no statistically significant difference between the sexes. The 
distribution of hypereosinophilia according to gender is shown in Table 7.3
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Table 7.2. Eosinophil counts in children from Inharrime schools according to presence of 
malaria infection
No Malaria Malaria All
Normal Eosinophil Count 17 (32.70%) 35 (67.3%) 52 (100%)
Hypereosinophilia (>1.5x109/L) 6 (31.6%) 13 (68.4%) 19 (100%)
All 23 (32.4%) 48 (67.6%) 71 (100%)
Table 7.3 Eosinophil counts in children from Inharrime schools according to gender
No hypereosinophilia Hypereosinophilia All
Female 27 (73.0%) 10 (27.0%) 37 (100%)
Male 25 (73.5%) 9 (26.5%) 34 (100%)
All 52 (73.2%) 19 (26.8%) 71 (100%)
Prevalence of Eosinophilia in Patients with established chronic EMF
We determined eosinophil counts from 169 patients out of the 175 from our registry. 
Severe hypereosinophilia was present in 44 (26.0%) at entry to the registry. The mean 
absolute eosinophil count was 1.2 x109/L (range 0-8.9) and the mean percentage of 
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eosinophils was 11% (range 0 to 64). The mean percentage of eosinophils that were 
degranulated and vacuolated was 16% (range 0-32) and 5.7%, respectively. 
As shown in Table 7.4 among the 43 patients with severe hypereosinophilia 
intraventricular thrombosis was present in 17 patients (39.5%), periorbital edema was 
found in 17 (39.5%), while asthma –like episodes where seen in 10 (23.2%) patients. 
Table 7.4. Clinical features according to the presence of hypereosinophilia 
There was a trend to increased frequency of eosinophil-related clinical abnormalities such 
as ventricular thrombosis, facial edema and asthma-like episodes in patients with 
hypereosinophilia. 
Only 9 were submitted to short course of oral corticoids, since the remaining patients had 
contraindications. The main contraindications for steroids were severe respiratory 
infections or malnutrition with high risk of reactivation of tuberculosis.
Clinical Features Hypereosinophilia (N 43) No hypereosinophilia (N126)
Intraventricular Thrombus 17 (39.5%) 50   (29.5%)
Facial or periorbital edema 17 (39.5%) 36  (21.3%)
Asthma-like episodes 10 (23.2%) 7  (4.1%)
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There was not a specific trend in the variation of blood eosinophilia in EMF patients. Out 
of the 24 consecutive patients tested on admission to the registry and six months after 
diagnosis that did not received steroids and did not reveal any parasitic infestation during 
follow up, eosinophilia decreased in 11, remained at the same level in 1, but increased in 
12 (Figure 7.1). 
Eotaxin blood levels
The results of the first experiment, involving the determination of eotaxin levels in 18 
patients with EMF are shown in Table 7.5a. The levels of eotaxin-1 were below the level 
of detection of the test in 16 out of 18 patients (the two measurable values were 122.7 and 
177.3 pM). Regarding eotaxin-2 it was detected in all samples and the mean levels, at 
114.3pM (± 47.7) ranging 62.4 to 205.4. The levels of eotaxin-3 were below the limit of 
detection of the assay for all but one sample (73.4 pM in a patient with absolute 
eosinophil count of 8.5 x 109/L). 
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Figure 7.1. Variation in percentage of eosinophils in 24 consecutive patients (P1 to P24) 
for whom eosinophil counts were performed at diagnosis (T0) and 6 months after follow 
up (T1), for whom no steroids had been administered. 
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Table 7.5a. Eotaxin levels of 15 EMF patients measured in heparin plasma samples
EMF patients Eotaxin-1
pM (pg/ml)
Eotaxin-2
pM (pg/ml)
Eotaxin-3
pM (pg/ml)
0008 * 81.9 *
0017 * 169.5 *
0020 * 99.0 *
0029 * 78.1 *
0030 * 114.7 *
0033 * 63.2 *
0036 * 205.4 *
0040 * 100.5 *
0064 * 66.5 *
0023 * 126.4 *
0043 122.7 107.5 *
0050 * 197.2 *
0051 * 62.6 *
0054 * 73.4 *
0062 177.3 200.4 73.4
0065 * 119.4 *
0070 * 105.3 *
0073 * 86.6 *
* Below the levels of detection of the assay 
Chapter 7 Immune Activation
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
277
Using EDTA samples the levels of eotaxin-1 were below the level of detection of the 
assay in 11 out of 66 samples tested. Regarding eotaxin-2 one sample had the levels 
above the limit of the assay. In contrast the levels of eotaxin-3 were below the level of 
detection of the assay for all 51 samples that were tested for this cytokine. The results 
obtained were not reproducible for the 12 samples that were re-tested. The results of the 
tests performed for EDTA samples are presented in Tables 7.5b,c.
Comparing the results of 49 EMF patients (46 with pure EMF and 3 with concurrence of 
RHD) with 5 controls with RHD we found that there was no clear relationship between 
the eotaxin levels and absolute eosinophil counts (Figure 7.2), and that no statistically 
significant difference existed between eotaxins levels in any of the three groups of 
patients (Figures 7.3).
Tissue eosinophilia
Tissue eosinophilia was rare in the excisional biopsies obtained from 29 patients. Out of 
the 12 patients with blood hypereosinophilia only one had marked tissue eosinophilia in 
the atrium. Remarkably, only one patient had severe ventricular eosinophilia (Figure 10 
Chapter 6) but did not have blood eosinophilia and was classified as mild EMF 
characterized by patchy mural fibrosis and predominant mitral valve affection. 
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Table 7.5b. Eotaxin-1 and eotaxin-2 levels of 15 EMF patients measured in undiluted 
and ½ diluted EDTA plasma samples
Code Eotaxin-1 
undiluted
PM
Eotaxin-1
½ diluted
pM 
Eotaxin-2
undiluted
pM 
Eotaxin-2
½ diluted
pM 
0023 7.8 2.9 75.7 124.2
0029 11.1 6.1 34.7 62.8
0033 8.0 4.3 37.9 75.7
0036 7.3 5.9 57.6 149.4
0040 5.6 2.8 43.9 99.8
0043 9.5 6.6 24.9 48.2
0050 11.5 8.5 87.8 164.4
0051 5.8 4.1 16.9 53.0
0054 7.9 3.5 40.8 68.4
0062 13.4 6.8 61.3 104.1
0063 7.3 1.5 46.9 100.7
0064 8.2 4.5 36.3 94.6
0065 6.3 3.1 31.8 76.6
0070 7.5 4.8 24.0 64.6
0073 13.1 4.1 223.1 125.7
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Table 7.5c. Blood levels of Eotaxins-1, -2 and -3 in 34 EMF patients measured in EDTA 
plasma samples at ½ dilution. 
Code Eotaxin-1
pM 
Eotaxin-2
pM 
Eotaxin-3
pM
0002 6.9 58.2 < min
0003 10.2 37.6 < min
0004 14.4 48.2 < min
0005 13.0 110.5 < min
0006 8.3 39.2 < min
0007 4.8 80.2 < min
0009 < min 11.1 < min
0016 4.3 21.7 < min
0023 < min 41.4 < min
0025 5.9 20.6 < min
0026 8.3 32.1 < min
0029 4.9 12.4 < min
0031 12.2 25.0 < min
0032 14.3 > max < min
0033 3.3 14.3 < min
0036 9.0 34.6 < min
0037 9.2 22.9 < min
0038 7.4 54.8 < min
0039 12.2 25.9 < min
0040 < min 22.4 < min
0041 13.2 41.6 < min
0042 9.3 36.3 < min
0043 < min 2.7 < min
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(continuation of Table 7.5c from previous page)
Code Eotaxin-1
pM 
Eotaxin-2
pM 
Eotaxin-3
pM 
0044 4.8 17.4 < min
0045 8.6 30.2 < min
0046 15.6 33/2 < min
0047 12.8 33.2 < min
0048 5.5 21.0 < min
0049 21.2 26.9 < min
0051 < min 9.5 < min
0052 7.9 35.4 < min
0053 9.3 27.1 < min
0054 < min 17.9 < min
0055 4.6 13.4 < min
0056 10.4 29.1 < min
0057 11.8 28.6 < min
0058 10.3 27.2 < min
0059 < min 20.1 < min
0061 5.7 14.1 < min
0062 10.3 42.2 < min
0063 < min 28.9 < min
0064 8.9 20.6 < min
0065 3.2 18.7 < min
0066 8.7 86.5 < min
0067 < min 39.5 < min
0068 5.3 29.7 < min
0069 1.5 26.1 < min
0070 < min 17.1 < min
0071 < min 10.7 < min
0072 6.1 28.2 < min
0073 < min < min < min
<min = below the level of detection
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Figure 7.2 Blood levels of eotaxin-1 (left) and eotaxin-2 (right) in 49 patients with EMF 
show noo clear correlation with the absolute eosinophil count in the blood
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Figure 7.3. Blood levels of eotaxin-1 and eotaxin-2 in patients with EMF (emf), 
rheumatic heart disease (rhd) or concomitance of RHD and EMF (mixed)
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Eotaxins in cardiac tissue
Eotaxins were detected in cardiac tissue from 2 patients with EMF, 2 patients with 
Rheumatic Heart Disease (RHD) and 2 patients with Congenital Heart Disease (CHD). 
Immunostaining showed that the chemoattractant was predominantly inside mononuclear 
inflammatory CD68 positive cells (macrophages or monocytes), but were also present in 
other cell types (Figure 7.4). The presence of eotaxins in the cardiac tissue was not 
associated with eosinophil recruitment.
Figure 7.4. Several types of inflammatory cells stained for Eotaxin-2 (top left), Eotaxin-1 
(top right) and Eotaxin-3 (bottom) inside and outside the vessels. The cells that stained 
more strongly were macrophages, monocytes and lymphocytes.
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7.3. Cytokine profile 
7.3.1. Introduction
Cytokines participate in a wide range of biologic processes and their effects on 
cardiovascular system include promotion of inflammation, intravascular coagulation, 
oxidative stress, cardiac structural and functional abnormalities, endothelial injury and 
cardiomyocyte or endothelial apoptosis (Dinarello, 2000; Mann et al, 1994). Cytokines 
that are involved in allergic reactions might also be increased in EMF patients.  
Among many cytokines, Interleukin 5 (IL-5) and Eotaxins (Eot) modulate eosinophil 
function. IL-5 plays a critical role in the differentiation, proliferation, migration, and 
activation of eosinophils (Chung, 2002). Eotaxins (-1, -2, -3) are chemotatic cytokines 
(chemokines) selective for eosinophils that act via CCR3 receptors (Jose et al, 1994). 
They can induce both the local recruitment of eosinophils from the microcirculation and 
rapid mobilization of eosinophils from the bone marrow, in synergy with IL-5 (Palframan 
et al, 1998). Animal models of pulmonary inflammation show that local eotaxin 
generation correlates with eosinophil accumulation (Humbles et al, 1997; Li et al, 1997).
IL-5 and Eotaxins have been recently identified as therapeutic targets for diseases 
associated with hypereosinophilia. In this context the clarification of their role and that of 
the eosinophil in the pathogenesis of EMF is of paramount importance. 
The objective of the study was to determine the presence of cytokines IL1α, IL1β, IL3, 
IL4, IL5, IL9, IL10 and IL13 in patients with EMF.
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7.3.2. Population and Methods
EMF patients and controls
Sixteen consecutive patients who had not been medicated with anti-inflammatory drugs 
were recruited from our EMF registry between October and December 2004 when 
coming for their appointments. At the time of participation in the study, these patients 
were in different stages of the disease with medical treatment consisting of diuretics, 
ACE-inhibitors, digitalis and β-blockers in most cases. Eight patients were taking oral 
anticoagulation.
Blood sample collection and storage
Blood samples were collected by puncture of the antecubital fossa and collected into 
heparin-tubes. Plasma was prepared by centrifugation at 3000rpm for 20 minutes at 4C. 
Samples were aliquoted into Eppendorf tubes and snap frozen, at -80 C and stored 
locally. They were transported to London on Cardice, restored at –80C and thawed 
immediately before analysis. 
Blood Assays
Cytokine levels were measured on heparin-plasma samples after defrosting at room 
temperature (RT), using protocol A of the Beadlyte Human Multi-Cytokine Beadmaster 
Kit. The kit was customized for IL1α, IL1β, IL3, IL4, IL5, IL9, IL10 and IL13. 
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The standards were re-suspended in tissue culture media provided in the kit and serial 
dilution was done. Each well was filled with 50l of standard/sample and 25l of bead 
solution supplied, and incubated for 2 hours in dark while shaking; 25l of reporter 
solution were added to each well, mixed gently using a voretex and incubated for 1.5 
hour in dark at RT. Then 25l of diluted streptavidin-phycoerythrin solution were added 
and left in dark for 30 min. Stop Solution was added and left for 5 min in dark at room 
RT. Reading was done using Luminex 100™ system
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7.3.3. Results
Several cytokines were below the limit of detection of our assay. Th2 cytokines had more 
detectable values when compared to the other cytokines. Remarkably all patients had 
measurable levels of IL-5. The mean level of IL-5 was 3.0 (range 2.1 to 9.3). 
There was no clear correlation between the eosinophil counts and the levels of cytokines 
in most patients. High levels of pro-inflammatory cytokines and hypereosinophilia 
coexisted in 2 out of 7 patients with high absolute eosinophil counts. Table 7.6
summarizes the clinical and echocardiographic findings, eosinophil counts and the blood 
levels of the cytokines measured in 16 patients with EMF.
Following these results suggesting problems in the lower part of the standard curves we 
decided to introduce a second wash in experiment in order to increase sensitivity. During 
the second experiment we also changed the patients with associated RHD, replacing them 
with healthy subjects. Unfortunately, due to excessive fibrin content in the plasma 
samples from EMF patients the reading procedure by the Luminex  100™ machine was 
impeded by blockage of the machine.
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Table 7.6. Summary of the clinical-echocardiographic findings, eosinophil counts and 
measured levels of the cytokines IL-1a, IL-1b, IL-3, IL-4, IL-5, IL-9, Il-10 and IL-13 in 
16 patients with EMF
Code Age
(y)
EMF  
Classif
Eos
(x109/L)
IL1a IL1b IL3 IL4 IL5 IL9 IL10 IL13
0073 13 R GII 8,4 - - - - 3.7 - 2.8 -
0036 11 B GIII 7,2 9.5 3.4 - 2.4 9.3 3.2 3.3 E
0063 18 R GIII 2,2 129.7 80.7 2.5 4.5 8.1 1.1 72.6
0051 13 R GIV 1,9 - - 137.0 - 2.6 - 2.4 -
0062 6 B GII 1,9 - - - - 2.8 - 6.4 -
0059 12 L GII 1,8 - - - - 2.4 - - -
0065 15 B GII 1,5 - - - - 2.5 - 1.8 -
0023 12 R GIV 0.4 - - - 2.7 2.2 2.4 1.4 -
0029 15 B GII 0.3 - - - 2.1 2.2 - 1.6 -
0033 12 B GI 0.2 - - - 2.4 2.3 - 2.3 -
0040 20 R GIV 0.3 E 2.5 - - 3.1 1.9 2.1 -
0043 13 B GIII 0 - - - - 2.1 - 5.4 -
0050 32 R GIV 0.1 - - - - 2.1 - 1.2 -
0054* 37 B GI* 0.1 - - - - 2.1 - - -
0064* 12 B GII* 0.4 - - - - 2.2 - 1.4 -
0070* 12 L GII* 0.2 - - - - 2.2 - - -
Y = years* Associated RHD; L left; R right; B bilateral; G grade; EOS absolute eosinophil count; IL 
Interleukin; - Below level of detection; E Error
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7.4. Antiheart antibodies
7.4.1. Introduction
The epidemiological and clinical similarities between EMF and RHD generated the 
hypothesis of the two conditions being different expressions of the same pathological 
process (Shaper et al, 1968a). Despite the pathogenesis of RHD being not completely 
understood, it is accepted that the response against Streptococcal infection of the upper 
airways and probably skin, causes the typical heart lesions through mechanisms 
immunologically mediated. 
EMF patients have been shown to have high prevalence of antiheart antibodies (Van der 
Geld et al, 1966; Shaper et al, 1968). The demonstration of bound Ig to the sarcolemmal 
and sub-sarcolemmal sites in myofibers (Van der Geld et al, 1966) was considered an 
indicator of autoimmune mechanism existing in EMF.
More recently immunological studies undertaken in India had divergent results. In one 
study EMF patients and matched controls had both raised immunoglobulin levels, 
although a higher proportion of patients had markedly raised serum levels of IgG, Ig A, 
Ig M and Ig E (Vijayaraghavan et al, 1984). However, antimoyocardial antibodies were 
not detected in sera and no bound immunoglobulins were observed in myocardial tissue 
of EMF patients, suggesting that there was no autoimmune reactivity in that series of 
patients (Kartha et al, 1984). Interestingly, the tropical immunological syndrome 
prevalent in Africa was absent in India (Vijayaraghavan et al, 1984).
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We therefore designed a study to assess the presence, frequency and specificity of 
circulating anti-myocardial antibodies of IgM and IgG classes in EMF patients from 
Mozambique.
7.4.2. Patients and Methods
Serum was obtained from 56 consecutive EMF patients with chronic disease from our 
registry between November 2004 and October 2005. 
Characteristic of patients
The mean age of the patients was 18 years (SD 11, range 6 to 49), and 35 (62.5%) were 
females. Thirty-two patients (57.1%) had biventricular disease, 20 (35.8%) had right 
ventricular disease and 4 (7.1%) had left ventricular EMF. The mean age was 18 years 
(range 6 to 49), and 35 (62.5%) were females. The majority of patients were in functional 
class III or IV of the NYHA (45; 80.3%) and 18 (32.1%) had atrial fibrillation. The mean 
eosinophil count was 0.4x109/L (IQ range 0.2-1.2). All patients had a negative blood 
smear for malaria at time of blood collection. The main characteristics of the patients are 
presented in Table 7.7.
Control subjects
Ten blood donors from the same population were used as controls. Their mean age was 
20 (SD 2, range 18 – 23) and 5 (50%) were females. 
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SDS-PAGE and Western Blotting
Normal ventricular myocardium was obtained from a donor heart and immediately frozen 
in liquid nitrogen. It was pulverized while still frozen and homogenized in 1% SDS. A 
protein assay was carried out using the dye-binding procedure of Bradford. Samples 
(25ug) were solubilosed and denatured by heating at 70C for 10 minutes in LDS sample 
buffer (Invitrogen). The samples were loaded onto 10% tris-bis gels and run at 60mA/gel 
until the tracking dye reached the end of the gel. Molecular weight markers (Amersham) 
were concomitantly run on each gel. The proteins were electrophoretically transferred to 
nitrocellulose at 30V for 1 hour.
Detection of antiheart antibodies
Nitrocellulose strips carrying separated lanes of myocardial proteins separated by SDS-
PAGE were blocked for 1h with 3% w/v nonfat dried milk (Marvel) in phosphate 
buffered saline containing 0.05% w/v Tween-20 (blocking solution). Strips were then 
incubated with patient’s serum, diluted 1:100 in blocking solution, and agitated for 1h at 
room temperature. After thorough washing in PBS-Tween strips were incubated for a 
further 1h in either peroxidase-conjugated rabbit antihuman IgG (Dako) or IgM (Dako) at 
a dilution of 1:500 in blocking solution. The strips were then washed thoroughly in PBS. 
Protein bands to which antiheart antibodies had bound were visualized using enhanced 
chemiluninescence detection system (ECL, Amersham). Blots were incubated with the 
detection reagent for 1 min and then exposed to Hyperfilm (Amersham) for 1, 2 and 5 
mins. The films were developed using an automated radiograph developer.
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Data Analysis
Quantitative data are given as means ± SD. The Fischer exact test was used to compare 
the positive results in patients and controls. A p value of less than 0.05 was considered 
statistically significant.
Table 7.7. Characteristic of patients participating in the study on antiheart antibodies
Variable Value (%)
Age (years) 18 ± 11
Male/Female 21/35
NYHA class I-II/III-IV 8  (14.3)
II 3  (5.4)
III 22 (39.3)
IV 23 (41.0)
Severity of EMF Mild (I) 13 (23.2)
Moderate (II) 8  (14.3)
Severe (III) 18 (32.1)
Advanced (IV) 17 (30.4)
Active/Quiescent disease 8  (14.3)
Atrial fibrillation 18  (32.1)
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7.4.3. Results
Detection of IgG and IgM 
Fifty-four (96.4%) EMF patients tested positive for anti-myocardial antibodies of the IgG 
class whilst 33 (58.9%) tested positive for those of the IgM class. Endomyocardial 
Fibrosis patients presented more circulating anti-myocardial antibodies in the serum 
when compared to healthy controls. The sera from control subjects showed minimal or no 
reactivity against myocardial proteins (Figures 7.5 and 7.6).
The frequency of IgG class anti-myocardial antibodies in patients with endomyocardial 
fibrosis and control subjects is presented in Table 7.8. Higher frequencies for IgG class 
were found in patients with EMF when compared with healthy controls. These 
differences were statistically significant for proteins of the following molecular weights: 
42 kD (33; 58.9% in patients versus 0 in controls; p=0.0009), 35 kD (32; 57.1% in 
patients vs 0 in controls; p= 0.0009) and 70 kD (23; 41.1% in patients versus 0 in 
controls; p=0.011). Patients had also higher frequencies of antiheart antibodies against 
proteins of 60 kD (18; 32.1% versus 0) and 90 kD (19; 33.9% versus 0) molecular 
weights, which were statistically nearly significant with p values of 0.051 and 0.052, 
respectively.
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Figure 7.5. IgG measured by WB in patients with EMF (left) and healthy controls from 
the same population matched for age and ethnics (right).
Figure 7.6. IgM and IgG measured by WB in patients with EMF.
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Table 7.8. Comparison of frequency of IgG class antiheart antibodies of different 
molecular weights in patients with established EMF and controls
Protein
Molecular Weight
(kD)
EMF
______ 56 ______
N+ (%)             N–
Controls
______ 10 ______
N+ (%)              N–
Fisher Exact Test
25 13 (23.2)           43 1 (10)                     9 0.68
30 13 (23.2)           43 0  (0)                    10 0.19
35 32 (57.1)           24 0  (0)                    10 0.0009
42 33 (58.9)           23 0  (0)                    10 0.0009
46 21 (37.5)          35 0  (0)                    10 0.024
60 18 (32.1)           38 0  (0)                    10 0.051
70 23 (41.1)           33 0  (0)                    10 0.011
80 24 (42.9)           32 1  (10)                   9 0.076
90 19 (33.9)           37 0  (0)                   10 0.052
100 20 (35.7)           36 2  (20)                   8 0.48
110 10 (17.9)           46 0  (0)                   10 0.34
150 15 (26.8) 41 2  (20)                   8 1.00
Regarding antibodies of the IgM class the difference in frequencies between EMF 
patients and control subjects was not statistically significant. All controls were negative 
for any of the IgM class antibodies. The proteins more frequently detected in EMF 
patients were 46 kD (17; 30.4% versus none in controls, p=0.053) and 80 kD (12; 21.4% 
versus none in controls, p=0.19). Table 7.9 shows the frequency of anti-myocardial 
antibodies of the IgM class in patients with endomyocardial fibrosis and control subjects. 
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Table 7.9. Comparison of frequency of IgM class antiheart antibodies of different 
molecular weights in patients with established EMF and controls
Protein
Molecular Weight
(kD)
EMF
56 
N+ (%)             N –
Controls
10 
N+                     N –
Fisher Exact Test
25 6    (10.7)            50 0                          10 0.58
35 8    (14.3)            48 0                          10 0.34
40 6    (10.7)            50 0                          10 0.58
42 9    (16.1)            47 0                          10 0.33
44 6    (10.7)            50 0                          10 0.58
46 17  (30.4)            39 0                          10 0.053
50 11  (19.6)            45 0                          10 0.19
60 11  (19.6)            45 0                          10 0.19
70 7    (12.5)            49 0                          10 0.58
80 12  (21.4)         44 0                          10 0.19
90 4    (7.1)              52 0                          10 1.00
100 6    (10.7)            50 0                          10 0.58
Reactivity according to disease activity and severity
Clearly the mean (± SD) number of antibodies was higher for left EMF (14.0 ± 9.1), than 
for BEMF (8.5 ± 6.0) and REMF (8.4 ± 4.2), but there were only 4 patients in the former 
group. There is not significant evidence that the mean number of antibodies differed 
between the types (p = 0.18, analysis of variance). 
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There were 35 patients with severe (grades 3 and 4) and 21 with mild-moderate disease 
(grades 1 and 2), and the mean (± SD) number of antibodies were respectively 9 ± 5 and 
9 ± 7. There was not significant evidence that the mean number of antibodies differed 
between less and more severe patients (p = 0.68, t-test).
The characteristics of the 8 patients with active disease are shown in Table 7.10. Four 
had BEMF, 2 had REMF and the remaining 2 had LEMF. According to the severity of 
cardiac lesions 2 patients had Mild, 3 had Moderate, 1 had Severe and 2 had Advanced 
EMF. The other patients had quiescent disease. There was strongly significant evidence 
that the mean number of antibodies is greater for patients with active disease (19.6 ± 3.7) 
compared to those with quiescent disease (7.1 ± 3.3) with p < 0.001. 
Table 7.10. Comparison of frequency of IgM class antiheart antibodies of different 
molecular weights in patients with established EMF and controls 
Code 0070 0069 0068 0066 0056 0048 0031 0030
EMF type LEMF LEMF BEMF BEMF BEMF BEMF REMF REMF
EMF severity II II II I I III IV IV
Number IgG 10 14 14 10 11 11 9 6
Number IgM 6 8 0 10 9 7 4 12
Total 16 22 14 20 20 18 13 18
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7.5. Discussion 
Blood Eosinophilia
At the time of diagnosis 26% of patients with established EMF had hypereosinophilia at 
levels that are used to define the hypereosinophilic syndrome. Similar results have been 
reported from reported from Nigeria (Manyanja-Kizza et al, 2000) and Uganda (Somers 
et al, 1972b; Freers et al, 1993). 
The characterization of eosinophils in patients with hypereosinophilia showed increased 
degranulation. During the episodes of hypereosinophilia most patients had clinical 
features that could be related to eosinophilic damage of the heart (intraventricular 
thrombosis) or recrudescence of heart failure with appearance of signs of congestion, 
asthma-like episodes and periorbital edema. The asthma-like episodes occurred in 
children with no previous personal or family history of asthma and could not be 
associated to any particular parasitic agent or allergen. We think that they may reflect the 
effects of increased eosinophils and their related products in the lungs, since eosinophil 
accumulation in the lungs also occurs in non-allergic asthma (Jose et al, 1994). 
The eosinophil counts in our patients with EMF varied without a particular trend during 6 
months follow up. Despite our efforts to identify parasitic infestations that are associated 
with severe eosinophilia, which are known to be prevalent in our community (namely 
schistosomiasis, helminthiasis and filariasis) the changes in eosinophil counts did not 
seem to be associated with new parasitic infestations. Similarly, neither the previous 
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history nor the presenting symptoms and signs allowed a diagnosis of allergy that would 
explain this increase in eosinophil counts.
In our population there was no difference of either the previous history of parasitic 
infestation or its prevalence at presentation when comparing patients with 
hypereosinophilia from those with normal eosinophil counts. Although there have been 
reports of patients who developed EMF after parasitic infestations (Brockington et al, 
1967; Ive et al, 1967; Brockington, 1974; Andy et al, 1981), results similar to ours were 
obtained in previous attempts to establish a relation between parasitism, eosinophilia and 
chronic EMF in endemic areas in Africa. Eosinophilia was as common in EMF patients 
as in controls in a study that concluded that degranulated eosinophils and significantly 
elevated levels of eosinophil granule basic proteins were not present in EMF (Urhoghide 
and Falase, 1987). A poor correlation between eosinophilia and parasitic infestations has 
also been reported in other series (Patel et al, 1977), and more recently, it was concluded 
that neither absolute/relative eosinophilia, nor the presence of helminthic infestation 
could be the only contributing factor to the pathogenesis of EMF (Ijaola and Falase, 
1988). Authors from Uganda proposed absolute eosinophilia as being a putative cause of 
EMF, and suggested that hypereosinophilia is an independent risk for EMF not 
attributable to parasitism (Rutakingirwa et al, 1999). However, it must be mentioned that 
when looking at hypereosinophilia in EMF patients with recent onset of disease, one 
study found a highly significant inverse relationship between hypereosinophilia and the 
duration of symptoms (Andy, 1998), suggesting that the frequency of hypereosinophilia 
in our patients would be higher had we detected them earlier. 
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We did not find a significant difference in the levels of eosinophilia in school children 
between those with and without EMF. Similarly, in Ugandan experience eosinophils do 
not affect patients with EMF any more than the population at large (Patel et al, 1977), nor 
has eosinophilia been recognized in the thrombotic and fibrotic endocardial lesions 
studied in biopsy (Somers et al, 1971) and necropsy specimens (Connor et al, 1967; 
Connor et al, 1968). In Nigeria degranulated eosinophils were absent in the blood and 
bone marrow aspirates of EMF patients, and the mean concentrations of eosinophil 
granule basic proteins were not different in patients and control subjects (Urhoghide and 
Falase, 1987). 
The role of hypereosinophilia in determining the cardiac damage is the hypothesis more 
frequently explored to explain the pathogenesis of EMF, because of the knowledge that 
exists of the Hypereosinophilic Syndrome in which the final damage to the heart is 
similar to that found in established EMF (Olsen, 1990). However, owing to results of 
several studies on EMF we must also consider the possibility of hypereosinophilia being 
part of the body response to an unknown insult that also results in cardiac damage seen in 
these patients, the two responses being independent. Prospective studies looking at 
hypereosinophilia and its determinants in individuals from endemic areas for EMF are 
therefore needed. 
Eosinophil-related cytokines
It has been accepted that eosinophils are largely under the control of IL-5 and eotaxins 
(Heath et al, 1997). These modulators of eosinophil function have been identified as 
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therapeutic targets for diseases associated with hypereosinophilia, hence our interest in 
investigating their presence in EMF patients. 
Although some studies were performed looking at the levels of IL-5 in EMF patients, no 
research has been undertaken trying to determine whether the level of eotaxins are 
elevated in EMF patients. In fact, there are no such studies in populations from tropical 
regions with high prevalence of eosinophilia. However, despite several problems faced 
by us during the setting up of the technique for determination of eotaxin blood levels, 
some changes to procedures of blood collection and extraction improved the results 
obtained by the assay. 
There is no agreement on the levels of eotaxins in healthy individuals, and no studies 
were done to determine the level of eotaxins in the Mozambican population. A wide 
range of eotaxin levels has been reported from studies in different populations from 
Europe and Asia, varying from 5 to 75 pM in plasma from normal subjects (Topping, 
2003; Fujisawa et al, 2002; Economou et al, 2001). The blood levels found in the 
majority of our patients are therefore within the normal ranges. Interestingly, high levels 
were found for all eotaxins in few patients with severe blood hypereosinophilia.
The determination of the cytokine profile using the multiplex technique was jeopardized 
by the high content of fibrin in the plasma samples from our patients Therefore the reuslts 
obtained will not be discussed in detail. WeIt is however of interest to mention that we 
were able to show that the blood levels of IL-5 in our patients, half of which had severe 
hypereosinophilia, were not increased. 
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An important consequence of the finding of abnormally high levels of fibrin in the 
plasma samples was the design of another study aiming at determining the presence of an 
abnormal pro-thrombotic factors and hemostatic dysfunction in patients with early onset 
EMF, which we present in Chapter 8.
Tissue Eosinophilia
Cardiac tissue eosinophilia was rare in established EMF, despite the presence of eotaxins 
in cardiac tissue. Out of the 25 patients studied, cardiac tissue eosinophilia was detected 
in 2, of which one had normal blood eosinophilia. These results are similar to those 
reported in other series of EMF patients (Connor et al, 1968; Somers et al, 1971; Chopra 
et al, 1989), and are in contrats with the usual pathology features in Hypereosinophilic 
Syndrome. Characteristically, in HES there are deposits of activated eosinophils and 
secreted eosinophil granule proteins in the necrotic and thrombotic lesions (Tai et al, 
1987), as well as persisting tissue eosinophilia and degranulation of eosinophils in the 
fibrotic stage (Frustaci et al, 1989). 
To our knowledge the study we designed was the first attempt at determining the 
presence of eotaxins in cardiac tissue of EMF patients and trying to correlate its presence 
with eosinophil recruitment and accumulation. The rational behind this research was the 
knowledge that in animal models of pulmonary inflammation local eotaxin generation 
correlates with eosinophil accumulation (Humbles et al, 1997, Li et al, 1997; Matthews et 
al, 1998). Interestingly, eotaxins where detected in cardiac tissue from EMF patients as 
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well as in those with RHD and CHD, suggesting that these cytokines may not have yet 
unidentified physiology roles. 
Although the number of patients involved in our pathology studies was small, their
results suggest that eosinophils and eotaxins do have neither an essential nor an exclusive 
role in established chronic EMF. They might however be involved in the pathogenesis in 
earlier stages of this condition. The temporal relationship between blood eosinophilia, 
blood levels of IL-5 and eotaxins, and structural abnormalities of the heart needs to be 
demonstrated on cohort studies. 
We acknowledge that the number of patients included in the studies is low and that the 
technique for testing eotaxins in cardiac tissue is yet being established. We think that an 
improvement to the assays for determination of eotaxins in humans is warranted to prove 
or discard the relevance of these cytokines in the pathogenesis of EMF. Also, the role of 
hypersensitivity, suggested from pathology studies (Connor et al, 1968) and the finding 
of markedly raised levels of IgE’s in some patients with EMF (Mathai et al, 1986) was 
not assessed in our studies.
Autoimmunity
Antiheart antibodies were detected in blood of EMF patients providing evidence for the 
role of autoimmunity in this cardiomyopathy. It seems however that this phenomenon is 
not exclusive to EMF since it was shown to occur in African patients irrespective of the 
nature of the heart condition (Shaper et al, 1967; Shaper et al, 1968b). Regarding the 
Indian experience, in a study using direct immunofluorescence on myocardial tissue 
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obtained at surgery or at autopsy from EMF patients no deposits of IgG, IgM or IgA were 
found in the myocardium, suggesting that there was no autoimmune reactivity in that 
series of patients (Mathai et al, 1986). 
The Western Blotting procedure, the technique used by us to detect IgG and IgM class 
antibodies in our studies, is the most sensitive and gives results that are easier to interpret 
(Dunn et al, 1991). Autoantibodies of the IgG class were more prevalent than those of 
IgM class, corroborating previous studies, which found IgG class immunoglobulins in 
larger numbers in patients with EMF (Carlisle et al, 1972). 
The significance of heart-reactive antibodies in cardiac disease has been the subject of 
intense debate. Some authors who point out that these antibodies occur commonly 
following several types of cardiac injury including surgery and myocardial infarction 
(Akl et al, 1992; Van der Geld et al, 1964;Latif et al, 1993) suggest a non-pathogenic 
role, a theory that had been supported by initial failure of attempts to demonstrate their in 
vitro and in vivo cytotoxicity (Thompson and Halbert, 1971). However, in recent years a 
cause-and-effect relationship was demonstrated between the presence of human cardiac 
myosin autoantibodies and impairment of myocyte contractility (Warraich et al, 2006), 
supporting the circumstantial evidence that implicates the participation of heart-reactive 
antibodies in certain forms of heart disease such as Rheumatic Heart Disease (Eichbaum 
et al, 1995; Shastry et al, 1988), cardiomyopathies (Das et al, 1973), postmyocardial 
infarction (Dressler’s) syndrome, and postpericardiotomy syndrome (Akl et al, 1992). 
Moreover, it has been recognized that antiheart antibodies play a major role in rejection 
events following transplantation (Warraich et al, 2000) and that immunosuppressive 
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therapy results in decrease in levels of these antibodies that is associated with 
improvement in clinical condition.
The molecular weights of 35 kD, 42 kD, and 70 kD correspond to Tropomyosin, Actine 
and Heat Shock Protein (HSP)-70, respectively. The first two are major components of 
the contractile apparatus of the myocyte whereas HSP-70 is a marker of cardiac damage. 
We could speculate as to the importance of the finding of antibodies to the 46 kD protein 
in nearly one third of our EMF patients. The 46 kD corresponds to the molecular weight 
of an integral membrane protein, component of specialized intercellular junctions, that 
serves as a receptor for Coxsackievirus (Baldwin et al, 2005), a virus commonly 
associated with myocarditis and cardiomyopathy (Takata et al, 2004; Cihakova et al, 
2004) and studied as one of the possible factors in the pathogenesis of EMF (Ijaola and 
Falase, 1990).
Additionally the molecular weight of 42 kD is known to correspond to Connexin43. 
Considering that the primary target of the disease is not known its relevance cannot be 
excluded and therefore further investigation on its possible role is warranted.
It has been suggested that antiheart antibodies are a non-invasive marker of early disease 
in some forms of cardiomyopathy (Caforio et al, 1997). They bind to their specific 
cardiac tissue in later stages of cardiomyopathy, explaining the reduction in circulating 
levels in advanced stages (Das et al, 1974). Follow-up studies on EMF patients diagnosed 
in earlier stages are needed to define the temporal changes that occur in the autoimmune 
response in this condition, and clarify the role of autoimmunity in its pathogenesis.
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There are some limitations to our study. The peaces of normal ventricular myocardium 
used for building the nitrocellulose strips also contain endothelial components of the 
vessels and elements of the extracellular matrix, which molecular weights may yet be 
unknown. We therefore acknowledge that the proteins identified cannot be attributed 
exclusively to the myocardium, and that is why we use the term “antiheart”. 
Although the primary target of injury is not yet identified in EMF, the most prominent 
lesions occur in the interstitium and affect the endocardium and subendocardial region. 
There is therefore need for further research aiming at identification of the sub-classes of 
immunoglobulins involved and the proteins targeted by these antibodies. 
The present work shows that immune markers are found in only a proportion of patients 
with EMF, suggesting that there would be some patients in whom endomyocardial 
damage is mediated by mechanisms other than autoimmunity.
Most of our patients were in grade III/IV heart failure, and as mentioned above several 
studies relate seropositivity for autoantibodies to heart failure rather than to any particular 
pathologic process (Akl et al, 1992; Van der Geld et al, 1964;Latif et al, 1993). Inclusion 
of a control group of patients with heart failure of other etiology would help clarify this 
issue.
Another limitation of the interpretation of the significance of these antiheart antibodies is 
that the cardiac, skeletal and smooth muscle may share antigenic determinants, and 
therefore the antibodies may not be entirely organ specific.
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7.6. Conclusions
The conclusions of these studies exploring the immune response in EMF are the 
following:
1. Severe blood eosinophilia is a common finding in both early onset and chronic EMF. It 
seems to be a major determinant of clinical signs in a subset of these patients, but does 
not correlate with the blood levels of eotaxins.  
2. Eotaxins are frequently detected in cardiac tissue while cardiac tissue eosinophilia is 
rare in established EMF, meaning that the presence of these chemoattractans is not 
associated with eosinophil recruitment or accumulation in the heart. 
3. Autoimmunity is present in a large subset of patients with established EMF. 
Autoimmune markers may provide adjunct tools for diagnosis and staging of EMF, 
potentially contributing to improve the management of EMF patients, by identifying 
those in whom immunosupression is of potential benefit. 
Further research is needed to clarify the role of eosinophils and their related cytokines, 
inflammatory cytokines and autoantibodies in EMF, since they represent excellent 
therapeutic targets for altering the natural history of EMF.
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Chapter 8
ENDOTHELIAL ACTIVATION AND HAEMOSTATIC 
DYSFUNCTION IN RECENT ONSET EMF
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8.1. Introduction
The endothelium is a multifunctional organ and biologically active interface between the 
blood components and the vascular smooth muscle. When activated it is a critical factor 
in many pathological conditions (Kurivila and Kartha, 2003) and could be involved in 
EMF, a disease characterized by clinical features of hypercoagulability. On the other 
hand, although the role of inflammation and the usefulness of measuring serum levels of 
inflammatory cytokines in cardiovascular diseases is well established (Nadar et al, 2004; 
Libby et al, 2002), no attempts at characterizing the biological profile of EMF patients 
have been made. 
Endothelial activation is characterized by a shift of function of the endothelium towards a 
proinflammatory state, reduced vasodilatation and prothrombotic properties and could be 
implicated in the pathogenesis of EMF. Edema and spontaneous intraventricular thrombi, 
findings suggesting impairment of endothelial function (Chong et al, 2004), are 
frequently observed in EMF patients (Chapter 5), and plasma obtained from EMF 
patients in our series seems to have abnormally high fibrin content (Chapter 7). 
We hypothesized that the endocardial injury resulting in endocardial activation and 
procoagulant changes might play a role in early phases of EMF, and designed a study to 
assess the presence of circulating markers of endothelial cell activation, inflammation and 
haemostasis disturbances, in EMF patients recruited soon after diagnosis.  
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8.2. Population and Methods
Patient details
We studied 35 patients recruited less than 6 months after the initial symptoms of disease 
with confirmed echocardiographic diagnosis of EMF. Twenty-seven patients were self-
referrals or referred from schools or medical units in Inharrime, whereas 8 patients were 
referred to the Mozambique Heart Institute from other endemic areas in Mozambique.
Controls 
Due to the ethical issues related to the obtention of informed consent for blood collection 
from healthy children controls were young adults from a pre-university school in the 
same geographic region of the Heart Institute (12) and recruited from “blood donors” 
(12) who are friends or family members of non-EMF patients asked to donate blood to 
their relatives pre-operatively. These controls were non-smokers, not taking medication 
and resident in Maputo for more than two years. They were unmatched for age and sex. 
Study period and inclusion criteria
From June 2006 to December 2006 we evaluated 43 patients who had EMF diagnosed 
within the previous six months. Eight patients were excluded because they were already 
receiving anticoagulants or anti-inflammatory medication, leaving 35 to evaluate. Malaria 
was excluded by a blood smear assessment. 
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Clinical evaluation of patients
The clinical evaluation of the patients included the assement of severall parameters 
namely: weight, height and heart rhythm at admission, New York Heart Association 
(NYHA) functional class of heart failure, the presence and the degree of splenomegaly, 
and the presence of signs of “active disease”. The degree of splenomegaly was 
determined by palpation and graded by using a system, which states five degrees of 
spleen enlargement (Chapter 5). Active disease was defined by the presence of 
unexplained fever, facial or periorbital swelling, body itching/urticaria and severe 
hypereosinophilia (absolute eosinophil count > 1.5 x 109), criteria used in previous 
studies (Andy, 1998). 
All individuals had transthoracic echocardiography to evaluate the presence and 
distribution of the fibrotic lesions in the endocardium and intraventricular thrombosis. On 
echocardiography endocardial thickening, the hallmark of the disease, had to be present 
for diagnosis, either in the wall or affecting the atrioventricular valves. Patients with 
EMF were classified according to the classification presented in Chapter 3.
The main characteristics of patients and controls are summarized in Table 8.1. As 
previously stated the controls were significantly older. The deleterious effects of the 
disease on habitus were assessed by measuring the BMI of patients. Twenty eight (80% 
of patients had one or more signs of active disease. Three quarters of the patients had 
splenomegaly with the majority of them having massive enlargement of the spleen. 
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Table 8.1. Clinical characteristics of recent onset EMF patients and healthy controls 
EMF (n = 35) Controls (n = 32)Variable
Median (Interquartile 
range)
Median (Interquartile 
range)
p-
value
Age (years) 13 (9-17) 17 (13-24) 0.004
Gender F/M 9/26 14/18
Weight (kg) 28 (19-38) NA
Height (cm) 131 (114-148) NA
BMI 16.2 (13.8-32.3) NA
Hemoglobin (g/dL) 11.4 (10.5-13.3) 11.4 (10.6-13.8) 0.78
Hematocrit (%) 37 (35-42) 37.1 (34-41) 0.59
Platelets (x109/L) 269 (179-321) 285 (228-344) 0.23
Leukocytes (x109/L) 7.3 (6.2-10) 7.1 (6.0-13.8) 0.37
NA not available
A summary of the clinical profile of EMF patients according to the location of cardiac 
lesions is presented in Table 8.2.
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Table 8.2. Comparison of the clinical profile of patients with the different types of EMF
Variables BEMF LEMF REMF P value*
No of patients 12 10 13
Weight (Kg) 29.0 (18.0-82.4) 27.5(17.0-48.0) 20.0 (9.6-78.5) 0.93
Height (cm) 127 (106-166) 134 (111-167) 125 (73-169) 0.33
Body Mass Index 27.8 (24.4-42.3) 28.3(23.5-32.7) 27.4 (21.7-40.9) 0.92
Ventricular      
dysfunction
2(16.7%) 5(50%) 4(30.8%) 0.25
Active EMF 10(83.3%) 7(70%) 11(84.6%) 0.56
Haemoglobin 
(g/dL)
11.6 (10.1-20.3) 10.9(5.2-15.1) 12.5(9.7-15.6) 0.13
Haematocrit (%) 39.6(29.8-65.6) 36.3(29.4-45.5) 39.3(32.0-48.7) 0.38
MCV (fL) 81.7(64.6-89.4) 80.9(72.5-87.0) 82.7(69.8-101.1) 0.64
Platelets (x109/L) 250(146-366) 229(123-482) 319(148-391) 0.55
Leukocytes 
(x109/L)
7.9 (5.5-12.5) 6.9 (4.3-16.9) 6.6(2.4-12.9) 0.19
ESR (mm/h) 12.5 (2.0-46.0) 15.75(1.0-48.0) 30.7(1.0-127) 0.92
C-Reactive Protein 
(mg/L)
2.4 (0.1-18.9) 3.6 (0.3-11.1) 2.0 (0.3-7.8) 0.81
MCV mean corpuscular volume; ESR erhytrosedimentation rate
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Blood sample collection and storage
Using a tourniquet, blood samples were collected after puncture of the antecubital fossa; 
the tourniquet was then loosened to obtain the blood samples. Blood was collected into 
siliconised glass tubes (Bectin Dickinson) either containing 1/10 by volume of 3.8% 
trisodium citrate or EDTA. Plasma was prepared by centrifugation at 3000rpm for 20 
minutes at 4C. Samples were aliquoted into Eppendorf tubes and snap frozen, at -80 C 
and stored locally. They were transported to London on Cardice and restored at –80C. 
They were thawed immediately before analysis. The analysing laboratory was blinded to 
the samples.
Assays
A full blood count including white blood cell count, eosinophil count, haemoglobin 
concentration, hematocrit, erythrocyte mean corpuscular volume and platelets was 
performed for patients and all controls except the 20 adult blood donors. C-reactive 
protein and erythrocyte sedimentation rate were measured for patients.
Enzyme linked immunosorbant assays (ELISA) were used to measure endothelial, 
haemostatic and inflammatory markers.  The assays were commercially based; solid-
phase ELISA’s whereby a specific monoclonal antibody for the antigen in question was 
pre-coated onto micro-test wells. Markers of endothelial dysfunction included soluble P-
selectin, (R&D Systems - UK), and soluble intercellular adhesion molecule ICAM (R&D 
Systems - UK). Inflammatory markers included interleukin-5 (IL 5) and interleukin-6 
(IL6), (both from R&D Systems - UK).  Haemostatic markers included plasminogen 
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activator inhibitor-1 (PAI-1), prothrombin fragment 1+2 (PF 1+2) (Dade Behring, 
Sysmex (UK)), soluble tissue factor (TF) (ADI, Axis- Shield - UK) and D-Dimers (Bio 
Pool, Trinity Biotech - UK).  The intra assay and interassay coefficients of variation for 
ICAM were 3.6% and 7.4%; for P-Selectin they were 5.2% and 8.9%; for TF they were 
6.0% and 5.0%; for PAI-1 were 3.3% and 2.9%; for PF1+2 they were 6.0% and 9.0%; for 
D-Dimers they were 3% and 4%; for IL-5 they were 4.2% and 7.1%; and for IL-6 they 
were 4.2% and 5%.
Statistical analysis
The results were not normally distributed even after logarithmic transformation. Thus 
they are presented using the median (and the interquartile range or range). The 
differences between the groups were assessed using the Mann-Whitney rank sum and the 
Kruskal-Wallis tests. Correlations were analysed using Spearmans rank order correlation. 
P value less than 0.05 was considered significant. Data were analysed using the statistical 
package Minitab.
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8.3. Results
Thirteen patients (38%) had right EMF, 12(34%) had bilateral EMF, and 10(28%) had 
left disease. Almost one third (11/35) had intraventricular thrombosis, 6 on the right side 
and 5 on the left ventricle. There were no significant differences in body mass index, 
signs of active disease, and full blood count or erythrocyte sedimentation rate between 
these three groups.
The medians of hemoglobin (11.4g%) and hematocrit (37%) were the same for patients 
and controls. This finding may be explained by the high prevalence of anemia in this 
tropical population and by the presence of cyanotic polycytemia in 3 patients with REMF 
due to reopening of the foramen ovale by increased right atrial pressure.
Both erythrocyte sedimentation rate and the C-reactive protein tended to be raised, with 
the levels being very high in some patients. 
The details of the haemostatic factors, markers of inflammation and endothelial 
dysfunction assessed in these patients are presented in Table 8.3. The Figures 8.1 and 
8.2 show the same results presented graphically. The patients had increased levels of 
eosinophils (median 1.2x109/L, Interquartile range [0.4-1.9]) when compared to controls 
(0.3x109/L; [0.2-0.5], p<0.006). As expected, the eosinophil counts were probably 
underlying protozoal and worm infestations. 
The levels of D-Dimers were significantly raised in patients with a median of 304ng/ml 
[116-574] versus the controls with 119ng/ml [61-226] with a p value of 0.001.
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Soluble TF levels were significantly increased in EMF patients (263 pg/ml [221-394] 
compared to controls (201pg/ml; [158-269], p=0.004). Equally, the serum levels of PAI-1 
in patients (68 ng/ml; [31-123]) were higher than in controls (40ng/ml; [27-78]), with a p 
value of 0.047.
Regarding ICAM, its levels were significantly increased in patients compared to controls, 
median 368ng/ml versus 152ng/ml, with interquantile (IQ) ranges of 251-470 and 91-193 
respectively (p<0.0001). ICAM levels correlated with PAI-1 (p<0.001), PF1+2 
(p=0.017), sTF (p=0.004) and D-Dimers (p=0.005). There was an inverse correlation 
with the weight (p=0.029), the height (p=0.002) and the body mass index (p=0.001). 
Figure 1 also shows that patients with Endomyocardial Fibrosis had higher levels of IL6 
(4.4pg/ml; [2.7-7.3]) when compared to controls (1.9pg/ml; [1.4-2.7]), p=0.0001. 
The levels of P-Selectin, PF 1+2 and IL5 did not differ between patients and controls. 
The median (IQ range) levels of patients were for P-Selectin 84ng/ml[62-102], for PF 
1+2 0.4mmol/L [0.2-0.7] and for IL5 13 pg/ml [8-16] when compared to controls that had 
73ng/ml[53-112; p=0.31], 0.5mmol/L[0.3-1.0; p=0.21] and 12pg/ml[7-20; p=0.89] 
respectively. 
The results of all parameters measured for patients according to the type of EMF are 
presented in Tables 8.4. The results are expressed in median (range).
A multivariate analysis suggested that the two most important variables differentiating 
patients from controls are soluble Tissue Factor (p=0.01) and IL6 (p=0.005). 
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Figure 8.1. Endothelial activation and hemostatic factors in EMF (cases) and controls
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Figure 8.2. Inflammation markers measured in EMF patients (cases) and controls
Chapter 8 Endothelial Activation and Haemostatic Dysfunction
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
319
Table 8.3. Comparison of the medians for the parameters measured in EMF 
patients and controls. The results in parentesis correspond to the interquantile 
ranges.
Parameter
(normal range)
Patients 
N(35)
Controls 
N(32)
p value 
Eosinophilia 
(< 0.5x103/µL)
1.2 (0.4-1.9) 0.3 (0.2-0.5) < 0.006
D-dimers
(< 145 ng/ml)
304 (116-574) 119 (61-226) 0.001
PF1+2 
(0.2-1.2 nmol/l)
0.4 (0.2-0.7) 0.5 (0.3-1.0) 0.21
sTF 
(40-300 pg/ml)
262 (221-394) 201 (158-269) 0.004
PAI-1
(0-33 ng/ml)
68 (31-123) 40 (27-78) 0.047
ICAM 
(117-311 ng/ml)
368 (251-470) 152 (91-193) < 0.0001
P-selectin 
(22-34 ng/ml)
84 (62-102) 73 (53-112) 0.31
IL-6 
(0.4-6.2 pg/ml)
4.4 (2.7-7.3) 1.8 (1.4-2.7) < 0.0001
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Table 8.4. Comparison of the results of all parameters measured for patients with 
different types of EMF. The results are expressed in median (range). 
Parameters BEMF (12) LEMF (10) REMF (13) p-value  
(ANOVA)
Eosinophilia 
(x103/µL)
1.4 (0.22-4.90) 1.2 (0.12-9.60) 1.2(0.19-1.78) 0.51
D-dimers 
(ng/ml)
213.5
(27.4-1212.3)
394 
(30.0-2271.0)
347 
(99.0-3722)
0.51
PF1+2 
(nmol/l)
0.44
(0.07-29.30)
0.49
(0.06-14.60)
0.31
(0.12-6.90)
0.77
sTF 
(pg/ml)
327.8
(225.2-470.2)
255.6
(216.5-587.9)
236.2
(158.1-603.5)
0.48
PAI-1 
(ng/ml)
67.1
(22.2-189.3)
102.2
(42.6-175.5)
36.7
(18.8-186.7)
0.039
ICAM 
(ng/ml)
371.5
(16.2-680.8)
372.8
(192.8-650.1)
285.1
(129.5-529.4)
0.55
P-selectin 
(ng/ml)
76.9
(57.7-218.5)
99.9
(58.6-138.5)
72.3
(4.9-347.3)
0.14
IL-5 
(pg/ml)
13.9
(4.5-41.6)
13.4
(8.4-32.0)
11.6
(4.6-35.3)
0.61
IL-6 
(pg/ml)
3.6
(1.8-41.6)
4.8
(2.5-614.9)
4.4
(1.5-48.4)
0.35
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8.4. Discussion
We have shown that patients with recent onset EMF have increased levels of IL-6, 
endothelial cell activation and increased fibrinolysis, strongly suggesting that 
inflammation, endothelial injury and pro-coagulant changes play an important role in the 
early phases of this condition. These patients usually present acute heart failure 
associated with unexplained fever, cough, progressive breathlessness, facial swelling and 
severe hypereosinophilia.
Soluble ICAM was used as a marker of endothelial cell activation since it is up regulated 
during the process of endothelial cell activation, with subsequent shedding into the 
plasma. PAI-1, the major inhibitor of tissue plasminogen activator, is produced by the 
endothelium and released by activated platelets; its plasma levels are greatly increased 
during endothelial cell activation. The generation of adhesion molecules and production 
of PAI-1 participate in the inflammatory response and contribute to a prothrombotic state. 
Our patients had high levels of circulating D-dimers indicating increased fibrin 
degradation related to break down of fibrin clot. Patients with EMF had increase levels of 
Soluble Tissue Factor (sTF), a marker of up-regulation of Tissue Factor. The levels of 
PF1+2, produced when prothrombin is activated to thrombin and therefore highly 
sensitive to coagulation turnover, did not differ in patients and controls. Also there was 
no difference in P-selectin levels and platelet counts in the two groups, suggesting that it 
is a better marker of platelet activation, more than a marker of endothelial cell activation. 
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The association of intracavitary thrombi with increased markers of endothelial cell 
activation suggests that there may be an active ongoing process in the endocardium. 
Although we cannot be certain if the increased markers of endothelial cell activation 
represent activation of the endothelial endocardium or a more widespread process, we 
can speculate as to the cause of these biological changes, which can be due to an ongoing 
infection, be part of an autoimmune mechanism, or be related to the cardiotoxicity of the 
eosinophil. 
Despite the higher levels of eosinophil counts found in our patients, only few could be 
considered as having severe hypereosinophilia for the standards of our setting, where 
there is a high prevalence of parasitic infections in the general population. We were 
surprised to find no correlation between the degree of eosinophilia, and endothelial cell 
and hemostatic activation. EMF and hypereosinophilic syndromes are thought to have 
similar pathogenic mechanisms (Brockington and Olsen, 1973; Andy, 1999), and patients 
with both conditions have eosinophils with unusual morphology, metabolically and 
functionally more effective than normal, with a large number showing evidence of 
degranulation (Rutakingirwa et al, 1999). 
The cardiotoxicity of the eosinophil is mediated by activation of heart mast cells by 
eosinophil granule proteins (Patella et al, 1996) and secretion of pro-fibrotic mediators 
(Swartz et al, 2004). In our study patients had higher levels of eosinophils in the blood 
when compared to controls. Our results confirm previous data reporting a highly 
significant inverse relationship between hypereosinophilia and the duration of symptoms 
in EMF patients (Andy 1998), and support suggestions that failure to show difference in 
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eosinophilia between EMF patients and controls has been related with the fact that most 
studies are done in patients with chronic established disease. Indeed, assuming that 
cardiac damage in EMF is triggered by parasite induced eosinophilia, a raised eosinophil 
count need not to be present in chronic disease. Further, helminth associated 
hypereosinophilia peaks during larval migration and tends to return to normal thereafter, 
implying that if parasite-induced eosinophilia is related to cardiac damage, the 
eosinophilia in EMF should be sought in early disease. 
We also measured the blood levels of IL-5, and showed that although they did not differ 
significantly between EMF patients and controls, they correlated with eosinophil count in 
the subgroup of patients (p=0.006). Due to its selectivity in the differentiation, activation, 
recruitment and survival of human eosinophils, IL5 is currently a target for drug therapy 
of eosinophil-mediated diseases (Garret et al, 2003; Sutton et al, 2005). Therefore, 
further research must be done in order to clarify this issue that could have an impact in 
management of EMF. 
The criteria currently available for diagnosis of EMF rely on confirmation of endocardial 
fibrous thickening, which occurs late in its natural history. Echocardiography allows the 
diagnosis of Endomyocardial Fibrosis in its thrombotic phase in patients with less 
pronounced fibrosis, but its specificity to identify small thrombus is relatively low. This 
study is the first attempt at characterizing the biomarker profile of recent onset EMF, 
which knowledge would be useful for population screening and identification of 
recrudescence on follow-up, particularly after surgery.
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Our findings could also have implications for the management of Endomyocardial 
Fibrosis, since they suggest that modulation of both inflammation and hemostasis might 
be a new therapeutic target in Endomyocardial Fibrosis, and might alter the natural 
history of the disease. Prednisone, Ace-inhibitors, β-blockers and appropriate 
anticoagulation have been shown to reduce fibrous thickening of the endocardium 
following apical obliteration by thrombus, to improve the clinical outcome and increase 
survival in Loeffler endocarditis (Lofiego et al, 2005; Davies et al, 1983) and could also 
be tested in EMF patients detected with hypereosinophilia and intraventricular 
thrombosis. 
Although supporting the role of endothelial activation in pathogenesis of endomyocardial 
fibrosis our results do not clarify, either the selective injury of the endocardial 
endothelium or the particular distribution of the lesions which are concentrated in the left 
ventricular apex, the recess behind the posterior leaflet of the mitral valve, and the 
trabecular portion of the right ventricle. The poor blood supply from the end coronary 
arteries to the apices and the sluggish blood flow at the same regions would contribute to 
increase the susceptibility of the endocardium to injury, creating conditions for apical 
thrombosis and subsequent fibrosis. The heterogeneity of the endothelium may also play 
a role (Aird, 2007).
We aimed at studying patients early in the course of their disease, by selecting patients 
with symptoms for less than 6 months but acknowledge that clinical manifestations of 
Endomyocardial Fibrosis can appear long after the initial insult. This clinical-
echocardiographic dissociation has been recognized particularly in REMF (Salemi et al, 
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2005), and is one of the reasons contributing to late presentation of patients to medical 
attention.
We also acknowledge that the majority of our patients had heart failure at presentation, 
and that this may have partially influenced some results as endothelial dysfunction and 
damage have been reported in congestive heart failure, using parameters different from 
those used by us (Chong et al, 2004).
High circulating levels of ICAM have been demonstrated in patients with heart failure 
and suspected myocardial inflammation (Klein et al, 1998). Although not proved, if 
Endomyocardial Fibrosis is caused by myocardial inflammation and damage, as it would 
be the case with the autoimmunity hypothesis, the levels of this marker could be solely 
the result of this insult. 
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8.5. Conclusions
Patients with recent onset EMF have increased levels of IL-6, endothelial cell activation 
and increased fibrinolysis, strongly suggesting that inflammation, endothelial injury and 
pro-coagulant changes play an important role in the early phases of this condition. The 
results suggest also that an insult to the endocardium may be involved in the pathogenesis 
of EMF. 
Further research is needed to confirm these findings since they can have important 
therapeuthical implications. The biomarkers identified could potentially be used on 
community studies for early detection and follow up.
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Chapter 9
MULTIFACETED INVESTIGATION ON THE ROLE OF MALARIA 
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9.1. Background 
The epidemiology of malaria and EMF are not absolutely superimposed. However, 
endemic regions for Endomyocardial Fibrosis (EMF) are also areas of high prevalence of 
malaria in Africa (Sliwa et al, 2005). Mozambique is an endemic area for Plasmodium 
falciparum malaria, the leading cause of morbidity and mortality in the country. The 
Inharrime District has the highest transmission rate of malaria in the country (Cuamba, 
2003) and is an area where EMF is endemic (Ferreira et al, 2002). 
The first studies relating malarial infection to EMF were done in Uganda, where the 
possibility of an immune mechanism was postulated. Several studies (Van der Geld et al, 
1966; Shaper et al, 1967; Shaper et al, 1968; Patel et al, 1971) showed the presence of an 
immunological syndrome consisting of high titers of malarial antibody, high titers of IgM 
and circulating antiheart antibodies in populations with high prevalence of EMF. The 
prevalence of antimalarial and antiheart antibodies did correlate (Shaper 1974), but it was 
not clear if the antibodies were the cause or the result of EMF. 
Mice infected with murine malaria parasite Plasmodium berghei (Eling et al, 1984; Eling 
et al, 1988) developed endomyocardial fibrotic lesions that mimic human disease, 
providing one of the best animal models for EMF. From the model of murine malaria 
there seems to be an indirect involvement of the malaria parasite in pathogenesis and the 
fibrotic lesions are related to long lasting and/or repeated episodes of parasitemia (Eling 
et al, 1983; Eling et al, 1984).
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Myocardial injury has been demonstrated in human severe and complicated malaria by P 
falciparum, and does not seem to result from lowered hemoglobin levels (Ehrhardt et al, 
2004; Ehrdardt et al, 2005). We hypothesize that an autoimmune lesion due to molecular 
mimicry between Plasmodium and human myosins might cause myocardial injury, and 
be involved in the pathogenesis Endomyocardial Fibrosis. 
Malarial infection is among the hypotheses that have been explored to explain the 
occurrence of Endomyocardial Fibrosis. Endemic regions for Endomyocardial Fibrosis in 
Africa are also areas of high prevalence of malaria (Sliwa et al, 2005), and in 
Mozambique this endemic area for Endomyocardial Fibrosis (Ferreira et al, 2002) has the 
highest transmission rate for P falciparum malaria in Mozambique (Cuamba, 2003). 
However, despite suggestions of its role in pathogenesis from an animal model (Shaper et 
al, 1967; Shaper et al, 1968b, Eling et al, 1988), the hypothesis of human malaria being 
involved in the pathogenesis of this cardiomyopathy has never been proven. 
In order to investigate the role of malaria in pathogenesis of Endomyocardial Fibrosis we 
designed a series of studies to determine:
(1) The prevalence of P falciparum malarial infection in children, the age group most 
frequently affected by EMF; 
(2) The presence of anti-malarial antibodies in the sera of patients with EMF and 
healthy controls from the same population; 
(3) The binding of sera from EMF patients to mouse heart; and
(4) The presence of markers of myocardial injury in children from the same 
population during episodes of severe or complicated P falciparum malaria.
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9.2. Population and Methods
9.2.1. Design of the research
The studies on the role of malaria in pathogenesis of malaria took place in Maputo city 
and in the remote rural district of Inharrime, extensively described in previous chapters. 
The recruitment of patients was done during the high transmission season, which occurs 
from October to April.
Between October and December 2004, we studied 6 consecutive EMF patients from our 
registry who were resident in Inharrime. We then selected 12 controls: 6 children 
matched for age and sex attending the local health centre for acute respiratory infections, 
and the 6 mothers of the previously selected children. All were submitted to 
echocardiographic examination to exclude EMF.  
The prevalence of malaria infection was measured in Inharrime District during the month 
of October 2006. The determination of myocardial damage in children with severe or 
complicated malaria was undertaken in a hospital serving a suburban area of Maputo 
between October 2007 and January 2008. 
9.2.2. Population 
The study for the estabishment of a cohort of school children determined the prevalence 
of malaria infection in school children. From the 323 schoolchildren eligible for the 
study, 296 had an informed consent signed by their parents and were therefore included 
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in the study. Blood samples were obtained from every fifth participant, meaning that tests 
for malaria were performed in 71 children.
At Inharrime district we also studied 6 EMF patients and 12 controls from the same 
population for detection of circulating antibodies to Plasmodium falciparum and 
reactivity of patient’s sera with mouse heart tissue
Finally, we determined the presence of markers of myocardial injury in severe malaria 
studying children between 5 and 15 years old admitted to a local hospital. Only children 
with the diagnosis of severe and/or complicated malaria (WHO 2000) were invited to the 
study. We selected 47 consecutive children fulfilling the inclusion criteria, namely 
confirmed P falciparum monoinfection in absence of any other known disease, and 
absence of blood transfusion or anti-malarials prior to blood collection. Severe anemia 
was defined as hemoglobin of 8g/dL or less. 
9.2.3. Blood collection and conservation
Blood samples were obtained by puncture of the antecubital vein. The blood was 
collected into siliconised glass tubes (Bectin Dickinson) either containing 1/10 by volume 
of 3.8% trisodium citrate or EDTA. Plasma was prepared by centrifugation at 3000rpm 
for 20 minutes at 4C. Samples were aliquoted into Eppendorf tubes and snap frozen, at –
80C and stored locally. They were transported to London on Cardice and restored at –
80C. For immunofluorescence, sera were thawed immediately prior to analysis and 
aliquots diluted 1:500 and 1:1000 in phosphate-buffered saline (PBS) containing 1% 
bovine serum albumin (BSA). The remaining serum was aliquoted and frozen at – 80C 
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to be used for the Western Blotting analysis. The analysing laboratory did not know the 
status of individual sera (EMF patients/controls). 
4. Assays
a) Immunofluorescence on mixed and synchronized P falciparum asexual blood stage 
parasites
Preparation of parasites
P falciparum clones IT04 of the Ituxi strain and C10 were cultured under standard 
conditions as described (Webb et al, 1996; Margos et al, 2004). Thin films of C10 were 
prepared on glass and dried under stream of air. Slides were fixed in cold acetone (-
20°C) for 10 minutes, air-dried and stored at - 20°C until further use. IT04 parasites were 
synchronised by sorbitol lyses. Schizonts were concentrated on a 66%v/v Percoll cushion 
(Dluzewski et al, 1984), washed in culture medium then allowed to grow for further 30-
60 minutes at 37°C before being collected for Western blot analysis. For this, IT04 
parasites were centrifuged at 1,000xg for 5 minutes. The supernatant was removed, 
protease inhibitor cocktail (Sigma) and 1 mM EDTA were added, and the parasite pellet 
stored at - 20°C. 
Immunofluorescence microscopy
Acetone-fixed smears of mixed stages of P falciparum strain C10 were probed for 1 h at 
room temperature with human immune serum from patients with EMF (1:1000) and the 
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twelve controls. The slides were washed in PBS, and then incubated with FITC-
conjugated goat anti-human antibody (Abcam,UK), diluted in 1:200 in PBS-BSA. Nuclei 
were counterstained with diamidino phenyl-indole (DAPI) (1μg/ml). Following washes 
with PBS, slides were mounted using ProLong mounting medium (Molecular Probes 
Europe BV, Leiden, The Netherlands). Cells were viewed using a Nikon Optiphot 
microscope equipped with differential interference contrast microscopy and 
interchangeable filter blocks for fluorescence. A cooled, monochromatic CCD camera 
was used to enhance and give artificial colour to the images that were assembled using 
Adobe Photoshop 7.0. 
P falciparum asexual parasites express stage-specific proteins. To establish whether sera 
from patients or controls react differently with parasite stages, in the microscopic analysis 
we distinguished between ring stages (R), early schizonts (S), late (budding) schizonts 
(LS), free merozoites (mz), and staining of the red blood cell (rbc) itself.
b) Western Blotting on Plasmodium falciparum mixed asexual stages using human sera
IT04 parasites were solubilized in sample buffer for SDS-PAGE and proteins were 
separated on 10% polyacrylamide gels using Introgen NuPAGE Bis-Tris MOPS buffer 
system and blotted on to microcellulose. The blots were blocked with PBS-1% skimmed 
milk and probed for 1 h with primary antibodies. Following washed with PBS, blots were 
visualized with a 1:3000 dilution HRP-conjugated goat anti-human-Ig (Sigma, UK).
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c) Immunofluorescence using human sera on mouse heart tissue (confocal 
immunohistochemistry)
Adult mouse hearts from Balb/c strain frozen by immersion in liquid nitrogen were cut 
(15m cryosections) and fixed in 4% paraphormaldehyde in PBS (pH 7.3) for 5 minutes 
at 4C prior to staining. Sections were blocked and primary antibody (sera from EMF 
patients using dilutions from 1:100 to 1:4000) was applied. Then the secondary 
antibodies diluted in PBS (1:75 and 1:200) were applied, sections were mounted in 
Vectashield (Vector Laboratories) and analyzed using Leica TCS-NT confocal laser 
scanning microscope. 
d) Diagnosis of malaria in the community studies 
Venous blood from each patient was collected into EDTA in sterile vacutainers during 
fieldwork. 
Rapid tests to detect the presence of HRPII (histidin-rich protein II) antigen of P 
falciparum in the blood were performed. Five l of whole blood was applied to the 
sample well and instructions for the use of the ICT Malaria P.f. Cassete Test were 
followed. Interpretation of the results was done according to manufacturer’s 
recommendations (ICT Diagnostics).  
Parasitemia was assessed by counting asexual forms of P falciparum on thin blood 
smears under a light microscope after staining with 10% Giemsa solution, and was 
expressed as percentage of infected red blood cells or using the system of crosses (0 to 
5+).
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e) Myocardial injury
Blood for the rapid tests for the measurement of Troponin-T levels was obtained through 
puncture of a peripheral vein, using tubes with lithium heparin. Semi-quantitative 
determination of cardiac troponin T (cTnT) was done using the CARDIAC reader 
instrument (Roche). The upper limit of normal cTnT blood levels was defined as 0.1µg/l 
(Immer et al, 1997). Table 9.1 shows the interpretation of the semi-quantitative 
dtermination of cTnT.
Table 9.1. Interpretation of the troponin levels using the cardiac reader
Troponin T blood levels CARDIAC Reader Significance
< 0.03 ng/ml NEGATIVE Low risk
Myocardial lesion absent
0.03 ng/ml to 0.1 ng/ml LOW
< 0.1 ng/ml
Moderate risk
Myocardial lesion possible 
0.1 ng/ml to 2 ng/ml Quantitative between 0.1 
and 2 ng/ml
High risk
Myocardial lesion present
> 2 ng/ml HIGH Massive myocardial lesion
5. Ethical issues 
Parents or participants (when older than 18 years) were informed of all procedures of the 
research project. All those included in the studies had given a written informed consent 
for the studies (or finger-print whenever the participant/parent was illiterated).
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9.3. Results
Prevalence of malaria in school children
The prevalence of malaria infection in school children of Inharrime was 67.6% (48/71). 
All children denied any symptoms. Malaria coexisted with EMF in 3 children out of 6 
with EMF (Table 9.2). There was no statistically significant evidence that the 
percentages of EMF detected differed whether malaria was present or not (p=0.34, chi-
square test). 
Table 9.2. Prevalence of malaria infection and EMF in schoolchildren
No EMF EMF All
Malaria negative 20 (87.0%) 3 (13.0%) 23 (100.0%)
Malaria positive 45 (93.8%) 3 (6.2%) 48 (100.0%)
All 65 (91.6%) 6 (8.4%) 71 (100.0%)
Anti-Plasmodium falciparum antibodies in sera of patients with EMF 
Anti-Pf antibodies were present in sera of both EMF patients and controls. The results of 
the microscopic analysis on immunofluorescence are shown in Table 9.3. There was no 
obvious difference in reactivity of sera to the different parasite stages between sera of 
EMF patients and controls.
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Table 9.3. Stages of P falciparum found in both patients with EMF and controls
Recognition pattern of sera from Mozambique on acetone-fixed P. falciparum IT04
Name Serum dilution Pos/negative Stages positive
EMF7 1:1,000 ++ LS, Mz, R
EMF8 1:1,000 + LS, Mz, rbc
EMF9 1:1,000 + LS (+), Mz (++)
EMF10 1:1,000/1:500 -/+
EMF11 1:1,000 +(+) S (++), Mz (+)
EMF12 1:1,000 ++ S, Mz, R, rbc
EMF13 1:1,000 + S
EMF14 1:1,000 ++ S, R, rbc, Mz
EMF15 1:1,000 ++ S, Mz, R
EMF16 1:1,000 + LS, Mz
EMF17 1:1,000 + S, Mz
EMF18 1:1,000 ++ S, Mz, R
E0008 1:1,000 ++ S, Mz, R
E0176 1:1,000 ++ S, Mz
E018 1:1,000 + S (++), Mz, R
E020 1:1,000 + S
E030 1:1,000 + S, rbc
E034 1:1,000 ++ S, Mz
Symbols indicate intensity of staining (- = negative; + = positive; ++ = strong positive). Parasite stages are 
abbreviated as following: R = ring stage; Mz = merozoite; S = schizont; LS = late schizont; rbc = red blood 
cell. 
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Figure 9.1 presents different stages of the parasite identified by immunofluorescence in 
patients and controls. In young trophozoites (or ring stages) malaria pigment is not visible 
while late trophozoites/early schizonts have some malaria pigment in their pigment 
vacuoles. Since there was no nuclear staining which would have allowed estimating the 
number of nuclei in the parasites, it is difficult to distinguish late trophozoites and early 
schizonts. Those parasites most likely to be trophozoites/early schizonts (judging from 
parasite size, the absence or amount of pigment) showed hardly any fluorescent staining 
but the red blood cell harbouring the parasite showed dotted staining which may perhaps 
be staining of proteins associated with Maurer's clefts or other parasite structures in the 
red blood cell. More developed schizonts show peripheral fluorescent staining. Mature 
schizonts showed fluorescent staining of internal structures probably labelling the 
periphery of developing merozoites. Rupturing schizonts showed fluorescent staining of 
surface and internal structures of individual merozoites. Free merozoites showed internal 
fluorescent staining (probably apical) reminiscent of apical complex structures (rhoptries, 
micronemes) or cytoskeletal structures. Details of these features are revealed in Figure 
9.2.
Binding of sera from EMF patients with mouse heart
The Western Blotting showed binding of sera to different mouse heart proteins with no 
specific pattern in any of the two groups (Figure 9.3). At the higher concentration of 
secondary antibody there was a noticeable background and most of the staining resulted 
from this. 
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Figure 9.1. Stages of the Plasmodium falciparum identified by immunofluorescence in 
some control subjects
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Figure 9.2. Composite of the different asexual stages of Plasmodium falciparum
identified by immunofluorescence, namely trophozoits/early schizonts (a), developed 
schizonts (b), mature schizonts (c), rupturing schizont (d), free merozoite (e and f)
a b c
d e f
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Figure 9.3. Western Blotting of sera of six EMF patients and twelve controls.
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Markers of myocardial injury in severe/complicated Plasmodium falciparum malaria
Parents of one child refused to participate. One child tested negative for the presence of P 
falciparum antigen HRPII and was excluded from the study. We therefore studied 45 
children. The clinical features of these patients are presented in the Table 9.4. All 
patients had fever, hyperpyrexia and chills, and 18 (20.0%) had seizures. 
Table 9.4. Frequency of clinical symptoms and signs in patients with severe and 
complicated malaria
Symptoms and signs Frequency Percentage
Fever, Chills, Hyperpyrexia 45 100%
Seizures 18 40.0%
Vomiting 17 37.8%
Severe anemia 10 26.7%
Impairment of consciousness 5 11.1%
Splenomegaly 2 4.4%
The mean age (± SD) was 7 (± 3.5) years, and 27 (60%) were females. Eleven children 
(28.9%) had severe blood parasitemia (greater than 0.5%). Eighteen (40%) patients had 
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cerebral malaria and 2 (4.4%) had heart failure thought to be due to severe anemia. Two-
thirds of the children had anemia (30; 66.7%), which was severe in 8 patients. The mean 
(± SD) hemoglobin level was 9.3 g/dL (± 2.2). Only two children (4.4%) had 
splenomegaly greater than grade I.
All children evaluated had undetectable (negative) levels of circulating cTnT indicating 
that myocardial injury did not occur in any of these patients with severe and complicated 
P. falciparum malaria.  
The electrocardiograms were all normal without signs suggestive of ischaemia. Systolic 
and diastolic function was preserved in all cases, but LV dimensions indexed for body 
surface area were abnormal in two children with severe anemia (2; 4.4%). 
All children were treated with intravenous quinine. There was no mortality.
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9.4. Discussion
The prevalence of malaria infection in school children of Inharrime is very high. Despite 
malaria being endemic in this rural area we did not expect to find active infection in more 
than 2/3 of the examined children. Of interest is the fact that these children had 
asymptomatic malaria, probably related to partial immunity, due to frequent biting by 
infecting mosquitos (Nielsen et al, 2002), considering that Inharrime is the area with the 
higest transmission rate in Mozambique.
Our results indicate that strong immunity against malaria infection by P falciparum is 
present in the population of this district, independent of the presence of EMF. There was 
no specific pattern of reactivity of sera from EMF patients and controls on both 
immunofluorescence and Western Blotting, with the groups presenting no difference in 
terms of stages of the parasites detected. 
The results of the search for the presence of antimyosin antibodies in blood using 
Western Blotting were negative. Since myosins from different species show high 
homology, we expected anti-human myosin activity to be detectable using human sera 
against mouse heart. Several bands were detected in both patients and controls, but none 
corresponded to the molecular weight of myosin, suggesting that patients with EMF do 
not have circulating anti-myosin antibodies. 
In the literature there are conflicting results regarding the prevalence of myocardial 
damage in P falciparum malaria. Circulating concentrations of cardiac proteins have been 
shown in patients with complicated and uncomplicated P falciparum malaria (Ehrhardt et 
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al, 2004; Ehrdardt et al, 2005). Myocardial damage in P falciparum malaria was rare 
when assessed by cTnT (Gunther et al, 2003) in a retrospective study of patients from 
Ghana of unspecified age and severity of P falciparum malaria. Our study included blood 
film microscopic diagnosis, confirmation of infection by rapid test for antigen HRP-2, 
strict criteria of severity of malaria, and echocardiographic examination confirmed the 
absence of myocardial dysfunction. For detection of myocardial damage we used cTnT, a 
marker that has high specificity and sensitivity in the assessment of myocardial damage 
in children (Immer et al, 1997). Since Troponin-T was not detected in any child studied 
during an episode of severe and/or complicated malaria, we conclude that severe and 
complicated P falciparum malaria is not associated with myocardial damage.
Limitations
There are some limitations to our studies on the role of malaria in pathogenesis of EMF. 
The numbers involved are small considering the extent of both diseases in this particular 
area. 
The rational for our studies was the knowledge that P falciparum has multiple myosins 
that are part of its motile apparatus and some are similar to mammalian myosins 
(Chaparro-Olaya et al, 2005). We therefore hypothesized that P falciparum has some 
myosins that would share homology with the human myosin. However, we used mouse 
heart in our studies and, therefore must acknowledge that the protein(s) involved in 
molecular mimicry could be those that are different in the two species (human and 
mouse) and therefore would not be detected using human sera against mouse tissue. 
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Reciprocal testing of highly specific anti-P falciparum antibodies against human cardiac
tissue and human heart proteins against Plasmodium falciparum purified myosins would 
help clarify this issue. 
On the other hand a certain amount of time is needed for the humoral response to be set 
up after the acute malaria episode. It can therefore be argued that myocardial injury might 
be detectable days or weeks following the acute episode of malaria, and not concomitant 
with the infection. Thus, for follow-up of children with severe and complicated malaria 
would be necessary to detect this response. We therefore agree with those who postulate 
that rospective studies on immune response against malaria should include serial 
measurements of anti-malarial antibodies, markers of myocardial damage, 
electrocardiography or echocardiography (Franzen et al, 1992).
Experimental work on murine malaria showed that infection of C57B1 mice with 
Plasmodium berghei (Eling et al, 1984; Eling et al, 1988) results in endomyocardial 
fibrotic lesions that mimic human disease, providing one of the best animal models for 
EMF. Several features of the condition produced in C57B1 mice infected with P. berghei
were similar to those observed in humans: the predilection of lesions for the right half of 
the heart, genetic factors involved in the disease, the absence of hypereosinophilia 
syndrome, the supposed role of thrombi covering endothelial lesions, as well as the role 
of recurrent inflammatory processes in the pathogenesis of the disease. 
From the model of murine malaria it would be concluded that the lesions are related to 
long lasting and/or repeated episodes of parasitemia. This work by Eling (1984) also 
suggested an indirect involvement of the malaria parasite. Despite the close correlation 
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between development of lesions and parasitemia, parasitized erythrocytes were not 
usually present in the affected areas (Eling et al, 1984), leading to the hypothesis of the 
initial event being the activation and release of macrophages through phagocytosis, or the 
effect of the products released by this activation. Indeed, early changes included sticking 
of macrophages to the endocardial endothelium, and migration to subendothelial areas 
associated with leakage and edema. Subsequently, subendothelial infiltrates of 
lymphocytes, neutrophil granulocytes, macrophages and fibroblasts were found (Eling et 
al, 1983; Eling et al, 1984). These endothelial lesions grew out until death of the host or 
until chemotherapy cleared the infection. Chemotherapy of the infection rapidly arrested 
thrombus formation and growth and initiated resorption of thrombotic material, resulting 
in fibrosis of the affected areas. 
More recently the attention of researchers has been directed to the importance of 
coagulation and hemorrhage disturbances in the molecular mechanisms of malaria (van 
der Heyde et al, 2006), since almost all clinical studies of P falciparum patients indicate a 
procoagulant state. Patients with severe falciparum malaria exhibit prolonged bleeding 
times, PT and PTT, and impaired platelet aggregation, and these clinical measurements of 
coagulopathy correlate well with the severity of malaria (Rojanasthien et al, 1992). 
Another recent knowledge acquired in recent years was the publication of reports of 
immune mimicry in malaria (MacDonald et al, 2001). The secretion of translational 
controlled tumor protein (TCTP), a homolog of histamin-releasing factor, by Plasmodium 
falciparum was demonstrated in vitro and in vivo. This protein causes histamine release 
from basophils and IL-8 secretion from eosinophils, substances that have been reported to 
Chapter 9 Investigating the Role of Malaria
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
348
be elevated in patients with malaria (Kurtzhals et al, 1998; Shanks and Wilairatanaporn, 
1992). Reports of rebound eosinophilia after malarial infection in Thailand (Sliwa et al, 
2005) also reinforce the need to explore the relationship between this parasitic infection 
and EMF, a disease that shares many similarities with the hypereosinophilic syndromes.  
In summary, the possibility of other mechanisms of P falciparum infection being 
involved in the pathogenesis of EMF must not be overlooked. Particularly, the role of 
endothelial dysfunction, inflammatory changes and pro-coagulant abnormalities must be 
addressed through experimental research using animal models and in vitro studies.
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9.5. Conclusions
The prevalence of malaria is high in this rural community where EMF is also endemic. 
EMF patients and healthy individuals from this community have increased humoral 
response to Plasmodium falciparum as measured by immunofluorescence and Western 
Bloting. Malaria affects equally children with and without EMF.
There is no evidence of early myocardial damage in Plasmodium falciparum severe and 
complicated malaria in children. Our results are against an early myocardial lesion in 
malaria and do not support the role of molecular mimicry between products of the 
Plasmodium falciparum and the human myosins. However, they cannot completely 
exclude the role of malaria in the pathogenesis of EMF. 
In the light of the recent progress in identification of markers of endocardial activation 
and myocardial damage, cohort studies involving larger number of participants are 
needed. These should include long-term monitoring of the pattern of antibody responses 
to Plasmodium falciparum malaria, as well as determination of the presence and kinetics 
of markers of endocardial activation, hemostatic dysfunction and myocardial damage 
following episodes of acute malaria. 
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Chapter 10 
EXPLORING IMMUNOGENETIC HETEROGENEITY IN EMF
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10.1. Background
EMF presents great phenotypic variability in terms of the distribution and severity of the 
lesions. The disease affects one or both sides of the heart in variable proportion, and its 
severity and mode of progression vary in different individuals, suggesting the possible 
influence of host factors in the establishment and outcome of EMF.
In Ugandan experience EMF was more common among immigrants from neighboring 
Rwanda and Burundi, with poor socio-economic conditions, who had settled in a specific 
geographic district of the country (Connor et al, 1967; Connor et al, 1968; Rutakingirwa 
et al, 1999). However, the disease also occurred in native Ugandans as well as in 
Europeans who have lived in tropical Africa (Brockington et al, 1967; Beck and Schrire, 
1971), suggesting that the condition could not be explained solely on the basis of ethnic 
factors or social deprivation.
Some clinical series from Uganda and Zambia reported familial cases of EMF in endemic 
regions (Adi, 1963; Patel et al, 1971). This finding was confirmed in epidemiological 
performed in the rural community we studied in Mozambique (Chapter 4). Using 
echocardiographic screening of the general population for diagnosis no correlation was 
found between the percentage of subjects with EMF in a family and the family size, but 
for each individual the chance of having the disease was higher when other members of 
the family had the disease. Although some authors suggest that there is no compelling 
evidence for supporting the contribution of inherited factors to the pathogenesis of EMF 
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(Mayosi and Somers, 2007), the familial occurrence of EMF could be explained by either 
genetic or environmental factors (Sliwa et al, 2005). 
In recent years, both infectious and autoimmune diseases have been associated with 
increased frequencies of various specific histocompatibility leukocyte antigens (HLA) 
that may be linked to immune response genes. Common diseases of presumed viral 
origin, which have been linked to HLA specificities, include lupus erythematosus, 
juvenile diabetes mellitus, rheumatoid arthritis, multiple sclerosis and rheumatic heart 
disease (Maharaj et al, 1987; Guedez et al, 1999). 
We hypothesize that hereditary factors, possibly immunological in nature, may contribute 
to genetic susceptibility in EMF, and that host-related factors may explain the 
dissimilarities in apparent clinical features. 
The aim of this study was to determine the allelic and haplotypic diversity of the HLA-A, 
HLA-B, HLA-C, HLA-DR and HLA-DQ loci in patients from the EMF registry of 
Mozambique and ethnically matched controls, to determine whether any HLA 
determinants could be implicated in susceptibility to or protection against the 
development of EMF, and to investigate the possible influence of genotype in 
determining distribution and severity of the cardiac lesions.
Chapter 10 Immunogenetic Heterogeneity 
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
353
10.2. Population and Methods
Study period and patients
Consecutive patients with EMF seen at the Heart Institute Mozambique between Nov 
2004 and August 2006 were submitted to clinical evaluation and echocardiographic 
evaluation for diagnosis and classification of EMF. The patients were referred from all 
regions of the country, but remarkably 43 (53.8%) came from one single province 
Inhambane. The median age was 15 years (IQ range 10-20). There were 44 (55.0 %) 
males. All patients were black.
At admission 67 (83.8%) were in NYHA functional classes III and IV. Twenty patients 
(25.0%) were in atrial fibrillation. Most had abnormalities in both sides of the heart 
(Bilateral EMF) 43 (53.8%), 27 (33.7%) had lone or predominant right-sided EMF and 
the remaining 10 (12.5%) had left-sided disease. According to the severity of structural 
lesions only 14 (17.5%) patients had mild lesions. 
The most frequent blood group among the patients was Orh+ 34 (56.7%). Two patients 
had associated rheumatic heart disease and one had concomitant myasthenia gravis.
Controls
The controls were 85 ethnically matched individuals from Mozambique who were blood 
donors. 
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Blood sample collection and storage
Blood was collected into siliconised glass tubes (Bectin Dickinson) containing EDTA 
and centrifuged for plasma preparation. After removal of the plasma the remaining cells 
were aliquoted into eppendorf tubes and snap frozen, at -80C and stored locally. They 
were transported to London on Cardice and restored at –80C, being thawed immediately 
before DNA extraction. The analysing laboratory was blinded to the samples.
DNA extraction 
DNA was extracted from the blood samples using a BioRobot M48 workstation and 
MagAttract DNA extraction kits (Qiagen). The DNA was stored at -40C.
HLA typing
Testing for HLA-A, -B, -C, -DRB1 and –DQB1 types was performed using commercial 
reverse PCR-SSOP kits (ReliTM, Invitrogen). Briefly, DNA is amplified using locus 
specific biotinylated primers and the resulting amplicons are hybridised to arrays of 
sequence specific oligonucleotide probes immobilised on nylon strips. The presence of an 
amplicon/probe complex is detected using a colorimetric reaction and appears as a blue 
line. The strips are scanned and the probe pattern is analysed and interpreted to give an 
HLA type.
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Ethics
The study was performed at the Maputo Heart Institute (Mozambique) in accordance with 
the ethical standards laid down in an updated version of the 1964 Declaration of Helsinki 
and after approval by the National Bioethical Committee of Mozambique.
Statistical analysis of results 
Results were analysed using software developed by J D’Amaro et al (1995). Control data 
were tested for deviation from Hardy-Weinberg equilibrium expectations. The 
differences in frequency of HLA types between patients and controls were tested for 
significance by means of the chi-square test (without Yates correction). Relative risk was 
calculated according to the method of Svejgaard et al (1986). 
The frequency of each A, B, C, DR and DQ type was compared between subjects with 
BEMF, REMF and LEMF using ANOVA.
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10.3. Results
In the control group all HLA loci tested (HLA-A, -B, -C, -DRB1 and –DQB1) conformed 
to random expectations of combinations of HLA types at each locus with all p values 
greater than 0.1. The percentage phenotype frequencies of HLA-A, HLA-B, HLA-C, 
HLA-DR and HLA-DQ types of patients with endomyocardial fibrosis and the control 
subjects are shown in Tables 10.1 to 10.5. 
In Tables 10.2, 10.3 and 10.5 the HLA alleles detected are shown as the equivalents of 
HLA specificities. Therefore in Table 10.2 HLA-B*1401 has been interpreted as HLA-
B*64, HLA-B*1402 as HLA-B*65, HLA-B*1501 as HLA-B*62, HLA-B*1503 as HLA-
B*72, HLA-B*1510 as HLA-B*71, HLA-B*1516 as HLA-B*63, and HLA-B*1521 as 
HLA-B*75. In Table 10.3 HLA-Cw*0303/11-13 has been interpreted as HLA-Cw9 and 
HLA-Cw*0302/04-08 has been interpreted as HLA-Cw10. Finally, in Table 10.5 HLA-
DQB1*0301/ has been interpreted as HLA-DQ7, HLA-DQB1*0302/ as HLA-DQ8 and 
HLA-DQB1*0303/ as HLA-DQ9.
In these 165 Mozambicans the HLA specificities with the highest frequencies in each of 
the HLA classes were: HLA-A*30 (67; 40.6%), -A*29 (40; 24.3%), -A*68 (35; 21.2%); -
B*58 (37; 22.4%), -B*72 and -B*44 (both 29; 17.5%), -B*42 (25; 15.2); -Cw*07 (96; 
58.2%), -Cw*04 (55; 33.3%), -Cw*06 (46; 27.9%); -DRB1*11 (69; 41.8%), -DRB1*13 
(51; 30.9%), -DRB1*15 (44; 26.7%); -DQB1*0301 or *07 (62; 37.6%), -DQB1*06 (63; 
38.2%) and -DQB1*02 (55; 33.3%). 
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The HLA types HLA-A*25, -A*26, -A*31, -A*69, -B*37, -B*38, -B*52, -B*54, -B*55, 
-B*56, -B*59, -B*67, -B*73 and -DRB1*16, although tested were not found in any of the 
patients and the controls.
Table 10.1 shows a comparison of the frequencies of HLA-A types for controls and 
patients, including patients with mild to moderate disease (grades I and II), and those 
with severe and advanced disease (grades III and IV). 
The frequency of HLA-A*23 was significantly reduced in the patients (8/80, 10%) when 
compared to the normal control subjects (20/85, 23.5%; p=0.018). When the patients are 
divided according to severity of the disease only the frequency of HLA-A*23 in patients 
with mild and moderate disease is significantly different. When comparing individuals 
with severe disease and normal control subjects we found differences in frequencies of 
HLA-A*33 (17.5% vs 5.9%; p=0.037).
The comparison of frequencies of HLA-B types for controls, all patients, patients with 
grades I+II and grades III+IV EMF is shown in Table 10.2. The frequency of HLA-B*58 
is raised in the patients compared to controls (27.5% vs 17.6%) but we found no 
statistically significant difference. While in patients with less severe disease the 
frequency is the same as that of controls, in patients with more severe disease it is 
significantly higher (37.5% vs 17.6; p=0.015). Most patients with grade IV EMF (6 out 
of 11; 54.5%) were positive for HLA-B*58. 
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Table 10.1. HLA-A phenotype frequencies in EMF patients and controls. Patients 
are ubdivided in twpo groups mild and moderate (EMF 1+ 2) or severe and advanced 
(EMF 3+4).
HLA-A 
type
Controls
N=85
% (n)
All patients
N= 80
% (n)
Patients
EMF 1 + 2
N= 40
% (n)
Patients
EMF 3+4
N= 40
% (n)
A*01 5.9 (5) 7.5 (6) 2.5 (1) 12.5 (5)
A*02 34.1 (29) 26.2 (21) 22.5 (9) 30.0 (12)
A*03 4.7 (4) 10.0 (8) 7.5 (3) 12.5 (5)
A*11 1.2 (1) 1.2 (1) 2.5 (1) 0
A*23 23.5 (20) 10.0 (8) 7.5 (3) 12.5 (5)
A*24 3.5 (3) 5.0 (4) 5.0 (2) 5.0 (2)
A*29 23.5 (20) 25.0 (20) 22.5 (9) 27.5 (11)
A*30 42.3 (36) 38.7 (31) 50.0 (20) 27.5 (11)
A*32 2.3 (2) 0 0 0
A*33 5.9 (5) 8.7 (7) 0 17.5 (7) *
A*34 1.2 (1) 6.2 (5) 5.0 (2) 7.5 (3)
A*36 3.5 (3) 2.5 (2) 2.5 (1) 2.5 (1)
A*43 0 2.5 (2) 5.0 (2) 0
A*66 4.7 (4) 2.5 (2) 0 5.0 (2)
A*68 20.0 (17) 22.5 (18) 32.5 (13) 12.5 (5)
A*74 9.4 (8) 15.0 (12) 10.0 (4) 20.0 (8)
*versus control, p=<0.05
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Table 10.2. HLA-B phenotype EMF frequencies in patients and controls. Patients 
are ubdivided in twpo groups mild and moderate (EMF 1+ 2) or severe and advanced 
(EMF 3+4).
HLA-B type Controls
N=85
% (n)
All patients
N= 80
% (n)
Patients
EMF 1 + 2
N= 40
% (n)
Patients
EMF 3+4
N= 40
% (n)
B*07 9.4 (8) 6.3 (5) 7.5 (3) 5.0 (2)
B*08 11.8 (10) 10.0 (8) 5.0 (2) 15.0  (6)
B*13 5.9 (5) 3.8 (3) 5.0 (2) 2.5 (1)
B*1401 (64) 1.2 (1) 0 0 0
B*1402 (65) 9.4 (8) 11.3 (9) 12.5 (5) 10.0 (4)
B* 1501 (62) 2.4 (2) 0 0 0
B*1503 (72) 20.0 (17) 15.0 (12) 12.5 (5) 17.5 (7)
B*1510 (71) 12.9 (11) 17.5 (14) 25.0 (10) 10.0 (4)
B*1516 (63) 0 3.8 (3) 2.5 (1) 5.0 (2)
B*1521 (75) 1.2 (1) 0 0 0
B*18 3.5 (3) 5.0 (4) 7.5 (3) 2.4 (1)
B*27 0 1.3 (1) 2.5 (1) 0
B*35 9.4 (8) 7.5 (6) 12.5 (5) 2.5 (1)
B*39 5.9 (5) 1.3 (1) 2.5 (1) 0
B*42 18.8 (16) 11.3 (9) 15.0 (6) 7.5 (3)
B*44 16.5 (14) 18.8 (15) 20.0 (8) 17.5 (7)
B*45 8.2 (7) 7.5 (6) 10.0 (4) 5.0 (2)
B*49 8.2 (7) 6.3 (5) 5.0 (2) 7.5 (3)
B*50 3.5 (3) 2.5 (2) 2.5 (1) 2.5 (1)
B*51 3.5 (3) 0 0 0
B*53 10.6 (9) 16.3 (13) 15.0 (6) 17.5 (7)
B*57 7.1 (6) 5.0 (4) 5.0 (2) 5.0 (2)
B*58 17.6 (15) 27.5 (22)* 17.5 (7) 37.5 (15)*
B*81 7.1 (6) 10.0 (8) 5.0 (2) 15.0 (6)
*versus control, p=<0.05
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Tables 10.3, 10.4 and 10.5 show the frequencies of HLA-C, -DR and -DQ types for 
controls and patients (subdivided in grade 1+2 and 3+4). There was no statistically 
significant difference between any of the four groups.
Table 10.3. HLA-B phenotype frequencies in EMF patients and controls
HLA-C type Controls
N=85
% (n)
All patients
N= 80
% (n)
Patients
EMF 1 + 2
N= 40
% (n)
Patients
EMF 3+4
N= 40
% (n)
Cw*01 1.2 (1) 0 0 0
Cw*02 18.8 (16) 16.3 (13) 12.5 (5) 20.0 (8)
Cw*0303 (9) 2.4 (2) 0 0 0
Cw*0302/04 (10) 14.1 (12) 16.3 (13) 27.5 (11) 5.0 (2)
Cw*04 32.9 (28) 33.8 (27) 35.0 (14) 32.5 (13)
Cw*05 0 2.5 (2) 5.0 (2) 0
Cw*06 28.2 (24) 27.5 (22) 22.5 (9) 32.5 (13)
Cw*07 60.0 (51) 56.3 (45) 50.0 (20) 62.5 (25)
Cw*08 10.6 (9) 13.8 (11) 12.5 (5) 15.0 (6)
Cw*12 4.7 (4) 2.5 (2) 2.5 (1) 2.5 (1)
Cw*14 1.2 (1) 6.3 (5) 5.0 (2) 7.5 (3)
Cw*15 1.2 (1) 2.5 (2) 2.5 (1) 2.5 (1)
Cw*16 10.6 (9) 5.0 (4) 7.5 (3) 2.5 (1)
Cw*17 23.5 (20) 12.5 (10) 15.0 (6) 10.0 (4)
Cw*18 14.1 (12) 11.3 (9) 7.5 (3) 15.0 (6)
p = not significant for all comparisons 
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Table 10.4. HLA-DR phenotype frequencies in patients and controls
HLA-DR type Controls
N=85
% (n)
All patients
N= 80
% (n)
Patients
EMF 1 + 2
N= 40
% (n)
Patients
EMF 3+4
N= 40
% (n)
DRB1*01 11.8 (10) 7.5 (6) 10.0 (4) 5.0 (2)
DRB1*0301 (17) 18.8 (16) 22.5 (18) 22.5 (9) 22.5 (9)
DRB1*0302 (18) 15.3 (13) 17.5 (14) 17.5 (7) 17.5 (7)
DRB1*04 2.4 (2) 5.0 (4) 2.5 (1) 7.5 (3)
DRB1*07 9.4 (8) 13.8 (11) 15.0 (6) 12.5 (5)
DRB1*08 7.1 (6) 12.5 (10) 7.5 (3) 17.5 (7)
DRB1*09 1.2 (1) 3.8 (3) 5.0 (2) 2.5 (1)
DRB1*10 5.9 (5) 2.5 (2) 2.5 (1) 2.5 (1)
DRB1*11 43.5 (37) 40.0 (32) 40.0 (16) 40.0 (16)
DRB1*12 10.6 (9) 12.5 (10) 10.0 (4) 15.0 (6)
DRB1*13 31.8 (27) 30.0 (24) 30.0 (12) 30.0 (12)
DRB1*14 0 3.8 (3) 2.5 (1) 5.0 (2)
DRB1*15 31.8 (27) 21.3 (17) 25.0 (10) 17.5 (7)
p = not significant for all comparisons 
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Table 10.5. HLA-DQ phenotype frequencies in patients and controls
HLA-DR type Controls
N=85
% (n)
All patients
N= 80
% (n)
Patients
EMF 1 + 2
N= 40
% (n)
Patients
EMF 3+4
N= 40
% (n)
DQB1*02 29.5 (25) 37.5 (30) 37.5 (15) 37.5 (15)
DQB1*0301 (7) 35.5 (30) 40.0 (32) 37.5 (15) 42.5 (17)
DQB1*0302 (8) 2.4 (2) 5.0 (4) 2.5 (1) 7.5 (3)
DQB1*0303 (9) 2.4 (2) 1.3 (1) 0 2.5 (1)
DQB1*04 15.3 (13) 18.8 (15) 20.0 (8) 17.5 (7)
DQB1*05 32.9 (28) 28.8 (23) 30.0 (12) 27.5 (11)
DQB1*06 58.8 (20) 53.8 (43) 55.0 (22) 52.5 (21)
p = non significant for all comparisons 
The comparison between HLA-A and HLA-B phenotype frequencies in patients with 
severe EMF and healthy controls are shown in Tables 10.6a and 10.6b, which also 
presents the p values for these comparisons. There were no statistically significant 
differences in frequencies beteen these two groups.
Regarding the HLA-B*58 type both patients and controls had the same frequencies of 
either B*5801/04 or B*5802/06. Table 10.7 shows the distribution of these allele groups 
in patients with EMF grades III+IV and in controls. Out of the 15 patients with EMF 3+4 
who were HLA-B*58, 9 were 5801/04, 6 were 5802/06 and 1 had both alleles (5801/04 
and 5802/06). There were 7 patients with mild to moderate EMF who had the HLA-B*58 
type; 5 were 5801/04, 3 were 5802/06 and 1 had both alleles (5801/04 and 5802/06). 
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Regarding the controls, out of the 15 who were HLA-B*58, 8 were 5801/04, 7 were 
5802/06, with one having both alleles. Only one subject, who had grade III EMF, was 
positive for both HLA-A*33 and HLA-B*58.
Table 10.6a. HLA-A phenotype frequencies in patients with severe EMF and controls
HLA-A type Severe EMF 
N= 40
% (n)
Controls
N=85
% (n)
p value
A*01 12.5(5) 5.9 (5) 0.177
A*02 30.0(12) 34.1 (29) 0.669
A*03 12.5(5) 4.7 (4) 0.101
A*11 0 (0) 1.2 (1) 0.767
A*23 12.5(5) 23.5 (20) 0.162
A*24 5.0 (2) 3.5 (3) 0.596
A*29 27.5 (11) 23.5 (20) 0.610
A*30 27.5 (11) 42.3 (36) 0.111
A*32 0 (0) 2.3 (2) 0.544
A*33 17.5 (7) 5.9 (5) 0.037
A*34 7.5 (3) 1.2 (1) 0.058
A*36 2.5 (1) 3.5 (3) 0.896
A*43 0 (0) 0 (0)
A*66 5.0 (2) 4.7 (4) 0.824
A*68 12.5 (5) 20.0 (17) 0.667
A*74 20.0 (8) 9.4 (8) 0.087
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Table 10.6b. HLA-B phenotype frequencies in patients with severe EMF and controls
HLA-B type Severe EMF
N=40
% (n)
Controls
N=85
% (n)
P value
B*07 5.0 (2) 9.4 (8) 0.542
B*08 15.0 (6) 11.8 (10) 0.570
B*13 2.5 (1) 5.9 (5) 0.508
B*1401 (64) 0 (0) 1.2 (1) 0.767
B*1402 (65) 10.0 (4) 9.4 (8) 0.837
B* 1501 (62) 0 (0) 2.4 (2) 0.544
B*1503 (72) 17.5 (7) 20.0 (17) 0.777
B*1510 (71) 10.0 (4) 12.9 (11) 0.695
B*1516 (63) 5.0 (2) 0
B*1521 (75) 0 (0) 1.2 (1) 0.767
B*18 2.5 (1) 3.5 (3) 0.896
B*27 0 (0) 0
B*35 2.5 (1) 9.4 (8) 0.184
B*39 0 (0) 5.9 (5) 0.114
B*42 7.5 (3) 18.8 (16) 0.110
B*44 17.5 (7) 16.5 (14) 0.832
B*45 5.0 (2) 8.2 (7) 0.590
B*49 7.5 (3) 8.2 (7) 0.969
B*50 2.5 (1) 3.5 (3) 0.896
B*51 0 (0) 3.5 (3) 0.276
B*53 17.5 (7) 10.6 (9) 0.253
B*57 5.0 (2) 7.1 (6) 0.746
B*58 37.5 (15) 17.6 (15) 0.015
B*81 15.0 (6) 7.1 (6) 0.140
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Table 10.7. Distribution of haplotype HLA-B*58 in EMF patients and controls
HLA-B*58 5801 5802
Patients N15 10 6
Controls N15 9 7
Comparison between patients with different types of EMF 
We compared the frequencies of all HLA types detected between the different clinical 
types of EMF according to the distribution of structural lesions in the heart. No difference 
in frequency was significantly different. We classified 78 patients according to the 
distribution of the lesions in the heart in three groups: BEMF (42), REMF (27) and 
LEMF (9). Table 10.8 shows the frequency of HLA-A*02, HLA-A*23, HLA-A*33 and 
HLA-B*58 in the different groups. HLA_B*58 is more frequent in the patients with 
bilateral and right EMF than in those with LEMF (11/42;26.2% for BEMF; 9/27;33.3% 
for REMF; and 1/9;11.1% for LEMF), but this result is not statistically significant. 
REMF differed from BEMF only for HLA-A*02  (11/27 vs 8/42, respectively; p=0.047).
Comparisons between the frequencies of haplotypes for patients with LEMF vs BEMF 
and LEMF vs REMF were not statistically significant. 
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Table 10.8. Distribution of haplotype HLA-B*58 and HLA-A*33 in EMF patients 
according to the type of disease
BEMF 
N (%)
REMF 
N (%)
LEMF 
N (%)
HLA-A*33 3/42 (7.1) 4/27 (14.8) 0/9 (0)
HLA-B*58 11/42 (26.1) 9/27 (3.3) 1/9 (11.1)
Comparison between controls and patients with different types of EMF 
There was no difference in frequency of any of the haplotypes when comparing patients 
with BEMF and LEMF with controls. When comparing patients with REMF to control 
subjects, we found statistically significant difference in the frequency of HLA-Cw*8 
(7/27 vs 9/76; p=0.041). 
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10.4. Discussion
The frequency of HLA-B*58 was increased in patients with severe EMF. More than half 
the patients with advanced EMF were positive for this haplotype, for which 15 different 
alleles have been recognized (www.ebi.ac.uk/cgi.bin/imgt). Of these, two contributed to 
the increase in the frequency of B*58 found in our population, namely 5801/04 and 
5802/06. Proportionately, the allele 5801/04 was slightly increased.
Despite no statistically significant difference between the frequency of HLA-A*33 
haplotype in EMF patients and controls, we also found an association between this HLA 
type and the presence of severe and advanced EMF (p=0.037). 
The association of the haplotypes HLA-A*33 and HLA-B*58 is frequent in the African-
American population of the United States of America (www.bioinformatics.nmdp.org). 
However, in the Mozambican series only one patient who had severe EMF out of the 80 
patients expressed both HLA-A*33 and HLA-B*58. Also, in the control subjects the 
association of HLA-A*33 and HLA-B*58 was not present in more individuals than 
would be expected by chance. Similar fidning has been reported from a study of another 
southern African population (from Botswana) (Novitsky et al, 2001). This absence of 
simultaneous occurrence of these two HLA types may be due to African-American 
ascendance being mainly from West Africa. 
The subanalysis of frequencies of the different haplotypes according to the type of EMF 
did not show any significant differences. The lower frequency of HLA-A*58 found in 
LEMF compared to that of BEMF and REMF, was not statistically significant probably 
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due to the small number of patients with isolated LEMF in our study. Whether this 
finding is of relevance in the view of the difference in natural history and prognosis of 
LEMF is an issue that needs further investigation involving larger groups of patients and 
controls. 
There are no studies on HLA typing in Mozambican populations. Despite the relatively 
small number of patients and controls included in our study we identified a high 
concordance of HLA class I antigen specificities with high frequencies with those found 
in the native population from Botswana (Novitsky et al, 2001), in which HLA-A*30, -
A*02, -A*23, -A*68, -B*58, -B*72, -B*42 and -B*48 were the HLA class I specificities 
observed at the highest frequency (Table 10.8). Regarding HLA class II antigen 
specificities a similar pattern was found with the highest frequencies being HLA-Cw*07, 
HLA-Cw*02, HLA-Cw*17 and HLA-Cw*06. DR and DQ specificities were not tested in 
that study. Our results therefore do not support those from Cao et al (2004) which 
showed remarkable allelic and haplotypic diversity in HLA class I loci between four sub-
Saharian populations (Kenya, Uganda, Mali, Zambia), and stressed the need for 
characterization of HLA systems in the different population of all regions of sub-Saharian 
Africa. 
Evidence suggesting a role of infections in EMF has come from reports of sporadic cases 
of EMF in foreigners after short visits to endemic areas (Brockington et al, 1967; Beck 
and Schrire, 1972), and is supported by the climatic and geographic restrictions of the 
disease (Buckman et al, 2008). Several infectious agents might be implicated namely 
Plasmodium (Eling et al, 1988), Schistosoma (Rashwan et al, 1995), Microfilaria 
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(Jaiyesimi, 1980), and Helminths (Andy, 1983), but none explains the occurrence of EMF 
in all regions where it has been described. Although not firmly established, autoimmunity 
has also been postulated to be of importance in the pathogenesis of EMF. Molecular 
mimicry between heart structures and proteins secreted by infectious agents that are 
targets for the host immune response has been suggested (Shaper et al, 1968b), but there 
is also the possibility of aberrant humoral, cellular and immunoregulatory responses, 
similar to those involved in pathogenesis of Chagas disease (Dos Reis et al, 2005). In 
recent years, both susceptibility to infections and autoimmune diseases have been 
associated with increased frequencies of various specific HLA haplotypes in populations 
from southern Africa (Lombard et al, 2006). We had therefore hypothesized that in our 
population HLA molecules were linked with susceptibility to or protection against the 
development of EMF and could also determine its severity. 
Our results are interesting in view of the reported association of HLA-B*58 haplotype 
with increased susceptibility to HIV infection in the African population of Botswana 
(Novitsky et al, 2001). Furthermore, a study of Rwandan population infected with HIV-1 
subtype A showed association of HLA-B*5802 with increased viral loads and rapid 
disease progression (Lazaryan et al, 2006), confirming the unfavorable effect this allele 
on viral load previously reported for HIV-1 subtype C in South Africa (Kiepela et al,
2004).
The significance of the association of HLA-A*33 and HLA-B*58 positivity with the 
severity of EMF lesions at presentation, is difficult to interpret in view of the incomplete 
understanding of its natural history. While some patients from our clinical series have a 
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steady disease with little or no progression after initial presentation, other reveal 
progression of structural and functional abnormalities on follow-up. We therefore think 
that systematic evaluation of HLA types must be extended to patients in earlier stages of 
EMF found in community-based studies to better correlate findings from HLA typing 
with disease susceptibility, severity and natural history.
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Conclusion 
This study shows evidence of immunogenetic heterogeneity in patients with EMF. HLA-
B*58 type is associated with severe EMF in the Mozambican population. Studies on 
HLA typing of the Mozamican population will allow better interpretation of the results 
obtained. Also, further research is needed to uncover the role of genetics in determining 
the type and mode of progression of EMF. 
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Chapter 11
MANAGEMENT OPTIONS
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11.1. Background
Currently, there is no specific treatment aimed at arresting or reversing the structural 
defects present in the heart of patients with EMF. Medical therapy is aimed at treating 
acute disease, heart failure and its complications, while surgery partially corrects some of 
the structural and hemodynamic abnormalities.
The medical treatment has been used with little success, an is associated to frequent 
admissions to hospital. EMF patients present usually in advanced stages needing very 
large doses of drugs to treat heart failure. The control of arrhythmias and thromboembolic 
episodes is also poor. Short courses of oral corticosteroids are currently used in EMF 
patients with hypereosinophilia and/or other signs of activity, but this has not been 
validated by clinical trials or systematic studies of the effects of the drugs on progression 
of the disease. 
The surgical treatment of EMF is currently based on four important facts (Metras, 1993): 
(1) severe disease is fatal if untreated; (2) the severe hemodynamic derangement caused 
by restriction of the diastolic filling and atrioventricular regurgitation can be corrected; 
(3) In most cases the myocardium remains healthy and unaffected and endocardectomy is 
feasible through a relatively well preserved cleavage plan; (4) Evidence of recurrence is 
controversial and low rates have been reported. The high morbidity and mortality 
associated with surgery (Valiathan et al, 1989; Moraes et al, 1999; Dubost, 1990), has led 
to a general preference for medical treatment for patients in NYHA classes I and II, and 
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due to the lack of human and material resources for open-heart surgery in most areas 
where EMF is endemic, there has been little improvement in surgical techniques. 
However, surgery has been shown to increase survival and quality of life (Metras et al, 
1982; Cherian et al, 1982; Gonzalez-Lavin et al, 1983), when compared to medical 
therapy. 
In Mozambique, open-heart surgery was performed for the first time in 2001 with the 
help of surgeons from European hospitals who have been working within a humanitarian 
programme mainly directed to pediatric surgery. Initially, patients with EMF would be 
excluded from surgery. However, with the starting of the research programme it was felt 
that, at least for some EMF patients with predominant left valvular disease, there was 
room for surgery and some surgeons started to operate those cases. At the beginning of 
my research project, with the institution of the National Registry, standardized diagnostic 
and management procedures including selection crtiteria for surgery were introduced. 
In this chapter we present and discuss the different therapeutic strategies applied for the 
management of EMF in Mozambique. First, we describe the drugs and medical 
procedures used for controlling heart failure and its complications. A second section of 
the chapter is dedicated to the description of the results of surgical technique performed 
in the institution, outside the EMF research programme. Finally, we describe a new 
management strategy evolved and applied by us, including both drug therapy and surgical 
options.
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Characterization of patients from the National Registry
Of the 175 patients from the clinical registry, which were all symptomatic, 20 (11.4%)
patients had mild EMF while 21 (12.0%) presented advanced EMF, and were therefore 
not considered for surgery. EMF patients with grade II (61; 34.3%) and grade III (73; 
41.7%) severity were all considered for surgery (Diagram 11.1). 
Diagram 11.1. Flowchart for selection of patients for surgery
National Registry of Mozambique
175 patients
20 Grade I
Asymptomatic
21 Grade IV
Advanced Disease
Inoperable
Patients considered for surgery
134 patients
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11.2. Descriptive study of the medical therapy and invasive procedures 
11.2.1. Methods 
We evaluated the medical files of all patients from the clinical registry and collected data 
on the drugs administered and invasive procedures performed, as well as the number of 
hospitalizations and deaths of patients under exclusive medical therapy.
11.2.2. Results
Of the 175 patients that are included in the registry, only 3 had no treatment.  The 
remaining 172 received drugs for the management of heart failure, prevention and 
treatment of arrhythmias and thromboembolism, control of hypereosinophilia and 
superimposed infections, as well as for the correction of nutritional deficiencies, mainly 
vitamins. The drugs most commonly used were the diuretics and β-blockers as shown in 
Table 11.1.
Management of Heart Failure
The anti-Heart Failure therapy involved the use of diuretics in all patients, vasodilators 
(mainly ACE-inhibitors) and β-blockers (mainly propranolol) in those with maintained 
blood pressure. 
The treatment of episodes of hypereosinophilia was done using immunosuppressive 
therapy with steroids. In total 43 patients had severe hypereosinophilia. In 21 of these
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corticosteroids were not used due to concurrent bacterial infections. In the 12 patients in 
whom a 10-days course of oral steroids at 1mg/kg/d was used, hypereosinophilia was 
reduced in only 6, did not change in 3 and increased in the other 3. 
The most frequent invasive procedures performed to alleviate heart failure were drainage 
of ascitic fluid (58 for 40 patients), pericardial fluid (21 for 18 patients) and pleural fluid 
(8 for 8 patients). Five patients in severe heart failure at diagnosis needed simultaneous 
pericardial and peritoneal drainage.
Table 11.1. Drugs most commonly used for management of EMF patients
Drugs N of Patients (%)
Furosemide 158 (90.3%)
Spirololactone/Amiloride 158 (90.3%)
Propranolol 104 (59.4%)
Captopril/Enalapril 98 (56.0%)
Digoxin 95 (54.3%)
Hydroclorothiazide 35 (30.0%)
Warfarin 33 (18.9%)
Aspirin 22 (12.6%)
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Management of Arrhythmia 
The management of the 47 patients with atrial arrhythmia (flutter or fibrillation) was 
done using mainly digoxin, propranolol, verapamil and amiodarone. Verapamil was used 
in 5 patients with contraindication for the use of β-blocker. Amiodarone was used in only 
two patients. Electrical cardioversion was used in two occasions for treatment of recent 
onset atrial fibrillation, associated to severe clinical deterioration. One patient submitted 
to electrical cardioversion had been recently operated and had developed low cardiac 
output syndrome associated with episodes of sustained atrial tachycardia and intermitente 
atrial fibrillation, which were not controlled with drug therapy.
Patients with ventricular hyperexcitability detected on routine ECG or 24h-holter 
monitoring were managed with oral propranolol. Two of them had advanced disease with 
marked ventricular fibrosis and died some weeks after the diagnosis. 
Management and prevention of thromboembolism
Despite the treatment with heparin followed by adequate oral anticoagulation with 
warfarin, out of the 7 patients admitted for pulmonary thromboembolism 4 died in less 
than one month. In two patients with left ventricular thrombus we suspected systemic 
embolism to the gut; both patients recovered on anticoagulation therapy without needing 
surgical intervention. Two patients presented for the first time with signs of recent 
cerebral embolism. 
Eighty-seven patients (49.7%) had indication for anticoagulation. The main indications 
were intra-cardiac thrombi and/or atrial fibrillation, which were present in 71(40.6%) and 
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46(26.3%) patients respectively (Table 11.2). Several patients had more than one 
indication for anticoagulation. 
Table 11.2. Indications for anticoagulation in EMF patients
Spontaneous high INR was found in 32 out of the 87 patients. Those were patients with 
severe disease and long-standing heart failure, presenting chronic congestive 
hepatomegaly, and were left without any anticoagulant therapy. Within the remaining 55 
with indication for chronic anticoagulation, only 33 were eligible for oral warfarin, while 
the other 22 were controlled with low doses of aspirin. The criteria used to consider the 
eligibility for permanent oral anticoagulation were the distance from a health care unit, 
understanding of the risks and complications of the medication, drug availability in the 
region of residence, possibility of testing the INR near the residence and financial 
constraints.
We only had one major hemorrhagic accident due to gastrointestinal bleeding.
Indication for anticoagulation N of patients (%)
Intracavitary thrombus 71 (40.6%)
Atrial fibrillation 46 (26.3%)
Pulmonary thromboembolism 15 (8.6%)
Systemic thromboembolism 12 (6.9%)
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Management of Malnutrition
Nutritional advice was given to patients with mild to moderate hypoproteinemia. Patients 
with kwashiorkor were referred to Pediatric Centers from the national health system for 
Nutritional Recovery (through intensive nutritional therapy with oral milk-oil-sugar 
mixture, vitamins and minerals).  
We had 12 patients with extreme cachexia, who had also severe cardiac failure and were 
admitted to our clinic for intensive nutritional and anti-heart failure therapy. From those, 
9 had structural lesions suitable for surgery but only 2 were operated. Three died while at 
hospital and 4 did not recover their nutritional status, remained in extreme cardiac 
cachexia and were refused surgery. 
Treatment of Infections
The most frequently associated infection was tuberculosis, found in 15 patients (8.6%). 
The prevalence of parasitic infestations in EMF patients at time of diagnosis and/or 
episodes of eosinophilia was as follows: 13 (7.4%) for malaria by Plasmodium 
falciparum, 13 (7.4%) for helminths, 10 (5.7%) for Scabies, 4 (2.2%) for Schistosoma 
mansoni, 2 (1.1%) for filaria by Wechereria bancrofti and 2 (1.1%) for Schistosoma 
Haematobium). 
None of our patients had associated infective endocarditis.
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Hospital Admissions
There were 71 patients from the clinical registry (40.6%) who were never admitted to 
hospital. Eighty-eight (50.3%) had 1 to 3 admissions to hospital, and 16 (9.1%) had more 
than 3 admissions during this 3-years period. There were in total 332 hospitalizations for 
the 104 patients who needed hospitalization. The main causes for admission to hospital 
after initial diagnosis and institution of therapy were the following: (1) interruption of 
medical therapy (105; 16.6%); (2) need for drainage of effusions (77; 23.2%) (3) 
complications related to drug therapy (55; 16.6%) (4) arrhythmia (45; 13.6%); (5) 
progression of the disease despite correct medication (25;7.5%); (6) thromboembolism 
(25; 7.5%). 
Clinical amelioration
The evolution of the functional class of the 124 patients with EMF on exclusive medical 
therapy is shown in Figure 11.1. We excluded from this analysis the 44 patients 
submitted to surgery and the 4 patients who were referred for evaluation of 
hypereosinophilia with no specific cardiovascular symptoms. 
Amelioration occurred in 81 (65.4%) patients. The NYHA remained unchanged in 37 
(29.8%). Three (2.4%) patients worsened during the follow up going from NYHA III to 
IV despite the treatment. Data were not available for 3 (2.4%) patients who were lost for 
follow-up. The detailed results of treatment in EMF patients from the clinical registry on 
exclusive medical therapy are presented in Diagram 11.2.
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NYHA IV 15 NYHA IV
28
NYHA III 12 NYHA III
15 20
NYHA II 6 NYHA II
8 8     2
NYHA I 10 NYHA I
Diagram 11.2. Evolution of NYHA functional class of the 124 EMF patients treated 
medically.
There was a reduction of patients in functional class III/IV from 85.5% at diagnosis, to 
47.5% after 6 months of treatment. The distribution of patients by functional class is 
presented in Table 11.3. 
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Figure 11.1 and Table 11.3 Distribution of NYHA functional class at diagnosis and after 
6 months for the 124 patients treated medically. 
NYHA class I II III IV
At diagnosis 12 (9.7%) 6 (4.8%) 62 (33.9%) 64 (51.6%)
After 6 months 25 (20.2%) 37 (29.8%) 38 (30.6%) 21 (16.9%)
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Survival of patients treated medically
The mean follow- up time was 60.7 (SE 3.5; CI 53.8- 67.7). Nineteen (15.3%) patients on 
exclusive medical therapy died during the follow up, of whom 10 had active disease.  
The mean survival of patients under medical therapy was 17.9 months (SE 3.3; CI 11.5 –
24.3). Figure 11.2 shows the survival curve of these patients, which was over 75 at 2 
years and around 68% after 5 years.
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Figure 11.2: Survival curve of patients submitted to medical therapy 
Chapter 11 Management 
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
385
11.2.3. Discussion
The drugs most commonly used for the treatment of EMF patients in our series were 
diuretics, ACE-inhibitors, Digoxin and β-blockers, which were used in more than half the 
patients. Adequate intensive medical therapy improved the general status and partially 
corrected heart failure in the majority of patients. Nevertheless, some died due to 
refractory heart failure and acute pulmonary thromboembolism despite maximal heart 
failure treatment and adequate anticoagulation, confirming the malignant nature of this 
condition. Resistance to medical therapy can be partially explained by the high 
prevalence of ascitis and intestinal wall congestion, which prevents correct absorption of 
drugs through the gut. However, in a considerable proportion of patients there was 
interruption of medication due to financial constraints, side effects of the drugs and/or 
cultural believes which lead to search for help from traditional healers owing to the fact 
that the medical therapy is perceived as ineffective in patients with severe ascitis. Thus, 
we cannot exclude that recrudescence of heart failure and progression of disease might be 
related to inadequate therapy.
Complications of medical therapy were frequent and constitute an important cause of 
admission to hospital. The ideal dosages for diuretics were difficult to achieve. Despite 
diuretics reducing pulmonary congestion, systemic blood volume, right atrial volume and 
pericardial constraint, they also decrease the cardiac output and cause severe electrolyte 
abnormalities, mainly hyponatremia.
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The availability of new drugs for the treatment of heart failure has probably contributed 
to the improvement in the mean survival of patients with EMF submitted to medical 
therapy in our series, when compared to that of patients from hospital series, in which the 
mean survival time after the onset of symptoms was 2 years (Somers et al, 1978). The 
possibility of preventing thromboembolic events through a more detailed diagnosis of 
intra-cardiac thrombi using echocardiography might also have played a role.
The choice of specific agents in each class was determined mainly by the availability of 
them in the local market and the costs to the patients. The great number of patients in 
digoxin and propranolol was determined by the high prevalence of atrial fibrillation or 
supraventricular ectopics beats.
Digoxin was used in all cases with established atrial fibrillation. Although it is known 
that this drug has no significant effect on cardiac function in patients in sinus rhythm, due 
to the long distances that some patients had to cover to get to a health unit, we were 
forced to use it prior to development of atrial fibrillation in patients with aneurysmal 
atria. The rational was to block the atrioventricular node and slow the ventricular rate at 
the time of conversion to atrial fibrillation, an event that is usually associated with high 
mortality due to severe hemodynamic compromise (Somers et al, 1972a).  
β-blockers were used to reduce heart rate in patients with severe diastolic dysfunction. 
However, several patients had contraindication for its use due to previous history of 
asthma, which was frequent in this series. In these cases Verapamil was the alternative. 
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Due to its high costs Sotalol and Amiodarone were only used for prophylaxis of 
recurrence of arrhythmia after electrical conversion or in the immediate post-operative 
period in patients with moderately dilated atria.
Oral steroids were administered in only 12 cases, a low frequency when compared to the 
number of patients with hypereosinophilia. The use of oral corticosteroids in patients 
with EMF and hypereosinophilia is not supported by clinical trials or longitudinal studies 
on the effects of this therapy. Several reports show that they have no or little influence on 
the natural course of EMF (Somers et al, 1972b; Somers et al, 1978; Somers 1990). More 
recently it was suggested that eosinophilia could be a putative cause of EMF independent 
of parasitism (Rutakingirwa et al, 1999). Therefore, the benefit of using them with no 
clear known advantage was balanced with the known disadvantages and risks in patients 
with pulmonary infections and high risk of activating tuberculosis, which is highly 
prevalent in our population (Dgedge et al, 2001; Salomao, 1991).
Aspirin was used in 22 (12.6%) patients mainly for its anti-platelet properties in those 
patients who could not afford or could not adhere to anticoagulant therapy. However, in a 
patient with confirmed atrial inflammation on pathology specimen obtained during 
surgery, we applied the drug as an adjuvant therapy to control tachycardia-induced 
cardiomyopathy with success. Inflammation is known to act as an initiator of atrial 
fibrillation (Boos et al, 2006) and, therefore we thought that the use of anti-inflammatory 
drugs would be recommended in this case. There were no signs of activity on physical 
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examination or peripheral blood in this patient, who had a favourable sustained clinical 
result following addition of aspirin to the anti-arrhythmic therapy. Although atrial 
arrhythmias have been attributed to the atrial stretch associated with the progressive 
dilatation and fibrosis of the atria, the possible role of atrial pancarditis in producing 
arrhythmia in EMF needs to be studied further as it could influence its management. 
Apart from their role in the treatment of heart failure durgs acting at the Renin-
Angiotensin-Aldosterone system have the potential to modulate the process of tissue 
fibrosis in vivo and in vitro (Zannad et al, 2000; Gallego et al, 2001; Shi et al, 2002). We 
therefore privileged the use of ACE-inhibitors and spironolactone in our patients in heart 
failure. However, in some cases we were limited by the high costs of these drugs in our 
setting. There is need for clinical trials showing the benefit of using these drugs in 
patients with EMF. Although not subjected to randomization patients with and without 
chronic administration of spironolactone and captopril/enalapril, might allow ascertaining 
the effect of these drugs in major end-points during follow up.
Chronic anticoagulation was used to prevent systemic or pulmonary thromboembolism in 
patients with very dilated atria with free tricuspid regurgitation and thrombi detected in 
atria or ventricles on echocardiography. Due to financial restrictions, thrombolysis and 
low-molecular weight heparins were not available for most patients with signs of recent 
thromboembolism, who were treated with intravenous or subcutaneous unfractionated 
heparin.
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Effusions were usually resistant to diuretic treatment and needed periodical drainage 
sometimes as an emergency procedure. Considerable clinical improvement was obtained 
after drainage (pericardiocentesis, paracentesis or thoracocentesis). Since the results of 
surgical procedures for the management of tense ascitis are not satisfactory we did not 
recommend them to our patients. The results of the Spitz-Holter shunt, draining the 
ascitis into the femoral vein, were disastrous (Jayesimi, 1982). Although it is logical to 
think that recurrent pericardial effusions can benefit from pericardio-pleural window or 
pericardioperitoneal shunt this remains to be shown in prospective studies. Our 
management of ascitis relied on frequent evacuation of fluid by paracenthesis. Most 
patients with REMF grade IV had to have repeated paracenthesis (3-6/year). Patients with 
very large ascitis tolerated well the evacuation of reasonable amounts of ascitic fluid. We 
usually evacuated 2-2.5L per procedure in children below 30 kg and up to 3-4 liters in 
those above 30kg body weight. When associated with reinforced diet, this approach did 
not aggravate albumin depletion, and was associated to noticeable improvement in 
response to oral medication. 
Electrical cardioversion to sinus rhythm was used only in 2 patients with atrial fibrillation 
and rapid ventricular response not responding to drug therapy, since the majority of 
patients needing this procedure had intracavitary thrombi or aneurysmal atria. We 
therefore think that the procedure should be reserved to patients with acute hemodynamic 
deterioration by recent onset atrial arrhythmia. In all other patients it has a low rate of 
success related to severe atrial dilatation and fibrosis of the atrial wall. Also there is a 
high risk of dislocating clots that are not seen on echocardiography. 
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11.3. Initial experience of surgery for EMF in Mozambique
11.3.1. Methods 
Surgery outside the research programme
The medical files of patients submitted to surgery outside the EMF research programme 
were evaluated. The researcher collected demographic data, clinical features, 
echocardiographic data, surgical techniques, and complications of surgery. The objective 
was to describe the results of the use of surgery in these patients.
11.3.2. Results 
Characterization of patients
Nineteen patients have been submitted to surgery outside the research programme. 
Eleven patients were males (58.0%) and the mean age was 11 years (SD 4.8; range 4-25). 
The mean body mass index is 15.5 (SD 2.7; range 10-21). All patients were in NYHA 
functional class III/IV. The mean CTI was 72.2 (SD 10.9) ranging from 51 to 92. Twelve 
(12; 63.0%) had signs of activity, of which eight had severe hypereosinophilia. 
The majority (16/19; 84.0%) of the patients had grade II EMF and the remaining 3 had 
grade III EMF. Eleven patients had bilateral EMF with predominance of left lesions, 7 
had “pure” LEMF 1 had REMF. This patient with isolated REMF had a thrombus in the 
right atrium. RV trabecular obliteration was present in 6 patients. Only one patient had 
atrial fibrillation. The characteristics of patients operated are presented in Table 11.4a.
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Table 11.4a: Characteristics of the patients operated for EMF outside the research 
programme
Code Age-
Sex
Weight-
Height
BMI HF Rhythm EMF 
Class
F-up Death
0010 5M 99/16 16.0 III SIN II B 42 No
0012 12M 135/23 12.8 IV SIN II B 14 Yes
0029 15M 135/32 17.3 III SIN II B 29 Yes
0059 12F 134/24 13.4 IV SIN II L 26 No
0061 11F 124/22 14.3 III SIN II L 44 No
0064 12F 140/28 14.3 III SIN II B 24 No
0067 15M 160/47 18.2 IV SIN II L 25 Yes
0072 14F 152/42 20.7 III SIN II B 12 No
0084 4M 88/16 13.6 IV SIN III R 0 Yes
0085 7F 109/16 12.9 IV SIN II L 0 Yes
0107 8M 125/20 12.9 III SIN II L 12 No
0109 7M 131/22 13.2 III SIN II L 12 No
0120 6F 98/14 15.0 III SIN II B 19 No
0123 13M 132/26 14.9 III SIN II L 15 No
0124 24F 158/52 21.0 III AF II L 56 No
0138 13M 140/30 15.3 IV SIN III B 31 No
0139 14M 152/38 16.4 III SIN II B 32 No
0145 4F 100/15 10.0 IV SIN II L 32 No
0159 12F 134/27 15.0 IV SIN II B 19 No
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Mitral regurgitation was the main indication for surgery in severe LEMF, and was present 
in 18 patients. The other patient had advanced REMF with thrombus in the RV and 
severe tricuspid regurgitation.
Surgical Technique
Mitral repair using the Carpentier ring was the most common technique used to treat 
LEMF (13/18 patients). In the remaining patients a biodegradable (Kalangos®) ring was 
used in one, annuloplasty and implantation of Gore-Tex bands was done in other, and 
mitral vale replacement was performed in 3 patients. Reduction of the left atrium was 
added to the mitral repair in 2 patients. Endocardial resection was not used for any patient 
with LEMF, but tricuspid valve annuloplasty or repair was needed in 5 patients. 
The patient with REMF was treated with drainage of pericardial effusion, thrombectomy, 
right endocardial resection, tricuspid plasty with use of Gore-Tex bands for annuloplasty, 
and bi-directional Glenn.
The surgical techniques used for the treatment of these 19 patients are summarized in 
Table 11.4b
Morbidity
The main complications of surgery were large pericardial effusion (5 patients), 
pericardial tamponade (1 patient), and accidents related to anticoagulation (2 patients). 
One patient had been taking warfarin for his mitral prosthesis and had severe urinary 
bleeding associated with bladder sequel of schistosomiasis. The other patient was taking 
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warfarin for her atrial fibrillation and developed hemopericardium during the first post-
operative days and went into pericardial tamponade. 
After 12 months follow-up mitral stenosis was present in three patients. The post-
operative complications are shown in Table 11.4b.
Mortality
The hospital mortality was 2/19 in this series. In one children due to incapacity to wean 
from the extra-corporal circulation machine and in the other due to low cardiac output 
syndrome. This child had pericardial effusion, severe ascitis, moderate liver dysfunction, 
complicated with syndrome of low cardiac output that lead to multi-organ failure, and 
died on day 17 after surgery. 
The mortality during the first post-operative year was 2/17. One patient had had mitral 
and tricuspid repair and developed refractory heart failure during the first post-operative 
year. The other, considered to have concomitant rheumatic heart disease, had had mitral 
valve repair and aortic valve repair, followed by several episodes of rheumatic acute 
carditis, did not comply with medication and developed atrial fibrillation complicated 
with a stroke that lead to death. 
One late death was unrelated to surgery (anaphylaxis to penicillin) in a patient in whom 
there was association with rheumatic heart disease. The overall mortality was 5/19 
(26.0%).  
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Table 11.4b: Surgical techniques and complications in EMF patients operated outside the 
research programme. 
Code Age-Sex EMF
Class
Indication Surgical
Technique
Complications Death
0010 5M II B MR Mrepair TR
0012 12M II B MR Mrepair TR Severe MR M12
0029 15M II B MR MP TR OAC
0059 12F II L MR Mrepair TR Lar Psychotic 
0061 11F II L MR Mrepair Bio ring* MS MR
0064 12F II B MR Mrepair Lareduction
0067 15M II L MR Mrepair Ao Plasty MS AF Stroke
0072 14F II B MR Mrepair Severe MR
0084 4M III R TR THR TB RVER TR Glenn LCO MOF D 17
0085 7F II L MR MP IOD D 0
0107 8M II L MR Mrepair PE MS
0109 7M II L MR Mrepair
0120 6F II B MR MP
0123 13M II L MR Mrepair**
0124 24F II L MR Mrepair PT OAC
0138 13M III B MR Mrepair BC PT
0139 14M II B MR Mrepair PE, Severe MR
0145 4F II L MR Mreapir
0159 12F II B MR Mrepair Mild MR 
MR mitral regurgitation; TR tricuspid regurgitation; Mrepair = repair with Carpentier ring; * biodegradable 
ring; ** annuloplasty without ring; Ao aortic valve; TB thrombectomy; RVER right ventricular endocardial 
resection; MP mitral mechanic prosthesis; BC bilateral commissurotomy; OAC anticoagulant complication; 
AF atrial fibrillation; MS mitral stenosis; LA left atrial; LCO low cardiac output; MOF multi-organ failure; 
IOD intraoperative death; PE large pericardial effusion; PT pericardial tamponade; M month; D day
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Follow-up
The mean follow-up of these patients was 22.8 months (SE 2.8; SD 15; range 0 to 56 
months). Three patients were lost for follow-up. Three patients who survived needed re-
operation: two patients developed mitral stenosis of the repaired valve and the remaining 
patient has partial dehiscence of the Carpentier ring with severe mitral regurgitation.
The mean survival time was 44 months (CI 33-55), limited to 59 months. The survival 
curve of these patients is shown in Figure 11.3.
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Figure 11.3: Survival curve of patients submitted to surgery for EMF outside the 
research programme. The survival time is limited to 59 months.
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11.3.3. Discussion
The initial experience of surgery for EMF at the Heart Institute consisted in operating 
mostly patients with LEMF with relatively little mural lesions and predominance of valve 
affection. The surgical technique was not standardized and did not include endocardial 
resection, even in BEMF with obliteration of the trabecular portion of the right ventricle. 
Correction of mitral regurgitation was done through mitral repair (15/19), which in most 
procedures involved the implantation of a Carpentier ring. 
The clinical and echocardiographic evaluation in the immediate post-operative period 
showed no stenosis. However, in the mid-term results revealed mitral stenosis in three 
patients. We think that the use of a rigid ring in patients with a disease that primarily 
involves fibrosis and little dilatation of the mitral annulus has contributed to this 
complication. Moreover, since the patients operated were mainly children and 
adolescents, their growth after surgery might also have played a role in development of 
stenosis. Whether the use of this ring must be considered a disadvantage in surgical 
treatment of EMF is something that has to be assessed in long-term follow up studies. 
The intraoperative death that occurred in this series was associated with incomplete 
diagnosis. The patient had a diagnosis of mitral regurgitation due to rheumatic heart 
disease when indcated for surgery. Intraoperatively, extensive endocardial fibrosis of the 
left ventricle was found and mitral regurgitation was in fact associated with complete 
absence of the posterior leaflet and severe thickening and retraction of the anterior leaflet. 
Mitral replacement was performed but this patient could not be weaned from 
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extracorporeal circulation. The death that occurred in the immediate post-operative was 
related to the presence of complications of long standing heart failure, severe ascitis and 
liver dysfunction at time of surgery in a patient with advanced REMF. 
Two deaths occurred during the first post-operative year associated to refractory heart 
failure that seemed to be related to recurrence of atrioventricular valve regurgitation soon 
after surgery. The control of atrioventricular valve function immediately after surgery 
showed mild mitral regurgitation in both patients that increased rapidly during the follow-
up. This rapid increase in valve dysfunction could be related to the persistence of marked 
compliance abnormality, since endocardial resection had not been performed.
Five out of the 6 patients with right ventricular trabecular obliteration developed large 
pericardial effusion lasting 3 to 6 months during immediately after surgery, despite 
diuretic and anti-inflammatory treatment. Two patients needed pericardial drainage in 
emergency due to pericardial tamponade. The persistence of right ventricular obliteration 
surely contributed to this complication and the signs of right heart failure observed in 
these patients. 
Mitral valve replacement was performed in 3 patients (6, 7 and 15 years), of which only 
one survived on long term follow-up. As said before one patient had an intraoperative 
death, while the other died from a non-prosthesis related event. 
The overall mortality was high (26%). The mean survival time at 44 months (limited to 
59 months) is acceptable. There were 3 patients lost for follow up. Two out of the 3 
patients awaiting re-intervention will need valve replacement for correction of post-
surgical mitral stenosis. 
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11.4. New Tailored Approach for the Management of EMF
11.4.1. Methods 
11.4.1.1. New surgical strategy
Our surgical approach started with thorough clinical and echocardiographic evaluation of 
the structural and functional abnormalities in patients proposed to surgery. Regarding the 
surgical strategy the decision was made by the researcher and the surgeon in all cases. 
We also used exclusion criteria and submitted all patients to intensive medical therapy 
prior to surgery, to correct signs of activity and optimize their clinical status. The 
researcher was responsible for the selection and preparation of the patients proposed to 
surgery. An international team lead by the main supervisor was constituted and included 
surgeons, anesthetists, perfusionist and intensive care nurses who contributed with their 
knowledge to the progression and optimization of surgical and post-surgical care. 
i. Selection of patients for surgery
The pre-operative evaluation of structural changes was based on transthoracic 
echocardiography. Using the new diagnostic and severity criteria decribed in Chapter 3 
we identified patients with structural lesions that would benefit from surgical correction 
through detailed description of the characteristics, localization and severity of the mural 
and valvular lesions. The most important contraindications for surgery were:
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(1) large long-standing ascitis refractory to medical therapy; (2) extreme cachexia not 
responding to therapy; (3) fixed pulmonary hypertension; (4) extensive endocardial 
fibrosis or calcification with impaired myocardial function; (5) considerable shortening of 
leaflets in which valve replacement was anticipated. 
ii. Pre-operative Care
The biological profile was evaluated in order to identify patients with active disease or 
contraindications for surgery. Prior to surgery patients were admitted to hospital for 
intensive medical therapy, for a period ranging from one week to one month. Multi-drug 
therapy was used for all including high doses of diuretics, angiotensin converting enzyme 
inhibitors, ferrous sulphate, vitamins and high content protein diet. 
Cardiac catheterization was considered for patients with indication for surgery for which 
echocardiography did not fully characterized the structural and hemodynamic 
abnormalities, as well as pulmonary pressures/resistances and response to pulmonary 
vasodilators, due to heart distortion or the presence of free tricuspid regurgitation. 
iii. Intraoperative evaluation
One surgeon (Professor MHY, the main supervisor) operated all patients. The researcher 
was present in the operating room to evaluate the macroscopic lesions, perform trans-
esophageal echocardiography, obtain pictures of the relevant stages of surgery and handle 
the specimens obtained for pathology studies. The intra-cardiac echocardiographic 
control aimed at controlling valve repair.
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iv. Postoperative follow-up
During the first two days the patients had temporary pacing, pericardial and pleural 
drains. Intravenous inotropes and anticoagulation were also used for the first 2 days. 
Clinical examination, electrocardiogram and echocardiography were performed daily 
during the first week, while the patients were in the hopsital. After discharge weekly 
appointments were done for the following six weeks. These amedical appointments were 
used to assess the appearance of pericardial effusion, atrial arrhythmia and to control the 
quality of anticoagulation. At the end of this period chest x-ray, hemogram and 24-h 
rhythm holter monitoring were performed. 
The medical therapy used after surgery included diuretics, vasodilators (mainly ACE-
inhibitors), anti-arrhythmic drugs, anticoagulants, aspirin, antibiotics, ferrous sulphate, 
and vitamins. 
11.4.1.2. Surgical Techniques
i. Surgery of Right EMF
A wide longitudinal right atriotomy was performed to expose the tricuspid valve. This 
was usually markedly dilated affording wide access to the right ventricular cavity (Figure 
11.4). The distribution and extent of pathological involvement of the tricuspid valve 
leaflets, chordae, right ventricular inflow tract and cavity were then carefully defined and 
dealt with accordingly. 
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Figure 11.4. The first step of the surgical intervention in BEMF and REMF was the 
exploration of right ventricular lesions done through a wide right atriotomy. This picture 
shows endocardial fibrosis, which involves the papillary muscles and thickening of 
chordae are visible.
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a) Mobilization of the Trabecular Part and Tricuspid Repair
In patients with obliteration of the trabecular portion of the right ventricle endocardial 
resection was started near the tricuspid annulus by retracting the leaflets of the valve. 
Where the latter was fused in some areas, it was mobilizedwhen feasible. Following the 
development of a cleavage plane by sharp dissection, a combination of sharp and blunt 
dissection was used to excise the thick fibrous endocardial lining (Figure 11.5). This 
process was continued into the ventricular cavity ensuring preservation and mobilization 
of the tricuspid valve chordae and papillary muscles, as well as avoidance of the 
conduction tissue. The part of the membrane covering the entry into the trabecular part 
was removed exposing the fused muscular tissue underneath it (Figure 11.6). This was 
followed by recreating a cavity inside the trabecular part by mainly separating the fused 
trabeculae but if necessary excising some muscular tissue taking care not to perforate the 
ventricular wall. In patients with complete fusion of the leaflets and chordae to the mural 
fibrosis, freeing of the tricuspid valve apparatus was performed followed by 
reconstruction of the valve using two bands of Gortex tubes. 
b) Other procedures
Right atrial reduction was performed in patients with aneurismal right atrium. It consisted 
of excision of atrial appendage and variable amount of atrial tissue. Glenn procedure was 
performed in patients who had small right ventricular cavity after endocardectomy, and 
as an initial step towards intra-cardiac correction that would be done in a second surgery.
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ii. Surgery of Left EMF
A wide longitudinal left atriotomy was performed to expose the mitral valve. The mitral 
annulus was usually moderately dilated affording adequate access to the inflow part of 
the left ventricle (Figure 11.7). In most cases assessment of the distribution and extent of 
pathological involvement of the mitral valve leaflets, chordae and papillary muscles 
could be carefully defined. However, in one patient with extensive involvement of the 
subvalvar apparatus and the apex, complete evaluation of the apical lesions was difficult, 
and left ventriculotomy was performed.  
a) Endocardial resection and Mitral Repair
Conservative endocardectomy was started below the level of the mitral annulus (Figure 
11.8), usually freeing the posterior leaflet and chordae and mobilizing the papillary 
muscles. Caution was taken to avoid damage of the subvalvar apparatus thus leaving 
some fibrotic tissue surrounding the basis of the papillary muscle. In some patients 
extension of chordae was needed and we performed it using Goretex material. The dilated 
mitral annulus was reduced through annuloplasty using Goretex bands (Figure 11.9). 
b) Left Atrial Reduction
The left atrial appendage was removed in all patients. In those with aneurismal left atrium 
this was associated to excision of large amount of left atrial tissue (Figure 11.10).
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Figure 11.5. Excision of the fibrotic tissue of the right ventricle
Figure 11.6. Release of myocardium underneath the fibrous plaque
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Figure 11.7. Exploration of left ventricular lesions done through left atriotmy
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Figure 11.8 Excision of left ventricular fibrotic endocardium (F) through the mitral valve
Figure 11.9. Mitral valve repair included annuloplasty using Goretex bands (arrow)
F
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Figure 11.10. Atrial appendage with several thrombi attached to the wall (top) and large 
portion of the atrium excised during atrial reduction (bottom)
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11.4.2. Results
Using the new approach for diagnosis and management of EMF we excluded 80 patients 
from surgery (46%) because they presented advanced grade lesions or had concomitant 
medical conditions that were considered contra-indications to surgery. The most
important contraindications were long-standing heart failure, refractory ascitis and fixed 
pulmonary hypertension (Table 11.5). Nineteen patients had already been operated. As 
mentioned above 20 patients had minimal lesions that did not require surgery. 
At the end, 56 patients with structural lesions that could be corrected by surgery were 
considered for surgical treatment under this new approach.  Ten patients died during 
preparation for surgery; the causes of death are presented in Table 11.6. Two patients 
refused surgery. One patient was pregnant at the time of surgery and died immediately 
after delivery. Nine patients are waiting for the operation and 10 were lost for follow-up 
during preparation for surgery.  We therefore operated 24 patients using this approach. 
Table 11.5. Main contraindications for surgery in EMF patients 
Contraindication for surgery Number of patients
Refractory ascitis 31
Fixed PHT 5
Extreme cachexia 4
Chronic thromboembolism 2
Sequelae of Pulmonary tuberculosis 2
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Table 11.6. Causes of death in patients with EMF while in preparation for surgery
Cause of death Number of patients
Refractory heart failure 4
Rapidly progressive disease 2
Pulmonary embolism 1
Unknown* 3
* Death at home reported by the family 
11.4.2.1. Characterization of patients selected for surgery
The mean age (±SD) of the patients was 12(±5) years, ranging from 6 to 22 years. There 
were 14 females (58.3%). The majority of patients (18; 75%) were in NYHA functional 
class IV. Twelve patients (50%) had BEMF, 8 (33.3%) had LEMF and 4 (16.7%) had 
REMF. Most patients had grade III lesions (17; 70.8%). Three patients were in atrial 
fibrillation. The mean cardiothoracic index was 72.5%. The mean body surface area was 
1.02 (± 0.26). Table 11.7 presents the main characteristics of the 24 patients operated. 
The mitral valve was severely affected in 21 cases of which one had associated stenosis. 
In one case there was mild MR associated with predominant REMF. The main 
mechanism of regurgitation was restriction of the movement or absence of the posterior 
mitral leaflet. Tricuspid regurgitation was present in all patients. The main mechanism of 
lesion was restriction of the movement of the leaflets due to involvement of the papillary 
muscles in the fibrotic plaque and dilatation of the annulus (16 patients), while the 
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remaining 8 patients had functional tricuspid regurgitation associated with annulus 
dilatation due to severe pulmonary hypertension caused by left sided disease.
11.4.2.2. Pre-operative Care
Four patients had β-blockers and digoxin. Five patients were under anticoagulant therapy: 
three had atrial fibrillation and two had severely dilated atria). Oral corticosteroids (7 to 
10 days) were given to two patients with hypereosinophilia. Pericardial drainage was 
performed to one patient who had active EMF. Paracentesis was performed for 2 patients 
with REMF who also had atrial arrhythmia with rapid ventricular response and 
pericardial effusion.
Cardiac catheterization was performed for 2 patients. One had LEMF with aneurismal 
left atrium and severe heart distortion that made it possible to estimate the pulmonary 
pressures and evaluate the size of the right ventricle on transthoracic echocardiography. 
The second patient had REMF with large ascitis and free tricuspid regurgitation. The 
patient was proposed for a palliative procedure (Glenn procedure) and needed evaluation 
of the pulmonary pressures.
11.4.2.3. Intraoperative Data
We performed 26 surgeries in the 24 patients with EMF. One patient was operated in a 
two-staged strategy: first a Glenn procedure was done followed by right ventricular 
endocardial resection one year later. Another patient was re-operated after failure of the 
initial mitral repair, due to dehiscence of Goretex band.
Chapter 11 Management 
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
411
Table 11.7. Characteristics of 24 patients submitted to surgery using the new tailored 
therapeutic approach
Code Age-
Sex
Weight-
Height
BMI HF Rhythm EMF
Class
F-up Periop
Mortality
0065 16M 155/38 15.8 III SIN II L 40 No
0068 10M 126/20 12.6 IV SIN II B 40 No
0048 12F 126/21.5 13.5 IV AF IV L 40 No
0009 7M 117/19 13.9 III SIN III B 40 No
0076 17F 150/32 14.2 IV SIN III L 36 No
0075 15M 144/27 13.0 IV SIN III L 36 No
0074 12M 139/27 14.0 IV SIN III B 36 No
0040 22F 163/45.6 17.2 IV AF III B 36 Yes
0143 8F 112/19.9 15.9 IV SIN II B 24 No
0062 9F 122/22.6 15.2 IV SIN III B 24 No
0128 16M 149/38 17.1 II SIN III L 24 No
0142 22M 167/45.5 16.3 IV AF III L 24 No
0144 16F 152/34.4 14.9 IV SIN III B 24 No
0125 22M 162/45 17.1 IV SIN III L 24 No
0052 8M 126/26 16.4 II SIN IV R 24 No
0146 12M 131/27 15.7 IV SIN III B 24 No
0152 6F 112/20 15.9 II SIN III R 14 No
0110 8M 105/18 16.3 IV SIN IV R 14 No
0163 10F 122/23 15.5 III SIN III B 14 No
0151 9M 110/19 15.7 II SIN II R 14 No
0169 21M 173/60.5 20.2 IV SIN III L 14 Yes
0180 10M 130/21.4 12.7 IV SIN III B 14 No
0167 10F 134/26.6 14.8 IV SIN III B 12 No
0179 9F 114/16.4 12.6 IV SIN III B 12 No
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The mean cardiopulmonary bypass time was 108 minutes (range 63 To 148).  The mean 
aortic clamping time was 71 minutes (range 32-112). Cold blood cardioplegia was used 
for all patients. Intravenous inotropes were used in the immediate post-operative period, 
between 6 and 48 hours. Weaning from the ventilator was possible in all patients after 3 
to 12 hours. The mean time at intensive care unit was 39 hours varying from 24 to 72, 
and the mean hospitalization time was 8 (± 2) days, ranging from 3 to 16 days. 
We performed a two-staged surgery in 1 patient with REMF. First a Glenn procedure was 
performed to this 6 years old boy in NYHA IV, with large hepatomegaly and ascitis. His 
clinical condition improved dramatically and therefore open-heart surgery could be 
performed one year later in better conditions.
11.4.2.4. Valve function
Prior to surgery 21 patients had MR grade 4/4, one had grade ¼ mitral regurgitation and 
two did not have any mitral dysfunction. All 22 patients with mitral regurgitation 
improved after surgery. However, mild incompetence appeared in 2 patients treated for 
REMF with no intervention to the left side of the heart during surgery. On 6-months 
follow up 9 patients did not have mitral regurgitation, 10 had mild, two had moderate and 
one had important (¾) mitral regurgitation. This last patient had been treated with 
biventricular endocardial resection, as well as mitral and tricuspid valve repair. The 
echocardiography now shows non-cooptation with a jet going to the inter-atrial septum 
and residual endocardial fibrosis in the apex. 
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Modified de Vega annuloplasty with reinforcement of the annuloplasty with Gore-Tex 
bands was used in all cases of tricuspid valve repair. Plasty of the subvalvar apparatus 
was performed in the 10 patients with REMF or BEMF, and consisted of mobilization of 
the papillary muscles and the use of Gore-Tex chordae. On 6-months follow-up there 
were 3/22 patients with moderate and 7/22 with mild tricuspid regurgitation. 
The follow up at 24 months was completed for 13 out of 14 patients. Eleven patients had 
no or mild mitral regurgitation. Equally 11 had no or mild tricuspid regurgitation. 
Residual moderate to severe mitral regurgitation was present in 2 patients. Moderate 
tricuspid regurgitation was also present in 2 patients treated for REMF, who had marked 
clinical improvement having only mild hepatomegaly, with the border of the liver 
palpable about 2cm below the costal border. 
Details of valve function before and after surgery are shown in appendix 7.
11.4.2.5. Ventricular size, shape and function,
The mean left ventricular end-diastole dimensions indexed for body surface area before 
surgery was 49.9 (11.2) mm, ranging from 27.2 to 67.0, and changed to 45.8 ( 6.2) 
mm, ranging from 31.3 to 55.8 after surgery. Regarding the end-systole dimensions they 
changed from a mean 29.2mm ( 6.0; range 16.9 – 43.1) to a mean of 30.4mm ( 7.1; 
range 22.1 – 50.0). When comparing the three types of EMF the LV dimensions were 
higher for the patients with BEMF with mean values indexed for body surface area were 
46.9mm ( 11.0) for the lateral dimension and 56.0mm ( 12.0) for the superior-inferior 
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dimension. The lateral dimension was smaller for REMF (29.6 ± 2.8mm) and the 
superior-inferior dimension was smaller for LEMF (46.0 ± 9.8mm).
The RV function was improved in 16 patients, unchanged in 3 and worsened in one. With 
respect to 3 patients there was no information about the right ventricular function after 
surgery (1 patient died and 2 did not appear for follow up). Sixteen patients had excellent 
right ventricular function and only one had poor function after surgery.
The mean sphericity indexes were reduced after surgery, changing from 0.81 (± 0.19) and 
1.10 (± 0.37) to 0.75 (± 0.14) and 0.87 (± 0.87), respectively for the left and right 
ventricles. The sphericity indexes after surgery were calculated for 20 patients, since we 
had two deaths in the immediate post-operative period and the follow up was not yet 
done for 2 patients. When comparing the different types of EMF, the sphericity indexes 
were higher for both the right ventricle and the right atrium before surgery, which mean 
values were respectively 1.34 and 1.70.
Appendix 8 presents the summary of the values of left and right ventricular dimensions 
indexed for body surface area and sphericity indexes for the three types of EMF.
The LV mean shortening fraction, considering the 20 patients with bilateral or 
predominant left EMF was 44.0% (± 7.4; range 30-59) before surgery. The ventricular 
function after surgery evaluated by a visual semi-quantitative scale was good in 23 out of 
the 24 patients. The left ventricular end-diastolic and end-systolic dimensions measured 
on M-mode, the systolic function and the values of E/A ratio of the transmitral flow after 
surgery are shown in Appendix 9.
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The velocity of the E wave of the transmitral flow was above 2m/s in 7 out of the 20 
patients with LEMF and BEMF. The mean value of the E/A ratio was 2.7  1.2, and 
changed to 2.0  0.8 after surgery. The E/A ratio before surgery was evaluated in 22 
patients, since 2 were in atrial fibrillation. It was calculated in only 19 patients after 
surgery (2 patients died and there were no data for 2 patients on follow up).
Right ventricular function was improved in all but 2 patients who had dilatation of the 
ventricle with thin wall (Appendix 10).
11.4.2.6. Atria size and shape
The mean lateral dimension of the left atrium was 55.0 mm ( 25.9; range 20.3 – 144.8) 
pre-operatively and was reduced to 43.2 mm ( 11.0; range 25.2 – 63.4) after surgery, 
while the superoinferior dimension changed from 65.2 mm before ( 15.3; range 38.9 –
94.2) to 57.0 mm ( 9.8; range 39.1 – 80.5) after surgery. The sphericity index for the left 
atrium was 0.85 ( 0.35) pre-operatively and decreased to 0.78 ( 0.14) after surgery. 
Regarding the right atrium the mean values of the lateral dimension, longitudinal 
dimension and sphericity index before surgery were 56.6 mm ( 22.9; range 20.6 –
107.0), 58.3 mm ( 16.7; range 33.6 – 97.2) and 0.95 ( 0.28; range 0.35 – 1.86), 
respectively. After surgery these mean values were 47.6 mm ( 17.5; range 24.3 – 88.6) 
for the lateral dimension, 51.6 mm ( 16.8; 26.4 – 88.6) for the longitudinal dimension 
and 0.92 ( 0.14; range 0.64 – 1.22) for the sphericity index. 
The summary of the values of left and right atrial dimensions indexed for body surface 
area and sphericity indexes for the three types of EMF is presented in Appendix 11.  
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11.4.2.7. Functional improvement (NYHA class)
Prior to surgery 20 (83.3%) patients were in NYHA III/IV. The NYHA functional class 
reduced after surgery in all patients, with 20 of the 22 survivors being asymptomatic one 
year after surgery, under low doses of diuretics and ACE-inhibitors. The changes in 
NYHA of patients before and after surgery are shown in Figure 11.11.
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Figure 11.11. Distribution of patients by functional class pre- and post-operatively 
NYHA I NYHA II NYHA III NYHA IV
Pre-operative 0 4 (16.7%) 3 (12.5%) 17 (70.8%)
Post-operative 20 (90.9%) 2 (9.1%) 0 0
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11.4.2.8. Change in cardiothoracic ratio
The mean cardio-thoracic ratio prior to surgery was 76.4% (± 12.1) whereas it was 62.0% 
(± 9.3) one year after the surgeries. The distribution of the cardio-toracic ratio before and 
after surgery is presented in Figure 11.12. In some patients the reduction in the cardio-
thoracic ratio was dramatic, as occurred in the patient with LEMF whose chest 
radiography is shown in Figure 11.13.
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Figure 11.12. Evolution of the cardiothoracic ratio before (24 patients) and after surgery 
(22 patients)
Chapter 11 Management 
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
418
Figure 11.13. Chest radiography of LEMF before (top) and 6 months after surgery 
(bottom), which included left endocardial resection, mitral repair and left atrial reduction. 
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11.4.2.9. Mortality and morbidity
There was no intraoperative death. The mortality rate was therefore 2/24 (8.3%). Two 
intrahospitalar deaths occurred during the immediate post-operative period (days 3 and 
10). Both were related to complications of pericardial drainage in emergency, for relief of 
pericardial tamponade that developed rapidly. 
The most important complications of EMF surgery were abundant pericardial effusion 
and tamponade, intraventricular thrombi and transitory rhythm disturbances (Table 11.8). 
Several complications occurred in only one patient namely low cardiac output syndrome, 
subdural hematome, superior vena cava syndrome, depression and pericardium-left 
pleural space fistula (after pericardial drainage).
Abundant pericardial effusion developed in 14 patients, with pericardial tamponade 
needing drainage in 4. In all cases the effusion developed rapidly within 24 to 48 hours. 
In all cases of pericardial tamponade there was severe affection of the right ventricle.
Eleven patients had transitory supraventricular arrhythmia. Of these 4 presented persising 
atrial rhythm disturbances during the first six months, namely intermittent atrial 
fibrillation and paroxysms of supraventricular tachycardia. In one patient with REMF in 
whom right atrial reduction was performed intermittent atrial fibrillation persists after 24 
months follow up. Transitory AV block lasting 24-48 hours was present in 3 patients with 
REMF who were submitted to endocardial resection.
The neurological complications were one subdural hematome that needed surgery and 
one post-operative depression.
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Table 11.8. Surgical technique and complications of the tailored approach
Code EMF
Class
Surgical Technique
Approach              Technique
CPB/AoC 
time(min)
Early Postoperative Complications Death
0065 II L LA                     MR 62/32 ______ No
0068 II B LA RA                  MR TR LAR 102/68 PE, AT, Low cardiac output No
0048 IV L LA RA              MR TR LER  LAR 135/88 ______ No
0009 III B LA RA              MR TR LER  LAR 94/63 ______ No
0076 III L LA RA                  MR TR LER 128/88 LVT, mild MS No
0075 III L LA RA                  MR TR LER 110/66 ______ No
0074 III B LA RA        MR TR LER RER LAR 102/82 PE, LVT, EB, Pleural Effusion No
0040 III B LA RA              MR TR LER LAR 102/70 PE/Pericardial Tamponade Yes
0143 II B LA RA                  MR TR LAR 88/57 Mild MS No
0062 III B LA RA        MR TR LER RER LAR 110/91 PE, Stroke No
0128 III L LA LV                MR LER LVT 140/112 Moderate Mitral Regurgitation No
0142 III L LA RA              MR TR LER LAR 88/58 Transitory Psychosis No
0144 III B LA                          MR LAR 88/57 ______ No
0125 III L LA RA        MR TR LER 89/60 ______ No
0052 IV R RA                        TR RER RAR 66/0 PE, Superior Vena Cava Syndrome No
0146 III B LA RA       MR TR LER RER LAR 128/88 PE, Moderate Mitral Regurgitation No
0152 III R RA        TR RER RAR 130/88 PE, Pleural Effusion No
0110 IV R RA                       TR RER RAR 119/77 PE, Paroxysmal AF, RAT No
0163 III B LA RA        MR TR LER RER LAR 98/63 Severe Mitral Regurgitation No
0151 II R RA                      TR RER RAR 148/79 PE No
0169 III L LA RA                MR TR LER 99/69 PE/Pericardial Tamponade Yes
0180 III B LA RA        MR TR LER RER LAR 135/105 ______ No
0167 III B LA RA        MR TR LER RER LAR 105/65 ______ No
0179 III B LA RA                MR TR LAR 137/94 ______ No
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Abbreviations for Table 11.8 on previous page
AF atrial fibrillation; 
AT atrial tachyarrhythmia
EB ectopic beats
LA left atriotomy
LAR left atrial reduction
LER left endocardial resection
LVT Left Ventricular Thrombus 
MR mitral repair
MS mitral stenosis 
PE pericardial effusion
RA right atriotomy
RAR right atrial reduction
RAT Right Atrial Thrombus 
RER right endocardial resection
TR tricuspid repair
Intra-ventricular thrombi in the immediate post-operative period occurred in 5 patients 
submitted to endocardial resection on the left ventricle. These patients were put on 
warfarin for three months. In one of them a subdural hematome developed despite normal 
INR values, and needed emergency neurosurgery for extraction of the hematome.
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Table 11.9. Surgical complications and its frequency
Complication No Patients (%)
Large pericardial effusion 14 (58.3%)
Pericardial tamponade 4 (16.7%)
Temporary atrial tachyarrhythmia or atrial fibrillation 11 (45.8%)
Ventricular arrhythmia 5 (20.8%)
Intra-cardiac thrombosis 5 (20.8%)
Transitory atrioventricular block 3 (6.4%)
Neurological complications 2 (8.3%)
Pleural effusion 2 (8.3%)
Superior Vena Cava Syndrome 1 (4.2%)
Pericardial-pleural fistula 1 (4.2%)
Permanent atrioventricular block 0
Infection 0
Residual (persistent) mitral regurgitation 2
Residual tricuspid regurgitation 1
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11.4.2.10. Re-intervention
Re-operation was needed in one patient with BEMF who developed acute heart failure 
related to mitral regurgitation due to dehiscence of the suture of the Goretex-built ring to 
the posterior annulus. This complication developed three weeks after left endocardial 
resection and mitral valve repair. A new mitral valve repair was performed and the 
patient is now well.
11.4.2.11. Survival and Recurrence
The mean follow up of patients operated for treatment of EMF is now 25 (± 10) months, 
ranging from 12 to 40 months. During the follow up there was no recurrence of the 
disease as evaluated by the presence of echocardiographic signs of endocardial 
thickening in areas where endocardial resection had been performed.  
The mean survival time is 38.6 months (CI 36-40). The survival curve of patients 
submitted to surgery using this new tailored approach is shown in Figure 11.14. 
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Figure 11.14: Survival curve of patients operated using the new surgical approach.
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11.5. Discussion
The optimization of the management of EMF requires a correct diagnosis and includes 
detailed characterization of anatomical and functional abnormalities for each patient.  
This precision in diagnosis allows the design of tailored strategies for treatment of the 
existing lesions, and prevents the progression to irreversible complications. 
Medical therapy was important in pre-operative care, to control heart failure, to treat 
superimposed pulmonary infections and also to manage complications of low cardiac 
output, especially cachexia. Since ascitis and pericardial effusion play a major role in 
determining symptoms, pre-operative care included the drainage of these effusions. 
Ascitis causes increased intraperitoneal pressure and consequently reduces the absorption 
of the intraluminal content of the bowel, including drugs administered orally. Evacuation 
of ascitis, despite draining considerable amounts of proteins, was associated to temporary 
clinical improvement and better response to medical therapy. Equally, the drainage of 
large pericardial effusions was associated with marked improvement probably due to 
alleviation of one of the components contributing to reduced atrial filling and low cardiac 
output. Indeed the thickened endocardial fibrous tissue causes combined systolic and
diastolic dysfunction which are aggravated by the presence of pericardial effusion. 
We performed cardiac catheterization in two patients to assess the volume of the RV, 
measure the pulmonary pressures and define the surgical strategy. This invasive 
procedure was indicated exclusively to patients undergoing surgery, because we feel that 
echocardiographic examination allows detailed evaluation of structural and hemodynamic 
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abnormalities in most patients. Additionally, there is frequently an imbalance between the 
information obtained and the risk of the procedure, which include stimulation of 
arrhythmia, thromboembolism and cardiac perforation. 
Reparative operations were developed and applied to target the specific components of 
the disease, which include: (1) fibrous plaques interfering with systolic and diastolic 
regional ventricular function; (2) reduction in ventricular volume caused by obliteration 
of the trabecular part of the right ventricle and the apical portion of the left ventricle; (3) 
immobilization of the papillary muscles of the mitral and tricuspid valves, which can be 
totally embedded in the ventricular wall; (4) chordal abnormalities; (5) fusion of the 
leaflets (mainly the posterior leaflet of the mitral valve) to the wall; (6) dilatation of the 
tricuspid and mitral annulus; (7) massive dilatation of the right and left atria.
Our initial surgical experience involved primarily the treatment of predominant or lone 
LEMF. With the understanding of the mechanisms of right ventricular obliteration, 
severe forms of right-sided disease were progressively included. 
The surgical technique includes partial or extensive endocardial resection according to 
the location and extension of the lesions, as well as the appreciation of their contribution 
to the abnormalities in the global cardiac function. Also, there is usually need for 
mobilization of the fused papillary muscles and leaflets, atrioventricular valve repair and 
atrial reduction. Avoidance of complete heart block is achieved through less radical 
endocardectomy, while the use of atrioventricular valve repair using a non-rigid ring 
contributed to reduction in complications related to valve prosthesis.
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We approached ventricular lesions through atriotomy. However, in a patient with LEMF 
with a calcified thrombus attached to the apex and subvalvar apparatus of the left 
ventricle, an apical incision was needed to release the mitral valve apparatus. In an 
attempt to improve the access to LV endocardial lesions while reducing the impact of 
ventriculotomy an alternative option is endocardectomy through aortotomy (Joshi et al, 
2003). 
Resection of the fibrous endocardium was associated with immediate improvement of the 
ventricular function in most cases. When apical fibrosis was resected, there was vigorous 
contraction of the apex with improvement in longitudinal left ventricular function 
immediately after surgery. In patients with right ventricular obliteration the reopening of 
the trabecular portion through endocardial resection and mobilization of the fused 
trabeculae was associated with improvement in right ventricular function and filling. In 
two patients increase in ventricular function unmasked a moderate mitral regurgitation 
previously classified as trivial.
Ventricular size and shape changed after surgery. Regarding the left ventricle the most 
important changes were increase in the longitudinal dimensions, leading to reduction in 
the sphericity index and a more normal shape of this chamber. The reduction of 
sphericity of the right ventricle was less marked post-operatively, since both the latero-
lateral and supero-inferior dimensions increased almost proportionally. 
There was reduction of the size of the dilated left atrial in all patients operated for 
treatment of Left or Bilateral EMF, with reduction of the sphericity. In patients with 
predominant unilateral disease there was reduction in the dimensions of the contra-lateral 
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atrium, related to reduction of the intra-atrial pressure on the treated side and consequent 
reduction of bulging of the inter-atrial septum.  
Conventional measurements of ventricular function like shortening and ejection fraction 
cannot be used because the assumptions applied to calculate these parameters are not 
present in most EMF patients. Indeed pre-operatively in left and bilateral EMF the left 
ventricle, instead of an ellipsoid is converted to a round cavity due to apical fibrosis and 
compensatory dilatation of the basal portion, leading to a round shape that is attested by 
the increase in its sphericity index. Additionally, advanced right-sided lesions distort the 
left ventricle that assumes a “banana” shape related to compression by an aneurismal 
right atrium and to change in shape that is associated with the marked retraction of the 
apex of the right ventricle. Moreover, postoperatively the paradoxical movement of the 
interventricular septum does not allow the use of the formula for calculation of the 
shortening fraction. Therefore, despite its limitations related to the fact that it only 
considers two dimensions of the cavities, the linear dimensions and sphericity indexes 
appear to be the most acceptable tools for evaluation of the effects of surgery on EMF 
patients.  
In patients with REMF and considerable reduction of the right ventricular size it appears 
that the addition of a cavopulmonary anatomosis to the procedure of endocardial 
resection or its use as a first stage of phased surgical treatment, improved the prognosis 
by reducing post-operative complications.
Our surgical results are superior to those reported earlier from Brazil, India and Ivory 
Coast (Moraes et al, 1993; Metras, 1993; Valiathan and Shymkrishnan, 1993). This may 
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be partially explained by the improvements in myocardial protection that occurred in the 
recent years, which now allow longer and safer open-heart surgery. The use of new drugs 
for the management of intra-operative and immediate post-operative complications may 
also have contributed to the amelioration of the prognosis after surgery. However, 
although these improvements might have played an important role on recovery of the 
myocardial function after this long and demanding surgery, we think that the detailed 
characterization of disease prior to surgery and the use of the new tailored techniques 
played a crucial role.
We did not have any intra-operative mortality. The two post-operative deaths were due to 
accidents related to drainage of pericardial tamponade, the most important complication 
of surgery both in terms of frequency and relevance for the prognosis. Knowledge of this 
fact has lead to changes in the way we manage and follow this complication, preventing 
deaths due to this complication after an initial learning curve. In previous series mortality 
reached 20 to 29% (Valiathan et al, 1989; Moraes et al, 1999; Dubost, 1990) and has 
been related to low cardiac output state and complete atrioventricular block following 
extensive endocardial resection.
Complete atrioventricular block did not occur in our experience. Transitory 
idioventricular rhythm was seen in most patients and complete bundle branch was the 
most important long-term complication. Supra-ventricular arrhythmias occurred in 14 out 
of 24 patients, but most were transitory. At six-months follow up all patients were in 
sinus rhythm, except one that had been in atrial fibrillation previous to surgery.
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We did not have any late deaths. Late mortality after EMF surgery in early series was 
also high (12,3%) during a shorter period of follow up (Valiathan et al, 1987), and has 
been mainly related to complications of valve prosthesis. Both, documented valve 
thrombosis or uncontrolled bleeding are reported to be frequent in those patients, due to 
poor compliance and control of anticoagulation. The uses of mitral and tricuspid repair in 
all patients and close follow up of complications after surgery have contributed to the low 
rate of complications in our series.
Recurrence of disease was not detected during follow up. In most patients the lesions 
found after surgery corresponded to fibrotic areas that were not accessible for endocardial 
resection during the surgical intervention. There are conflicting reports of recurrence of 
EMF after surgery. Although most authors state that recurrence is low after long follow-
up, even in those patients that go back to their areas of origin, few cases have been 
reported on reoperation in Brazilian series and appearance of EMF lesions on the 
contralateral ventricle after surgery has also been reported in proportions varying from 6 
to 18,8% (Moraes et al, 1999; Moraes et al, 1999). Longer follow up of patients in our 
series is warranted in order to clarify this issue.
All but one patient from our series were in functional class III/IV prior to surgery, despite 
multiple drug therapy at high doses. All surviving patients had marked clinical 
improvement, including those for which the echocardiographic results do not seem 
excellent on follow up, and had reduction of cardiomegaly as assessed by chest 
radiography and echocardiography. Our findings corroborate those from other studies, 
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which have shown that cardiomegaly is a major determinant of clinical symptoms, since 
leading to reduction in exercise capacity (Abrahams 1967; Mady et al, 2005). 
Considering that most patients excluded from surgery had irreversible cardiac damage 
and/or complications of long-standing heart failure like hepatic dysfunction, fixed 
pulmonary hypertension and cachexia, it appears that early indication of surgery could 
further contribute to improved prognosis in this condition. Although the issue of timing 
for surgery has been debated, no consensus has been reached due to lack of knowledge 
about the etiology and natural history. The high mortality and morbidity associated with 
surgery have lead to late indication of surgical treatment of EMF, despite the several 
studies showing the superiority of surgery over medical therapy (Metras et al, 1982; 
Cherian et al, 1982; Gonzalez-Lavin et al, 1983) and the report of low recurrence 
(Valiathan and Shyamkrishnan, 1993; Moraes et al, 1993). Our results support the early 
indication of surgery to all symptomatic patients before severe cardiac damage has 
occurred. 
This study represents the results of our initial experience with a new tailored surgical 
approach to EMF.  Therefore, the number of patients and the follow-up period are 
relatively limited. Nevertheless, the lessons learned regarding disease presentation and 
operability of this neglected, yet highly prevalent disease are important.  
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11.6. Conclusions
The present results indicate that a thorough understanding of the pathophysiology of the 
disease and careful patient management and follow-up result in satisfactory outcomes in 
symptomatic patients. However, good surgical skills and adequate environment for 
follow up of patients after surgery are mandatory.  
Based on our initial experience, complete and meticulous removal of all endocardial 
fibrotic tissue without compromising the conduction system or the integrity of the sub-
valvular apparatus is a key element. Although no cases of EMF recurrence have yet been 
observed, continued clinical and echocardiographic follow-up are mandatory. Further 
research is necessary to identify prognostic factors and help in determining the ideal 
timing of surgery. We hope that continued research into the pathophysiology and the 
therapeutic management of this neglected condition will lead to a significant decrease in 
the burden of disease in children and young adults in developing countries.
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Chapter 12
CONCLUSIONS AND FUTURE DIRECTIONS
We here describe a series of studies on the epidemiology, clinical-laboratory profile and 
management on Endomyocardial Fibrosis (EMF), a major health challenge and one of the 
leading neglected diseases worldwide. This condition affects several million people 
throughout the world with a very poor prognosis and, although known since the middle of 
20th century, it has received little attention from the scientific community in the last 
decades and therefore did not benefit from a modern management and research approach. 
The evolution of the anatomical phenotype of early stages remains unclear despite major 
developments in imaging techniques, since these techniques are still expensive and not 
readily available in most endemic areas. However, the use of these modern imaging tools 
may uncover the mechanisms of disease, hence the need to apply them on research that 
should also include genetics and molecular biology. 
This thesis is the first attempt at using these modern tools and innovative approaches to 
investigate EMF, and integrates large-scale epidemiological studies with clinical research 
and laboratory investigations aiming at unveiling the pathogenesis of the condition. Our 
main results concern epidemiology, diagnosis and management of EMF. New 
interrogations are raised regarding the mechanisms involved. 
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EPIDEMIOLOGY 
Echocardiographic screening and establishment of cohorts 
Echocardiographic screening has shown that EMF is common in Inharrime affecting 
nearly 20% of the population, and that young age, male gender and familial 
predisposition are important determinants of the disease. This imaging tool enables the 
detection of individulas in early phases of the disease whose follow up has given new 
insights into the natural history of this condition. 
Since echocardiography uncovers the presence of asymptomatic disease we conclude that 
it is the most powerful tool for screening of EMF, and should be also used to assess the 
progression of anatomical and hemodynamic abnormalities as well the response to 
interventions in cohort studies.
DIAGNOSIS
Phenotype characterization, evolution and surgical indications
The use of echocardiography allows a confident non-invasive diagnosis of EMF, is 
essential for indication of surgery and choice of operative techniques, and has the 
potential to be used to define prognosis. 
Our studies show that EMF presents great phenotypic variability with lesions varying 
from patchy endocardial thickening without any hemodynamic changes, to extensive 
mural and atrioventricular valve endocardial fibrosis with resulting structural and 
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hemodynamic changes. Although severe and debilitating forms of the disease are the 
most common forms of presentation to hospitals, mild asymptomatic disease is common 
in the community. 
The most characteristic echocardiographic features of EMF are: (1) endocardial 
thickening affecting the walls and/or the atrioventricular valves; (2) obliteration of the 
trabecular portion of the right ventricle, the left ventricular apex or the atrioventricular 
valve recesses; (3) ventricular thrombi or spontaneous contrast in the absence of 
ventricular dysfunction; (4) reduction of ventricular cavity volume; and, (5) restriction of 
atrioventricular valve mobility due to its partial or complete adherence to the ventricular 
walls. However, echocardiography allowed the definition of several minor features that 
are suggestive of EMF and can be considered initial signs of disease. Follow up of these 
changes is necessary to validate this hypothesis.
EMF is a unique form of cardiomyopathy with particular pathophysiology. There is 
association of diastolic and systolic dysfunction, atrioventricular valve dysfunction and 
abnormal shape of the ventricles. Therefore, the assumptions usually made regarding 
ventricular shape and that are the basis for calculating parameters that assess ventricular 
function cannot be applied for most cases of EMF. Thus, the use non-conventional 
measurements and indices to evaluate ventricular function and assess the results of 
treatment is mandatory. We privileged ventricular and atrial linear dimensions, sphericity 
indices and the visual scale for evaluation of systolic function. The reduction of the 
sphericity index seems a useful marker of improvement after surgery for all cavities 
except the right ventricle, which shows variable shape post-operatively.   
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MANAGEMENT
Evolving new therapeutic approaches
Currently, there is no effective medical therapy for EMF. Our studies of the biological 
profile in EMF suggest that a subset patients present markers of inflammation, increased 
thrombolysis and autoimmunity. Thus, they can potentially benefit from the use of anti-
inflammatory drugs, immunomodulators and anticoagulants, an hypothesis that should be 
tested through clinical trials. 
The diagnostic and severity score system presented and applied in our work represents 
the first attempt at standardization of echocardiographic examination of EMF. It offers a 
management-driven tool that is essential for selection of patients who can benefit from 
surgery, as well as for design of tailored strategies and techniques for surgery. Most 
structural and functional abnormalities of EMF can be partially corrected through fibrous 
tissue resection, atrioventricular valvar repair, atrial reduction and partial cavo-
pulmonary anastomosis. Late diagnosis determines poor overall prognosis in this 
condition, hence the need for early diagnosis and better timing of surgery.
The use of new approaches and innovative tailored surgical techniques improves the early 
and medium-term results of surgery. However, long-term follow up is needed to assess 
the rate of recurrence, survival free of major events. 
Surgery, by allowing detailed examination of the heart “in vivo”, improves the 
understanding of the pathophysiology of EMF, and will hopefully help defining the 
optimal timing for surgery.
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MECHANISMS OF THE DISEASE
Factors involved in pathogenesis 
In an attempt to uncover the pathogenesis of EMF this thesis has searched evidence for 
inflammation, allergy, autoimmunity, endothelial markers, prothrombotic factors, 
immunogenetic susceptibility and the possible role of malaria infection in inducing EMF.
Our results suggest a role of inflammation, allergy, autoimmunity, pro-thrombotic factors 
and endothelial dysfunction in EMF. However, the timing and relevance of each of these 
abnormalities, particularly their relation to clinical features of recrudescence and 
progression of structural abnormalities, needs further investigation.
Although no relation was found between the presence of EMF lesions and malaria 
infection, we think that this issue needs also to be investigated exploring the recent 
knowledge of the pathology of malaria, particularly endothelial dysfunction, 
inflammatory changes and pro-coagulant abnormalities.
The evidence for immunogenetic susceptibility in determining the severity of EMF might 
explain the differences in phenotypic variability, mode of progression and familial 
predisposition. However, larger studies characterizing the genetic profile of the 
unaffected individuals in Mozambique and individuals with EMF in the community are 
mandatory to clarify the precise role of genetic factors in the pathogenesis of this 
condition. 
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Future Directions
The epidemiological research has established cohorts of individuals who are well 
phenotyped by echocardiographic examination and who will be followed to assess 
incidence and progression of EMF. Future research should include prospective case-
control studies to identify the mechanisms of the disease, and define the role of 
environmental factors in pathogenesis, namely parasites, viruses, diet and allergens. 
The usefulness of cavity linear dimensions, sphericity indexes and visual scales 
for evaluation of the systolic function must be validated in larger series, as a tool for 
assessing the results of surgery. On the other hand research shall concentrate on 
evaluation of the prognostic value of features like the extent and depth of fibrosis, 
involvement of the papillary muscles in the fibrotic process, severe shortening of the 
leaflets and the presence of severe ascitis. Similarly, the influence of the surgical strategy 
and the techniques used must be evaluated.
In recent years we have witnessed the gain of new knowledge in several fields 
that are relevant to understanding EMF, namely endothelial cell biology, inflammation, 
hemostasis, regulation of collagen synthesis, remodeling and mechanisms of fibrosis. 
However, this has not been paralleled by improvement in knowledge of EMF.
The definition of the biological profile of EMF patients is of paramount 
importance, particularly the clarification of the role of the eosinophil. Eosinophil cationic 
protein (ECP) released from activated eosinophils increases the release of TGF- β1 from 
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fibroblasts, and this is thought to be the mechanism by which they cooperate in 
remodeling of the extracellular matrix leading to airway fibrosis in asthmatic patients 
(Zagai et al, 2007).  Eotaxins, on the other hand, are chemotactic cytokines highly 
selective for eosinophils and are known as their most potent chemoattractant. They can 
induce both the local recruitment of eosinophils from the microcirculation and rapid 
mobilization of the bone marrow eosinophils, in synergy with IL5 (Collins et al, 1995; 
Palframan et al, 1998), and may be produced by many of the cells found in cardiac tissue, 
namely smooth-muscle cells, endothelial cells, alveolar macrophages, lymphocytes, 
eosinophils.
The relevance of antiheart antibodies in EMF must also be clarified. There is a 
possibility of homology of these heart antigens with native pathogens, and attempts must 
be made at identifying the nature of the specific antigens as well as assess the functional 
cytotoxicity of those circulating antiheart antibodies. Another challenge remains the 
identification of specific markers of endocardial endothelium.
Improvement in knowledge in all these areas should stimulate research aiming at 
testing therapeuthical interventions that can alter the natural history of the disease, 
preventing its progression to advanced forms. Clinical trials targeting the eosinophil and 
its related cytokines are recommended since drugs to control hypereosinophilia, high 
levels of IL-5 and eotaxins are currently available (Rothenberg et al, 2008; Sutton et al, 
2005; Morokata et al, 2006). The assessement of the efficacy of the anti-inflammatory 
drugs in active disease is also warranted, although caution must be taken in endemic 
tropical areas, where the risk of infections bacterial and parasitic infestations is very high. 
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Although structutal abnormalities are present in all components of the heart tissue, 
the hallmark of EMF is the sub-endocardial deposition of large numbers of fibroblasts, 
the predominant cellular mediators of fibrosis, which origin is still unclear. It could be the 
consequence of passage of fibroblast stimulatory factors from the vessels to the 
interstitium caused by abnormal coronary vascular permeability or the consequence of 
direct insult to the endocardial endothelium leading to endothelial activation, proven to 
be present in our studies in recent onset EMF (Chapter 8). Endothelial cell activation has 
the potential to induce subendocardial fibrosis, since endothelial cells can synthesize both 
basic fibroblast growth factor (b-FGF) and platelet-derived growth factor (PDGF/NO). 
Injured cells would release these factors, leading to potent growth-promoting activity for 
fibroblasts (Endeman and Schiffrin, 1992). 
The assumption that adult fibroblasts are originally derived from embryonic 
mesenchymal cells and that they increase solely as a result of the proliferation of resident 
adult fibroblasts has been challenged. There is evidence that during fibrosis, bone 
marrow-derived fibroblasts and epithelial cells also contribute to fibroblast accumulation, 
by way of a process called endothelial-to- mesenchymal transition (Iwano et al, 2002; 
Zeisberg et al, 2007; Friedman, 2007; Gressner et al, 2007). This critical process to 
embryonic development of the heart (Eisenberg and Markwald, 1995), is thought to be 
regulated by inductive signals such as TGF-β and bone morphogenic proteins (Bujak and 
Frangogiannis, 2007), and could be involved in the pathogenesis of EMF, a hypothesis 
that needs to be investigated. Moreover, the concept of the irreversibility of cardiac 
fibrosis or scarring of the heart must be reviewed  (Towbin (2007) considering the recent 
References 
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
441
of a compound that inhibits TGF-β1 endothelial-mesenchymal transition, blocks fibrosis 
and reduces the amount of fibrous tissue in mice (Zeisberg et al, 2007).
Another important line of research is the measurement of cardiac collagen 
turnover by use of serological markers, a useful tool for monitoring cardiac tissue repair 
and fibrosis in experimental models and clinical conditions (Zannad et al, 2001). The 
biological and immune profile of EMF is that of a systemic disease with cardioselectivity 
of fibrotic lesions, the reason for which is not known. The recent discovery of the 
expression of tissue factor in the myocardium but not in other muscle types (Mackman 
2008; Pawlinski et al, 2007) might explain why is the heart the sole organ predisposed to 
primary thrombosis and subsequent fibrosis in this condition. 
Research focusing on these issues should be performed using cardiac tissue and 
blood obtained from participants in prospective studies, since it could be of value for 
unveiling the sequence of events that lead to fibrosis. On the other hand, better 
understanding of the endocardial endothelium and identification of specific markers of its 
injury is mandatory. Attempts at isolation of endocardial cells and fibroblasts from the 
heart are needed in order to allow the design of in vitro studies looking at the effects of 
pro-fibrotic stimuli in those cells. Another possibility would be the development of 
animal models of endomyocardial fibrosis to allow the testing of insults that could lead to 
fibrosis of the endocardium and adjacent myocardium, as well exploration of the effects 
of currently available modulators of inflammation, thrombosis and fibrosis on 
endocardial fibrosis, myocardial fibrosis and collagen turnover. 
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Another area of future research will be the genetics aiming at clarification the role
of heredity in determining familial predisposition and immunogenetic susceptibility 
found in our studies. This could be done through genetic epidemiological studies in 
endemic and non-endemic areas, looking for candidate genes known to have a role in 
fibrosis, as well as searching for genetic polymorphisms to biological markers with 
relevance to the mechanisms of inflammation, thrombosis and fibrosis.
Geographic variation in prevalence of EMF has been recognized within countries. 
We aknowledge that the results presented in this thesis reflect the situation in one specific 
region with high prevalence of EMF. Replication of similar programs of translational 
research in endemic countries might allow the validation of clinical, biological and 
echocardiographic criteria proposed by us for diagnosis of early disease. It is also 
important to implement standardized national registries/databases and identify centers of 
excellence in which state-of-the-art surgical management and conditions for optimum 
research are available. The ethical issues associated with the implementation of such 
large-scale screening and management programmes for a condition with unknown 
etiology and ineffective treatment must not be underestimated, and availability of clinical 
follow up in the concerned areas must be garanteed in order to insure acceptance of these 
research programs by the communities. 
This thesis has probably raised more questions than it has answered. However, we 
believe that it addresses critical issues regarding the diagnosis, contributes to better 
understanding and management of EMF, and will hopefully stimulate further research 
looking at new therapeutic targets for the disease. 
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APPENDIX 2A
PREVALENCE STUDY – ENDOMYOCARDIAL FIBROSIS
DATA COLLECTION
CODE________________ PSN ________________
ADRESS ______________________________________________________ 
CONTACT ___________________
NAME ___________________________________________________________ 
AGE _______ DATE OF BIRTH _________ 
RACE  B O SEX F M “PARENTESCO” ___________
ECOCARDIOGRAPHY
NORMAL EMF RHD CHD OTHER
4 cavities parasternal LA sub-costal
BLOOD COLLECTION YES NO
REMARKS:
_________________________________________________________________ 
_________________________________________________________________ 
DATE _______________ RESEARCHER ______________________ 
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APPENDIX 2B
PROSPECTIVE STUDY – ENDOMYOCARDIAL FIBROSIS
DATA COLLECTION (TIME 0)
CODE________________ TEACHER ________________
SCHOOL ___________________________________________________________ 
ADRESS ____________________________________________________________ 
CONTACT __________________________________________________________ 
STUDENT___________________________________________________________  
PARENTS ___________________________________________________________ 
AGE _______ DATE OF BIRTH _________  RACE  B/O SEX F M
ECOCARDIOGRAPHY
NORMAL EMF RHD CHD OTHER
4 cavities parasternal LA sub-costal
BLOOD COLLECTION YES NO
REMARKS:
_________________________________________________________________ 
_________________________________________________________________ 
DATE _______________ RESEARCHER ____________________ 
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APPENDIX 3
Echocardiographic measurements used in the studies
LEFT
Aortic root dimensions
LVEDD/LVESD (shortening fraction)
LVEDV/LVESV (ejection fraction)
LVEDA/LVESA (area shortening fraction)
PW/Sp thickness
LA linear dimensions: AP, L, SI
Sphericity index (L/SI)
LA area, LA volume
Dimension of the mitral annulus
Doppler: E wave, A wave, E/A; IVRT, DT
Severity of MR
RIGTH
Linear dimensions RVOT
RV area
RVEDA/RVESA (shortening fraction)
Visual evaluation of contractility (+ to +++)
RV linear dimensions (L, SI)
AW thickness (S and D)
RA linear dimensions (L, SI)
Sphericity index (L/SI)
RA area
Dimensions of the tricuspid annulus
Doppler: E wave, A wave, E/A
Severity of TR
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APPENDIX 4
LIST OF SELECTED SCHOOLS
Ten primary schools were randomly selected from a total of 50. All students from second 
level were invited to participate in the cohort follow-up study.
SCHOOLS N OF STUDENTS TEACHERS 
Senduza II 31 Armando Francisco
Cuaiaia 43 Armando António/Gaspar Languisso
Mahalamba 118 P. Mahique/ Olga Malate/ R. Cumbi/C. Lisure
Inhantumbo 47 Teresa Júlio/Luis Nhiuane
Mahessa 35 Jerónimo Muholiciane/Ernesto Hele
Coche 47 Julião Paulo/Francelino Deve
Magula 38 Domingas Fernando/Mariamo Abdula
Incuane 58 Horácio Xavier/Arlindo Afonso Cumbi
Cambula 33 Lídia Machava/João Chambe
Chilorane 40 Basílio Zango/Rafael Augusto
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APPENDIX 5
MEMBERS OF THE SURGICAL TEAMS
From Imperial College and Magdi Yacoub Institute:
Professor Sir Magdi Yacoub Surgeon/Supervisor
From IASO Genral Hospital, Athens - Greece:
Professor Stergios Theodoropoulos Surgeon
Dr Vassilis Kolias Surgeon
Dr Angelos Katsianis Surgeon
Elias Lazaros Perfisionist
Yianna Siourdaki Scrub nurse
Nicoleta Dionysiou Scrub nurse
Thomas Zikopoulos Scrub nurse
Kyraki Charitaki ICU nurse
From Onasis Cardiac Surgery Centre, Greece:
Dr Nicolaus Giannopoulos Surgeon
From University Hospital Coimbra, Portugal:
Ricardo ICU nurse
António ICU nurse
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APPENDIX 6
SURGICAL REPORT
NAME NID EMF
DIAGNOSIS
(Scheme of the lesions must be schematised on the back)
LEFT VENTRICLE Adherence/Absence of posterior cusp
Patchy fibrosis Thrombus Calcification
White regular opacity/Deep scarring .inflow tract .apex .posterior wall
Fibrosis/Shortening/Thickening/Calcification papillary muscles/chordae 
RIGHT VENTRICLE Patchy fibrosis Thrombus Calcification
White regular opacity/Deep scarring .inflow tract .apex .posterior wall
Cavity dimensions Conus/Infundibulum dilatation RV atrialization
Fibrosis/Shortening/Thickening/Calcification papillary muscles/chordae 
PERICARDIUM
Pericardial effusion/resection RV notch
ECC Time ______ min Failure to come off bypass
TECHNIQUE:___________________________________________________________ 
________________________________________________________________________
SURGEON: ________________ DATE: ____________ 
Biopsy: LV  RV MV TV LA RA PC
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APPENDIX 7: Mitral and tricuspid valve function of the 24 EMF patients prior 
and after surgery (* Mitral Stenosis associated; † death; . follow up less than 24 months)
Code BSA EMF
Class
Before surgery
MR              TR
After surgery 6M
MR              TR
After surgery 24M
MR                TR
0065 1.28 II L 4/4 2/4 0  0 
0048 0.87 IV L 4/4  0 0 0 0
0076 1.15 III L 4/4 4/4 2/4  ? ?
0075 1.04 III L 4/4 4/4  0 0 0
0128 1.25 III L 4/4 2/4 2/4 0  
0142 1.36 III L 4/4 2/4  0 * 0
0125 1.42 III L 4/4 4/4  0  0
0169 1.71 III L 4/4 2/4 † † † †
0068 0.84 II B 4/4 4/4  0  0
0009 0.79 III B 4/4 4/4 0 0 0 0
0074 1.02 III B 4/4 4/4 0 0 0 0
0040 1.44 III B 4/4 4/4 † † † †
0143 0.79 II B 4/4     1/4
0062 0.88 III B 4/4 4/4  2/4  2/4
0144 1.21 III B 4/4  0 0 0 0
0146 0.99 III B 4/4 2/4    2/4
0163 0.82 III B 4/4 4/4 0 0 . .
0180 0.88 III B 4/4 4/4 0 0 . .
0167 1.00 III B 4/4 4/4 1/4  . .
0179 0.72 III B 4/4 4/4   . .
0052 0.95 IV R 0 4/4    0
0152 0.79 III R 0 4/4 1/4 2/4 . .
0110 0.72 IV R  4/4 0 2/4 . .
0151 0.76 II R 4/4  0 0 . .
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APPENDIX 8: Ventricular linear dimensions indexed for body surface area and 
sphericity indexes of the 24 EMF patients before and after surgery. (†death; ? unknown)
Code EMF
Class
LL/SI LV 
dimensions (mm)
Before      After
LV 
Sphericity Index 
Before        After
LL/SI RV 
dimensions (mm)
Before        After 
RV 
Sphericity Index
Before        After
0065 II L 38/51 34/48 .76 .73 34/30 22/28 1.14 .78
0048 IV L 48/61 44/59 .80 .75 49/53 37/45 .94 .82
0076 III L 38/39 36/46 .98 .78 47/50 37/44 .94 .86
0075 III L 53/49 39/58 1.08 .69 49/49 34/41 1.0 .84
0128 III L 40/41 50/45 .98 1.11 26/38 26/34 .67 .77
0142 III L 34/33 35/51 1.03 .70 23/31 29/38 .74 .77
0125 III L 30/47 30/49 .65 .61 30/35 25/37 .84 .70
0169 III L 32/29 † .92 † 29/25 † 1.2 †
0068 II B 55/67 57/66 .83 .88 50/41 38/48 1.2 .80
0009 III B 52/66 61/68 .82 .89 49/51 47/51 .98 .93
0074 III B 36/60 33/58 .61 .58 40/36 34/50 1.1 .69
0040 III B 40/36 † 1.12 † 49/50 † .98 †
0143 II B 53/66 57/77 .81 .74 28/57 37/ 49 .49 .75
0062 III B 48/57 41/57 .84 .72 42/43 48/63 .98 .77
0144 III B 47/52 40/60 .91 .67 33/31 35/41 .84 .84
0146 III B 29/51 49/53 .58 .93 41/30 42/50 1.4 .84
0163 III B 70/61 58/63 1.14 .93 50/38 51/46 1.3 1.11
0180 III B 49/58 ? .85 ? 36/38 ? 1.0 ?
0167 III B 44/48 37/47 .92 .79 48/42 36/48 1.2 .75
0179 III B 53/71 ? .75 ? 42/53 ? 0.8 ?
0052 IV R 33/48 42/48 .70 .87 34/27 25/41 1.2 .62
0152 III R 28/53 38/54 .53 .70 51/24 49/30 2.1 1.63
0110 IV R 28/67 43/69 .42 .62 63/43 49/47 1.5 1.03
0151 II R 29/63 38/79 .46 .49 54/26 75/68 2.1 1.10
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APPENDIX 9: Left ventricular systolic and diastolic function before and 1 year after 
surgery, EDD/ESD indexed for body surface area (*assessed by visual scale;†death; ? unknown). 
Code EMF
Class
LVEDD/LVESD 
Before            After
SF            Function*
Before          After
E/A wave ratio
Before After
0065 II L 50.6/27.8 44.5/24.5 46.0 +++ 4.0 1.9
0048 IV L 64.8/31.8 47.8/24.7 51.0 +++ 2.8 1.5
0076 III L 43.5/30.4 43.3/30.5 30.0 ++ 1.8 1.4
0075 III L 57.7/30.8 49.3/33.6 47.0 +++ 3.2 1.8
0128 III L 53.8/36.8 44.0/25.6 32.0 +++ 6.7 2.6
0142 III L 36.8/21.2 36.0/22.1 43.0 +++ AF AF
0125 III L 42.3/21.8 31.3/22.4 49.0 +++ 1.5 0.5
0169 III L 31.6/18.7 † 41.0 † 1.7 †
0068 II B 66.7/34.5 55.8/50.0 49.0 +++ 1.9 2.0
0009 III B 58.2/29.4 55.1/40.5 51.0 +++ 2.0 1.3
0074 III B 41.9/23.8 42.2/39.5 43.0 ++ 1.8 1.5
0040 III B 41.3/27.1 † 35.0 † AF †
0143 II B 58.0/32.9 52.9/36.6 44.0 ++ 2.3 1.5
0062 III B 55.8/23.1 51.5/27.8 59.0 +++ 2.8 1.3
0144 III B 57.9/30.8 42.7/25.6 47.0 +++ 1.5 1.6
0146 III B 49.7/31.4 47.0/28.0 37.0 +++ 3.1 2.0
0163 III B 67.0/32.6 50.0/28.1 52.0 +++ 3.4 3.6
0180 III B 54.0/28.3 ? 48.0 ? 1.3 ?
0167 III B 46.1/27.6 45.8/28.8 40.0 ++ 3.2 2.8
0179 III B 66.7/43.1 ? 36.0 ? 1.6 ?
0052 IV R 27.2/16.9 38.9/25.0 a) +++ 2.0 1.6
0152 III R 38.0/35.5 46.7/27.5 a) +++ 3.4 2.8
0110 IV R 49.5/30.6 49.5/30.6 a) +++ 3.8 3.0
0151 II R 40.4/33.6 41.1/37.0 a) +++ 4.3 3.4
Appendices 
________________________________________________________________________
_____________________________________________________________________ 
Epidemiology, Pathogenesis and Management of Endomyocardial Fibrosis
502
APPENDIX 10: Right ventricular function assessed by visual scale in the 24 EMF 
patients before and after surgery (†death; ? unknown)
Code EMF
Class
RV systolic function
Before                             After
0065 II L ++ +++
0048 IV L ++ +++
0076 III L ++ +
0075 III L + +++
0128 III L +++ +++
0142 III L ++ ++
0125 III L ++ +++
0169 III L + †
0068 II B ++ +++
0009 III B ++ +++
0074 III B + ++
0040 III B + †
0143 II B ++ +++
0062 III B + +++
0144 III B ++ +++
0146 III B +++ +++
0163 III B ++ +++
0180 III B ++ ?
0167 III B ++ +++
0179 III B +++ ?
0052 IV R + +++
0152 III R + ++
0110 IV R + +++
0151 II R + +++
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APPENDIX 11: Atrial linear dimensions indexed for body surface area and sphericity 
indexes of the 24 EMF patients before and after surgery (†death; ? unknown)
Code EMF
Class
LL/SI LA 
dimensions (mm)
Before        After
Sphericity Index 
Before        After
LL/SI RA 
dimensions (mm)
Before        After
Sphericity Index 
Before        After
0065 II L 63/70 45/50 0.90 0.90 51/53 46/49 0.97 .94
0048 IV L 126/55 52/55 2.29 0.95 51/55 34/38 0.93 0.90
0076 III L 42/50 34/55 0.84 0.62 51/55 30/39 0.93 0.77
0075 III L 78/98 62/62 0.80 1.00 56/70 49/52 0.80 0.95
0128 III L 80/69 52/62 1.16 0.84 36/42 40/33 0.86 1.22
0142 III L 93/105 56/72 0.89 0.78 28/52 33/36 0.35 0.92
0125 III L 60/76 42/72 0.79 0.59 42/50 46/52 0.84 0.89
0169 III L 50/72 † 0.70 † 49/60 † 0.82 †
0068 II B 57/68 45/57 0.84 0.79 35/47 32/44 0.75 0.73
0009 III B 43/56 37/49 0.77 0.76 55/48 43/48 1.15 0.90
0074 III B 55/79 52/57 0.70 0.92 53/58 46/48 0.92 0.96
0040 III B 74/101 † 0.74 † 88/98 † 0.90 †
0143 II B 50/63 29/41 0.80 0.71 53/50 50/42 1.06 1.09
0062 III B 48/61 39/56 0.79 0.70 42/62 50/58 0.68 0.87
0144 III B 77/94 52/60 0.82 0.87 30/51 32/50 0.59 0.64
0146 III B 32/49 42/60 0.66 0.70 65/58 62/51 1.12 1.22
0163 III B 64/66 52/66 0.97 0.79 54/60 48/56 0.90 0.86
0180 III B 63/70 ? 0.90 ? 54/62 ? 0.87 ?
0167 III B 51/63 48/49 0.81 0.98 70/56 38/41 1.25 0.93
0179 III B 55/58 ? 0.95 ? 36/42 ? 0.86 ?
0052 IV R 28/40 39/46 0.70 0.85 78/42 41/53 1.86 0.78
0152 III R 16/47 20/45 0.34 0.80 78/72 70/70 1.09 1.00
0110 IV R 18/28 22/41 0.65 0.54 77/70 46/51 1.10 0.91
0151 II R 22/47 28/56 0.47 0.50 68/53 58/60 1.29 0.97
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